No.	Generic Name	MDC	Category	Indication(s)	Dosage
1	Abacavir Sulphate 600 mg and Lamivudine 300 mg Tablet	J05AR02964T1001XX	A*	Antiretroviral combination therapy of HIV infection in adults and adolescents from 12 years of age with the following criteria: i)Patients unsuitable or failed other HAART treatment; ii)Patients who are at high risk of renal impairment iii)Patients with osteoporosis or at high risk of bone loss	ADULTS & ADOLESCENT (> 12 years of age): Recommended dose is one tablet once daily. Not to be used in adults or adolescents weigh less than 40kg. CHILDREN : Not recommended
2	Acarbose 50 mg Tablet	A10BF01000T1001XX	A/KK	Only for treatment of: i) Non insulin dependent diabetes mellitus (NIDDM) when diet therapy is insufficient; ii) Non insulin dependent diabetes mellitus (NIDDM) in combination with existing conventional oral therapy where glycaemic control is inadequate	Initially 50 mg daily, increase to 3 times daily up to 100 mg 3 times daily. Max 200 mg 3 times daily
3	Acetazolamide 250 mg Tablet	S01EC01000T1001XX	B	Reduction of intraocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucoma	250mg 1-4 times a day, the dosage being titrated according to patient response
4	Acetazolamide 500 mg Injection	S01EC01000P4001XX	B	Reduction of intra-ocular pressure in open-angle glaucoma, secondary glaucoma and peri-operatively in angle-closure glaucoma	Adult : 250-1000mg per 24hours, usually in divided doses for amounts over 250mg daily
5	Acetylcysteine 200 mg/ml Injection	V03AB23520P3001XX	A*	Antidote for paracetamol poisoning	Diluted with dextrose 5% and infused IV. Initial, 150 mg/kg IV in 200 ml over 60 minutes, then 50 mg/kg IV in 500 ml over 4 hours, followed by 100 mg/kg IV in 1000 ml over 16 hours. Total dose: 300mg/kg in 20 hour
6	Acetylsalicylic Acid 100 mg, Glycine 45 mg Tablet	B01AC06259T1001XX	B	Prevention of myocardial infarct, stroke, vascular occlusion and deep vein thrombosis. Transient ischaemic attacks	1 tablet daily
7	Acetylsalicylic Acid 300 mg Soluble Tablet	N02BA01000T4001XX	C	Mild to moderate pain	300 - 900 mg every 4 - 6 hours as required. Max 4 g daily. Use in children not recommended

No.	Generic Name	MDC	Category	Indication(s)	Dosage
8	Acitretin 10 mg Capsule	D05BB02000 C1001XX	A*	i) Severe form of psoriasis including erythrodermic psoriasis and local or generalized pustular psoriasis. ii) Severe disorders of keratinization, such as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other disorders of keratinization which may be resistant to other therapies	ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). In disorders of keratinization, maintenance therapy of less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods
9	Acitretin 25 mg Capsule	D05BB02000 C1002XX	A*	i) Severe form of psoriasis including erythrodermic psoriasis and local or generalized pustular psoriasis. ii) Severe disorders of keratinization, such as -congenital ichthyosis -pityriasis rubra pilaris -Darier's disease -other disorders of keratinization which may be resistant to other therapies	ADULT: initially 25-30 mg daily for 2-4 weeks, then adjusted according to response, usually within range 25-50 mg daily for further 6-8 weeks (max: 75 mg daily). In disorders of keratinization, maintenance therapy of less than 20mg/day and should not exceed 50mg/day CHILD: 0.5mg/kg daily occasionally up to 1 mg/kg daily to a max. 35 mg daily for limited periods
10	Acriflavine 0.1% Lotion	D08AA03000 L6001XX	C+	Infected skin, lesions, cuts, abrasions, wounds and burns.	Apply undiluted three times daily to the affected part.
11	Actinomycin D (Dactinomycin) 500 mcg/ml Injection	L01DA01110 P4001XX	A	i) For solid tumours ii) Gestational trophoblastic disease	i) ADULT: 500 mcg IV daily for max of 5 days. CHILD: 1.5 mg/m2 once every 3 weeks (if weight less than 10 kg, 50 mcg/kg) ii) 500 mcg IV on Days 2, 4, 6, 8, 10, repeat every 7 - 10 days or 500 mcg IV bolus on Days 1 and 2, repeat every 15 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
12	Acyclovir 200 mg Tablet	J05AB01000T 1001XX	A/KK	i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster)	i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2 years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times daily
13	Acyclovir 200 mg/5 ml Suspension	J05AB01000L 8001XX	A*	i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg.Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster)	i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2 years, half adult dose; more than 2 years, adult dose. v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD: less than 2 years; 400mg 4 times daily, more than 2 years; 800 mg 4 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
14	Acyclovir 250 mg Injection	J05AB01000P4001XX	A*	Treatment and prophylaxis of herpes simplex in immunocompromised, severe initial genital herpes and Varicella - Zoster	ADULT: 5 mg/kg by IV infusion 8 hourly for 5 days, doubled to 10mg/kg every 8 hourly in varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for at least 10 days in encephalitis; possibly for 14 - 21 days). NEONATE & INFANT up to 3 months with disseminated herpes simplex: 20mg/kg every 8 hourly for 14 days (21 days in CNS involvement), varicella-zoster 10-20mg/kg every 8 hourly usually for 7 days. CHILD, 3 months - 12 years: Herpes simplex or Varicella Zoster: 250 mg/m2 8 hourly for 5 days, doubled to 500 mg/m2 8 hourly for varicella-zoster in the immunocompromised and in simplex encephalitis (usually given for 10 days in encephalitis)
15	Acyclovir 3% Eye Ointment	S01AD03000G5101XX	A*	Only for the treatment of herpes simplex keratitis	Apply 1 cm 5 times daily. Continue for at least 3 days after healing
16	Acyclovir 5% Cream	D06BB03000G1001XX	A*	Herpes simplex infections of the skin, including initial and recurrent labial and genital herpes simplex infections	Apply every 4 hours for 5 - 10 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
17	Acyclovir 800 mg Tablet	J05AB01000T 1002XX	A/KK	i) Mucocutaneous Herpes Simplex infection in immunocompromised and AIDS patients ii) Primary and recurrent Varicella Zoster infection in immunocompromised and AIDS patients iii) Severe Kaposi Varicella Eruption (Eczema herpeticum) iv) Severe primary HSV infections (eg. Neonatal herpes, encephalitis, eczema herpeticum, genital herpes, gingival stomatitis, vaginal delivery with maternal vulva herpes) v) Severe and complicated varicella infection (eg. Encephalitis, purpura fulminans) vi) Severe zoster infection in paediatrics (eg. Encephalitis, purpura fulminans, immunocompromised patients and facial, sacral and motor zoster)	i) ADULT: initially 400 mg 5 times daily for 7 - 14 days. CHILD less than 2 years: 200 mg 4 times daily, CHILD more than 2 years: 400 mg 4 times daily ii), iii) and iv) ADULT: 200 - 400 mg 4 times daily. CHILD: less than 2 years, half adult dose; more than 2 years, adult dose v) ADULT: 800 mg 5 times daily for 7 days vi) ADULT: 20 mg/kg (maximum: 800 mg) four times daily for 5 days, CHILD 6 years: 800 mg four times daily. CHILD less than 2 years; 400mg 4 times daily, more than 2 years; 800mg 4 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
18	Adalimumab 40 mg Injection	L04AB04000 P5001XX	A*	i) Third line treatment of: - Severe rheumatoid arthritis - Psoriatic arthritis - Ankylosing spondylitis after failure of conventional DMARDs or other biologics. ii) Treatment of adults with moderate to severe chronic plaque psoriasis who have not responded to, have contraindication or are unable to tolerate phototherapy and/or systemic therapies including acitretin, methotreaxate and cyclosporine. iii) Crohn's Disease - a) For treatment of moderately to severely active Crohn's Disease in adult patients who have inadequate response to conventional therapy; b) For treatment of moderately to severely active Crohn's Disease in adult patients who have lost response to or are intolerant to infliximab. iv) Ulcerative Colitis - For treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies	i) Severe rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis : Subcutaneous 40 mg every other week ii)Chronic plaque psoriasis : Initial, 80 mg SC, followed by 40 mg SC every other week starting one week after the initial dose. iii) & iv) Crohn's disease & Ulcerative colitis: 160mg at week 0 (dose can be administered as four injections in one day or as two injections per day for two consecutive days) and 80mg at week 2. After induction treatment, the recommended maintenance dose is 40mg every other week via subcutaneous injection.
19	Adapalene 0.1% Cream	D10AD03000 G1001XX	A*	Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoyl peroxide or topical tretinoin [third line treatment]	Apply once daily to the affected areas after washing at bedtime
20	Adapalene 0.1% Gel	D10AD03000 G3001XX	A*	Acne vulgaris where comedones, papules and pustules predominate in those sensitive to benzoyl peroxide or topical tretinoin [third line treatment]	Apply once daily to the affected areas after washing at bedtime

No.	Generic Name	MDC	Category	Indication(s)	Dosage
21	Adefovir Dipivoxil 10 mg Tablet	J05AF08000T1001XX	A*	i) Treatment of chronic HBeAg positive and HBeAg negative hepatitis B infection in adults with compensated liver function (lamivudine should be tried first) ii) Lamivudine-resistant chronic hepatitis B virus infection with either compensated or decompensated hepatitis function (only by hepatologist and gastroenterologist for approved indications)	Adult (18-65 years): 10mg Once Daily Renal Dose Adjustment : 10mg every 48hours (30-49ml/min); 10mg every 72hours (10-29ml/min); 10mg every 7 days (Hemodialysis)
22	Adenosine 3mg/ml Injection	C01EB10000P3001XX	B	Rapid conversion of paroxysmal supraventricular tachycardia to sinus rhythm	ADULT: Initially: 3 mg given as a rapid IV bolus (over 2 seconds). Second dose: If the first dose does not result in elimination of the supraventricular tachycardia with in 1 or 2 minutes, 6 mg should be given also as a rapid IV bolus. Third dose: If the second dose does not result in elimination of the supraventicular tachycardia within 1-2 minutes, 12 mg should be given also as a rapid IV bolus
23	Adrenaline Acid (Epinephrine) Tartrate 1 mg/ml Injection	C01CA24123P3001XX	B	Cardiopulmonary resuscitation	1 mg by intravenous injection repeated every 3-5 minutes according to response
24	Agomelatine 25 mg Tablet	N06AX22000T1001XX	A*	Major depression	The recommended dose is 25mg once daily at bedtime, maybe increased to 50mg once daily at bedtime.
25	Albendazole 200 mg Tablet	P02CA03000T1001XX	C+	i) Single or mixed infestations of intestinal parasites ii) Strongyloides infection	i)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
26	Albendazole 200 mg/5 ml Suspension	P02CA03000 L8001XX	C+	i) Single or mixed infestations of intestinal parasites ii) Strongyloides infection	i)Child 12-24months: 200mg as a single dose ii) Adult & Child above 2 years: 400mg as a single dose for 3 consecutive days; Child 12 - 24months: 200mg as a single dose for 3 consecutive days
27	Alcohol 70% Solution	D08AX08000 L9901XX	C+	Use as antiseptic and disinfectant	Apply to the skin undiluted or when needed
28	Alendronate Sodium 70 mg and Cholecalciferol 5600 IU Tablet	M05BB03972 T1002XX	A*	Osteoporosis in post menopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk.	1 tablet once weekly [70mg/5600 IU]. Patient should receive supplemental calcium or vitamin D, if dietary vitamin D inadequate. The tablet should be taken at least half an hour before the first food, beverage, or medication of the day with plain water only. To facilitate delivery to stomach and thus reduce the potential for esophageal irritation, it should only be swallowed upon arising for the day with a full glass of water and patient should not lie down for at least 30 minutes and until after their first food of the day.
29	Alendronate Sodium 70 mg Tablet	M05BA04520 T1001XX	A*	Osteoporosis in post menopausal women with a history of vertebral fracture and whom oestrogen replacement therapy is contraindicated. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk.	70 mg once weekly. Swallow the tablet whole with a full glass of plain water only on an empty stomach at least 30 minutes before breakfast (and any other oral medication); stand or sit upright for at least 30 minutes and do not lie down until after eating breakfast

No.	Generic Name	MDC	Category	Indication(s)	Dosage
30	Alfacalcidol 0.25 mcg Capsule	A11CC03000 C1001XX	A/KK	i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis	Initial dose ADULT and CHILD above 20kg body weight: 1 mcg daily; CHILD under 20kg body weight: 0.05mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily
31	Alfacalcidol 1 mcg Capsule	A11CC03000 C1002XX	A/KK	i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis	Initial dose ADULT and CHILD above 20kg body weight: 1 mcg daily; CHILD under 20kg body weight: 0.05mcg/kg/day. Maintenance dose : 0.25 mcg to 2 mcg daily
32	Alfacalcidol 2 mcg/ml Drops	A11CC03000 D5001XX	A*	i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis	NEONATES : 0.1 mcg/kg/day
33	Alfacalcidol 2 mcg/ml Injection	A11CC03000 P3001XX	A*	Treatment of: i) Renal osteodystrophy in patients on haemodialysis ii) Hypoparathyroidism and pseudohypoparathyroidism iii) Adjunct to the management of tertiary hyperparathyroidism iv) Rickets and osteomalacia v) Osteoporosis	Adult: Initially, 1 mcg daily. Maintenance: 0.25-1 mcg daily. Child: Premature infants and neonates: 0.05-0.1 mcg/kg daily; <20 kg: 0.05 mcg/kg daily. Elderly: 0.5 mcg daily.
34	Alfentanil HCl 0.5 mg/ml Injection	N01AH02110 P3001XX	A*	For use as short acting narcotic analgesic in short procedures and day-care surgical procedures	Initial dose: 20 - 40 mcg/kg. Supplemental dose: 15 mcg/kg or infusion 0.5 - 1.0 mcg/kg/min
35	Alfuzosin HCl 10 mg Tablet	G04CA01110 T1001XX	A*	Treatment of functional symptoms related with benign prostatic hypertrophy (BPH)	10 mg once a day pre bed

No.	Generic Name	MDC	Category	Indication(s)	Dosage
36	Alglucosidase alfa 5 mg/ml Injection	A16AB07000 P4001XX	A*	Infantile-onset Pompe disease	20 mg/kg of body weight administered once every 2 weeks as an intravenous infusion. Monitoring It is suggested that patients be monitored periodically for IgG antibody formation. Patients who experience Infusion-associated reactions suggestive of hypersensitivity may be tested for IgE antibodies to alglucosidase alfa. Treated patients who experience a decrease in benefit despite continued treatment with Alglucosidase Alfa, in whom antibodies are suspected to play a role, may be tested for neutralization of enzyme uptake or activity.
37	Alkaline Nasal Douche	R01A000999 L5001XX	B	To remove nasal plug	To be diluted with an equal volume of warm water before use
38	Allopurinol 100 mg Tablet	M04AA01000 T1002XX	A/KK	i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia	Initial dose: 100-300 mg daily. Maintenance: 300-600 mg daily. Maximum: 900 mg daily
39	Allopurinol 300 mg Tablet	M04AA01000 T1001XX	A/KK	i) Frequent and disabling attacks of gouty arthritis (3 or more attacks/year). ii) Clinical or radiographic signs of erosive gouty arthritis. iii) The presence of tophaceous deposits. iii) Urate nephropathy. iv) Urate nephrolithiasis. v) Impending cytotoxic chemotherapy or radiotherapy for lymphoma or leukaemia	Initial dose: 100-300 mg daily. Maintenance: 300-600 mg daily. Maximum: 900 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
40	All-Trans Retinoic Acid 10 mg Capsule	L01XX14000C1001XX	A*	Acute promyelocytic leukaemia	Induction: 45 mg/m2 daily for 30 - 90 days. Maintenance: 45 mg/m2 daily for 2 weeks every 3 months. Renal/or hepatic insufficiency: 25mg/m2 daily for 30-90 days. Refer to protocols
41	Alprazolam 0.25 mg Tablet	N05BA12000T1001XX	A/KK	Anxiety disorders	0.25 - 0.5 mg 3 times daily (elderly or debilitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
42	Alprazolam 0.5 mg Tablet	N05BA12000T1002XX	A	Anxiety disorders	0.25 - 0.5 mg 3 times daily (elderly or debilitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
43	Alprazolam 1 mg Tablet	N05BA12000T1003XX	A	Anxiety disorders	0.25 - 0.5 mg 3 times daily (elderly or debilitated 0.25 mg 2-3 times daily), increased if necessary to a total dose of 3 mg/day. Not recommended for children
44	Alprostadil 500 mcg/ml Injection	C01EA01000P3001XX	A*	For treatment of congenital heart diseases which are ductus arteriosus dependent	0.05 - 0.1 mcg/kg/min by continuous IV infusion, then decreased to lowest effective dose
45	Alteplase 50 mg per vial Injection	B01AD02000P4001XX	A*	Thrombolytic treatment of acute ischaemic stroke.	0.9 mg/kg (maximum of 90 mg) infused over 60 minutes with 10% of the total dose administered as an initial intravenous bolus. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging technique.
46	Aluminium Hydroxide 600 mg Tablet	A02AB01250T1001XX	A	Dyspepsia, hyperphosphataemia	600 mg- 1.2 g 4 times daily and at bedtime or as required

No.	Generic Name	MDC	Category	Indication(s)	Dosage
47	Amantadine HCl 100 mg Capsule	N04BB01110 C1001XX	B	Parkinson's disease	Initial dose: 100 mg daily and is increased to 100 mg twice daily (not later than 4 p.m.) after a week. Elderly over 65 years: less than 100 mg or 100 mg at intervals of more than 1 day
48	Amikacin 125 mg/ml Injection	J01GB06183P 3003XX	A	Infections due to susceptible organisms	ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
49	Amikacin 250mg/ml Injection	J01GB06183P 3002XX	A	Infections due to susceptible organisms	ADULT: (IM or IV): 15 mg/kg/day 8 - 12 hourly for 7 - 10 days. Maximum: 1.5 g/day. CHILD: 15 mg/kg/day 8 - 12 hourly. Maximum: 1.5 g/day. Neonates: Initial loading dose of 10 mg/kg followed by 7.5 mg/kg/day 12 hourly. Maximum 15mg/kg/day
50	Amiloride HCl 5 mg & Hydrochlorothiazide 50 mg Tablet	C03EA01900 T1001XX	B	i) Diuretic as an adjunct to the management of oedematous states ii) Hypertension	i) Initially 1 - 2 tab daily adjusted according to response. Max: 4 tabs daily. ii) 1 -2 tabs daily as a single or divided dose
51	Amino Acids Injection	B05BA01910 P3001XX	A	Source of amino acids in patients needing IV nutrition	Dose to be individualized. ADULT usually 500-2000 ml by IV. ADULT usual requirement for amino acid: 1-2 g/kg/day
52	Amino Acids with Electrolytes Injection	B05BA10910 P3002XX	A	Source of amino acids and electrolytes in patients needing IV nutrition	Dose to be individualized. ADULT usual requirement for amino acid 1-2 g/kg/day
53	Amino Acids with Glucose with Electrolytes Injection	B05BA10910 P3003XX	A	Source of amino acids, carbohydrate and electrolytes in patients needing IV nutrition	Dose to be individualized. ADULT usual requirement for amino acid 1-2 g/kg/day, carbohydrate 4-6 g/kg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
54	Amino Acids, Glucose and Lipid with Electrolytes Injection	B05BA10910 P3001XX	A	Source of amino acids, carbohydrate, lipid and electrolytes in patients needing IV nutrition	Dose to be individualized. ADULT: 500 - 2000 ml daily given by IV. ADULT usual requirement for amino acid 1-2 g/kg/ day, carbohydrate 4-6 g/kg/day, lipid 2-3 g/kg/day
55	Aminophylline 25 mg/ml Injection	R03DA05000 P3001XX	B	Reversible airways obstruction, acute severe brochospasm	Adult: Loading dose: 5 mg/kg (ideal body weight) or 250-500 mg (25 mg/ml) by slow injection or infusion over 20-30 min. Maintenance infusion dose: 0.5 mg/kg/hr. Max rate: 25 mg/min. Child: Loading dose: same as adult dose. Maintenance dose: 6 mth-9 yr: 1 mg/kg/hr and 10-16 yr: 0.8 mg/kg/hr.
56	Amiodarone 200 mg Tablet	C01BD01110 T1001XX	A*	Arrhythmias	200 mg 3 times daily for 1 week, then reduced to 200 mg twice daily for another week. Maintenance dose, usually 200 mg daily or the minimum required to control the arrhythmia
57	Amiodarone 50 mg/ml Injection	C01BD01110 P3001XX	A*	Arrhythmias when other drugs are contraindicated or ineffective	Initial infusion of 5mg/kg via large venous access over 20-120 minutes with ECG monitoring; subsequent infusion given if necessary according to response up to a maximum of 1.2 g in 24 hours
58	Amisulpride 100 mg Tablet	N05AL05000 T1001XX	A*	Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominate	Predominantly negative episodes: 50-300 mg once daily adjusted according to the patient's response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient's response. Should be taken on an empty stomach (Preferably taken before meals)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
59	Amisulpride 400 mg Tablet	N05AL05000 T1002XX	A*	Treatment of psychoses, particularly acute or chronic schizophrenia disorders characterized by positive symptoms(e.g. delusion, hallucinations, thought disorders) and/or negative symptoms(e.g. blunted emotions, emotional and social withdrawal) including when the negative symptoms predominate	Predominantly negative episodes: 50-300 mg once daily adjusted according to the patient's response. Mixed episodes with positive and negative symptoms: 400-800 mg/day in 2 divided doses adjusted according to the patient's response. Should be taken on an empty stomach (Preferably taken before meals)
60	Amitriptyline HCl 25 mg Tablet	N06AA09110 T1001XX	B	Depression	Initially 25mg 3 times a day. Maintenance: 25-100mg daily in divided doses. Hospitalized patient: 100mg/day &gradually increase to 200-300mg/day. ADOLESCENT and ELDERLY: initially 20-30mg/day in divided doses w/ gradual increments. CHILD under 16 years are not recommended
61	Amlodipine 10 mg and Valsartan 160 mg Tablet	C09DB01935 T1003XX	A/KK	Essential hypertension in patients whose blood pressure is not adequately controlled by monotherapy	Doses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg
62	Amlodipine 10 mg Tablet	C08CA01000 T1002XX	B	Hypertension	5 mg once daily. Max: 10 mg once daily
63	Amlodipine 5 mg and Valsartan 160 mg Tablet	C09DB01935 T1002XX	A/KK	Essential hypertension in patients whose blood pressure is not adequately controlled by monotherapy	Doses range from amlodipine besylate 5 mg/valsartan 160 mg to amlodipine besylate 10 mg/valsartan 320 mg ORALLY once daily, with dose titration occurring every 1 to 2 weeks if necessary. MAX amlodipine besylate 10 mg/valsartan 320 mg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
64	Amlodipine 5 mg Tablet	C08CA01000 T1001XX	B	Hypertension	5 mg once daily. Max: 10 mg once daily
65	Amlodipine besylate 10mg, valsartan 160mg, hydrochlorothiazide 12.5mg tablet	C09DX01941 T1001XX	A/KK	Treatment of essential hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension.	One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is reached within 2 weeks of change in dose. The maximum recommended dose of amlodipine besylate/valsartan/HCTZ is 10/320/25 mg. It can be taken with or without food. It is recommended to take it with some water.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
66	Amlodipine besylate 10mg, valsartan 160mg, hydrochlorothiazide 25mg tablet	C09DX01941 T1002XX	A/KK	Treatment of essential hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension.	One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is reached within 2 weeks of change in dose. The maximum recommended dose of amlodipine besylate/valsartan/HCTZ is 10/320/25 mg. It can be taken with or without food. It is recommended to take it with some water.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
67	Amlodipine besylate 5mg,valsartan 160mg,hydrochlorothiazide 12.5mg tablet	C09DX01941 T1004XX	A/KK	Treatment of essential hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension.	One tablet daily i) A patient whose blood pressure is not adequately controlled on dual therapy with amlodipine besylate/valsartan/HCTZ. ii) For convenience, patients receiving valsartan, amlodipine and HCTZ from seperate tablets may be switched to amlodipine besylate/valsartan/HCTZ containing the same component dosses. Dosage may be increased after 2 weeks. The maximum antihypertensive effect of amlodipine besylate/valsartan/HCTZ is reached within 2 weeks of change in dose. The maximum recommended dose of amlodipine besylate/valsartan/HCTZ is 10/320/25 mg. It can be taken with or without food. It is recommended to take it with some water.
68	Amlodipine Camsylate 5 mg and Losartan Potassium 100 mg Tablet	C09DB06935 T1002XX	A/KK	Treatment of essential hypertension in adults patients whose blood pressure is not adequately controlled on either monotherapy	Amlodipine 5mg/losartan 50mg OR amlodipine 5mg/losartan 100mg orally once daily. MAXIMUM DOSE: amlodipine 5mg/losartan 100mg. No dosage adjustment in mild renal impairment. Not recommended in moderate to severe renal impairment or in patients on dialysis. Not recommended in patients who require lower dose of losartan (25mg). Not recommended in patients < 18 years as safety and efficacy is not established in this group

No.	Generic Name	MDC	Category	Indication(s)	Dosage
69	Amlodipine Camsylate 5 mg and Losartan Potassium 50 mg Tablet	C09DB06935 T1001XX	A/KK	Treatment of essential hypertension in adults patients whose blood pressure is not adequately controlled on either monotherapy	Amlodipine 5mg/losartan 50mg OR amlodipine 5mg/losartan 100mg orally once daily. MAXIMUM DOSE: amlodipine 5mg/losartan 100mg. No dosage adjustment in mild renal impairment. Not recommended in moderate to severe renal impairment or in patients on dialysis. Not recommended in patients who require lower dose of losartan (25mg). Not recommended in patients < 18 years as safety and efficacy is not established in this group
70	Ammonium Bicarbonate, Tincture Ipecac, etc Mixture	R05CA04900 L2101XX	C	Cough	Adults, the elderly and children over 12 years: 10-20ml, repeated after 4 hours if required. Not more than 4 doses to be taken in any 24 hours.
71	Amorolfine 5 % Nail Lacquer	D01AE16110 L5001XX	A*	Fungal nail infections	Apply to affected nail once or sometimes twice a week after filling and cleansing, allow to dry, treat finger nail for 6 months, toe nail for 9 - 12 months (review at intervals of 3 months)
72	Amoxicillin & Clavulanate 228 mg/5 ml Syrup	J01CR02961F 2102XX	A/KK	Infections caused by susceptible organisms	Mild to Moderate infection: 25mg/kg/day (based on Amoxicillin dose) in 2 divided dose. Severe infection: 45mg/kg/day (based on Amoxicillin dose) in 2 divided dose
73	Amoxicillin 1 g & Clavulanate 200 mg Injection	J01CR02961P 4002XX	A	Infections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitis	CHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly
74	Amoxicillin 250 mg Capsule	J01CA04012C 1001XX	B	Infections caused by susceptible strains of gram positive and gram negative organisms	ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly

No.	Generic Name	MDC	Category	Indication(s)	Dosage
75	Amoxicillin 500 mg & Clavulanate 125 mg Tablet	J01CR02961T 1002XX	A/KK	Infections due to beta-lactamase producing strain where amoxicillin alone is not appropriate. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection & osteomyelitis	ADULT & CHILD more than 12 years: Mild to moderate infections: 625 mg twice daily.
76	Amoxicillin 500 mg and Clavulanate 100 mg Injection	J01CR02961P 4001XX	A	Infections caused by susceptible organisms. Respiratory tract, skin, soft tissue, GUT infection, septicaemia, peritonitis, post-operative infection and osteomyelitis	CHILD less than 3 months: 30mg/kg 12 hourly. 3 months - 12 years: 30 mg/kg 6 - 8 hourly. ADULT: 1.2 g by IV or intermittent infusion 6 - 8 hourly
77	Amoxicillin 500 mg Capsule	J01CA04012C 1002XX	B	Infections caused by susceptible strains of gram positive and gram negative organisms	ADULT: 250 - 500 mg 3 times daily. CHILD: 20 - 40 mg/kg/day in divided doses 8 hourly
78	Amoxicillin Trihydrate 125 mg/5 ml Syrup	J01CA04012F 1001XX	B	Infections caused by susceptible strains of gram positive and gram negative organisms	CHILD less than 10 years: 125 - 250 mg 8 hourly. CHILD less than 20 kg: 20 - 40 mg/kg/day in 3 - 4 divided doses
79	Amphotericin B 0.15% Eye Drops	S01A000801 D2002XX	A	Fungal infection of the cornea	1 drop hourly or 2 hourly
80	Amphotericin B 0.25% Eye Drops	S01A000801 D2003XX	A	Fungal infection of the cornea	1 drop hourly or 2 hourly
81	Amphotericin B 50 mg Injection	J02AA01801P 4001XX	A	Systemic fungal infections	ADULT: 0.25 mg/kg/day by IV infusion. Gradually increase if tolerated to 1 mg/kg/day. Maximum in severe cases: 1.5 mg/kg daily or on alternate days. For neonates, lower doses are recommended
82	Ampicillin Sodium & Sulbactam Sodium 250 mg/5 ml Suspension	J01CR01961F 2101XX	A	Treatment of susceptible bacterial infections	ADULT: (1-) 2-6g daily CHILDREN: (25-) 50-100mg/kg daily PREMATURE AND NEWBORNS: 25-50mg/kg daily
83	Ampicillin Sodium & Sulbactam Sodium 375 mg Tablet	J01CR01961T 1001XX	A/KK	Treatment of susceptible bacterial infections	ADULT: 375-750mg twice daily CHILDREN AND INFANTS: 25-50mg/kg/day in 2 divided doses, if ≥ 30kg use an adult dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
84	Ampicillin Sodium 1g & Sulbactam Sodium 500mg Injection	J01CR01961P 4002XX	A	Treatment of susceptible bacterial infections	ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam. CHILD: 150-300 mg/kg/day 6 - 8 hourly. Prophylaxis of surgical infections: 1.5 - 3 g at induction of anaesthesia. May be repeated 6 - 8 hourly. NEONATES: First week of life, 75mg/kg/day in divided doses every 12 hour
85	Ampicillin Sodium 500 mg & Sulbactam Sodium 250 mg Injection	J01CR01961P 4001XX	A	Treatment of susceptible bacterial infections	ADULT: 1.5 - 12 g/day in divided doses 6 - 8 hourly. Maximum: 4 g Sulbactam per day. CHILD: 150-300mg/kg/day 6 - 8 hourly. Prophylaxis: 1.5 -3 g at induction of anaesthesia. May be repeated 6 - 8 hourly
86	Ampicillin Sodium 500 mg Injection	J01CA01520P 4001XX	B	Treatment of susceptible bacterial infections (non beta-lactamase-producing organisms); meningitis	250 - 500 mg IM/IV every 4 - 6 hours. Maximum: 400 mg/kg/day. Meningitis: 2 g 6 hourly. CHILD: 150 mg/kg/daily IV in divided doses. Usual children dose less than 10 years, half adult dose
87	Ampicillin Trihydrate 125 mg/5 ml Suspension	J01CA01012F 2101XX	B	Treatment of susceptible bacterial infections (non beta-lactamase-producing organisms)	CHILD: 50 - 100 mg/kg/day 4 times daily. Under 1 year: 62.5 - 125 mg 4 times daily, 1 - 10 years: 125 - 250 mg 4 times daily
88	Anastrozole 1 mg Tablet	L02BG03000 T1001XX	A*	Treatment of hormone responsive metastatic or locally advanced breast cancer after failure of tamoxifen	1 mg daily
89	Anidulafungin 100mg Injection	J02AX06000P 3001XX	A*	Treatment of invasive candidiasis, including candidemia in adults when intolerance or resistance to Amphotericin B or Fluconazole	Loading dose of 200 mg on day 1, then 100 mg once daily thereafter for at least 14 days after the last positive culture.
90	Antazoline HCl, Tetrahydrozoline HCl and Benzalkonium Cloride Eye Drops	S01GA52110 D2001XX	A/KK	Hay fever, conjunctivitis, allergic conjunctivitis, vernal keratoconjunctivitis and eczematosa	ADULT: Instill 1 drop, 3 - 4 times daily, into the lower eyelid. CHILD 2 - 12 years : Instill 1 drop daily or twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
91	Anti RhD Gamma Globulin 250 mcg/2 ml Injection (500 units=100 mcg)	J06BB01000P3001XX	B	Prevention of Rh(D) sensitisation by IM injection to rhesus-negative woman after delivery of rhesus-positive infant	50 - 100 mcg within 72 hours after incompatible blood transfusion: 25 mcg (125 units) per ml transfused blood, up to 1000 mcg
92	Antilymphocyte/ Antithymocyte Immunoglobulin (from Horse) Injection	L04AA03000P3001XX	A*	i) To be used when conventional anti-rejection therapy is not successful ii) Treatment of aplastic anaemia not responding to oxymethalone after 3 months, in which there is persistent pancytopenia with repeated attacks of septicaemia and bleeding. iii) Severe aplastic anaemia with the following parameters: a) Granulocyte less than 0.5x109/L b) Platelet less than 20x109/L c) Reticulocyte less than 20x109/L iv) As a conditioning regime prior to transplant. v) Graft-versus-host disease treatment	10 - 30 mg/kg body weight daily. Slow IV infusion (over at least 4 hours) diluted in 250 - 500 ml Normal Saline. For Graft versus host disease treatment:40 mg/kg/day
93	Antirabies Immunoglobulin (Human) 300 iu/2ml	J06BB05000P3001XX	B	Treatment of rabies, post-exposure	20 iu/kg; half by IM and half by infiltration around the wound
94	Antithymocyte Immunoglobulin (from rabbit) Injection	L04AA04000P3001XX	A*	i)Prophylaxis of acute graft rejection ii)Treatment of acute graft rejection iii)Prophylaxis of acute and chronic graft versus host disease iv)Treatment of steroid-resistant, acute graft versus host disease v)Treatment of aplastic anemia	i)1.0 - 1.5 mg/kg/day for 2 - 9 days after transplantation of a kidney, pancreas or liver, for 2 - 5 days after heart transplantation ii)1.5 mg/kg/day for 3 - 14 days iii)2.5 - 5.0 mg/kg/day for 4 days iv)2.5 - 5.0 mg/kg/day for 5 days v)2.5 - 3.5 mg/kg/day for 5 days
95	Antivenene Cobra Injection	J06AA03000P3002XX	B	Treatment of patients who exhibit manifestations of systemic envenoming following a bite by Cobra (Naja kaouthia).	Initial dose of 100ml of reconstituted antivenene given by slow intravenous infusion (2ml/min). Subsequent dose can be given every 12 hours according to the clinical symptoms. As product may differ from batches and manufacturer, it is strongly recommended to refer to the product insert on dosing

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					recommendation.
96	Antivenene Pit Viper Injection	J06AA03000P3001XX	B	Treatment of patients who exhibit manifestations of systemic envenoming following a bite by Malayan Pit Viper (Calloselasma rhodostoma).	Initial dose of 30ml of reconstituted antivenene given by slow intravenous infusion (2ml/min). Subsequent dose can be given every 6 hours according to the clinical symptoms. As product may differ from batches and manufacturer, it is strongly recommended to refer to the product insert on dosing recommendation.
97	Antivenene Serum (Sea snake) 1000 units Injection	J06AA03000P3003XX	B	Treatment of patients who exhibit manifestations of systemic envenoming following a bite by sea snake.	1000 units by IV infusion over 1/2 to 1 hour. In severe cases 3000 -10000 units may be required
98	Antivenene Serum Snake polyvalent Injection	J06AA03000P3004XX	B	Treatment of patients who exhibit manifestations of systemic envenoming following a bite by Indian Cobra (Naja naja),Common Krait (Bungarus caeruleus), Russell's Viper (Daboia russelli) and Saw-scaled Viper (Echis carinatus)	Recommended initial dose is 20ml by intravenous infusion. The injection should be given very slowly as 5 minutes by direct slow intravenous route or 1hour by infusion. If symptoms continue, further doses are administered as required until symptoms completely disappear
99	Aprepitant 125 mg Capsule	A04AD12000C1002XX	A*	In combination with other antiemetic agents for prevention of delayed nausea and vomiting associated with initial and repeat course of highly emetogenic chemotherapy	125 mg 1 hour prior to chemotherapy on Day 1. To be given as part of a 3-day regimen that includes a corticosteroid and a 5-HT3 antagonist
100	Aprepitant 80 mg Capsule	A04AD12000C1001XX	A*	In combination with other antiemetic agents for prevention of delayed nausea and vomiting associated with initial and repeat course of highly emetogenic chemotherapy	80 mg once daily in the morning on Days 2 and Day 3. To be given as part of a 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist

No.	Generic Name	MDC	Category	Indication(s)	Dosage
101	Aprotinin 10,000 KIU/ml Injection	B02AB01000 P3001XX	A*	Only for Open Heart Surgery (extracorporeal circulation)	All patients should receive a 1 ml IV test dose at least 10 minutes prior to loading dose. Initially 2 million KIU bolus followed by 2 million KIU in heart-lung machine followed by a slow infusion of 500,000 KIU/hr until end of surgery. CHILD: 20,000 KIU/kg/day
102	Aqueous Cream	D02AX00000 G1001XX	C+	Dry skin	As a soap or apply to the skin as an emollient cream
103	Aripiprazole 10mg Tablet	N05AX12000 T1001XX	A*	i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorder	Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour
104	Aripiprazole 15mg Tablet	N05AX12000 T1002XX	A*	i) Treatment of acute episodes of schizophrenia and for maintenance of clinical improvement during continuation therapy. ii) Treatment of acute manic episodes associated with bipolar I disorder	Schizophrenia: 10 or 15 mg/day. Maintenance dose: 15 mg/day. Bipolar mania: Starting dose: 15 or 30 mg/day. Dose adjustment should occur at intervals of not less than 24 hour
105	Arsenic Trioxide 1 mg/ml Injection	L01XX27550P 3001XX	A*	Relapsed acute promyelocytic leukaemia (APML). To be prescribed by consultant haematologist only	Induction: 0.15 mg/kg/day IV until bone marrow remission. Total induction dose ≤ 60 doses. Consolidation : 0.15 mg/kg/day IV for 25 doses in 5 weeks (5 days per week, followed by 2 days interruption; treatment should begin 3-6 weeks after completion of induction therapy).

No.	Generic Name	MDC	Category	Indication(s)	Dosage
106	Artemether 20mg + Lumefantrine 120mg	P01BE52981 T1001XX	B	Acute uncomplicated falciparum malaria	ADULT and CHILD over 12 years weighing over 35 kg : 4 tablets as a single dose at the time of initial diagnosis, again 4 tablets after 8 hours and then 4 tablets twice daily (morning and evening) on each of the following two days (total course comprises 24 tablets). INFANT and CHILD weighing 5 kg to less than 35 kg : A 6 dose regimen with 1 to 3 tablets per dose, depending on bodyweight
107	Artesunate 100 mg and Mefloquine HCl 220 mg Tablet	P01BF02000T 1002XX	A	Treatment of acute uncomplicated Plasmodium falciparummalaria, resulting either from P. falciparum mono-infection or mixed infection with P. vivax.	Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days
108	Artesunate 25 mg and Mefloquine HCl 55 mg Tablet	P01BF02000T 1001XX	A	Treatment of acute uncomplicated Plasmodium falciparummalaria, resulting either from P. falciparum mono-infection or mixed infection with P. vivax.	Weight 5-8kg, Age 6-11 months, Dose: One tablet 25/55mg OD x 3 days Weight : 9-17kg, Age 1-6 years, Dose : Two tablet 25/55mg OD x 3 days Weight :18-29kg, Age 7-12 years, Dose :One tablet 100/220mg OD x 3 days Weight ≥30kg, Age ≥13 years, Dose:Two tablet 100/220mg OD x 3 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
109	Artesunate 60 mg Injection	P01BE03000 P3001XX	A	Treatment of severe malaria caused by Plasmodium falciparum in adults and children	2.4mg of artesunate/kg body weight, by intravenous (IV) or intramuscular (IM) injection, at 0, 12 and 24 hours, then once daily until oral treatment can be substituted. For adults and children with severe malaria or who are unable to tolerate oral medicines, artesunate 2.4 mg/kg body weight IV or IM given on admission (time = 0), then at 12 hrs and 24 hrs, then once a day for 5-7 days is the recommended treatment.
110	Ascorbic Acid 100 mg Tablet	A11GA01000 T1002XX	C+	Vitamin C deficiency	ADULT: 100-250 mg once or twice daily CHILD: 100 mg three times daily for one week followed by 100mg daily until symptoms abate.
111	Ascorbic Acid 500 mg Tablet	A11GA01000 T1003XX	C+	Vitamin C deficiency	ADULT: 100-250 mg once or twice daily CHILD: 100 mg three times daily for one week followed by 100mg daily until symptoms abate.
112	Ascorbic Acid 500 mg/2 ml Injection	A11GA01000 P3001XX	B	For prevention and treatment of scurvy	Therapeutic: Not less than 250 mg daily in divided doses
113	Atenolol 100 mg Tablet	C07AB03000 T1002XX	B	Hypertension, angina pectoris, myocardial infarction and arrhythmias	Hypertension and arrythmias; 50 - 100 mg daily, Angina; 100 mg daily, Myocardial infarction; individualised
114	Atenolol 50 mg Tablet	C07AB03000 T1001XX	B	Hypertension, angina pectoris, myocardial infarction and arrhythmias	Hypertension and arrythmias; 50 - 100 mg daily, Angina; 100 mg daily, Myocardial infarction; individualised

No.	Generic Name	MDC	Category	Indication(s)	Dosage
115	Atomoxetine HCl 10 mg Capsule	N06BA09110 C1001XX	A*	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
116	Atomoxetine HCl 18 mg Capsule	N06BA09110 C1002XX	A*	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
117	Atomoxetine HCl 25 mg Capsule	N06BA09110 C1003XX	A*	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
118	Atomoxetine HCl 40 mg Capsule	N06BA09110 C1004XX	A*	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
119	Atomoxetine HCl 60mg Capsule	N06BA09110 C1005XX	A*	Attention deficit hyperactivity disorder (ADHD) in children 6 years and older who do not respond to methylphenidate or who have intolerable effects or have tics. Diagnosis should be made according to DSM IV criteria or the guidelines in ICD-10	CHILD and ADOLESCENTS up to 70 kg: Initially 0.5 mg/kg/day for at least 7 days then increased according to response. Maintenance: 1.2 mg/kg/day. ADULTS and ADOLESCENTS more than 70 kg: Initially 40 mg/day for at least 7 days then increased according to response. Maintenance: 80 mg/day. Max 100 mg/ day
120	Atorvastatin 20 mg Tablet	C10AA05000 T1002XX	A/KK	Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy	10 mg once daily. Maximum: 80 mg daily
121	Atorvastatin 40 mg Tablet	C10AA05000 T1001XX	A/KK	Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy	10 mg once daily. Maximum: 80 mg daily
122	Atorvastatin 80 mg Tablet	C10AA05000 T1004XX	A/KK	Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy	10 mg once daily. Maximum: 80 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
123	Atosiban 7.5 mg/ml Injection	G02CX01122 P3001XX	A*	To delay imminent preterm birth in pregnant women with i) Regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes ii) A cervical dilation of 1 to 3 cm (0 - 3 nulliparas) and effacement of ≥ 50% iii) Age ≥ 18 years iv) A gestational age from 28 until 33 completed weeks v) A normal foetal heart rate.	Initial intravenous bolus dose of 6.75mg (using 7.5mg/ml solution for injection). Immediately followed by a continuous high dose infusion (loading infusion 300 mcg/min using 7.5mg/ml concentrate for solution for infusion) during three hours, followed by lower infusion of 100mcg/min up to 45 hours. Duration of treatment should not exceed 48 hours. Total dose given during a full course should not exceed 330mg of the active substance.
124	Atracurium Besylate 10 mg /ml in 2.5 ml Injection	M03AC04197 P3001XX	A*	Muscle relaxant in general anaesthesia, Endotracheal intubation, Aid controlled ventilation.	Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal intubation dose: 0.5-0.6 mg/kg. Supplementary dose: 0.1-0.2 mg/kg as required. Continuous infusion rates of 0.3-0.6 mg/kg/hr to maintain neuromuscular block during long surgical procedure.
125	Atracurium Besylate 10 mg /ml in 5 ml Injection	M03AC04197 P3002XX	A*	Muscle relaxant in general anaesthesia, Endotracheal intubation, Aid controlled ventilation.	Adult & childn >2 mth 0.3-0.6 mg/kg IV. Endotracheal intubation dose: 0.5-0.6 mg/kg. Supplementary dose: 0.1-0.2 mg/kg as required. Continuous infusion rates of 0.3-0.6 mg/kg/hr to maintain neuromuscular block during long surgical procedure.
126	Atropine Sulphate 0.3%, Cocaine HCl 1.7%, Adrenaline Acid Tartrate 0.03% Mydriatic Injection	S01F000183P 3001XX	A	Subconjunctival injection to dilate pupils resistant to topical mydriatics	1 - 2 drops

No.	Generic Name	MDC	Category	Indication(s)	Dosage
127	Atropine Sulphate 1% Eye Drops	S01FA01183 D2001XX	B	Determination of refraction, strabismus, iritis and iridocyclitis, after extra or intracapsular extraction of lens	PREOPERATIVE MYDRIASIS : one drop of a 1% solution supplemented with one drop of 2.5 or 10% phenylephrine prior to surgery. ANTERIOR UVEITIS or POSTOPERATIVE MYDRIASIS : one drop of a 1% or 2% solution up to 3 times a day
128	Atropine Sulphate 1mg/ml Injection	A03BA01183 P3001XX	B	i) Reduce vagal inhibition,salivary and bronchiol secretion in anaesthesia ii) Reversal of excessive bradycardia iii) Reversal of effect of competitive muscle relaxants iv) Overdosage with other compounds having muscarinic action v) Organophosphate poisoning	i) Adult: 300-600 mcg IM/SC 30-60 minutes before anaesthesia. Alternatively, 300-600 mcg IV immediately before induction of anaesthesia. Child: >20 kg: 300-600 mcg; 12-16 kg: 300 mcg; 7-9 kg: 200 mcg; >3 kg: 100 mcg. Doses to be given via IM/SC admin 30-60 minutes before anaesthesia.ii) Adult: 500 mcg every 3-5 minutes. Total: 3 mg. Max Dosage: 0.04 mg/kg body weight.iii) Adult 0.6-1.2 mg before or with anticholinesterase iv) Adult: 0.6-1 mg IV/IM/SC, repeated every 2 hr. v) Adult: 2 mg IV/IM, every 10-30 minutes until muscarinic effects disappear or atropine toxicity appears. In severe cases, dose can be given as often as every 5 minutes. In moderate to severe poisoning, a state of atropinisation is maintained for at least 2 days and continued for as long as symptoms are present. Child: 20mcg/kg given every 5-10 minutes.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
129	Azacitidine Powder for suspension for injection 100mg/vial	L01BC07000P4001XX	A*	First line therapy for intermediate-2 and high risk MDS, CMMOL with 10-29% blasts with no transplant option and elderly AML with 20-30% blasts and multiline age dysplasia.	Recommended starting dose for the first treatment cycle, for all patients regardless of baseline haematology laboratory values, is 75mg/m2 of body surface area. Injected subcutaneously. Daily for 7 days, followed by a rest period of 21 days (28 day treatment cycle)
130	Azathioprine 50 mg Tablet	L04AX01000T1001XX	A	i) Prophylaxis of rejection in organ and tissue transplant ii) Auto-immune diseases iii) Rheumatoid arthritis	i) Adult: 1-5 mg/kg/day. Adjust dose according to clinical response and haematological tolerance. Dose may also be given via IV administration. ii) Adult: 1-3 mg/kg/day. Discontinue treatment if there is no improvement after 12 week. iii) Adult: Initially, 1 mg/kg/day given in 1-2 divided doses for 6-8 week, may increase by 0.5 mg/kg every 4 week until response or up to 2.5 mg/kg/day. Maintenance: Reduce dose gradually to achieve the lowest effective dose.
131	Azelaic Acid 20% Cream	D10AX03000G1001XX	A*	Acne vulgaris	Apply twice daily (sensitive skin, once daily for 1st week). Treatment should not exceed 6 months
132	Azithromycin 200 mg/5 ml Granules	J01FA10011F1001XX	A*	Treatment of complicated respiratory tract infections not responding to standard macrolides	CHILD 36 - 45 kg: 400 mg, 26 - 35 kg: 300mg, 15 - 25 kg 200 mg, less than 15 kg: 10 mg/kg. To be taken daily for 3 days or to be taken as a single dose on day 1, then half the daily dose on days 2 - 5

No.	Generic Name	MDC	Category	Indication(s)	Dosage
133	Azithromycin 250 mg Tablet	J01FA10011T1001XX	A*	i) Treatment of complicated respiratory tract infection not responding to standard macrolides ii) Adult treatment of uncomplicated genital infections due to Chlamydia trichomatis or susceptible Neisseria gonorrhoea iii) Prophylaxis against Mycobacterium avium complex in patients with advanced HIV	i) 500 mg daily for 3 days ii) 1 g as a single dose iii) 1 g weekly
134	Azithromycin 500 mg Injection	J01FA10011P4001XX	A*	Only for treatment of severe atypical pneumonia	500 mg IV as a single daily dose for a minimum of two days followed by 500 mg oral dose as a single daily dose to complete a 7 - 10 days course
135	Bacampicillin 400 mg Tablet	J01CA06000T1001XX	B	Infections caused by ampicillin-sensitive gram positive& gram negative microorganisms	ADULT: 400 mg twice daily. Severe infection: 800 mg twice daily. CHILD more than 25 kg: 12.5 - 25 mg/kg 12 hourly
136	Baclofen 10 mg Tablet	M03BX01000T1001XX	B	Spasticity of the skeletal muscle	ADULT: 5 mg 3 times daily. Max: 80 mg daily. CHILD: 0.75 - 2 mg/kg daily (more than 10 years, maximum: 2.5 mg/kg daily)
137	Balanced Salt Solution	B05CB10907L5001XX	A	For irrigation during ocular surgery	Irrigate as directed
138	Balanced Salt Solution PLUS (fortified with sodium bicarbonate, glucose & glutathione)	B05CB10905L5001XX	A	For irrigation during intraocular surgery especially in patients with poor cornea endothelium and poorly controlled diabetes	Irrigate as directed
139	Barium Sulphate Suspension	V08BA01183L8001XX	B	For x-ray examination of the alimentary tract: i) Oesophagus ii) Stomach and duodenum iii) Colon	i) Up to 150 ml of a 50% - 200% suspension orally ii) Up to 300 ml of a 30% - 200% suspension orally iii) Up to 2 liter of a 30% - 200% suspension orally
140	Basiliximab 20 mg Injection	L04AC02000P3001XX	A*	Prophylaxis of acute organ rejection in de novo renal transplantation.	ADULT & CHILD 2 years and above & 35 kg or more: 20 mg /dose. 2 years or more but less than 35kg: 10 mg/dose. First dose given within 2 hours before start of transplantation and

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					second dose 4th day after transplant
141	BCG 81 mg/3 ml	L03AX03000 P3001XX	A*	Superficial bladder cancer	81 mg intravesically once weekly for 6 weeks, followed by treatments at 3, 6, 12, 18, and 24 months after initial treatment
142	BCG Vaccine Freeze-Dried Injection	J07AN01000 P4001XX	C+	For the prevention of tuberculosis	0.1 ml by intradermal injection. INFANT under 12 months: 0.05 ml
143	Beclomethasone Dipropionate 100 mcg/dose Inhaler	R03BA01133 A2101XX	B	Prophylaxis of asthma especially if not fully controlled by bronchodilators	Adults: The usual maintenance dose is one to two inhalations (200-400 mcg) twice daily. If needed, the dose can be increased up to 1600 mcg/day divided in two to four doses : Children 6-12 years old: One inhalation (200 mcg) two times daily and dose may be increased up to 800 mcg/day in divided two to four doses if necessary.
144	Beclomethasone dipropionate 100mcg and formoterol fumarate dehydrate 6mcg pressurized inhalation solution	R03AK07986 A2101XX	A/KK	Regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2 agonist) is appropriate in: i. Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2 agonist or ii. Patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists	Dose recommended for patients 18 years and above. One or two inhalations twice daily. The maximum daily dose is 4 inhalations daily. No need to adjust dose in elderly patients. There are no data available for use in patients with hepatic or renal impairment.
145	Beclomethasone Dipropionate 200 mcg/dose Inhaler	R03BA01133 A2102XX	A/KK	Prophylaxis of asthma especially if not fully controlled by bronchodilators	ADULT: 1 - 2 puff twice daily. May increase to 2 puff 2 - 4 times daily CHILD: 1 puff twice daily. May increase to 1 puff 2 - 4 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
146	Beclomethasone Dipropionate 50 mcg/dose Nasal Spray	R01AD01133 A4101XX	A/KK	Prophylaxis and treatment of perennial and seasonal allergic rhinitis and vasomotor rhinitis	ADULT and CHILD over 6 years: Apply 100 mcg (2 sprays) into each nostril twice daily or 50 mcg (1 spray) into each nostril 3 - 4 times/day. Maximum 400 mcg daily (8 sprays). When symptoms controlled, reduce dose to 50 mcg (1 spray) into each nostril twice daily
147	Benzalkonium 0.01% Cream	D08AJ01000 G1001XX	B	Prevention and treatment of nappy rash	Wash and dry baby's bottom. Apply by spreading the cream evenly paying particular attention to the fold of the skin, after every nappy change
148	Benzalkonium Chloride Disinfectant Solution	V07AV00100 L9908XX	C	Low level disinfectant suitable for general cleaning and disinfection of hard surface	Cleaning purposes: Dilute 1 in 10. Disinfection, use undiluted
149	Benzathine Penicillin 2.4 MIU (1.8 g) Injection	J01CE08702P 4001XX	B	i) Treatment of mild to moderately severe infections due to Penicillin G-sensitive organisms ii) Treatment of syphillis	i) ADULT: 1.2 mega units IM ii) For syphillis: 2.4 mega units weekly for 1 - 3 weeks
150	Benzhexol 2 mg Tablet	N04AA01110 T1001XX	B	i) Parkinson's disease ii) Drug induced parkinsonism iii) Dystonias	ADULT: Initially 1 mg daily, increase gradually. Maintenance: 5 - 15 mg daily in 3 - 4 divided doses. (Max 15mg/day)
151	Benzoic Acid Compound Half Strength (Paed) Ointment	D01AE12952 G5001XX	C	Tinea infections of the skin	Apply sparingly to affected area once or twice daily
152	Benzoic Acid Compound Ointment	D01AE12952 G5002XX	C	Tinea infections of thickened skin of palms and soles	Apply sparingly to affected area once or twice daily
153	Benzoin Compound Tincture	D08AX00000 L5001XX	C	Infected skin, lesions, cuts, abrasions, wounds and burns	Apply undiluted to the skin 1 or 2 times daily. Duration of therapy, may be weeks to months depending on the infection being treated
154	Benzoyl Peroxide 10% Gel	D10AE01241 G3002XX	B	Mild to moderate acne vulgaris	Apply 1-2 times daily preferably after washing with soap and water
155	Benzoyl Peroxide 5% Gel	D10AE01241 G3001XX	B	Mild to moderate acne vulgaris	Apply 1-2 times daily preferably after washing

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					with soap and water
156	Benzydamine HCl 0.15% Solution	A01AD02110 M2001XX	B	For relief of painful condition of the oral cavity	Used as a 30 seconds gargle or rinse, undiluted. ADULT 15 ml. CHILD less 12 years 5-15 ml. Uninterrupted treatment should not be more than 7 days
157	Benzydamine Hydrochloride 3.0 mg/ml throat spray	A01AD02110 A4201XX	A*	Temporary relief of painful conditions of the mouth and throat including tonsillitis, sore throat, radiation mucositis, aphthous ulcers, pharyngitis, swelling, redness, inflammatory conditions, post-orosurgical and periodontal procedures. (For pediatric and otorhinolaringology use. Restrict to patients who are not able to gargle)	ADULTS and CHILDREN OVER 12 YEARS: 2-4 sprays (1-2mg) directly onto the sore/inflamed area and swallow gently. Repeat every 1 1/2 to 3 hours as necessary. CHILDREN 6-12 YEARS: 2 sprays (1mg) directly onto sore/ inflamed area and swallow gently. Repeat every 11/2 to 3 hours as necessary. CHILDREN UNDER 6 YEARS: Not recommended. Uninterrupted treatment should not exceed seven days, unless under medical supervision
158	Benzyl Benzoate 12.5 % Emulsion (Child)	P03AX01252 L2001XX	C	Scabies and pediculosis, for child under 2 years	After bath, apply over the whole body, neck down and leave on for 24 hours then wash off. Reapply for another 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases
159	Benzyl Benzoate 25 % Emulsion (Adult)	P03AX01000 L2002XX	C+	Scabies and pediculosis	After bath, apply over the whole body, neck down and leave on for 24 hours then wash off. Reapply for another 24 hours, the first repeat application should be within 5 days of the initial application, a third application may be required in some cases

No.	Generic Name	MDC	Category	Indication(s)	Dosage
160	Benzylpenicillin 1 mega unit (600 mg) Injection	J01CE01702P4001XX	B	i) Infections caused by susceptible organisms ii) Infective endocarditis	i) Adult: 600mg - 3600mg (1 - 6 mega units) daily, divided into 4 to 6 doses. Higher doses (24 mega units) in divided doses may be given in serious infections such as meningitis. Child 1 month to 12 years old: 100mg/kg/day in 4 divided doses, not exceeding 4g/day; Infants 1 -4 weeks: 75mg/kg/day in 3 divided doses; Newborn Infants: 50mg/kg/day in 2 divided doses ii)7.2 to 12g (12 - 20 mega units) maybe given daily in divided doses
161	Benzylpenicillin 10,000 units/ml Eye Drops	S01AA14702D2002XX	B	Eye infection	1-2 drops every 15 minutes or accordingly to needs of the patient
162	Benzylpenicillin 2,500 units/ml (1.5 mg/ml) Eye Drops	S01AA14702D2001XX	B	Eye infection	1-2 drops every 15 minutes or accordingly to needs of the patient
163	Benzylpenicillin 5 mega units (3 g) Injection	J01CE01702P4002XX	B	i) Infections caused by susceptible organisms ii) Infective endocarditis	i) ADULT: 600 - 1200 mg IM 4 times daily, increased if necessary in more serious infections. CHILD: 50 - 100 mg/kg body weight daily IV in 2 - 4 divided doses ii) ADULT: 7.2 g daily by slow IV infusion in 6 divided doses
164	Beractant Intratracheal Suspension (200 mg phospholipids in 8 ml vial)	R07AA02000L8001XX	A*	Treatment of newborn baby with birth weight of 700 g or greater undergoing mechanical ventilation for respiratory distress syndrome, whose heart rate and arterial oxygenation are continuously monitored	100 mg/kg (4 ml/kg) body weight intratracheally up to 4 doses in 1st 48 hr. Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.
165	Betahistine Dihydrochloride 16 mg Tablet	N07CA01110T1002XX	A/KK	Vertigo, tinnitus and hearing loss associated with Meniere's disease	Given in doses of 8 to 16 mg orally 3 times daily (total 24 to 48 mg/day) preferably with food. CHILD not recommended
166	Betahistine Dihydrochloride 24 mg Tablet	N07CA01110T1003XX	A*	Vertigo, tinnitus and hearing loss associated with Meniere's disease	24-48mg in divided doses daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
167	Betahistine Dihydrochloride 8 mg Tablet	N07CA01110 T1001XX	A/KK	Vertigo, tinnitus and hearing loss associated with Meniere's disease	Given in doses of 8 to 16 mg orally 3 times daily (total 24 to 48 mg/day) preferably with food. CHILD not recommended
168	Betamethasone 0.5 mg Tablet	H02AB01000 T1001XX	A	Suppression of inflammatory and allergic disorders, congenital adrenal hyperplasia, cerebral oedema	0.5 - 9 mg daily in divided doses. CHILD: 0.5 - 7.5 mg/m2/day divided every 6 - 12 hours
169	Betamethasone 17-Valerate 0.01-0.05% Cream	D07AC01256 G1001XX	B	Eczemas, prurigo nodularis, limited psoriasis in appropriate in sites	Apply sparingly to affected area 2 - 3 times daily then reduced to once daily when improvement occurs
170	Betamethasone 17-Valerate 0.01-0.05% Ointment	D07AC01256 G5001XX	B	Eczema, prurigo nodularis, limited psoriasis in appropriate in sites	Apply sparingly to affected area 2 - 3 times daily then reduced to once daily when improvement occurs
171	Betamethasone 17-Valerate 0.1% Cream	D07AC01256 G1002XX	A	Eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis)	Apply sparingly to affected area 2 - 3 times daily then reduced to once daily when improvement occurs
172	Betamethasone 17-Valerate 0.1% Ointment	D07AC01256 G5002XX	A	Eczema, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis)	Apply sparingly to affected area 2-3 times daily then reduced to once daily when improvement occurs
173	Betamethasone Disodium Phoshate 0.1% Ear Drops	S03BA03162 D1001XX	B	Non-infected inflammatory conditions	Apply 2 - 3 drops every 2 - 3 hours, reduce frequency when relief obtained
174	Betamethasone Disodium Phoshate 0.5% Ear Drops	S03BA03162 D1002XX	B	Non-infected inflammatory conditions	Apply 2 - 3 drops every 2 - 3 hours, reduce frequency when relief obtained
175	Betamethasone Disodium Phosphate 0.1% Eye Drops	S01BA06162 D2001XX	A	Non-infected inflammatory conditions of the eyes	1 - 2 drops every 1 - 2 hours until controlled then reduce frequency
176	Betamethasone Disodium Phosphate 0.1% Eye Ointment	S01BA06162 G5101XX	A	Non-infected inflammatory conditions of the eyes	2 - 4 times daily or at night when used with eye drops
177	Betamethasone Disodium Phosphate and Neomycin Sulphate 0.5% Ear Drops	S03CA06991 D1001XX	B	Allergic dermatosis in the ear	Apply 2 - 3 drops 3 - 4 times daily, reduce frequency when relief obtained

No.	Generic Name	MDC	Category	Indication(s)	Dosage
178	Betamethasone Disodium Phosphate and Neomycin Sulphate Eye Drops	S01CA05991 D2001XX	A	Infected inflammatory conditions of the eyes	2 - 3 drops every 2 - 3 hours
179	Betamethasone Sodium Phosphate 4 mg/ml Injection	H02AB01162 P3001XX	B	Pre-operative and in serious trauma or illness, shock, as adjunctive therapy in rheumatoid disorders, ocular, dermatologic and respiratory allergic and inflammatory states	Usual intravenous doses are up to 9 mg/day of the sodium phosphate salt only. CHILD: IM: 0.5 - 7.7 mg base/m2/day divided every 6 - 12 hours. ADOLESCENT and ADULT, IM: 0.6 - 9 mg divided every 12 - 24 hours
180	Betaxolol 0.25% Eye Suspension	S01ED02110 D2001XX	A	Chronic open-angle glaucoma, ocular hypertension	One to two drops in the affected eye(s) twice daily
181	Bicalutamide 50 mg Tablet	L02BB03000T 1001XX	A*	Advanced prostate cancer in combination with LHRH analogue therapy or surgical castration.	50 mg once daily (morning or evening), with or without food. Take on the same time each day. Adult: When used with gonadorelin analogue: Usual dose: 50 mg once daily. May be started with or at least 3 days before starting gonadorelin analogue therapy.
182	Bimatoprost 0.03% Ophthalmic Solution	S01EE03000 D2001XX	A*	Lowering of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive to another intraocular pressure lowering medication	1 drop in affected eye(s) once daily at evening
183	Bisacodyl 10 mg Suppository	A06AB02000 S2002XX	C	i) Constipation ii) Bowel preparation for radiological procedures and surgery	i) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally
184	Bisacodyl 5 mg Suppository	A06AB02000 S2001XX	C	i) Constipation ii) Bowel preparation for radiological procedures and surgery	i) ADULT and CHILD over 10 years: 10 mg, CHILD less than 10 years 5 mg insert rectally ii) ADULT 10-20 mg, CHILD over 4 years 5 mg the following morning before procedures insert rectally

No.	Generic Name	MDC	Category	Indication(s)	Dosage
185	Bisacodyl 5 mg Tablet	A06AB02000 T1001XX	C	i) Constipation ii) Bowel preparation for radiological procedures and surgery	i) ADULT and CHILD over 10 years 5-10 mg, CHILD 4-10 years 5 mg. To be taken at night for effect on the following morning ii) ADULT 10-20 mg the night before procedures, CHILD over 4 years 5 mg the night before procedures
186	Bismuth Subnitrate, Iodoform and Liquid Paraffin Paste	R01AX30984 G6001XX	B	As a mild antiseptic for wounds and abscesses. Sterile gauze impregnated with paste for packing cavities after otorhinological surgery	As directed for local application
187	Bisoprolol Fumarate 2.5 mg Tablet	C07AB07000 T1001XX	B	Treatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics	1.25 mg once daily to 5 - 10 mg daily
188	Bisoprolol Fumarate 5 mg Tablet	C07AB07000 T1002XX	B	Treatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics	1.25 mg once daily to 5 - 10 mg daily
189	Bleomycin HCl 15 mg Injection	L01DC01110 P4001XX	A	Squamous cell carcinoma, germ cell tumours, lymphomas. Routes: SC, IM, IV (either as bolus or as infusion over 24 hours), intra-arterial, intra-pleural	15 - 30 mg weekly in divided doses or 10 - 20 mg/m2 once or twice weekly or 10 mg/m2 slow bolus in 15 minutes D1 and D15. Total dosage:should not exceed 300 mg. CHILD: 10 - 15 mg/m2 over 6 hours every 3 - 4 weeks
190	Boric Acid with Spirit 2% w/v Ear Drops	S02AA03000 D1001XX	C	Perforated eardrum	3 drops instilled into affected ear 3 - 4 times daily
191	Bortezomib 3.5 mg Injection	L01XX32000P 3001XX	A*	i) Treatment of multiple myeloma in patient who have received at least one prior therapy. ii) For use in combination with conventional therapy for the treatment of previously untreated multiple myeloma patients who are not eligible for haematopoietic stem cell transplantation.	1.3 mg/ m2/dose given as IV bolus injection twice weekly for two weeks (days 1, 4, 8, and 11) followed by a 10-day rest period (days 12-21). At least 3 days should elapse between consecutive doses of bortezomib

No.	Generic Name	MDC	Category	Indication(s)	Dosage
192	Bosentan 125 mg tablet	C02KX01000 T1001XX	A*	For the treatment of pulmonary arterial hypertension (PAH) in patients with WHO Class III or IV symptoms, to improve exercise ability and decrease the rate of clinical worsening (To be used by those who are trained and specialized in treating and managing PAH)	Initially 62.5 mg bd for 4 weeks, then increase to the maintenance dose of 125 mg bd
193	Brimonidine Tartrate 0.15% Ophthalmic	S01EA05123 D2001XX	A*	Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension	1 drop in the affected eye(s) 3 times daily
194	Bromazepam 3 mg Tablet	N05BA08000 T1002XX	A	Anxiety disorders	Adult: Initially, 6-18 mg daily in divided doses. Doses up to 60 mg daily have been used. Elderly: Max initial dose: 3 mg daily
195	Bromhexine HCl 4 mg/2 ml Injection	R05CB02110 P3001XX	A	Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport	4 to 8 mg SC, IM or IV 2 - 3 times daily (maximum 24mg/ day). Elderly: Max initial dose: 3 mg daily.
196	Bromhexine HCl 4 mg/5 ml Elixir	R05CB02110 L1001XX	B	Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport	1) Adults: 10 ml three times a day. Can increase up to 15 ml four times a day. 2)Children 5 to 12 years : 5 ml four times a day 3)Children 2 to 5 years: 5 ml two times a day
197	Bromhexine HCl 8 mg Tablet	R05CB02110 T1001XX	B	Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucous secretion and impaired mucous transport	ADULT and CHILD more than 12 years : 8 mg 3 times daily, 6 - 12 years : 4 mg 3 times daily, 2 - 6 years : 4 mg 2 times daily
198	Bromocriptine Mesilate 10 mg Tablet	G02CB01196 T1003XX	A/KK	i) Hypogonadism or Galactorrhoea ii) Acromegaly	i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
199	Bromocriptine Mesilate 2.5 mg Tablet	G02CB01196 T1001XX	A/KK	i) Hypogonadism or Galactorrhoea ii) Acromegaly	i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
200	Bromocriptine Mesilate 5 mg Tablet	G02CB01196 T1002XX	A/KK	i) Hypogonadism or Galactorrhoea ii) Acromegaly	i) Initially 1 - 1.25 mg at bedtime increased gradually, usual dose: 7.5 mg daily in divided doses. Max 30 mg daily ii) 1.25 - 2.5 mg at bedtime for 3 days and may be increased by 1.25 - 2.5 mg every 3 - 7 days up to 30 mg a day in divided doses
201	Budesonide 1 mg/2 ml Nebuliser Solution	R03BA02000 A3002XX	B	Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators	ADULT: Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses
202	Budesonide 100 mcg/dose Inhaler	R03BA02000 A2101XX	B	Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators	ADULT: 200 - 1600 mcg daily in 2 - 4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years 200 - 800 mcg, 2 - 7 years 200 - 400 mcg. To be taken orally in 2 - 4 divided doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
203	Budesonide 160 mcg and Formoterol 4.5 mcg Inhalation	R03AKO7989 A2101XX	A/KK	i) Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. ii) Symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) & a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.	Asthma Maintenance therapy Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended. Maintenance & relief Adult ≥18 yr 320 mcg/day either as 160 mcg bd or 320 mcg either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed; however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. Childn & adolescent <18 yr Not recommended. COPD Adult ≥18 yr 320 mcg bd.
204	Budesonide 200 mcg/dose Inhalation	R03BA02000 A2102XX	B	Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators	ADULT: 200 - 1600 mcg daily in 2 - 4 divided doses. Maintenance with twice daily dosing. CHILD more than 7 years 200 - 800 mcg, 2 - 7 years 200 - 400 mcg. To be taken orally in 2 - 4 divided doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
205	Budesonide 320 mcg and Formoterol 9 mcg Inhalation	R03AK07989 A2102XX	A/KK	i) Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. ii) Symptomatic treatment of patients with severe COPD (FEV1<50% predicted normal) & a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.	Asthma; Maintenance therapy: Adult ≥18 yr 160 mcg to 320 mcg bd. Some patients may require up to a max of 640 mcg bd. Adolescent 12-17 yr 160 mcg to 320 mcg bd. Childn 6-11 yr 160 mcg bd, <6 yr Not recommended. Maintenance & relief: Adult ≥18 yr 320 mcg/day either as 160 mcg bd or 320 mcg either morning or evening. For some patients a maintenance dose of 320 mcg bd may be appropriate. Patients should take 160mcg additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 960 mcg should be taken on any single occasion. A total daily dose of more than 1280 mcg is not normally needed, however a total daily dose of up to 1920 mcg could be used for a limited period. Patients using more than 1280 mcg daily should seek medical advice, should be reassessed & their maintenance therapy reconsidered. Children & adolescent less than 18 yr: Not recommended. COPD; Adult more than or equal to 18 yr: 320 mcg bd.
206	Budesonide 500 mcg/2 ml Nebuliser Solution	R03BA02000 A3001XX	B	Maintenance treatment of asthma as prophylactic therapy especially if not fully controlled by bronchodilators	ADULT: Initially 1 - 2 mg twice daily. CHILD 3 months - 12 years of age : 500 mcg - 1 mg. Maintenance dose : half of the above doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
207	Budesonide 64mcg Nasal Spray	R01AD05000 A4103XX	A	Seasonal allergic, perennial rhinitis and nasal polyposis	ADULT and CHILD 6 years and older. Rhinitis: 2 spray into each nostril once daily in the morning or 1 spray into each nostril twice daily. Nasal polyps : 2 spray twice daily
208	Bumetanide 0.5 mg/ml Injection	C03CA02000 P3001XX	A*	Oedema used in furosemide allergic patient	IV injection: 1 - 2 mg repeated after 20 mins. IV infusion: 2 - 5 mg over 30 - 60 mins
209	Bumetanide 1 mg Tablet	C03CA02000 T1001XX	A*	Oedema used in furosemide allergic patient	1 mg in the early evening. Up to 5 mg daily in severe cases
210	Bupivacaine 0.125% Epidural Injection	N01BB01110 P3004XX	A	Epidural analgesia for postoperative pain relief.	Infuse at 6 - 15 ml/hour. Not to exceed 2 mg/kg in a single dose.
211	Bupivacaine 0.5 % Heavy Injection	N01BB01110 P3003XX	A	Used for spinal anaesthesia	ADULT: 2 - 4 ml. Not to exceed 2 mg/kg in a single dose
212	Bupivacaine 0.5 % Injection	N01BB01110 P3002XX	B	For peripheral sympathetic nerve and epidural (excluding caudal) anaesthesia and obstetrics anaesthesia	Regional nerve block or epidural block: 15 - 30 ml. Nerve block of finger or toe: 2 - 6 ml. Maximum: 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml in adults of average weight
213	Bupivacaine 0.5 % with Adrenaline 1:200,000 Injection	N01BB51975 P3001XX	B	Regional nerve block or epidural block.	10 - 40 ml (0.25 %) or maximum : 2 mg/kg body weight in any 4 hours period, equivalent to 25 - 30 ml of 0.5% solution
214	Buprenorphine 10mcg/hr transdermal patch	N02AE01110 M7001XX	A*	Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. Not suitable for the treatment of acute pain. Restrictions: For elderly patients or patients with comorbidities/difficult to swallow	Once weekly transdermal patch/for hospital use only. Patient aged 18 years and over. Initial dose: 5mcg/hr For elderly: Renal impairment. No special dose adjustments necessary in patients with renal impairment Hepatic impairment Patients with hepatic insufficiency should be carefully monitored during the treatment with buprenorphine patch. Alternate therapy should be

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					considered. Patch should be used with cautions in severe hepatic impairment patient
215	Buprenorphine 5mcg/hr transdermal patch	N02AE01110 M7003XX	A*	Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. Not suitable for the treatment of acute pain. Restrictions: For elderly patients or patients with co - morbidities/difficult to swallow	Once weekly transdermal patch/for hospital use only. Patient aged 18 years and over. Initial dose: 5mcg/hr For elderly: Renal impairment. No special dose adjustments necessary in patients with renal impairment Hepatic impairment Patients with hepatic insufficiency should be carefully monitored during the treatment with buprenorphine patch. Alternate therapy should be considered. Patch should be used with cautions in severe hepatic impairment patient
216	Busulfan 2 mg Tablet	L01AB01000 T1001XX	A	i) Chronic myeloid leukaemia (CML) and other myeloproliferative diseases ii) Haemopoietic stem cell transplant (HSCT)- refer to specific protocols	i) ADULT: Initial: 2 - 4 mg daily. Maintenance: 0.5 - 2 mg daily. Stop when white blood cell less than 20 x 109/L. CHILD: 60 mcg/kg body weight daily ii) CHILD: Induction 60 mcg/kg body weight daily (maximum 4 mg) if leucocytes more than 20,000/mm3 and platelets more than 100,000/mm3. Maintenance 10 - 30mcg/kg (maximum 2 mg daily)
217	Busulfan 6 mg/ml Injection	L01AB01000 P3001XX	A*	For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia in selected cases with high risk of liver toxicity and intolerance to oral busulfan. To be prescribed by paediatric oncologist and consultant haematologist trained in transplant only.	0.8 mg/kg of ideal body weight or actual body weight, whichever is lower via central venous catheter as a 2-hour infusion on the basis of every 6 hours for 4 days, for a total of 16 doses. For obese or severely obese patients, IV Busulfan should be administered based on adjusted ideal body weight

No.	Generic Name	MDC	Category	Indication(s)	Dosage
218	Cabergoline 0.5 mg Tablet	G02CB03000 T1001XX	A*	i) Treatment of hyperprolactinaemic disorders ii) Prevention of puerperal lactation and suppression of lactation in HIV infected mothers only	i) 0.5mg per week given in 1 or 2 (one-helf of one 0.5mg tablet) doses per week ii) HIV mothers only: Prevent lactation 2 tab first day after delivery. Interruption of laction : 0.25mg 12 hourly for 2 days
219	Calamine Cream	D04AX00000 G1001XX	C+	Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.	Apply to the affected area as required, 1-3 times daily
220	Calamine Lotion	D04AX00000 L8001XX	C+	Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.	Apply to the skin as required and allow to dry, 1-3 times daily
221	Calamine with 0.25 - 0.5% Menthol Lotion	D04AX00952 L6001XX	C	Soothes and relieves nappy rashes, prickly heat, minor skin irritations, insect bites and sunburn, Pruritic skin conditions.	Apply to the skin as required and allow to dry, 1 - 3 times daily
222	Calamine with 0.5% Phenol Cream	D04AX00952 G1001XX	C	For use as a mild astringent	Apply to the affected area as required
223	Calamine with 2 - 6% Precipitated Sulphur Lotion	D04AX00952 L6002XX	C	Acne vulgaris	Apply to the skin as required and allow to dry, 1 - 3 times daily
224	Calcipotriol 50 mcg/g Cream	D05AX02000 G1001XX	A*	Only for the treatment of Psoriasis Vulgaris	ADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose should not exceed 100 g. CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm weekly, over 12 years maximum 75gm weekly
225	Calcipotriol 50 mcg/g Ointment	D05AX02000 G5001XX	A*	Only for the treatment of Psoriasis Vulgaris	ADULT Apply to the affected skin lesions twice daily. Maintenance therapy may be achieved with less frequent application. The weekly dose should not exceed 100 g. CHILD over 6 years, apply twice daily. 6-12 years maximum 50gm

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					weekly, over 12 years maximum 75gm weekly
226	Calcipotriol 50 mcg/ml Scalp Solution	D05AX02000 L9901XX	A*	Only for the treatment of Psoriasis Vulgaris	Apply to scalp twice daily. Maximum 60 mL weekly.
227	Calcipotriol Hydrate 50 mcg/g & Betamethasone Dipropionate 0.5 mg/g Ointment	D05AX52952 G5001XX	A*	Resistant plaque psoriasis	Apply once daily up to 4 weeks with maximum weekly dose of 100g and maximum treatment area 30% of body surface
228	Calcipotriol monohydrate 50 mcg/g and Betamethasone dipropionate 0.5 mg/g Gel	D05AX52952 G3001XX	A*	Topical treatment of scalp and non-scalp plaque psoriasis vulgaris in adults	Should be applied to affected areas once daily. The recommended treatment period is 4 weeks for scalp areas and 8 weeks for non-scalp areas. The body surface area treated with calcipotriol containing products should not exceed 30% and maximum dose should not exceed 15g or 100g/ week
229	Calcitonin (synthetic Salmon) 100 IU Injection	H05BA01000 P3002XX	A*	Acute hypercalcaemia	5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. Renal impairment: Dosage adjustment needed.
230	Calcitonin (Synthetic Salmon) 200 IU Nasal Spray	H05BA01000 A4101XX	A*	Osteoporosis	200 units daily
231	Calcitonin (Synthetic Salmon) 50 IU Injection	H05BA01000 P3001XX	A*	Acute hypercalcaemia	5-10 IU per kg body weight in 500mL physiological saline daily by i.v. infusion over at least 6 hours or by slow i.v. injection in 2-4 divided doses spread over the day. Renal impairment: Dosage adjustment needed.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
232	Calcitriol 0.25 mcg Capsule	A11CC04000 C1001XX	A/KK	i)Established postmenopausal osteoporosis ii) Renal osteodystrophy in patients on haemodialysis iii)Hypoparathyroidism and rickets iv)Secondary hyperparathyroidism in renal failure	i) 0.25 mcg 2 times daily; ii) Initial dose 0.25 mcg. In patients with normal or only slightly reduced serum calcium levels, doses of 0.25 mcg every other day is sufficient; iii) 0.25 mcg/day given in the morning; iv) ADULT and CHILD 3 years and older : Initially 0.25 mcg/ml. CHILD less than 3 years : 10 to 15 ng/kg/day "
233	Calcitriol 1 mcg/ml Injection	A11CC04000 P3001XX	A*	Management of hypocalcaemia and/or secondary hyperparathyroidism in patients undergoing chronic renal dialysis	Initially dose, depending on severity, 1 mcg (0.02 mg/kg) to 2 mcg 3 times weekly, approximately every other day
234	Calcitriol 2 mcg/ml Injection	A11CC04000 P3002XX	A*	Management of hypocalcaemia and/or secondary hyperparathyroidism in patients undergoing chronic renal dialysis	Initially dose, depending on severity, 1 mg (0.02 mg/kg) to 2 mg 3 times weekly, approximately every other day
235	Calcium Carbonate 500 mg Capsule	A12AA04121 C1001XX	A/KK	i) Elemental calcium supplementation ii) Phosphate binder in chronic renal failure patients	ADULT: Typical oral doses of calcium carbonate range from about 3gm to 7gm daily in divided dose. US National Foundation suggest the calcium-based phosphate binder should not exceed 1.5gm daily in those with kidney failure. CHILD (12-18 years old): 1.25gm 3 or 4 times daily with or before meals and adjusted as necessary.
236	Calcium Carbonate 500 mg Tablet	A12AA04121 T1001XX	A/KK	To be used only for elemental calcium supplementation and phosphate binding activity in patients with chronic renal failure	Initial 2.5 g daily and increased up to 17 g daily
237	Calcium Chloride Dihydrate, Sodium Chloride, Magnesium Chloride Hexahydrate, Sodium Acetate Trihydrate,Potass	B05BB01905 P6002XX	A	Replacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent.	The maximum infusion rate depends on the needs of the patient in fluid replacement and electrolytes, patient's weight, clinical condition, and biological status. Adults, elderly, adolescents:500ml-3L/24hr. Babies, children:

No.	Generic Name	MDC	Category	Indication(s)	Dosage
	ium Chloride, and Malic Acid Solution				20ml to 100ml/kg/24 hr.
238	Calcium Disodium Edetate 200 mg Injection	V03AB03999 P3001XX	A	Lead Poisoning	IM (Lead encephalopathy): 1000 mg/m (2)/day IM in divided equal doses 8 to 12 hours apart, for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated. Do not exceed the recommended daily dosage. IV: 1000 mg/m (2)/day administered IV over 8 to 12 hours for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated.
239	Calcium Gluconate 10% Injection	A12AA03000 P3001XX	B	i)Acute hypocalcaemia ii)Hypocalcaemic tetany iii)Cardiac resuscitation	i) 1-2 g (2.25-4.5 mmol). CHILD 50 mg/kg ii) ADULT 1g (2.2 mmol) by slow IV injection followed by continuous infusion of 4 g (8.8 mmol) daily iii) IV or intracardiac injection, 10 ml
240	Calcium Lactate 300 mg Tablet	A12AA05125 T1001XX	C	For prophylaxis of calcium deficiency and treatment of chronic hypocalcaemia	ADULT 1-5 g daily in divided doses
241	Calcium Polystyrene Sulphonate Powder	V03AE01999 F2101XX	A	Hyperkalemia resulting from acute or chronic renal failure	15 - 30g daily in 2-3 divided doses. Each dose should be suspended in 30 - 50ml of water and administered orally
242	Capecitabine 150 mg Tablet	L01BC06000T 1002XX	A*	i) Metastatic breast cancer in elderly and poor performance status patients and refractory to taxanes. ii) Metastatic colon cancer, first line in elderly and poor performance status patients. iii) Colon cancer, adjuvant therapy for stage III (Duke's Stage C) following surgery. iv) First line treatment of patients with advanced gastric cancer in combination with a platinum-based regimen	i) & ii) 1250 mg/m2 twice daily (morning and evening) for 2 weeks, every 21 days. iii) Recommended for a total of 24 weeks (8 cycles of 2 weeks of drug administration and 1 week rest period. Iv) In combination with platinum on day 1, give capecitabine 1250 mg/m2 twice daily for 14 days. Repeated every 3

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					weeks for 8 cycles or optimum number of cycles
243	Capecitabine 500 mg Tablet	L01BC06000T1001XX	A*	i)Metastatic breast cancer in elderly and poor performance status patients and refractory to taxanes ii) Metastatic colon cancer, first line in elderly and poor performance status patients iii) Colon cancer, adjuvant therapy for stage III (Duke's Stage C) following surgery iv) First line treatment of patients with advanced gastric cancer in combination with a platinum-based regimen	i) & ii) 1250 mg/m2 twice daily (morning and evening) for 2 weeks, every 21 days iii) Recommended for a total of 24 weeks (8 cycles of 2 weeks of drug administration and 1 week rest period iv) In combination with a platinum on day 1, give capecitabine 1250 mg/m2 twice daily for 14 days. Repeated every 3 weeks for 8 cycles or optimum number of cycles
244	Captopril 25 mg Tablet	C09AA01000T1002XX	B	i) Hypertension ii) Congestive heart failure iii) Post-myocardial infarction iv) Diabetic nephropathy	i) Initially 12.5 mg twice daily. Maintenance: 25-50 mg 2 - 3 times daily, may be increased to maximum 450 mg/day in divided doses ii) Initially 6.25 - 12.5 mg 3 times daily, increase after several days to 25 - 50 mg 3 times daily iii) Start 3 days after MI Initially 6.25 mg daily, gradually increased to 37.5 mg daily in divided doses. May increase after several week to 150 mg/day in divided doses if needed and tolerated iv)75 - 100 mg daily in divided dose.
245	Carbachol 0.01% Intraocular Solution	S01EB02100D2001XX	A	For intraocular use for miosis during surgery	Instill no more than 0.5 ml gently into the anterior chamber

No.	Generic Name	MDC	Category	Indication(s)	Dosage
246	Carbamazepine 100 mg/5 ml (2% w/v) Syrup	N03AF01000 L9001XX	A	Epilepsy	ADULT: Initially, 100-200 mg once or twice daily gradually increased by increments of 100-200 mg every 2 week. Maintenance: 0.8-1.2 g daily in divided doses. CHILD: 10-15 years: 0.6-1 g daily; 5-10 years: 400-600 mg daily; 1-5 years: 200-400 mg daily; less than or equal to 1 year: 100-200 mg daily. Alternatively, 10-20 mg/kg body weight daily in divided doses. Max: Adult: 1.6 g daily
247	Carbamazepine 200 mg CR Tablet	N03AF01000 T5001XX	A	Epilepsy	ADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age
248	Carbamazepine 200 mg Tablet	N03AF01000 T1001XX	B	i) Epilepsy ii) Trigeminal neuralgia	i) ADULT: 100 - 200 mg 1 - 3 times daily increased gradually to usual dose of 0.8 - 1.2 g daily in divided doses. CHILD: Up to 1 year: 100 - 200 mg daily; 1 - 5 yrs: 200 - 400 mg daily; 5 - 10 years: 400 - 600 mg daily; 10 - 15 years: 0.6 - 1 g daily ii) The initial dosage of 200 to 400mg should be slowly raised daily until freedom from pain is achieved (normally at 200mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. In elderly patients, an initial dose of 100mg twice daily is recommended.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
249	Carbamazepine 400 mg CR Tablet	N03AF01000 T5002XX	A	Epilepsy	ADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age
250	Carbamide (Urea) 10 % Cream	D02AE01000 G1001XX	B	Contact irritant dermatitis, infantile eczemas, acute and chronic allergic eczemas, icthyosis, hyperkeratotic	Apply sparingly and rub into affected area 2 - 3 times daily and when required after cleansing skin
251	Carbetocin 100 mcg/ ml Injection	H01BB03000 P2001XX	A*	Prevention of uterine atony and postpartum hemorrhage following elective cesarean section under epidural or spinal anaesthesia	A single IV dose of 100mcg (1ml) is adminitered by bolus injection, slowly over 1minute, only when delivery of the infant has been completed by caesarean section under epidural or spinal anaesthesia, before or after delivery of the placenta.
252	Carbimazole 5 mg Tablet	H03BB01000 T1001XX	B	Hyperthyroidism	ADULT: Initially, 10-60mg daily in divided doses given 8 hourly. Maintenance: 5 to 20mg daily. CHILDREN > 6 years: Initially 15mg daily in divided doses. CHILDREN 1-6 years: Initially 7.5mg daily in divided doses
253	Carboplatin 150 mg Injection	L01XA02000 P4001XX	A*	Adult solid tumours, paediatric tumours. Salvage therapy for lymphoma	360 - 400 mg/m2 BSA, by IV infusion over 15 mins to 1 hour on Day 1 every 4 weeks. Alternatively, prescription may be based on Area Under Curve (AUC) calculations. CHILD: 500-600 mg/m2 over 1 hour once every 3 weeks. Salvage regimes in lymphomas - refer to specific protocols. Starting dose in renal impairment, please refer to product insert.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
254	Carboplatin 450 mg Injection	L01XA02000 P4002XX	A*	Adult solid tumours, paediatric tumours. Salvage therapy for lymphoma	360 - 400 mg/m2 BSA, by IV infusion over 15 mins to 1 hour on Day 1 every 4 weeks. Alternatively, prescription may be based on Area Under Curve (AUC) calculations. CHILD: 500-600 mg/m2 over 1 hour once every 3 weeks. Salvage regimes in lymphomas - refer to specific protocols. Starting dose in renal impairment, please refer to product insert.
255	Carboprost Tromethamine 250 mcg Injection	G02AD04999 P3001XX	A*	Postpartum haemorrhage refractory to oxytocin	Initially 250 mcg deep IM inj. The dose may be repeated at intervals of 15-90 min if necessary. Max total dose: 2 mg.
256	Cardioplegia solution containing Potassium Chloride, Magnesium chloride & Procaine HCl Injection	B05XA16934 P3001XX	A*	For myocardial preservation(prevent myocardial damage) during cardiac surgery	Dilute 20 ml to 1 L of Ringer solution (cooled to 2-8 °C prior to use). Initial rapid instillation into aortic root at 300 ml/m² body surface area/min for 3 minutes. Should myocardial activity persist or recur instill at 300ml/m² body surface area/min for 2 minutes
257	Carvedilol 25 mg Tablet	C07AG02000 T1002XX	A/KK	Treatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics	3.125 mg twice daily for 2 weeks, then 6.25 mg twice daily for 2 weeks, then 12.5 mg twice daily for 2 weeks then 25 mg twice daily (titrated up to the highest tolerated level). Max: <85 kg: 25 mg bid; >85 kg: 50 mg bid.
258	Carvedilol 6.25 mg Tablet	C07AG02000 T1001XX	A/KK	Treatment of stable moderate to severe congestive cardiac failure in addition to ACEI's and diuretics	3.125 mg twice daily for 2 weeks, then 6.25 mg twice daily for 2 weeks, then 12.5 mg twice daily for 2 weeks then 25 mg twice daily (titrated up to the highest tolerated level). Max: <85 kg: 25 mg bid; >85 kg: 50 mg bid.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
259	Caspofungin Acetate 50 mg Injection	J02AX04122P 4001XX	A*	i) Confirmed systemic fungal infection in patients who are refractory or intolerant to other fungal therapies. ii) For pediatric patient (12 month and older) for the following indications : a) Empirical therapy for presumed fungal infections in febrile, neutropenic patients b) Treatment of invasive candidiasis, including candidemia and the following Candida infections ; intra-abdominal abscesses, peritonitis and pleural space infections c) Treatment of esophageal candidiasis d) Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of others therapy (eg : Amphotericin B)	i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70 mg infused over 1 hour followed by subsequent doses of 50 mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV infusion over approximately 1 hour ii) For all indications, a loading dose of 70mg/m2 on D1 followed by maintenance dose of 50mg/m2 od.
260	Caspofungin Acetate 70 mg Injection	J02AX04122P 4002XX	A*	For adult and pediatric patient (12 month and older) for the following indications: a) Treatment of invasive candidiasis, including candidemia and the following Candida infections ; intra-abdominal abscesses, peritonitis and pleural space infections b) Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of others therapy (eg : Amphotericin B) c) Treatment of esophageal candidiasis (need to follow the current indications)	i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70 mg infused over 1 hour followed by subsequent doses of 50 mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV infusion over approximately 1 hour daily ii) Child (12months to 17 years) : For all indication) A single 70mg/m2 loading dose (not to exceed an actual dose of 70mg) by slow IV infusion over 1hour; followed by 50mg/m2 (not to exceed an actual dose of 70mg)
261	Cefaclor 125 mg/5 ml Suspension	J01DC04000F 2101XX	A	Infections caused by susceptible organisms including Staphylococcus aureus and H. influenzae, treatment of sinusitis and infections involving the respiratory tract, skin and skin structure, bone and joint, and urinary tract	CHILD :> 1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid. Maximum: 1 g daily
262	Cefaclor 375 mg MR Tablet	J01DC04010T 5001XX	A	i) Adult pharyngitis, tonsillitis, skin& soft tissue infections ii) Bronchitis iii) Pneumonia iv) Lower	i) 375 mg twice daily ii) 375 mg or 500 mg twice daily iii) 750mg twice daily iv) 375mg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
				UTI	twice daily or 500 mg once daily
263	Cefaclor 500 mg Capsule	J01DC04000C1002XX	A	Infections caused by susceptible organisms including Staphylococcus aureus and H. influenzae, treatment of sinusitis and infections involving the respiratory tract, skin and skin structure, bone and joint, and urinary tract	ADULT: 250 mg 3 times daily for 10 days. For severe infections, double the dosage. Maximum: 4 g daily. CHILD :> 1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid. Maximum: 1 g daily
264	Cefazolin Sodium 1 g Injection	J01DB04520P3001XX	A	Infection caused by cefazolin-sensitive microorganism, infection of the respiratory tract, urogenital tract, skin and soft tissue, bile duct, bones and joint, endocarditis, systemic septic infection, peri-operative/ surgical prophylaxis	ADULT: Uncomplicated infections: 500 - 1000 mg 2 - 3 times daily. Moderately severe and severe infections: 500 - 1000 mg 3 - 4 times daily. Severe life-threatening infections: 1 - 1.5 g 4 times daily. Rarely, dose up to 12 g daily. CHILDREN >1 month: 25-50mg/kg/day in 3-4 divided dose
265	Cefepime 1 g Injection	J01DE01110P4002XX	A*	Febrile neutropenia, septicaemia, lower respiratory tract infection, urinary tract infection, skin and skin structure infections, gynaecologic and intra-abdominal infections	ADULT: 1 - 2 g twice daily for most infections. For severe infections including febrile neutropenia: 2 g 3 times daily. CHILD:2 mth - 16 yr: ≤40 kg: 50 mg/kg every 8-12 hr for 7-10 days
266	Cefepime 500 mg Injection	J01DE01110P4001XX	A*	Febrile neutropenia, septicaemia, lower respiratory tract infection, urinary tract infection, skin and skin structure infections, gynaecologic and intra-abdominal infections	ADULT: 1 - 2 g twice daily for most infections. For severe infections including febrile neutropenia: 2 g 3 times daily. CHILD: 2 mth - 16 yr: ≤40 kg: 50 mg/kg every 8-12 hr for 7-10 days
267	Cefoperazone Sodium 1 g Injection	J01DD12520P4002XX	A	Infections due to gram-negative bacteria	ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly

No.	Generic Name	MDC	Category	Indication(s)	Dosage
268	Cefoperazone Sodium 2 g Injection	J01DD12520 P4003XX	A	Infections due to gram-negative bacteria	ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly
269	Cefoperazone Sodium 500 mg & Sulbactam Sodium 500 mg Injection	J01DD62000 P4001XX	A	i) Treatment of infections due to multi-drug resistance pathogens producing B-lactamase ii) Treatment of infections caused by Acinetobacter species	ADULT: 1 - 2 g twice daily. In severe or refractory infections the daily dosage of sulbactam/cefoperazone may be increased up to 8g (4g cefopreazone activity) CHILD: 40 - 80 mg/kg/day in 2 to 4 equally divided doses; in serious or refractory infections, may increase to 160mg/kg/d in 2 - 4 equally divided doses.
270	Cefoperazone Sodium 500 mg Injection	J01DD12520 P4001XX	A	Infections due to gram-negative bacteria	ADULT: 1 - 2 g twice daily IM or IV. By IV, adult dose may be doubled. Maximum: 16 g daily in divided doses. CHILD & INFANT: 50 - 200 mg/kg/day in 2 - 4 divided doses. NEONATE less than 8 days: 50 - 200 mg/kg/day 12 hourly
271	Cefotaxime 1 g Injection	J01DD01520 P4002XX	A	Infections due to gram-negative bacteria	ADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses
272	Cefotaxime 500 mg Injection	J01DD01520 P4001XX	A	Infections due to gram-negative bacteria	ADULT: 1 g 12 hourly (up to 12 g/day in severe cases). CHILD: 50 - 180 mg/kg/day in 4 - 6 divided doses
273	Ceftaroline Fosamil 600mg Powder for concentrate for solution for infusion	J01D102000P 4001XX	A*	Treatment of complicated skin and soft tissue infections (cSSTI) in adults Restriction: Restricted for only complicated SSTI in patients who are unable to tolerate or not responding to vancomycin.	600mg administered every 12 hours by intravenous infusion over 60 minutes for 5-14 days. Dose adjustment in renal impairment: - CrCl > 30 to ≤50 ml/min : 400mg every 12 hours - CrCl < 30ml/min is not recommended

No.	Generic Name	MDC	Category	Indication(s)	Dosage
274	Ceftazidime 1 g Injection	J01DD02520 P4003XX	A	Severe gram negative bacterial infections	ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
275	Ceftazidime 2 g Injection	J01DD02520 P4004XX	A	Severe gram negative bacterial infections	ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
276	Ceftazidime 250 mg Injection	J01DD02520 P4001XX	A	Severe gram negative bacterial infections	ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
277	Ceftazidime 500 mg Injection	J01DD02520 P4002XX	A	Severe gram negative bacterial infections	ADULT: 1 g 8 hourly or 2 g 12 hourly. In severe infections: 2 g 8 hourly. CHILD: 25 - 150 mg/kg/day in 2 - 3 divided doses
278	Ceftriaxone 0.25 g Injection	J01DD04520 P4001XX	A/KK	i) Gonorrhoea ii) Chancroid	i) 250 mg by deep IM injection ii) single IM injection 250 mg only. For severe infection up to 100 mg/kg/day
279	Ceftriaxone 0.5 g Injection	J01DD04520 P4002XX	A	Infections caused by susceptible organisms	ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. INFANT & CHILD, 3 weeks - 12 years: 20 - 80 mg/kg body weight daily. CHILD with body weight 50 kg or more: adult dose. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg
280	Ceftriaxone 1g Injection	J01DD04520 P4003XX	A	Infections caused by susceptible organisms	ADULT: 1 - 2 g once daily. Severe infection: 4 g daily at 12 hour intervals. INFANT & CHILD, 3 weeks - 12 years: 20 - 80 mg/kg body weight daily. CHILD with body weight 50 kg or more: adult dose. NEONATE up to 2 weeks: 20 - 50 mg/kg body weight daily, not to exceed 50 mg/kg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
281	Cefuroxime Axetil 125 mg Tablet	J01DC02233T1001XX	A/KK	Upper and lower respiratory tract, genito-urinary tract, skin & soft tissue and urinary tract infections (UTI)	ADULT: 250 mg twice daily; UTI: 125 mg twice daily. CHILD:30 mg/kg/day in 2 divided doses, up to 500 mg daily
282	Cefuroxime Axetil 125 mg/5 ml Suspension	J01DC02233F2101XX	A	Infections caused by susceptible organisms	30 mg/kg/day in 2 divided doses, up to 500 mg daily.
283	Cefuroxime Axetil 250 mg Tablet	J01DC02233T1002XX	A/KK	Upper and lower respiratory tract, genito-urinary tract, skin & soft tissue and urinary tract infections (UTI)	ADULT: 250 mg twice daily; UTI: 125 mg twice daily. CHILD:30 mg/kg/day in 2 divided doses, up to 500 mg daily
284	Cefuroxime Sodium 1.5 g Injection	J01DC02520P4003XX	A	Infections caused by susceptible organisms, surgical prophylaxis	ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV
285	Cefuroxime Sodium 250 mg Injection	J01DC02520P4001XX	A	Infections caused by susceptible organisms, surgical prophylaxis	ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV
286	Cefuroxime Sodium 750 mg Injection	J01DC02520P4002XX	A	Infections caused by susceptible organisms, surgical prophylaxis	ADULT: 750 mg every 6 - 8 hours as IM or IV. Severe infections: 1.5 g every 6 - 8 hours as IV. CHILD: 30 - 100 mg/kg/day in 3 - 4 divided doses or 2-3 divided doses in neonates. Surgical prophylaxis: 1.5 g IV

No.	Generic Name	MDC	Category	Indication(s)	Dosage
287	Celecoxib 200 mg Capsule	M01AH0100 0C1001XX	A	i) Osteoarthritis ii) Rheumatoid Arthritis iii) Acute pain iv) Ankylosing Spondylitis	i) ADULTS: 200 mg once daily. May increase to 200 mg bid, if necessary. CHILD not recommended ii) 100mg twice daily, increased if necessary to 200 mg 2 times daily; CHILD not recommended iii) 400mg as a single dose on first day followed by 200mg once daily on subsequent days iv) Initial, 200 mg once daily or 100 mg twice daily; if no effect after 6 weeks, may increase to max. 400 mg daily in 1-2 divided doses. If no response following 2 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment
288	Celecoxib 400 mg Capsule	M01AH0100 0C1002XX	A*	i) Osteoarthritis ii) Rheumatoid Arthritis iii) Acute pain iv) Ankylosing Spondylitis	i) ADULTS: 200 mg once daily. CHILD not recommended ii) 100 mg twice daily, increased if necessary to 200 mg 2 times daily; CHILD not recommended iii) 400 mg as a single dose on first day followed by 200 mg once daily on subsequent days iv) Initial, 200 mg once daily or 100 mg twice daily; if no effect after 6 weeks, may increase to max. 400 mg daily in 1-2 divided doses. If no response following 2 weeks of treatment with 400 mg/day, consider discontinuation and alternative treatment
289	Cephalexin Monohydrate 125 mg/5 ml Syrup	J01DB01010F 2101XX	B	Respiratory tract infections, ear, nose and throat infections, urinary tract infections, obstetric and gynaecologic infections	CHILD: 25 - 100 mg/kg/day every 6 hourly. Maximum: 4 g daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
290	Cephalexin Monohydrate 250 mg Capsule	J01DB01010C1001XX	B	i) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumonia	i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg daily in divided doses. Max: 4 g daily.
291	Cephalexin Monohydrate 250 mg Tablet	J01DB01010T1001XX	B	i) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumonia	i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg daily in divided doses. Max: 4 g daily.
292	Cephalexin Monohydrate 500 mg Capsule	J01DB01010C1002XX	B	i) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumonia	i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day
293	Cephalexin Monohydrate 500 mg Tablet	J01DB01010T1002XX	B	i) Respiratory tract infection, urinary tract infection ii) Complicated, recurrent or chronic infections, bronchitis iii) Pneumonia	i) 250 mg 6 hourly ii) 250 - 500 mg 6 hourly iii) 1 - 1.5 g 3 times daily or 4 times daily. Maximum: 6 g/day Child: 25-100 mg/kg daily in divided doses. Max: 4 g daily.
294	Cetirizine HCl 10 mg Tablet	R06AE07110T1001XX	A/KK	Urticaria, allergic dermatoses (insect bites, atopic eczema), perennial rhinitis, allergic rhinitis	ADULT and CHILD over 6 years: 10 mg daily or 5 mg twice daily. Child 2-6 years: 5 mg once daily or 2.5 mg twice daily
295	Cetrimide 1-2% Lotion.	D08AJ04000L6001XX	C+	As shampoo and cleansing agent	Apply to affected area
296	Cetrorelix 0.25 mg Injection	H01CC02122P4001XX	A*	Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques	Given by SC 0.25 mg/day, given either in the morning beginning on the day 5 or 6 of ovarian stimulation or in the evening beginning on day 5, and continued until ovulation induction

No.	Generic Name	MDC	Category	Indication(s)	Dosage
297	Cetuximab 5 mg/ml Solution for Infusion	L01XC06000P 5002XX	A*	For neo-adjuvant treatment of KRAS wild type metastatic colorectal cancer with the aim of liver resection with the following conditions: i) The primary colorectal tumour has been resected or is potentially resected. ii)The metastatic disease is confined to the liver and is unresectable iii) The patient is fit enough to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab. iv)The treatment is limited to 16 weeks	Administered once a week. The very first dose is 400mg cetuximab per m2 body surface area with a recommended infusion period of 120 minutes. All subsequent weekly doses are 250mg per m2 body surface area each with a recommended infusion period of 60 minutes. The maximum infusion rate must not exceed 10mg/min.
298	Charcoal, Activated 250 mg Tablet	A07BA01000 T1001XX	C	i) Diarrhoea and food poisoning ii) Reduce absorption of drugs, plant, inorganic poison and chemicals in poisoning cases	i) ADULT 0.5-1 g given 3-4 times daily. CHILD half adult dose. ii) Need to be dissolved in liquid (slurry consistency). ADULT and CHILD over 12 years: initial 30-100 g or 1-2 g/kg; repeat initial dose as soon as possible or 20-50 g every 2-6 hours. CHILD over 1-12 years, 25-50 g or 1-2 g/kg; may repeat half the initial dose every 2-6 hour as needed. CHILD to 1 year of age, 1 g/kg; may repeat half the initial dose every 2-6 hours as needed. For maximum efficacy administer within 1 hour after ingestion of toxic compound
299	Charcoal, Activated 50 g Granules	A07BA01000 F1001XX	A	Emergency treatment of acute oral poisoning and drug overdose	ADULT: Acute poisoning: 50 - 100g in suspension. Severe poisoning: 50 - 100g as an initial dose followed by 20g every 4 - 6 hours. CHILDREN: 1g/kg/dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
300	Chloral Hydrate 200 mg/5 ml Mixture	N05CC01010 L2101XX	B	Preoperative sedation	ADULT: 0.5 - 1 g (max 2 g) with plenty of water at bedtime. CHILD: Neonate: 30-50 mg/kg; up to 100 mg/kg may be used with respiratory monitoring. 1 mth-12 yr: 30-50 mg/kg (max: 1 g); up to 100 mg/kg (max: 2 g) may be used; 12-18 yr: 1-2 g. Doses to be taken 45-60 minutes before procedure. May be given rectally if oral route is not available.
301	Chlorambucil 2 mg Tablet	L01AA02000 T1001XX	A	Low grade lymphoma, chronic lymphocytic leukaemia. Ovarian cancer	General: Initial: 0.1 -0.2 mg/kg body weight daily for 4 - 8 weeks maintanance : given either by reduced daily dosage or intermittent course of treatment. Chronic Lymphocytic Leukaemia: initial : 0.15mg/kg/day untill total leukocyte count has fallen to 10,000peruL, then resumed treatment untill 4 weeks after the end of the first course then continued at a dosage 0.1mg/kg/day.
302	Chloramphenicol 0.5% Eye Drops	S01AA01000 D2001XX	C	Broad spectrum antibiotic in superficial eye infections	Instill 1 drop of a 0.5% solution every 2 hr. Increase dosage interval upon improvement. To continue treatment for at least 48 hr after complete healing
303	Chloramphenicol 1% Eye Ointment	S01AA01000 G5101XX	C	Treatment of ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol susceptible organisms	ADULT and CHILD : Apply to the conjunctiva, a thin strip (approximately 1 cm) of ointment every 3 hours or more frequently
304	Chloramphenicol 125 mg/5 ml Suspension	J01BA01126L 8001XX	B	Typhoid fever, salmonella infections, meningitis, cholera, anaerobic and rickettsial infections	CHILD: 25 - 50 mg/kg/day in 4 divided doses. Severe infections, premature& full-term infants less than 2 weeks: 25mg/kg/day in divided doses. Full-term infants more than 2 weeks: up to 50mg/kg/day in

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					divided doses
305	Chloramphenicol 250 mg Capsule	J01BA01126C1001XX	B	Treatment of typhoid, paratyphoid fevers, bronchopneumonia and enteric infection	ADULT: 500 mg 4 times daily or 50 mg/kg/day in 4 divided doses. Maximum dose: 4 g/day. CHILD: 25 - 100 mg/kg/day in 4 divided doses
306	Chloramphenicol 5% w/v Ear Drops	S02AA01000D1001XX	C	Acute otitis media, otitis externa with perforation	Apply 2 - 3 drops into the ear 2 - 3 times daily. Not to be used for long term
307	Chloramphenicol Sodium Succinate 1 g Injection	J01BA01520P4001XX	B	Treatment of typhoid, paratyphoid fevers, bronchopneumonia and enteric infection	Adult:50 to 100 mg/kg/day in 4 divided doses. Premature and full-term neonates: 25 mg/kg/day in 4 divided doses. Full-term infants >2 wk: 50 mg/kg/day in 4 divided doses. Children: 50-100 mg/kg/day in 4 divided doses
308	Chlorhexidine Gluconate 0.2 % Mouthwash	R02AA05137M2001XX	C	As a gargle	Rinse mouth with 10 ml for about 1 minute twice daily
309	Chlorhexidine Gluconate 2% in Alcohol 70% Solution	D08AC52137L9902XX	C	Use as disinfectant in central venous catheter care bundle	Skin Preparation: Use Chlorhexidine Gluconate 2% in Isopropyl Alcohol 70% and allow to dry. Catheter access: Apply to catheter ports or hubs prior to accessing the line for administering fluids or injections
310	Chlorhexidine Gluconate 4% Scrub	D08AC02137M9901XX	C+	Surgical hand scrub/disinfection, pre-op skin preparation	Surgical hand disinfection: Apply 5ml to clean hands and forearms for 1 min. Rinse and repeat with another 5ml for a further 2 minutes, and then rinse and dry. General skin disinfection: Apply appropriate quantity to wet area and scrub for 1 min. Rinse thoroughly & dry
311	Chlorhexidine Gluconate 5% Solution	D08AC02137L9901XX	C+	i) Preoperative skin disinfection ii) Wounds or burns iii) Emergency disinfection of instruments	i) & iii) 1 : 10 in 70 % Alcohol ii) 1 : 100

No.	Generic Name	MDC	Category	Indication(s)	Dosage
312	Chlorhexidine Gluconate 5% Solution 1:10 in 70% alcohol with lanolin as emollient	D08AC52137 L9901XX	C+	To be used undiluted for hand and skin disinfections	Pre-op surgical hand disinfection: Spread 5ml thoroughly over both hands and forearms, rubbing vigorously. When dry apply a further 5ml and repeat procedure. Antiseptic hand disinfection on the ward: Spread 3ml thoroughly over the hands and wrist rubbing vigorously until dry. Disinfection of patient's skin: Prior to surgery, apply to a sterile swab and rub thoroughly over the operation site for a minimum of 2 mins
313	Chlorinated Lime Powder	V07AV00000 F9901XX	C	Antiseptic and disinfectants	Not applicable
314	Chlorinated Lime Solution & Buffered Acetate Solution	D08A000999 G9901XX	C	Wound or ulcer	Apply to affected areas undiluted as a cleansing agent
315	Chloroquine Phosphate 250 mg Tablet (150 mg Chloroquine base)	P01BA01162 T1001XX	C	Treatment of malaria - acute attack	ADULT 600 mg base stat, 300 mg 6 - 8 hours later and a further 300 mg on each of 2 following days. CHILD 3 - 4 years: 150 mg base stat, 75 mg 6 hours later, then 75 mg daily for 2 days. CHILD 5 - 8 years : 300 mg stat, 150 mg 6 hours later, then 150 mg daily for 2 days
316	Chlorpheniramine Maleate 10 mg/ml Injection	R06AB04253 P3001XX	B	Allergic conditions	10 - 20 mg IM or SC, repeated if required. Not to exceed 40 mg in 24 hours. 10 - 20 mg over 1 minute by slow IV
317	Chlorpheniramine Maleate 2 mg/5 ml Syrup	R06AB04253 L9001XX	C	Symptomatic treatment of allergic conditions responsive to antihistamine	CHILD 1 - 2 years : 1 mg twice daily, 2 - 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily), 6 - 12 years : 2 mg every 4 - 6 hours (maximum 12 mg daily)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
318	Chlorpheniramine Maleate 4 mg Tablet	R06AB04253 T1001XX	C	Symptomatic treatment of allergic conditions responsive to antihistamines	ADULT: 4 mg every 4 - 6 hours. Maximum 24 mg daily. CHILD 1 - 2 years : 1 mg twice daily, 2 - 5 years : 1 mg every 4 - 6 hours (maximum 6 mg daily), 6 - 12 years : 2 mg every 4 - 6 hours (maximum 12 mg daily)
319	Chlorpromazine HCl 100 mg Tablet	N05AA01110 T1002XX	B	Psychosis mania and agitation	ADULT: Initial dose - 25 mg 3 times daily according to response up to 1 g daily. PAEDIATRIC: Up to 5 years: 0.5 mg/kg body weight every 4 - 6 hours (Maximum 40 mg daily). CHILD 6 - 12 years: A third to half adult dose (Maximum 75 mg daily)
320	Chlorpromazine HCl 25 mg Tablet	N05AA01110 T1001XX	B	Psychosis mania and agitation	ADULT: Initial dose - 25 mg 3 times daily according to response up to 1 g daily. PAEDIATRIC: Up to 5 years: 0.5 mg/kg body weight every 4 - 6 hours (Maximum 40 mg daily). CHILD 6 - 12 years: A third to half adult dose (Maximum 75 mg daily)
321	Chlortetracycline 1% Eye Ointment	S01AA02000 G5101XX	B	Eye infections requiring a broad spectrum antibiotic	Apply thin strip (approximately 1 cm) to the conjuctiva 2 to 4 hourly or more frequently.
322	Chlortetracycline 1-3 % Cream	D06AA02000 G1001XX	B	Bacterial skin infections	Apply directly to affected area twice daily as required for 1 - 2 weeks
323	Cholera Vaccine	J07AE01000P 3001XX	B	Immunisation of cholera	Prophylactic ADULT: First dose of 0.5 ml SC/IM followed after 1 - 4 weeks by a second dose of 1 ml. CHILD: 1 - 5 years: 0.1 ml (1st dose), 0.3 ml (2nd dose). CHILD; 5 - 10 years: 0.3 ml (1st dose), 0.5ml (2nd dose). Booster: For optimum long-term protection, a booster dose is recommended for adults

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					after 2 years. Children 2-6 years should receive a booster dose after 6 months.
324	Cholestyramine Resin 4 G	C10AC01000 M4001XX	A	i) Hypercholesterolemia ii) Familial hypercholesterolemia - heterozygous iii) Generalized atherosclerosis iv) Diarrhoea due to bile acid malabsorption v) Pruritus of skin associated with partial biliary obstruction	Hypercholesterolemia: Adjunct: initial, 4 g orally 1-2 times daily, maintenance, 8 to 16 g in divided doses, max 24 g daily CHILD: 50 - 150 mg/ kg 6 - 8 hourly oral
325	Choline Salicylate 8.7%, Cetylkonium Chloride 0.01% Dental Gel	N02BA03900 G3001XX	B	For relief of the pain and discomfort in mouth ulcers and sores, infant teething and denture irritation	Apply to area 4 times daily
326	Choriogonadotropin Alfa 250 mcg/0.5 ml Injection in Prefilled Syringe	G03GA01000 P5001XX	A*	i)Women undergoing superovulation prior to assisted reproductive techniques such as in-vitro fertilization (IVF) ii)Anovulatory or oligo-ovulatory women	250 mcg 24-48 hour after the last administration of an FSH or hMG preparation, when optimal stimulation of follicular growth is achieved.
327	Chorionic Gonadotrophin Human (HCG) 5000 IU Injection	G03GA01000 P4001XX	A*	i)Treatment of infertile women to induce ovulation ii) As a luteal support in controlled ovarian hyperstimulation cycles	i) & ii)Induction of ovulation: 5000 - 10,000 units one day following last dose of menotropin. Up to 3 repeat injections of 5000 units each may be given within the following 9 days to prevent insufficiency corpus luteum
328	Ciclesonide 160mcg Inhaler	R03BA08000 A2101XX	A*	Prophylactic treatment of asthma in adults, adolescents and children over 6 years (follow current indication) Not meant for 6 yo)	For adults and adolescents over 12 years of age with mild to moderate asthma is 160 to 640mcg per day: severe asthma dose may be increased to 1280mcg per day.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
329	Ciclosporin 100 mg Capsule	L04AD01000 C1002XX	A*	Only for: i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema vii) Treatment of chronic ocular inflammatory disorders/uveitis	i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day. vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5 mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in resistant cases. Maintenance: Less than 5 mg/kg/day especially during remission

No.	Generic Name	MDC	Category	Indication(s)	Dosage
330	Ciclosporin 100 mg/ml Drink Solution	L04AD01000 L5002XX	A*	Only for : i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe Rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anaemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema	i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
331	Ciclosporin 25 mg Capsule	L04AD01000 C1001XX	A*	Only for: i) Patients in whom donor specific transplantation cannot be carried out and in young children to minimise side-effects of steroids ii) Follow-up cases of bone marrow transplant iii) Patients with severe rheumatoid arthritis not responding to other second line drugs iv) Patients with idiopathic nephrotic syndrome who are steroid toxic or poor response to cyclophosphamide v) Severe aplastic anemia, pure red cell aplasia vi) Cases of recalcitrant psoriasis and atopic eczema vii) Treatment of chronic ocular inflammatory disorders/uveitis	i & ii) Initially 12.5 - 15 mg/kg/day, beginning on the day before transplant. Maintenance approx 12.5 mg/kg/day for 3 - 6 months before being tapered off to zero by 1 year of transplantation iii) 3 mg/kg/day in 2 divided doses for first 6 weeks. May increased gradually to maximum 5 mg/kg. Treatment withdrawn if no response after 3 months iv) ADULT: 5 mg/kg/day in 2 divided doses. CHILD: 6 mg/kg/day in 2 divided doses. Patients with permitted levels of kidney failure, the starting dose must not more than 2.5 mg/kg/day v) 12 mg/kg/day vi) 2.5 mg/kg/day in 2 divided doses increasing if there is no improvement after 4 weeks by 0.5 -1 mg/kg/month up to maximum 5 mg/kg/day vii) 5 mg/kg/day in 2 divided doses, may increase to 7 mg/kg/day in resistant cases. Maintenance: Less than 5 mg/kg/day especially during remission
332	Ciclosporin 50 mg/ml Injection	L04AD01000 P3001XX	A*	i) Post bone marrow transplant ii) Solid organ transplant	i) 3 - 5 mg/kg/day until tolerate orally ii) 2 - 3 mg/kg/day for recipients who are unable to take orally
333	Cilostazol 100 mg Tablet	B01AC00000 T1002XX	A*	Improvement of the maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis.	100 mg twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
334	Cimicifuga Racemosa Rhizome Extract 20 mg Tablet	HG03WA500 1T1001XX	A	Traditionally used for the relief of hot flushes, sweating, restlessness associated with menopause	20 mg twice daily
335	Cinnarizine 25 mg Tablet	N07CA02000 T1001XX	B	Vestibular disorders	One tablet 3 times daily
336	Ciprofloxacin 100 mg/50 ml Injection	J01MA02125 P3001XX	A	Treatment of infections due to susceptible bacterial strains	ADULT: the dosage range is 100-400mg twice daily Gonorrhoea: 100mg single dose Upper and Lower Urinary Tract Infection: 100mg bd Upper and Lower Respiratory Tract Infection: 200mg bd-400mg twice daily Cystic Fibrosis with psuedomonal Lower RTI: 400mg bd Others: 200-400mg bd inhalation Anthrax: 400mg bd
337	Ciprofloxacin 200 mg/100 ml Injection	J01MA02125 P3002XX	A	Treatment of infections due to susceptible bacterial strains	Suggest to rephrase ADULT: the dosage range is 100-400mg twice daily Gonorrhoea: 100mg single dose Upper and Lower Urinary Tract Infection: 100mg bd Upper and Lower Respiratory Tract Infection: 200mg bd-400mg twice daily Cystic Fibrosis with psuedomonal Lower RTI: 400mg bd Others: 200-400mg bd inhalation Anthrax: 400mg bd
338	Ciprofloxacin 250 mg Tablet	J01MA02110 T1001XX	A	Treatment of infections due to susceptible bacterial strains	ADULT: 125-750 mg twice daily. Acute gonorrhoea: a single dose of 250 mg
339	Ciprofloxacin 500 mg Tablet	J01MA02110 T1002XX	A	Treatment of infections due to susceptible bacterial strains	ADULT: 125-750 mg twice daily. Acute gonorrhoea: a single dose of 250 mg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
340	Ciprofloxacin HCl 0.3% Ophthalmic Solution	S01AX13110 D2001XX	A*	Treatment of bacterial infections caused by susceptible strains in i) corneal ulcers ii) bacterial conjunctivitis	i) 2 drops every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the rest of the first day. Second day: 2 drops every hour. Subsequent days (3rd - 14th day): 2 drops every 4 hours. Treatment may be continued after 14 days if corneal re-epithelialization has not occurred ii) 1 - 2 drops every 2 hours into the conjunctival sac while awake for 2 days and 1-2 drops every 4 hours while awake for the next 5 days
341	Cisatracurium Besylate 2 mg/ml Injection	M03AC11197 P3001XX	A*	As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation. Restricted to patients with lung problem such as asthma.	Administered as bolus intravenous injection. May be administered as infusion in ICU patients at a rate of 3mcg/kg/min. Adult dose: a) Induction: 0.15mg/kg over 5-10 secs, b) Maintenance: 0.03 mg/kg. Children 2-12 years: a) Induction: 0.1 mg/kg over 5-10 secs, b) Maintenance: 0.02 mg/kg
342	Cisplatin 10 mg Injection	L01XA01000 P3001XX	A	Germ cell tumours, ovarian tumours, adult solid tumours, lymphomas	Germ cell tumours: 20 mg/m2 daily for 5 days every 3 weeks for 3 - 4 courses. Ovarian tumours: 75 mg/m2 once every 3 weeks as part of combination therapy with paclitaxel or 50-60mg/m2 IV once every 3 weeks as a single agent. Baseline creatinine clearance, pretreatment hydration and forced diuresis are mandatory. CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols

No.	Generic Name	MDC	Category	Indication(s)	Dosage
343	Cisplatin 50 mg Injection	L01XA01000 P3002XX	A	Germ cell tumours, ovarian tumours, adult solid tumours, lymphomas	Germ cell tumours: 20 mg/m2 daily for 5 days every 3 weeks for 3 - 4 courses. Ovarian tumours: 75 mg/m2 once every 3 weeks as part of combination therapy or 100 mg/m2 IV once every 3 weeks as a single agent. Baseline creatinine clearance, pretreatment hydration and forced diuresis are mandatory. CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols CHILD: 100mg/m2 over 6 hours once every 3 weeks. Lymphomas: Refer to protocols
344	Clarithromycin 125 mg/5 ml Granules	J01FA09000F 1001XX	A*	Treatment of complicated respiratory tract infections not responding to standard macrolides	CHILD: 8 - 12 years: 30 - 40 kg 10 mL, 4 - 8 years: 20 - 29 kg 7.5 mL, 2 - 4 years: 12 - 19 kg 5 mL, 1 - 2 years: 8 - 11 kg 2.5 mL, less than 8 kg: 7.5 mg/kg. To be given twice daily. Maximum dose: 1g/day
345	Clarithromycin 250 mg Tablet	J01FA09000T 1001XX	A*	Only for i) treatment of complicated respiratory tract infection not responding to standard macrolides ii) eradication of Helicobacter pylori infection	i) 250 - 500 mg twice daily. Up to 6 - 14 days ii) 500 mg twice daily with omeprazole & amoxicillin. Up to 2 weeks
346	Clarithromycin 500 mg Injection	J01FA09000P 3001XX	A*	Only for treatment of complicated respiratory tract infection not responding to standard macrolides	Susceptible infections Adult: 500 mg bid for 2-5 days. Dose to be infused over 60 minutes in a 0.2% solution; revert to oral therapy whenever possible. Child: 1 mth-12 yr: 7.5 mg/kg every 12 hr. Dose to be given via infusion into proximal vein. Dosage Recommendation CrCl (ml/min)<30 : Half the dosage or double dosing interval

No.	Generic Name	MDC	Category	Indication(s)	Dosage
347	Clindamycin HCl 300 mg Capsule	J01FF01110C 1001XX	A*	i) Skin and soft tissue infections, bone& joint infections ii) Cerebral toxoplasmosis iii) Children less than 8 years old: Treatment and prophylaxis of malaria in combination with quinine, as an alternative to doxycycline	i) ADULT: 150 - 300 mg every 6 hours; up to 450 mg every 6 hours in severe infections; Max: 1.8g/day CHILD: 3 - 6 mg/kg every 6 hours. Children weighing <10 kg should receive at least 37.5 mg every 8 hr. ii) 600 mg 6 hourly for 6 weeks iii) 10mg/kg twice a day, in combination with quinine. The combination to be given for 7 days
348	Clindamycin Phosphate 150 mg/ml Injection	J01FF01162P 3001XX	A*	i) Skin and soft tissue infections, bone & joint infections ii) Cerebral toxoplasmosis	i) ADULT: 0.6 - 2.7 g daily (in 2 - 4 divided doses); up to 4.8 g daily; CHILD over 1 month, 20 - 40 mg/kg/day or 350 mg/m2/day in 3 - 4 divided doses ii) 1200 mg every 6 hours for 3 weeks followed by 300 mg orally every 6 hours for another 3 weeks
349	Clobazam 10 mg tablet	N05BA09000 T1001XX	A*	As adjunctive therapy in patients with epilepsy not adequately stabilised with their basic medication.	The initial dose in adults and adolescents >15 yr should be low (5 to15mg daily), if necessary, increased gradually to a maximum daily dose of about 80mg. Doses of up to 30mg may be taken as a single dose in the evening. The initial dose in children from 3 to15 yr is normally 5mg. A maintenance dose of 0.3 to 1.0mg/kg body weight daily is usually sufficient.
350	Clobetasol Propionate 0.05% Cream	D07AD01133 G1001XX	A	Short term treatment only of more resistant dermatoses eg. psoriasis, recalcitrant eczemas, lichen planus, discoid lupus erythematosus and other conditions which do not respond satisfactorily to less potent steroids	Apply sparingly once or twice daily, changing to lower potency therapy as soon as condition is controlled. For mild to moderate use maximum for 2 weeks. For moderate to severe maximum duration 4 consecutive weeks. Max: 50 g/week

No.	Generic Name	MDC	Category	Indication(s)	Dosage
351	Clobetasol Propionate 0.05% Ointment	D07AD01133 G5001XX	A	Short term treatment only of more resistant dermatoses eg. psoriasis, recalcitrant eczemas, lichen planus, discoid lupus erythematosus and other conditions which do not respond satisfactorily to less potent steroids	Apply sparingly once or twice daily, changing to lower potency therapy as soon as condition is controlled. For mild to moderate use maximum for 2 weeks. For moderate to severe maximum duration 4 consecutive weeks. Max:50 g/week
352	Clobetasone Butyrate 0.05% Cream	D07AB01255 G1001XX	A/KK	Eczema and dermatitis of all types	Apply up to four times daily until condition improves, then reduce frequency
353	Clobetasone Butyrate 0.05% Ointment	D07AB01255 G5001XX	A	Eczema and dermatitis of all types	Apply up to four times daily until condition improves, then reduce frequency
354	Clodronate 800 mg Tablet	M05BA02011 T1011XX	A*	Treatment of hypercalcaemia due to malignancy	2 tablets in single or two divided doses
355	Clofazimine 100 mg Capsule	J04BA01000C 1002XX	B	i) Previously untreated leprosy patients ii) Leprosy patients resistant to sulphones iii) Suppression of lepra reactions	i) ADULT: 100 mg each other day or 50 mg daily with 100mg Dapsone & 300mg once a month with 600mg rifampicin under supervision. Maximum: 200 mg/day. CHILD: 10-14 yr: 50mg clofazimine on alternate days with 50mg dapsone & 150 mg clofazimine with 450 mg rifampicin once a month.Maximum: 100 mg/day. ii) 100 mg daily iii) 200-300mg usually effective. Treatment with minimum suppression dose continued for at least 6 months

No.	Generic Name	MDC	Category	Indication(s)	Dosage
356	Clofazimine 50 mg Capsule	J04BA01000C 1001XX	B	i) Previously untreated leprosy patients ii) Leprosy patients resistant to sulphones iii) Suppression of lepra reactions	i) ADULT: 100 mg each other day or 50 mg daily with 100mg Dapsone & 300mg once a month with 600mg rifampicin under supervision. Maximum: 200 mg/day. CHILD: 10-14 yr: 50mg clofazimine on alternate days with 50mg dapsone & 150 mg clofazimine with 450 mg rifampicin once a month.Maximum: 100 mg/day. ii) 100 mg daily iii) 200-300mg usually effective. Treatment with minimum suppression dose continued for at least 6 months
357	Clomiphene Citrate 50mg Tablet	G03GB02136 T1001XX	A	Anovulatory infertility	50 mg daily from 2nd - 6th or 5th - 9th day of menstrual cycle. Increase dose gradually by increments of 50 mg if there is no response until a dosage of 200 mg daily is achieved (starting as early as 30 days afer the previous course). Further treatment may not be recommended if pregnancy has not occurred after a total of 6 treatment cycles.
358	Clomipramine HCl 25 mg Tablet	N06AA04110 T1001XX	A	Depression, obsessive-compulsive disorder.	Initially 10 mg daily, increased gradually as necessary to 30 - 150 mg daily in divided doses or as a single dose at bedtime; max 250 mg daily. ELDERLY initially 10 mg daily increased carefully over approximately 10 days to 30 - 75 mg daily; Child: ≥10 yr: Initially, 25 mg daily increased gradually over 2 wk. Max: 3 mg/kg/day or 100 mg daily, whichever is smaller. Give in divided doses. Once titrated, dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					may be given as a single dose at bedtime.
359	Clonazepam 0.5 mg Tablet	N03AE01000 T1001XX	B	i) Epilepsy ii) Non-epileptic myoclonus	i) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided into 3 doses, may be increased in increments of 0.5mg every 3 days until seizures are controlled. Maintenance dose: 3-6mg/day. Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03 mg/kg/day in 2-3 divided doses, increased by no more than 0.25-0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16 years: initial dose 1-1.5mg/day in 2-3 divided dose, may be increased by 0.25-0.5mg every third day until individual maintenance dose of 3-6mg/day is reached.
360	Clonazepam 2 mg Tablet	N03AE01000 T1002XX	B	i) Epilepsy ii) Non-epileptic myoclonus	i) & ii) ADULT: Initial dose should not exceed 1.5mg/day divided into 3 doses, may be increased in increments of 0.5mg every 3 days until seizures are controlled. Maintenance dose: 3-6mg/day. Maximum: 20mg/day. CHILD up to 10 years: initial dose 0.01-0.03 mg/kg/day in 2-3 divided doses, increased by no more than 0.25-0.5mg every third day, maximum 0.2mg/kg/day. CHILD 10-16 years: initial dose 1-1.5mg/day in 2-3 divided dose, may be increased by 0.25-0.5mg every third day until individual maintenance dose of 3-6mg/day is reached.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
361	Clonidine HCl 0.025 mg Tablet	N02CX02110 T1001XX	A	Rapid opiod detoxification combination use with naltrexone	Rapid detoxification in 4-5 days (use with naltrexone): 6 mcg/kg ORALLY divided in 3 doses 6 to 8 hours apart the first day, increasing to 11 mcg/kg divided in 3 doses given day two, tapering to 0.6 mcg/kg the third day. Rapid opioid detoxification for 7 days (use with naltrexone) : 0.1 to 0.2 mg every 4 hours as needed
362	Clopidogrel 75 mg Tablet	B01AC04192 T1001XX	A*	Prevention of myocardial infarct, stroke or established peripheral arterial disease. As second/third line treatment in patients who are sensitive to acetylsalicylic acid & intolerant to ticlopidine	75 mg once daily
363	Clostridium Botulinum Toxin Type A 100 units	M03AX01000 P4001XX	A*	i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy	20 - 200 units 3 months once
364	Clostridium Botulinum Type A toxin haemagglutinin complex 300 units/vial powder for injection	M03AX01000 P4003XX	A*	i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy	Initially 20 U/kg divided between both calf muscles. May be titrated 10-30 U/kg up to max of not >1000 U/patient. Should only be used in children > 2 years of age. Repeat injections given not less than 3 months from previous injection.
365	Clostridium botulinum Type A toxin haemagglutinin complex 500U/vial powder for injection	M03AX01000 P4002XX	A*	i) Focal dystonias ii) Hemifacial spasm iii) Spasticity including cerebral palsy	Initially 20 U/kg divided between both calf muscles. May be titrated 10-30 U/kg up to max of not >1000 U/patient. Should only be used in children > 2 years of age. Repeat injections given not less than 3 months from previous injection.
366	Clotrimazole 1% Cream	D01AC01000 G1001XX	B	Cutaneous candidiasis, Tinea corporis, Tinea cruris, Tinea pedis and Tinea versicolor	Rub in gently onto affected and surrounding skin 2 or 3 times daily continuing for about 2 weeks beyond the dissapearance of all symptoms

No.	Generic Name	MDC	Category	Indication(s)	Dosage
367	Clotrimazole 1% Ear Drop	S02AA00000 D1002XX	B	Otomycosis; concomitant therapy with antibiotics and corticosteroid ear drops	4 to 5 drops 3 to 4 times daily
368	Clotrimazole 1% Solution	D01AC01000 L6001XX	A	Cutaneous candidiasis, tinea orporis, tinea cruris, tinea pedis and tinea versicolor	Apply gently onto affected and surrounding skin area 2 or 3 times daily continuing for 2-4 weeks
369	Clotrimazole 200 mg Vaginal Tablet	G01AF02000 S1002XX	B	Vaginal candidiasis	200 mg once daily, preferably at bedtime for three consecutive days
370	Clotrimazole 500 mg Vaginal Tablet	G01AF02000 S1003XX	B	Vaginal candidiasis	500 mg as a single one-time dose
371	Cloxacillin Sodium 125 mg/5 ml Suspension	J01CF02520L 8001XX	B	Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci	Child: 50-100 mg/kg in divided doses every 6 hr
372	Cloxacillin Sodium 250 mg Capsule	J01CF02520C 1001XX	B	Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci	ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in divided doses every 6 hr.
373	Cloxacillin Sodium 250 mg Injection	J01CF02520P 4001XX	B	Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci infections	ADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours
374	Cloxacillin Sodium 500 mg Capsule	J01CF02520C 1002XX	B	Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci	ADULT: 250 - 500 mg every 6 hours. Child: 50-100 mg/kg in divided doses every 6 hr.
375	Cloxacillin Sodium 500 mg Injection	J01CF02520P 4002XX	B	Treatment of susceptible bacterial infections, notably penicillinase-producing staphylococci infections	ADULT: 250 to 500 mg every 6 hours depending on type and severity of infection. CHILD less than 20 kg: 25 to 50 mg/kg/day in equally divided doses every 6 hours
376	Clozapine 100 mg Tablet	N05AH02000 T1002XX	A	Treatment of resistant schizophrenia	Initial dose: 12.5 mg (once or twice) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
377	Clozapine 25 mg Tablet	N05AH02000 T1001XX	A	Treatment of resistant schizophrenia	Initial dose: 12.5 mg (once or twice) daily, increase slowly in steps of 25 - 50 mg up to 300 mg daily within 2 - 3 weeks. Maximum 900 mg/day
378	Coal Tar 1- 6 % in Betamethasone 17 - Valerate 0.01 % Ointment	D05AA00946 G5003XX	B	Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis	Apply to the affected areas sparingly 1-2 times daily
379	Coal Tar 1-9% Ointment	D05AA00000 G5001XX	B	Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis. Used as a mild astringent for the skin, as a soothing and protective application in eczema and as a protective to slight excoriation	Apply sparingly to the affected area 1-3 times daily starting with low strength preparations
380	Coal Tar 20% Solution	D05AA00000 L5201XX	B	Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis	Use 100 ml in a bath
381	Coal Tar and Salicylic Acid (various concentrations) Ointment	D05AA00946 G5002XX	B	Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis	Apply to the affected areas
382	Coal Tar with Salicylic Acid (various concentrations) Solution	D05AA00000 L5202XX	B	Dandruff, seborrhoeic dermatitis, atopic dermatitis, eczema and psoriasis	Apply to the affected areas or as in product leaflet
383	Cocaine 10% Solution	N01BC01110 L5001XX	B	To produce local anaesthesia or vasoconstriction during endoscopic nasal surgery, turbinectomy septoplasty, polypectomy etc	Maximum total dose recommended for application to the nasal mucosa in healthy adult is 1.5 to 2 mg/kg of a 10% cocaine solution
384	Cocois Co. Ointment	D05AA00946 G5001XX	B	Scalp psoriasis and severe seborrhoeic dermatitis	Rub a small amount into the scalp gently

No.	Generic Name	MDC	Category	Indication(s)	Dosage
385	Colchicine 0.5 mg Tablet	M04AC01000 T1001XX	B	i) Acute gout and prophylaxis of recurrent gout. ii) Leucocytoclastic Vasculitis either cutaneous or systemic involvement, Behcet's syndrome, Urticarial vasculitis, Systemic sclerosis, Sweet's syndrome and severe recalcitrant aphthous stomatitis	i) Initial dose, 0.5-1.2 mg, and then 0.5-0.6 mg every hour until relief of pain is obtained or vomiting or diarrhoea occurs (Maximum: 8 mg). The course should not be repeated within 3 days. Prevention of attacks during initial treatment with allopurinol or uricosuric drugs: 0.5 mg 1-3 times daily. ii) 0.5 mg 1-3 times daily depends on disease and severity, up to a maximum of 3 mg/day
386	Colloidal Bismuth Subcitrate 120 mg Tablet	A02BX05136 T1001XX	A	Eradication therapy for Helicobacter Pylori in combination with antibiotics and antisecretory drugs	240 mg twice daily for 1-2 weeks
387	Compound Sodium Lactate (Hartmanns Solution)	B05XA30125 P6001XX	C	Replacement of extracellular losses of fluid and electrolytes, as an alkaliniser agent	100-1000 ml by IV or according to the needs of the patient
388	Conjugated estrogens 0.3 mg Tablet	G03CA57000 T1003XX	A	i) Osteoporosis associated with oestrogen deficiency ii) Female hypoestrogenism iii) Vasomotor symptoms associated with oestrogen deficiency iv)atrophic vaginitis and urethritis	i) 0.3 - 0.625 mg daily ii) 0.3-1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily
389	Conjugated Estrogens 0.625 mg & Medroxyprogesterone Acetate 2.5 mg Tablet	G03FA12295 T1002XX	A	Management of moderate to severe vasomotor symptoms associated with menopause, prevention and management of postmenopausal osteoporosis, atropic vaginitis and atropic urethritis in post menopausal woman with intact uterus	1 tablet daily
390	Conjugated Oestrogens 0.625 mg Tablet	G03CA57000 T1001XX	A	i) Osteoporosis associated with oestrogen deficiency ii) Female hypoestrogenism iii) Vasomotor symptoms associated with oestrogen deficiency iv)atrophic vaginitis and urethritis	i) 0.3 - 0.625 mg daily ii) 0.3-1.25mg daily for 3weeks, then off for 1 week iii) & iv) 0.3mg-1.25mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
391	Conjugated Oestrogens 0.625 mg/g Cream	G03CA57000 G1001XX	A	Atrophic vaginitis and post menopausal atrophic urethritis	Intravaginally or topically 0.5-2g daily, depending on severity of condition. Administration should be cyclic, with 3 weeks on conjugated estrogens and one week off. Estrogens should be used for the shortest duration possible when treating atrophic vaginitis. Every 3 to 6 months attempts should be made to taper or discontinue therapy and conjugated estrogens should be titrated to give the lowest possible dosage to control symptoms
392	Continuous Ambulatory Peritoneal Dialysis (CAPD) Solution containing 2.3% glucose (Calcium 1.75mmol/L) & (Calcium 1.25mmol/L)	B05DB00908 H2504XX	B	For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre	Dose depending on clinical cases
393	Continuous Ambulatory Peritoneal Dialysis Solution containing 1.5% Dextrose	B05DB00908 H2501XX	B	For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre	Dose depending on clinical cases
394	Continuous Ambulatory Peritoneal Dialysis Solution containing 2.5% Dextrose	B05DB00908 H2502XX	B	For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre	Dose depending on clinical cases
395	Continuous Ambulatory Peritoneal Dialysis Solution containing 4.25% Dextrose	B05DB00908 H2503XX	B	For chronic renal diseases requiring dialysis and acute therapy-resistance renal failure eg. prior to transfer to a dialysis centre	Dose depending on clinical cases

No.	Generic Name	MDC	Category	Indication(s)	Dosage
396	Copper 250 mm2 Intrauterine Device	G02BA02000 M9001XX	B	Intrauterine contraception	One unit intrauterine device to be inserted into the uterine cavity on the last day of the menstrual flow or in the first days afterwards. It is advised that the Multiload Cu 250 devices are replaced every 3 years
397	Copper 375 mm2 Intrauterine Device	G02BA02000 M9002XX	B	Contraception	One unit intrauterine device to be inserted into the uterine cavity on the last day of the menstrual flow or in the first days afterwards. It is advised that the Multiload Cu 375 devices are replaced every 5 years
398	Copper Sulphate Crystal	D08A000183 F9901XX	C	Wounds	The tip of the crystal should be moistened by dipping in water and applied carefully to the lesion
399	Corifollitropin Alfa 100mcg/0.5ml solution for injection	G03GA09000 P5001XX	A*	Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program Restriction: As second line treatment alternative to other recombinant FSH	Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
400	Corifollitropin Alfa 150mcg/0.5ml solution for injection	G03GA09000 P5002XX	A*	Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in woman participating in an Assisted Reproductive Technology (ART) program Restriction: As second line treatment alternative to other recombinant FSH	Women with Body Weight ≤60 kg: A single dose of 100 mcg should be administered. Women with Body Weight >60 kg: A single dose of 150 mcg should be administered. Details : Refer to Product Information
401	Cortisone Acetate 5 mg Tablet	H02AB10122 T1002XX	B	For salt losing congenital adrenal hyperplasia in newborn and paediatric patients	20-30 mg/m2 daily. Doses may be divided with two-thirds in the morning and one-third late in the afternoon

No.	Generic Name	MDC	Category	Indication(s)	Dosage
402	Crotamiton 10 % Cream	P03A000000 G1001XX	A/KK	i) Pruritus ii) Scabies iii) Insect bite reactions	i) and iii) Massage into affected area until the medication is completely absorbed. Repeat as needed. Apply 2 or 3 times daily ii) Apply to the whole body from below the chin. 2nd application is applied 24 hr later. May need to use once daily for up to 5 days.
403	Cyanocobalamin 0.1 mg Injection	B03BA01000 P3001XX	B	i) Prophylaxis of anaemia ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption	i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). Maintenance: 100 mcg monthly to sustain remission OR AS PRESCRIBED.
404	Cyanocobalamin 1 mg Injection	B03BA01000 P3002XX	B	i) Prophylaxis of anaemia associated with Vitamin B12 deficiency ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption	i) Prophylaxis of anaemia: 250-1000 mcg IM every month ii) Uncomplicated pernicious anaemia or Vitamin B12 malabsorption: Initial 100 mcg daily for 5-10 days followed by 100-200 mcg monthly until complete remission is achieved. Maintenance: up to 1000 mcg monthly. CHILD 30-50 mcg daily for 2 or more weeks (to a total dose of 1-5mg). OR AS PRESCRIBED.
405	Cyanocobalamin 50 mcg Tablet	B03BA01000 T1002XX	B	Vitamin B12 deficiency of dietary origin	ADULT 50-150 mcg daily. CHILD 50-105 mcg daily in 1-3 divided doses
406	Cyclopentolate 0.2% with Phenylephrine 1% Eye Drops	S01GA55990 D2001XX	A	Dilating agent for premature babies	1 drop every 5 - 10 minutes; not exceeding three times to produce rapid mydriasis. Observe infants closely for

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					at least 30 minutes
407	Cyclopentolate 0.5% Eye Drops	S01FA04000 D2001XX	A	Mydriasis and cycloplegia	1 drop of solution in eye(s); may repeat after 5 to 10 minutes if needed. INFANT : Single instillation of 1 drop of 0.5% solution in the eye; apply pressure to nasolacrimal sac for 2 to 3 minutes; observe infant closely for at least 30 minutes for signs or symptoms of systemic absorption
408	Cyclopentolate 1% Eye Drops	S01FA04000 D2002XX	A	Mydriasis and cycloplegia	ADULT: 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. CHILD: 1 drop of solution in eye(s); may repeat after 5-10 minutes if needed. Pre-treatment on the day prior to examination is usually not necessary. If desirable, 1 or 2 drops may be instilled the evening prior to examination.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
409	Cyclophosphamide 1 g Injection	L01AA01000 P4002XX	A	i) Solid tumours (adult and paediatric), leukaemia, non-Hodgkin's lymphoma, multiple myeloma ii) Severe lupus nephritis (Class III and IV) iii) Other systemic vasculitis iv) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis v) Pemphigus vulgaris	i) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols ii) 750 mg/m2 BSA monthly for 18 months iii) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression iv) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals v) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide

No.	Generic Name	MDC	Category	Indication(s)	Dosage
410	Cyclophosphamide 200 mg Injection	L01AA01000 P4001XX	A	i) Solid tumours (adult and paediatric), leukaemia, non-Hodgkin's lymphoma, multiple myeloma ii) Severe lupus nephritis (Class III and IV) iii) Other systemic vasculitis iv) Systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis v) Pemphigus vulgaris	i) ADULT: 600 - 750 mg/m2 IV once every 3 weeks as part of combination regime. CHILD: Dose variable depending on disease and protocol. Range 600 mg/m2 to 2 g/m2 infusion over 1 hour to 6 hours (lower doses can be given as bolus). Care with pre and post-hydration. Mesna to be given with doses more than 1 g/m2. Higher doses are used in haematopoetic stem cell transplant-refer to specific protocols ii) 750 mg/m2 BSA monthly for 18 months iii) 750 mg/m2 BSA monthly for 6 months. Dose can be adjusted up to 1,000 mg/m2 BSA to achieve adequate leucocyte suppression iv) 500 - 1000 mg intravenously (Regime varies according to indication). Starting dose may be given fortnightly then at monthly intervals followed by 3 monthly intervals v) 500 mg infusion on the 2nd day of the dexamethasone-cyclophosphamide pulsed regime, the cycle is repeated every 4 weeks up to 6 cycles or till remission followed by oral cyclophosphamide

No.	Generic Name	MDC	Category	Indication(s)	Dosage
411	Cyclophosphamide 50 mg Tablet	L01AA01000 T1001XX	A	i) Solid tumours, leukaemia, lymphoma, autoimmune disorders, autoimmune bullous diseases, connective tissue disease, pyoderma gangrenosum ii) For severe lupus nephritis (Class III & IV), systemic vasculitis and steroid resistant/dependent nephrotic syndrome iii) Systemic lupus erythematosus (SLE), rheumatoid arthritis, polyarteritis nodosa, wegener granulomatosis	i) ADULT: 50 - 100 mg/day. Monitor full blood count (FBC), liver function, urine microscopy and renal function. CHILD, up to 1 year: 10 - 20 mg daily, 1 - 5 years: 30 - 50 mg daily, 6 - 12 years: 50 - 100 mg daily ii) 2 mg/kg/day for 3 - 4 months iii) 1 - 1.5 mg/kg/day orally in divided doses
412	Cycloserine 250 mg Capsule	J04AB01000C 1001XX	A*	Multi-Drug Resistance Tuberculosis treatment failure. (For respiratory physicians)	ADULT: Initial: 250 mg every 12 hours for 14 days, then administer 0.5 - 1 g daily in 2 divided doses for 18 - 24 months (maximum daily dose: 1 g). CHILD: 2-12 yr: 5 mg/kg bid; 12-18 yr: 250 mg bid for 2 wk then adjusted to a max dose of 1 g daily
413	Cyclosporine Ophthalmic Emulsion 0.05%	S01XA18000 D2001XX	A*	To increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking anti inflammatory drugs or using punctal plugs.	1 drop twice a day in each eye approximately 12 hours apart.
414	Cyproterone Acetate 2 mg & Ethinyloestradiol 0.035 mg Tablet	G03HB01954 T1001XX	A*	Androgen dependent diseases in women	1 tablet daily for 21 days on the first day of the cycle, followed by 7 tab free days. Starting on day 2 to 5 is allowed, but during the first cycle a barrier method is recommended for the first 7days of tablet taking.
415	Cyproterone Acetate 50 mg Tablet	G03HA01122 T1001XX	A*	Carcinoma of prostate	i) After orchidectomy, 100 mg once daily or twice daily ii) If used together with LHRH agonists, the initial dose is 100 mg twice daily for 5 to 7 days before the start of LHRH agonist, then 100 mg twice daily for 3 to 4

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					weeks together with the LHRH agonist
416	Cytarabine 1 g Injection	L01BC01000P4004XX	A	i) Central nervous system lymphoma ii) Meningeal leukemia iii) Non Hodgkin's Lymphoma iv) High dose cytarabine as conditioning to cytoreduce the disease before stem cell transplant for relapsed or refractory leukemia v) As salvage for acute lymphocytic leukemia vi) As salvage for acute myeloid leukemia vii) As palliative chemotherapy in elderly acute myeloid leukemia/ myelodysplastic syndrome	Standard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher doses for intensification/consolidation : 1000 - 3000 mg/m2 daily over 3 - 5 days, depending on specific protocols. CHILD: Dose variable depending on disease and protocol. Range from 100 mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20 mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE)
417	Cytarabine 100 mg Injection	L01BC01000P4002XX	A	i) Central nervous system lymphoma ii) Meningeal leukemia iii) Non Hodgkin's Lymphoma iv) High dose cytarabine as conditioning to cytoreduce the disease before stem cell transplant for relapsed or refractory leukemia v) As salvage for acute lymphocytic leukemia vi) As salvage for acute myeloid leukemia vii) As palliative chemotherapy in elderly acute myeloid leukemia/ myelodysplastic syndrome	Standard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher doses for intensification/consolidation : 1000 - 3000 mg/m2 daily over 3 - 5 days, depending on specific protocols. CHILD: Dose variable depending on disease and protocol. Range from 100 mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20 mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
418	Cytarabine 500 mg Injection	L01BC01000P 4003XX	A	i) Central nervous system lymphoma ii) Meningeal leukemia iii) Non Hodgkin's Lymphoma iv) High dose cytarabine as conditioning to cytoreduce the disease before stem cell transplant for relapsed or refractory leukemia v) As salvage for acute lymphocytic leukemia vi) As salvage for acute myeloid leukemia vii) As palliative chemotherapy in elderly acute myeloid leukemia/ myelodysplastic syndrome	Standard doses 100 - 200 mg/m2 daily over 5 - 10 days. Higher doses for intensification/consolidation : 1000 - 3000 mg/m2 daily over 3 - 5 days depending on specific protocols. CHILD: Dose variable depending on disease and protocol. Range from 100 mg/m2 to 3 g/m2 twice daily. May be given as SC, IV bolus or infusion. Intrathecal dose: Less than 1 year: 15 mg, 1 - 2 years: 20 mg, 2 - 3 years: 25 mg, more than 3 years: 30 mg. (ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE)
419	Dabigatran Etexilate 110 mg Capsule	B01AE07999 C1002XX	A*	i) Prevention of venous thromboembolic events in patients who have undergone total knee replacement or total hip replacement surgery ii) Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)	i) Following total knee replacement: Initially ADULT 110mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 28-35 days ii) Recommended daily dose is 300mg taken orally as 150mg hard capsule twice daily. Therapy should be continued lifelong. Patients aged 80 years and above should be treated with a dose of 220mg daily , taken orally as one 110mg capsule twice daily. Special patient population for Renal Impairment : Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					initiation of treatment with Dabigatran to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30 ml/min)
420	Dabigatran Etexilate 75 mg Capsule	B01AE07999 C1001XX	A*	Prevention of venous thromboembolic events in patients who have undergone total knee replacement or total hip replacement surgery	Following total knee replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 6-10 days Following total hip replacement: Initially ADULT 110 mg (ELDERLY, 75 mg) within 1- 4 hours after surgery, then 220 mg (ELDERLY, 150 mg) once daily thereafter for 28-35 days
421	Dabigatran Etexilate150 mg Capsule	B01AE07999 C1003XX	A*	Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)	Recommended daily dose is 300mg taken orally as 150mg hard capsule twice daily. Therapy should be continued lifelong. Patients aged 80 years and above should be treated with a dose of 220mg daily , taken orally as one 110mg capsule twice daily. Special patient population for Renal Impairment : Renal function should be assessed by calculating the creatinine clearance (CrCl) prior to initiation of treatment with Dabigatran to exclude patients for treatment with severe renal impairment (i.e. CrCl < 30 ml/min).
422	Dacarbazine 100 mg Injection	L01AX04000 P4001XX	A*	i) Malignant melanoma, sarcomas, neuroblastomas and other childhood solid tumours ii) Hodgkin's Disease	i) 250 mg/m2 for 5 days, may be repeated every 3 weeks ii) 375 mg/m2 IV every 2 weeks

No.	Generic Name	MDC	Category	Indication(s)	Dosage
423	Danazol 100 mg Capsule	G03XA01000 C1001XX	A/KK	i)Endometriosis and gynaecomastia ii)Menorrhagia iii)Prophylaxis of hereditary angioedema	i)200 - 800 mg daily for max of 9 months ii)200 mg daily for 12 weeks ii)400 mg daily. Reduce to 200 mg daily after 2 months attack free period
424	Danazol 200 mg Capsule	G03XA01000 C1002XX	A/KK	i)Endometriosis and gynaecomastia ii)Menorrhagia iii)Prophylaxis of hereditary angioedema	i)200 - 800 mg daily for max of 9 months ii)200 mg daily for 12 weeks ii)400 mg daily. Reduce to 200 mg daily after 2 months attack free period
425	Dapsone 100 mg Tablet	J04BA02000T 1001XX	B	i)Leprosy ii) Dermatitis herpetiformis	i) ADULT: 6 - 10 mg/kg weekly/ 1.4mg/kg daily (around 50 - 100 mg daily). CHILD: 1 - 2 mg/kg/day. Maximum: 100 mg/day ii) ADULT: 50 - 300 mg daily
426	Daunorubicin HCl 20 mg Injection	L01DB02110 P4001XX	A*	i) Acute myeloblastic leukaemia (AML) ii) Acute lymphoblastic leukemia (ALL)	i) 45 - 60 mg/m2 IV daily for 3 - 5 days ii) 25 - 45 mg/m2 once a week for first 4 weeks during induction phase. Caution: Total cumulative dose of daunorubicin and doxorubicin must not exceed 500 mg/m2 due to risk of cardiotoxicity. CHILD: 30-45 mg/m2/dose infusion over 6 hours. Schedule depends on protocol. Need to check cardiac function closely by echocardiography every cumulative dose of 100mg/m2 to max. 360 mg/m2

No.	Generic Name	MDC	Category	Indication(s)	Dosage
427	Decitabine 50 mg Injection	L01BC08000P3001XX	A*	Myelodysplastic syndromes (MDS) including: Previously treated and untreated de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups	15 mg/m2 by continuous IV infusion over 3 hours repeated every 8 hours for 3 days. Repeat this treatment cycle every 6 weeks for a minimum of 4 cycles. However, complete or partial response may take longer than 4 cycles. Treatment may be continued as long as there is continued
428	Deferasirox 125 mg Dispersible Tablet	V03AC03000T4001XX	A*	Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients aged 2 years and above	Initial 20 mg/kg/day. Starting dose can also be based on transfusion rate and existing iron burden. Max is 30 mg/kg/day
429	Deferasirox 500 mg Dispersible Tablet	V03AC03000T4002XX	A*	Treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients aged 2 years and above	Initial 20 mg/kg/day. Starting dose can also be based on transfusion rate and existing iron burden. Max is 30 mg/kg/day
430	Deferiprone 500 mg Tablet	V03AC02000T1001XX	A*	Treatment of iron overload in patients with thalassemia major for whom desferrioxamine therapy is contraindicated or inadequate. Add on therapy to desferrioxamine for thalassemia patients with cardiac complication	25 mg/kg 3 times a day for total daily dose of 75 mg/kg. Doses greater 100 mg/kg are not recommended
431	Denosumab in 1.0 mL solution (60 mg/mL) Pre-filled syringe (subcutaneous injection)	M05BX04000P4001XX	A*	Post-Menopausal Osteoporosis.	A single subcutaneous injection of 60 mg administered once every 6 months. Patients should receive calcium and vitamin D supplements whilst undergoing treatment.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
432	Desferrioxamine B Methanesulphonate 0.5 g Injection	V03AC01196 P3001XX	A	i) Acute iron poisoning in children ii) Investigation and treatment of haemochromatosis iii) Diagnosis and treatment of aluminium toxicity in patients with renal failure and dialysis iv) Chronic iron toxicity or overload	i) 2 g by IM immediately and 5 g by mouth after gastric lavage ii) 0.5 - 1.5 g by IM injection daily iii) Diagnosis: 5 mg per kg by slow intravenous infusion during the last hour of haemodialysis. Treatment: 5 mg per kg once a week by slow intravenous infusion during the last hour of dialysis iv) 30 - 50 mg/kg
433	Desflurane Liquid	N01AB07000 L5001XX	A	i) Induction and maintenance of anaesthesia in adult ii) Maintenance of anaesthesia in infants & children	ADULT: Induction , initially 3% in oxygen or nitrous oxide/oxygen and increased by 0.5%-1% every 2-3 breaths or as tolerated (up to 11%), until loss of consciousness. Maintenance: 2.5%-8.5% with or without concomitant nitrous oxide CHILD: maintenance, inhaled in concentrations of 5.2%-10% with or without concomitant nitrous oxide
434	Desloratadine 5 mg Tablet	R06AX27000 T1001XX	A*	Allergic rhinitis and chronic idiopathic urticaria	ADULT & CHILD more than 12 years : 5 mg once daily. CHILD: 6-11 yr: 2.5 mg; 1-5 yr: 1.25 mg; 6-11 mth: 1 mg. Doses to be taken once daily
435	Desmopressin 0.1 mg Tablet	H01BA02122 T1001XX	A	i)Central diabetes insipidus ii)Primary nocturnal enuresis iii)Treatment of nocturia associated with nocturnal polyuria in adult	i)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg at night. May be increased to 0.2 mg and then to 0.4 mg by means of weekly increase
436	Desmopressin 0.2 mg Tablet	H01BA02122 T1002XX	A	i)Central diabetes insipidus ii)Primary nocturnal enuresis iii)Treatment of nocturia associated with nocturnal polyuria in adult	i)ADULT and CHILD : 0.1-0.2mg 3 times daily, up to 0.1-1.2mg daily ii) ADULT & Child≥5 yr 0.2-0.4mg at night iii)Initially 0.1 mg at night. May be increased to 0.2 mg and then to 0.4 mg by means of weekly increase

No.	Generic Name	MDC	Category	Indication(s)	Dosage
437	Desmopressin 100 mcg/ml Nasal Spray	H01BA02122 A4101XX	A	i) Diabetes Insipidus ii) Primary nocturnal enuresis	i) ADULT : 10 - 20 mcg 1-2 times daily. CHILD: 5 - 10mcg 1-2 times daily ii) 10-40 mcg nocte
438	Desmopressin Acetate 4 mcg/ml Injection	H01BA02122 P3001XX	A	Diabetes insipidus	ADULT : 1 - 4 mcg IV daily. CHILD :0.4 mcg daily
439	Desogestrel 0.075 mg Tablet	G03AC09000 T1001XX	A*	Contraception. Only for women who should not take combined oral contraceptives (COCs) eg Obese, smoker, migraine, breast feeding	Tablets must be taken in the order directed on the package every day at about the same time with some liquid as needed. One tablet is to be taken daily for 28 consecutive days. Each subsequent pack is started immediately after finishing the previous pack.
440	Desogestrel 150 mcg & Ethinylestradiol 20 mcg Tablet	G03AA09954 T1002XX	A/KK	Oral contraception	One tablet daily for 21 days starting on 1st day of menses followed by 7 tablet-free days.
441	Desogestrel 150 mcg & Ethinylestradiol 30 mcg Tablet	G03AB05954 T1001XX	C+	Contraception	1 tablet daily for 21 days, subsequent courses repeated after 7 day interval (during which withdrawal bleeding occurs)
442	Desvenlafaxine Succinate 50 mg Extended Release Tablet	N06AX23999 T5002XX	A*	Major depression	Recommended dose is 50mg once daily, with or without food.
443	Dexamethasone 0.5 mg Tablet	H02AB02000 T1001XX	A	Croup, septic shock, cerebral oedema and respiratory distress syndrome including status asthmaticus	0.5 - 9 mg daily, depending upon the disease being treated. Up to 15 mg daily in severe disease
444	Dexamethasone and Neomycin Sulphate and Polymyxin B Eye Ointment	S01CA01990 G5101XX	A	Treatment of ocular inflammation when concurrent use of an antimicrobial is judged necessary	Apply 1 - 1.5 cm 3 - 4 times daily, may be used adjunctively with drops at bedtime
445	Dexamethasone and Neomycin Sulphate and Polymyxin B Sulphate Ophthalmic Suspension	S01CA01990 D2001XX	A	Treatment of ocular inflammation when concurrent use of an antimicrobial is judged necessary	1 - 2 drops hourly for severe cases and 4 - 6 hourly for mild infection
446	Dexamethasone Sodium	S01BA01162 D2001XX	A	Acute steroid responsive inflammatory and allergic	1 - 2 drops 4 - 6 times a day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
	Phosphate 0.1% Eye Drops			conditions	
447	Dexamethasone Sodium Phosphate 4 mg/ml Injection	H02AB02162 P3001XX	B	Croup, septic shock, cerebral oedema and respiratory distress syndrome including status asthmaticus	Initially 0.5 - 9 mg IM, IV or infusion daily, depending upon the disease being treated
448	Dexchlorpheniramine Maleate 2 mg Tablet	R06AB02253 T1001XX	B	Symptomatic treatment of allergic rhinitis and allergic dermatoses	ADULT : 2 mg 3 times daily. CHILD : 1 - 12 years : 2 mg 3 times daily
449	Dexchlorpheniramine Maleate 2 mg/5 ml Syrup	R06AB02253 L9001XX	B	Symptomatic treatment of allergic rhinitis	CHILD 2 - 5 years : 0.5 mg every 4 - 6 hours; 6 - 11 years : 1 mg every 4 - 6 hours
450	Dexmedetomidine HCl 100 mcg/ml Injection	N05CM1811 0P4001XX	A*	i) Sedation of intubated and mechanically ventilated ICU patients. For use only by specialist anaesthetist ii) For sedation of non-intubated patients prior to and/or during surgical and other procedures	i) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr ii) Not to be infused for more than 24 hours, 1 mcg/kg over 10 minutes as loading dose. Maintenance dose: 0.2 - 0.7 mcg/kg/hr
451	Dextran 40 Injection	B05AA05000 P6001XX	A*	Condition associated with peripheral local slowing of the blood flow, prophylaxis of post surgical thromboembolic disease	Initially 500-1000 ml by infusion, further doses are given according to the patient's condition
452	Dextrose 10% Injection	B05BA03000 P6002XX	B	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient
453	Dextrose 20% Injection	B05BA03000 P6003XX	B	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient
454	Dextrose 30% Injection	B05BA03000 P3004XX	B	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient
455	Dextrose 5% Injection	B05BA03000 P6001XX	B	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient

No.	Generic Name	MDC	Category	Indication(s)	Dosage
456	Dextrose 50% Injection	B05BA03000 P3005XX	B	For parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient	According to the needs of the patient
457	Dextrose Powder	V04CA02000 F2101XX	B	Use as a diagnostic agent for diabetes	75 g stat
458	Diatrizoate Meglumine and Sodium Amidotrizoate Solution	V08AA01254 L9901XX	A	i) Contrast medium for the radiological examination of the gastrointestinal tract (primarily in cases in which barium sulphate is contraindicated) ii) Computerised tomography in abdominal region iii) Treatment of Mecolinium ileus	i) ADULT and CHILD more than 10 year, ORALLY: 60 - 100 ml RECTALLY, contrast medium should be diluted with 3-4 times its volume of water. ORALLY: CHILD less than 10 years,: 15- 30 ml NEWBORN, INFANT contrast medium should be diluted with 3 times its volume of water. RECTALLY: CHILD more than 5 years, contrast medium should be diluted with 4-5 times its volume of water. Younger patients a dilution with 5 times its volume is recommended ii) Adult, orally, 25-77 mL in 1000 mL tap water 15-30 minutes prior to imaging
459	Diazepam 2 mg Tablet	N05BA01000 T1001XX	B	i) Muscle spasm of varied aetiology, including tetanus ii) Anxiety disorders	i) ADULT: 2-10 mg 3-4 times daily. CHILD 6 months and older: 0.12 - 0.8 mg/kg daily in divided doses, every 6-8 hours ii) ADULT : 2 mg 3 times daily, increased in severe anxiety to 15 - 30 mg daily in divided doses. ELDERLY (or delibitated) half adult dose. CHILD (night terrors), 1 - 5 mg at bedtime
460	Diazepam 5 mg Rectal Solution	N05BA01000 G2001XX	C	Status epilepticus, skeletal muscle spasm	Status epilepticus - ADULT: 0.5 mg/kg repeated after 12 hours if necessary. CHILD (febrile convulsions, prolonged or recurrent): 0.5 mg/kg (maximum 10 mg), repeated if necessary. Not recommended for children below 2 years

No.	Generic Name	MDC	Category	Indication(s)	Dosage
461	Diazepam 5 mg Tablet	N05BA01000 T1002XX	B	i) Muscle spasm of varied aetiology, including tetanus ii) Anxiety disorders	i) ADULT: 2-10 mg 3-4 times daily. CHILD 6 months and older: 0.12 - 0.8 mg/kg daily in divided doses, every 6-8 hours ii) ADULT : 2 mg 3 times daily, increased in severe anxiety to 15 - 30 mg daily in divided doses. ELDERLY (or delibitated) half adult dose. CHILD (night terrors), 1 - 5 mg at bedtime
462	Diazepam 5 mg/ml Injection	N05BA01000 P3001XX	B	i) Status epilepticus ii) Skeletal muscle spasm iii) Anxiety disorders	i) Status epilepticus, by slow IV: 5-10 every 10-15 minute (rate not more than 5 mg/min), to a total dose of 30 mg, may repeat in 2 hour if needed. Infants 30 days to 5 years, 0.05-0.3 mg/kg/dose given over 2-3 minutes, every 15-30 minutes to a total dose of 5 mg, repeat in 2-4 hours if necessary. CHILD more than 5 years, 1 mg by slow IV, every 2-5 minutes, maximum 10 mg, repeat in 2-4 hours if necessary ii) Skeletal muscle spasm, by slow IV or IM, 5-10 mg repeated if necessary in 3-4 hours. CHILD (tetanus): 30 days - 5 years, 1-2 mg IM or IV slowly every 3-4 hours as needed. 5 years and above, 5-10 mg IM or IV slowly every 3-4 hours if needed iii) Anxiety disorders, 2-10 mg by slow IV (not more than 5 mg/min). Repeat if necessary every 3-4 hours
463	Diclofenac 1% Gel	M02AA15520 G3001XX	A	Post-traumatic inflammation of the tendons,ligaments & joints. Localised forms of soft tissue rheumatism and degenerative rheumatism	Apply 3 - 4 times daily and gently rubbed in

No.	Generic Name	MDC	Category	Indication(s)	Dosage
464	Diclofenac 100mg Suppository	M01AB05520 S2004XX	A	Pain and inflammation in rheumatic disease and juvenile arthritis	Diclofenac Suppositories are normally inserted one, two or three times a day up to a maximum total daily dose of 150 mg.
465	Diclofenac 12.5 mg Suppository	M01AB05520 S2001XX	A	Pain and inflammation in rheumatic disease and juvenile arthritis	ADULT: 75 - 150 mg daily in divided doses. CHILD 1-12 years, 12.5- 25 mg daily
466	Diclofenac 25 mg Suppository	M01AB05520 S2002XX	A	Pain and inflammation in rheumatic disease and juvenile arthritis	ADULT: 75 - 150 mg daily in divided doses. CHILD 1-12 years, 12.5- 25 mg daily
467	Diclofenac 50 mg Tablet	M01AB05520 T1001XX	B	Pain and inflammation in rheumatic disease	ADULTS: Initial dose of 150 mg daily. Mild or long term: 75 - 150 mg daily in 2 to 3 divided doses after food. Maximum 200mg/day. PAEDS more than 6 months : 1 - 3 mg/kg body weight daily in divided doses. Maximum 3mg/kg/day (Max 150mg/day).
468	Diclofenac Sodium 50 mg Suppository	M01AB05520 S2003XX	A	Pain and inflammation in rheumatic disease and juvenile arthritis	ADULTS: 75 - 150 mg daily in divided doses. Maximum 150mg/day. PAEDS more than 6 months : 1 - 3 mg/kg body weight daily in divided doses. Maximum 3mg/kg/day (Max 150mg/day).
469	Diclofenac Sodium 75 mg/3 ml Injection	M01AB05520 P3001XX	A/KK	Pain and inflammation in rheumatic disease	IM 75 mg once daily (2 times daily in severe cases) for not more than 2 days. Max 150mg/day. Not suitable for children.
470	Didanosine 100 mg Tablet (ddI)	J05AF02000T 1002XX	A*	HIV infection, in combination with other antiretrovirals	ADULT less than 60 kg: 125 mg twice daily or 250 mg once daily; more than 60 kg: 400 mg once daily or 200 mg twice daily. CHILD: 2 weeks to less than 3 months: 50mg/m2 twice daily; 3-8 months: 100mg/m2 twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
471	Didanosine 2 g Oral Solution (ddI)	J05AF02000F 2101XX	A*	HIV infection, in combination with other antiretrovirals	ADULT less than 60 kg: 125 mg twice daily or 250 mg once daily; more than 60 kg: 400 mg once daily or 200 mg twice daily. CHILD: 2 weeks to less than 3 months: 50mg/m2 twice daily; 3-8 months: 100mg/m2 twice daily
472	Didanosine 25 mg Tablet (ddI)	J05AF02000T 1001XX	A*	HIV infection, in combination with other antiretrovirals	ADULT less than 60 kg: 125 mg twice daily or 250 mg once daily; more than 60 kg: 400 mg once daily or 200 mg twice daily. CHILD: 2 weeks to less than 3 months: 50mg/m2 twice daily; 3-8 months: 100mg/m2 twice daily
473	Didanosine 250 mg Enteric Coated Capsule	J05AF02000C 1001XX	A*	HIV infection, in combination with other antiretrovirals	ADULT less than 60 kg: 250 mg once daily; 60 kg or greater: 400 mg once daily. Dose may varies if taken in combination with tenofovir
474	Didanosine 400 mg Enteric Coated Capsule	J05AF02000C 1002XX	A*	HIV infection, in combination with other antiretrovirals	ADULT less than 60 kg: 250 mg once daily; 60 kg or greater: 400 mg once daily. Dose may varies if taken in combination with tenofovir
475	Dienogest 2mg tablet	G03DB08000 T1001XX	A/KK	Treatment of endometriosis	One tablet daily. Treatment can be started on any day of menstrual cycle. Tablets must be taken continously without regard to vaginal bleeding.
476	Diethylcarbamazine Citrate 50 mg Tablet	P02CB02136 T1001XX	B	i) Bancrofti filariasis, onchocerciasis, loasis, creeping eruption ii) Ascariasis iii) Tropical eosinophilia	i) 1 mg/kg on the first day and increased gradually over 3 days to 6 mg/kg daily in divided doses. This dosage is maintained for 21 days. ii) 13 mg/kg once daily for 7 days. CHILD : 6 - 10 mg/kg 3 times daily for 7 days iii) 6 mg/kg/day in 3 divided doses for 21 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
477	Digoxin 0.25 mg Tablet	C01AA05000 T1001XX	B	Heart failure , with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)	Rapid digitalisation: 0.75 - 1.5 mg in divided doses over 24 hours; less urgent digitalisation, 250 mcg-500 mcg daily (higher dose may be divided). Maintenance : 62.5mg -500 mcg daily (higher dose may be divided) according to renal function and , in atrial fibrillation, on heart rate response; usual range, 125-250 mcg daily (lower dose may be appropriate in elderly)
478	Digoxin 250 mcg/ml Injection	C01AA05000 P3001XX	A	Heart failure with atrial fibrillation, supraventricular arrhythmias (particularly atrial fibrillation)	Rapid digitilisation: ADULT & CHILD over 10 years, initially 0.75 - 1.5 mg, followed by 250 mcg 6 hourly until digitilisation is complete
479	Digoxin 50 mcg/ml Elixir	C01AA05000 L1001XX	B	Heart failure, supraventricular arrhythmias (particularly atrial fibrillation)	Rapid digitalization, give in divided doses; PREMATURE: 20-30 mcg/kg; FULLTERM: 25-35 mcg/kg; CHILD 1-2 years : 35 to 60 mcg/kg; CHILD 2-5 years: 30-40 mcg/kg; CHILD 5-10 years: 20- 35 mcg/kg; CHILD over 10 years: 10-15 mcg/kg. For daily maintenance doses or for gradual digitalization, give 20% to 30% of oral digitalizing dose for premature infants or 25% to 35% of oral digitalizing dose for all other pediatric patients
480	Digoxin 62.5 mcg Tablet	C01AA05000 T1002XX	B	Heart failure, with atrial fibrillation, supraventricular arrhythmias (particularly, atrial fibrillation)	Rapid digitalisation: 1-1.5 mg in divided doses over 24 hours; less urgent digitalisation, 250 mcg-500 mcg daily (higher dose may be divided). Maintenance: 62.5 - 500 mcg dailly (higher dose may be divided) according to renal fuction, and in atrial fibrillation, on heart-response; usual range

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					:125 - 250 mcg daily (lower doses may be appropriate in the elderly)
481	Dihydrocodeine Tartrate 30 mg Tablet	N02AA08123 T1001XX	B	For the control of moderate to severe chronic pain	ADULT: 30 - 60 mg every 4 - 6 hours. PAED, over 4 yrs: 0.5 - 1 mg/kg body weight every 4-6 hours
482	Dihydroergocristine or Co-dergocrine Mesilate 1 mg Tablet	C04AE01196 T1001XX	A/KK	Adjunct in elderly with mild to moderate dementia, prevention of migraine and vascular headache	3-6 mg daily in divided doses
483	Diltiazem HCl 30 mg Tablet	C08DB01110 T1001XX	B	Treatment of angina pectoris in the following cases: i) inadequate response or intolerance to beta-blockers and Isosorbide Dinitrate ii) contraindication to beta-blockers iii) coronary artery spasm	Initially 30mg tds, may increase to 60mg tds (elderly initially twice daily; increased if necessary to 360 mg daily.
484	Dimenhydrinate Injection 10ml/vial (50mg/ml)	N07CA00000 P2001XX	B	Prevention and relief of motion sickness, treatment of vertigo, nausea or vomiting associated with electroshock therapy, anaesthesia and surgery; labyrinthine disturbances and radiation sickness.	Usual Adult & Adolescent Dose: Antiemetic; or Antivertigo agent ? Intramuscular, 50 mg repeated every four hours as needed. Intravenous, 50 mg in 10 mL of 0.9% sodium chloride injection, administered slowly over a period of at least two minutes, repeated every four hours as needed. Usual Pediatric Dose: Antiemetic; or Antivertigo agent ? Intramuscular, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, every six hours as needed, not to exceed 300 mg per day. Intravenous, 1.25 mg per kg of body weight or 37.5 mg per square meter of body surface, in 10 ml of 0.9% sodium chloride injection, administered slowly over a period of at least two minutes, every six hours as needed, not to exceed 300

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					mg per day.
485	Dimenhydrinate Syrup 15mg/5ml	N07CA00000 L9003XX	B	For prevention and treatment of motion sickness. Also used as anti-emetic agent in irradiation sickness, postoperative vomiting, drug induced nausea and vomiting, and for symptomatic treatment of nausea and vertigo due to Meniere`s disease and other labyrinthine disturbances.	ADULT: 50-100 mg every 4 hours as needed. For motion sickness, take medicine at least 30 minutes, and preferably 1-2 hours before travelling. Usual adult prescribing limit: Up to 400 mg daily. CHILD: Children 6-12 years: 25-50 mg every 6-8 hours as needed (maximum of 150 mg daily).
486	Dimenhydrinate Tablet 50mg	N07CA00000 T1001XX	B	Prevention and treatment of the nausea, vomiting and dizziness associated with motion sickness. Symptomatic treatment of nausea and vertigo caused by Meniere's disease and other vestibular disturbances.	ADULT: 50-100 mg every 4 hours as needed. For motion sickness, take medicine at least 30 minutes, and preferably 1-2 hours before travelling. Usual adult prescribing limit: Up to 400 mg daily. CHILD: 6-12 years: 25-50 mg every 6-8 hours as needed (maximum of 150 mg daily).
487	Dimercaprol 50 mg/ml Injection	V03AB09000 P3001XX	B	Poisoning by antimony, arsenic, bismuth, gold, mercury, possibly thallium; adjunct (with calcium disodium edetate) in lead poisoning	By IM: 2.5 - 3 mg/kg every 4 hours for 2 days, 2 - 4 times on the third day, then 1 - 2 times daily for 10 days or until recovery. For ophthalmic use : instillation of 50 mg/ml oily solution in conjunctival sac, within 5 minutes of contamination
488	Dinoprostone (Prostagladin E2) 3 mg Vaginal Tablet	G02AD02000 S1001XX	A	Induction of labour	3 mg vaginal tablet to be inserted high into the posterior formix. A second 3 mg tablet may be inserted after 6-8 hours if labour is not established. Max 6 mg
489	Diosmin 450 mg and Hesperidin 50 mg Tablet	C05CA53931 T1001XX	A/KK	i) Haemorrhoids ii) Chronic venous insufficiency	i) Acute attack: 6 tablets daily for the first 4 days, then 4 tablets daily in 2 divided doses for 3 days and 2 tablets thereafter. Chronic: 2 tablets daily ii) 2 tab daily with meals

No.	Generic Name	MDC	Category	Indication(s)	Dosage
490	Diphenhydramine Hydrochloride 10 mg/5 ml Oral solution	R06AA02110 L1001XX	C	Cough and allergic rhinitis	Allergic rhinitis :1) Adults & Children over 12 years of age : 25 to 50 mg 3 to 4 times a day 2) Children 6 to 12 years of age: 10 mg 3 to 4 times a day 3) Children 1 to 6 years of age: 5 mg 3 to 4 times a day. Maximum daily dosage <300 mg (adults and children) Cough and cold : 1)Adults: 25 mg every 4 hrs. Not to exceed 150 mg in 24 hours 2) Children (6 to 12years): 12.5 mg every 4 hours. Not to exceed 75 mg in 24 hours 3) Children (2 to 6 years): 6.25 mg every 4 hours. Not to exceed 25 mg in 24 hours
491	Diphenhydramine Hydrochloride 14 mg/5 ml Expectorant	R06AA52110 L2101XX	C	Cough	ADULT : 5 - 10 ml 2 - 3 times daily. CHILD : 2.5 - 5 ml 2 - 3 times daily (not to be used in children less than 2 years of age)
492	Diphenhydramine Hydrochloride 7 mg/5 ml Expectorant	R06AA52110 L9003XX	C	Cough	ADULT : 5 - 10 ml 2 - 3 times daily. CHILD : 2.5 - 5 ml 2 - 3 times daily (not to be used in children less than 2 years of age)
493	Diphenoxylate with Atropine Sulphate Tablet	A07DA01922 T1001XX	B	Acute diarrhoea	ADULT initially 4 tablet followed by 2 tablet 4 times daily until diarrhoea is controlled
494	Diphtheria and Tetanus Vaccine Injection	J07AM51963 P3001XX	C+	Immunisation against diphtheria and tetanus	Prophylactic: 2 or 3 doses by deep SC or IM injection, 0.5 or 1 ml. Each second dose at 4 - 6 weeks then 4 - 6 months. Booster at 4 - 6 years
495	Diphtheria Antitoxin Injection	J07AF01000P 3001XX	B	Diphtheria	Therapeutic: 10,000 - 30,000 units by IM or IV. Increase to 40,000 - 100,000 units in severe cases. Doses up to 30,000 units may be given IM
496	Diphtheria, Pertussis, Tetanus and	J07AG52000 P3001XX	C	Immunisation of children against Haemophilus Type B infections, diphtheria, tetanus and pertussis	0.5 ml given by IM

No.	Generic Name	MDC	Category	Indication(s)	Dosage
	Conjugated Haemophilus Type B 10 mcg Vaccine				
497	Diphtheria, Pertussis, Tetanus and Hepatitis B Vaccine	J07CA05963P3001XX	C+	Active immunisation against diphtheria, tetanus, pertussis and hepatitis B in infants from 6 weeks onwards	Primary vaccination: 3 doses of 0.5 ml each within the first 6 months of life. Administer each dose at intervals of at least 4 weeks. A booster dose can be administered in the second year of life
498	Diphtheria, Pertussis, Tetanus Vaccine Injection	J07AJ52963P3001XX	C	Prophylactic immunisation against diphtheria, pertussis and tetanus	By deep SC or IM injection: 3 doses each of 0.5 or 1 ml with intervals of 6 - 8 weeks and 4 - 6 months respectively between the doses. Booster 1 and 5 years after primary immunisation
499	Diphtheria, Tetanus, Acellular Pertussis, Inactivated Polio Virus, Haemophilus Influenza Type B (DTaP-IPV-HiB) Vaccine Injection (Single Dose)	J07CA06963P3001XX	C+	Immunisation of children against Diphtheria, Tetanus, Acellular Pertussis, Polio and Haemophilus Influenza Type B infection	Primary : 0.5 ml by IM at 1 - 2 months intervals Booster : Second year of life
500	Dipyridamole 75 mg Tablet	B01AC07000T1001XX	B	As an adjunct to oral anticoagulation/ antiplatelet therapy in the prophylaxis of cerebrovascular events	75-150 mg 3 times daily to be taken 1 hour before meals
501	Distigmine Bromide 5 mg Tablet	N07AA03320T1001XX	A	i) Myasthenia gravis ii) Prevention and treatment of post-operative intestinal atony, urinary retention and neurogenic bladder	i) ADULT : 5 mg daily 30 minutes before breakfast. Increase at intervals of 3 - 4 days if necessary to maximum of 20 mg daily. CHILD : Up to 10 mg daily according to age ii) Urinary retention : 5 mg daily 30 minutes before breakfast. Neurogenic bladder : 5 mg daily or on alternate days 30 minutes before breakfast

No.	Generic Name	MDC	Category	Indication(s)	Dosage
502	Dithranol 0.1 - 5% in Vaseline/ Ointment	D05AC01000 G5001XX	A	Short contact treatment for plaque psoriasis and alopecia areata	For application to skin or scalp. 0.1-0.5% suitable for overnight treatment. 1-2% for max 1 hour.
503	Dithranol 1 % in Lassars Paste	D05AC01000 G6001XX	A	Treatment of quiescent or chronic psoriasis of the skin, scalp and alopecia areata	Apply liberally and carefully to the lesions with a suitable applicator. A dressing may be applied
504	Dobutamine 12.5 mg/ml Injection	C01CA07110 P3001XX	A	Hypotension and heart failure	Initial 0.5-1 mcg/kg/min by IV, maintenance 2.5-10mcg/kg/min. Frequently,doses up to 20mcg/kg/min are required for adequate hemodynamic improvement. On rare occasions,infusion rates up to 40mcg/kg/min
505	Docetaxel 40mg/ml Injection	L01CD02000 P3002XX	A*	i) Adjuvant treatment of patients with high risk node-positive breast cancer in combination with doxorubicin and cyclophosphamide ii) Breast cancer, locally advanced or metastatic, not previously on cytotoxic therapy, in combination with doxorubicin iii) First line therapy in non small cell lung cancer in stage 3- 4 and performance status 0-1, in combination with cisplatin iv) Inoperable locally advanced squamous cell carcinoma of head and neck, in combination with cisplatin and 5-FU for induction treatment v) Prostate cancer, in combination with prednisolone	i) 75 mg/m2 IV over 1 hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles ii) 75 mg/m2 IV over 1 hour every 3 week in combination with doxorubicin 50 mg/m2 iii) Administer IV over 1 hour every 3 weeks. Chemotherapy-naive patients 75 mg/m2 immediately followed by 75 mg/m2 cisplatin over 30-60 mins or carboplatin (AUC 6 mg/mL/min) over 30-60 minutes. Monotherapy of non small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy 75 mg/m2 iv) 75 mg/m2 as a 1 hour infusion followed by cisplatin 75 mg/m2 over 1 hour, on day one, followed by 5-fluorouracil as a continuous infusion at 750 mg/m2 per day for five days. This regimen is administered every 3 weeks for 4 cycles.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
506	Domperidone 1 mg/ml Suspension	A03FA03000 L8001XX	B	Nausea, vomiting, dyspepsia, gastro-esophageal reflux	Chronic dyspepsia : CHILD 2.5 mL/10 kg body weight 3 times daily and once more in the evening if necessary. Dosage may be doubled in adults & childs over 1 year. Acute and subacute conditions (particularly nausea and vomiting). CHILD: 5 mL/10 kg bodyweight. All to be taken 3-4 times daily
507	Domperidone 10 mg Tablet	A03FA03253 T1001XX	B	Nausea, vomiting, dyspepsia, gastro-esophageal reflux	Chronic dyspepsia ADULT 10 mg 3 times daily. Acute and subacute conditions (particularly nausea and vomiting):ADULT 20 mg 3-4 times daily
508	Donepezil HCl 10 mg Tablet	N06DA02110 T1002XX	A	Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease. [psychiatrists and neurologists only]	5 - 10 mg once daily at bedtime. Maximum 10 mg daily
509	Donepezil HCl 5 mg Tablet	N06DA02110 T1001XX	A	Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease.	5 - 10 mg once daily at bedtime. Maximum 10 mg daily
510	Donepezil Hydrochloride 10mg Orodispersible Tablet	N06DA02110 T4002XX	A*	Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease. [psychiatrists and neurologists only]	Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg.
511	Donepezil Hydrochloride 5mg Orodispersible Tablet	N06DA02110 T4001XX	A*	Treatment of mild to moderate dementia in Alzheimer's disease, as well as in patients with severe Alzheimer's disease. [psychiatrists and neurologists only]	Initiated at 5mg/day (one a day dosing), should be maintained for at least 1 month in order to allow the earliest clinical responses and to allow steady state concentration to be achieved. The maximum recommended daily dose is 10 mg.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
512	Dopamine HCl 40 mg/ml Injection	C01CA04110 P3001XX	B	Non-hypovolemic hypotension	Initial dose 2-5 mcg/kg/min with incremental changes of 5-10 mcg/kg/min at 10-15 minutes intervals until adequate response is noted. Most patients are maintained at less than 20 mcg/kg/min. If dosage exceeds 50 mcg/kg/min, assess renal function frequently
513	Doripenem Monohydrate 500 mg Injection	J01DH04000 P4001XX	A*	Ventilator-associated pneumonia (VAP) patients at risk or involving multidrug resistant pathogens especially Pseudomonas aeruginosa infections	500mg every 8 hours as a one hour infusion for 5 to 14 days according to severity, site of infection and the patient's clinical response.
514	Dorzolamide HCl 2% Ophthalmic Solution	S01EC03110 D2001XX	A*	All glaucoma patients where beta-blockers are contraindicated and when intraocular pressure is not well controlled by other drugs	Monotherapy : 1 drop 3 times daily. Adjunctive therapy with an ophthalmic beta-blocker : 1 drop 2 times daily. When substituting for another ophthalmic antiglaucoma agent with this product, discontinue the other agent after proper dosing on one day and start Trusopt on the next day. If more than 1 topical ophthalmic drug is used, the drugs should be administered at least 10 mins apart
515	Dothiepin HCl 25 mg Capsule	N06AA16110 C1001XX	A	Depression of any aetiology	Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended

No.	Generic Name	MDC	Category	Indication(s)	Dosage
516	Dothiepin HCl 75 mg Tablet	N06AA16110 T1001XX	A	Depression of any aetiology	Initially 75 mg (ELDERLY 50-75 mg) daily in divided doses or single dose at bedtime, increased gradually as necessary to 150 mg daily (ELDERLY 75 mg may be sufficient), up to 225 mg daily in some circumstances. CHILD is not recommended
517	Doxazosin Mesilate 4 mg CR Tablet	C02CA04196 T5001XX	A*	Benign Prostatic Hyperplasia	4 mg once daily to maximum 8mg/day
518	Doxorubicin HCl 10 mg Injection	L01DB01110 P4001XX	A	i) Solid tumours, leukaemia, non-Hodgkin's lymphoma ii) Leukaemia (ALL induction) iii) Multiple myeloma	i) 30 - 75 mg/m2 IV as a single dose at 21 day intervals ii) 25 - 45 mg/m2 once a week for the first 4 weeks during induction or re-induction phase (refer to specific protocol. Caution: Total cumulative dose of doxorubicin must not exceed 550 mg/m2 due to risk of cardiotoxicity. CHILD: 30 mg/m2/dose over 6 - 24 hours for 1 - 2 days. Need to check cardiac function closely by echocardiography every cumulative dose of 100 mg/m2 to maximum 360 mg/m2 iii) 9 mg/m2 over 24 hours infusion for 4 days at monthly intervals

No.	Generic Name	MDC	Category	Indication(s)	Dosage
519	Doxorubicin HCl 50 mg Injection	L01DB01110 P4002XX	A	i) Solid tumours, leukaemia, non-Hodgkin's lymphoma ii) Leukaemia (ALL induction) iii) Multiple myeloma	i) 30 - 75 mg/m2 IV as a single dose at 21 day intervals ii) 25 - 45 mg/m2 once a week for the first 4 weeks during induction or re-induction phase (refer to specific protocol. Caution: Total cumulative dose of doxorubicin must not exceed 550 mg/m2 due to risk of cardiotoxicity. CHILD: 30 mg/m2/dose over 6 - 24 hours for 1 - 2 days. Need to check cardiac function closely by echocardiography every cumulative dose of 100 mg/m2 to maximum 360 mg/m2 iii) 9 mg/m2 over 24 hours infusion for 4 days at monthly intervals
520	Doxycycline 100 mg Capsule	J01AA02000C 1001XX	B	Infections due to susceptible organisms	ADULT: 200 mg on the first day followed by 100 mg daily. Severe infections: 200 mg daily
521	Doxycycline 100 mg Tablet	J01AA02000T 1001XX	B	Infections due to susceptible organisms	ADULT: 200 mg on the first day followed by 100 mg daily. Severe infections: 200 mg daily
522	D-Penicillamine 0.25 g Capsule	M01CC01000 C1001XX	A	i) Treatment of severe lead poisoning, it is used as adjunctive treatment following initial treatment with another chelating agent. May also be used as sole therapy in the treatment of asymptomatic patients with moderately elevated blood concentrations ii) Wilson's Disease: to aid in elimination of copper ions	i) Heavy metal poisoning: 900mg-1800mg daily. Duration of treatment is dictated by the urinary heavy metal excretion. Simultaneous oral vitamin B6 replacement with at least 40mg daily is essential ii) Wilson's disease: 0.25g - 1.5g daily on an incremental basis. Maximal daily dose: 2g. Maintenance dose: 0.75g - 1g daily
523	Duloxetine 30 mg Capsule	N06AX21110 C1001XX	A*	Major depressive disorder, diabetic peripheral neuropathic pain	ADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended

No.	Generic Name	MDC	Category	Indication(s)	Dosage
524	Duloxetine 60 mg Capsule	N06AX21110 C1002XX	A*	Major depression, diabetic peripheral neuropathic pain	ADULT: 60 mg once daily up to a maximum dose of 120mg/day (in divided doses) CHILD and ADOLESCENT under 18 years not recommended
525	Dutasteride 0.5 mg Capsule	G04CB02000 C1001XX	A*	Benign prostatic hyperplasia in men with an enlarged prostate gland	0.5 mg daily
526	Dutasteride 0.5mg and Tamsulosin 0.4mg Capsule	G04CA52953 C1001XX	A*	Combination therapy for the treatment of moderate to severe symptoms of BPH with: i) Large prostate (>30g) ii) Poor risk or not fit for surgery iii)Those who are awaiting their turn for surgery	One capsule daily
527	Dydrogesterone 10 mg Tablet	G03DB01110 T1001XX	A/KK	i) Dysmenorrhoea ii) Endometriosis iii) Dysfunctional uterine bleeding (to arrest and to prevent bleeding) iv) Threatened abortion v) Habitual abortion vi) Post menopausal complaints (hormone replacement therapy in combination with oestrogen)	i) 10 mg bd from day 5 - 25 of cycle ii) 10 mg bd - tds from day 5 - 25 of the cycle or continuously iii) To arrest bleeding :10 mg bd with an oestrogen once daily for 5 - 7 days, To prevent bleeding : 10 mg bd with an oestrogen once daily from day 11 - 25 of the cycle iv) 40 mg at once, then 10mg 8hrly until symptoms remit v) 10 mg bd until 20th week of pregnancy vi) 10-20 mg daily during last 12-14 days of each cycle
528	Edrophonium Chloride 10 mg/ml Injection	N07AA00100 P3001XX	B	i) For reversal of neuromuscular block ii) Diagnosis of myasthenia gravis	i) Intravenous injection on over several minutes, 500 - 700 mcg/kg (after or with atropine sulphate 600 mcg) ii) Intravenous injection 2 mg followed by 8 mg if no response occurs within 30 seconds. CHILD: 20 mcg followed by 80 mcg/kg after 30 seconds

No.	Generic Name	MDC	Category	Indication(s)	Dosage
529	Efavirenz 100 mg Capsule	J05AG03000 C1002XX	A*	Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg
530	Efavirenz 200 mg Capsule	J05AG03000 C1003XX	A*	Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg
531	Efavirenz 50 mg Capsule	J05AG03000 C1001XX	A*	Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
532	Efavirenz 600 mg Tablet	J05AG03000T1001XX	A/KK	Combination therapy for HIV infections with a protease inhibitor and or Nucleoside Reverse Transcriptase Inhibitors (NRTIs)	ADULT: 600 mg once daily. ADOLESCENT & CHILD less than 17 years, more than 40 kg: 600 mg once daily, 32.5 - less than 40 kg: 400 mg once daily, 25 - less than 32.5 kg: 350 mg once daily, 20 - less than 25 kg: 300 mg once daily, 15 - less than 20 kg: 250 mg once daily, 13 - less than 15 kg: 200 mg once daily. No studies in children less than 3 years or less than 13 kg. Formulation unsuitable for children less than 40 kg
533	Eltrombopag Olamine 25 mg Film-coated Tablet	B02BX05999T1001XX	A*	Short term use in idiopathic thrombocytopenic purpura patients as bridging therapy for splenectomy or surgery and in cases of severe bleeding.	Individualised dosage based on the patient's platelet count. Adult Initially 50 mg once daily. East Asian patient 25 mg once daily. Then, adjust dose to maintain platelet count ≥50,000/microliter. Max: 75 mg daily.
534	Emulsificants Ointment	D02AC00952G5001XX	C	Xerosis and ichthyosis	Use as a soap and emollient
535	Enalapril 10 mg Tablet	C09AA02253T1002XX	B	i) Hypertension ii) Congestive heart failure	i) Initially 5 mg daily, (ELDERLY 2.5 mg once daily), usual maintenance dose 10 - 20 mg daily. Maximum: 40 mg/day in 1 - 2 divided doses ii) Initially 2.5 mg daily, usual maintenance dose 20 mg daily in 1 - 2 divided doses; maximum: 40 mg/day
536	Enalapril 20 mg Tablet	C09AA02253T1003XX	B	i) Hypertension ii) Congestive heart failure	i) Initially 5 mg daily, (ELDERLY 2.5 mg once daily), usual maintenance dose 10 - 20 mg daily. Maximum: 40 mg/day in 1 - 2 divided doses ii) Initially 2.5 mg daily, usual maintenance dose 20 mg daily in 1 - 2 divided doses; maximum: 40 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
537	Enalapril 5 mg Tablet	C09AA02253 T1001XX	B	i) Hypertension ii) Congestive heart failure	i) Initially 5 mg daily, (ELDERLY 2.5 mg once daily), usual maintenance dose 10 - 20 mg daily. Maximum: 40 mg/day in 1 - 2 divided doses ii) Initially 2.5 mg daily, usual maintenance dose 20 mg daily in 1 - 2 divided doses; maximum: 40 mg/day
538	Enoxaparin Sodium 20 mg Injection	B01AB05520 P5001XX	A*	i) Prevention of Deep Vein Thrombosis(DVT) especially in perioperative and high risk surgical cases ii) Treatment of DVT iii) Unstable angina and non Q wave Myocardial Infarction	i) Prophylaxis fo DVT especially in surgical patients: moderate risk, 20 mg SC approximately 2 hours before surgery then 20 mg every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic surgery, medical patients, 40mg every 24 hours for at least 6 days until patient ambulant, max 14 days. ii) Treatment of DVT or pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5 days and until adequate oral anticoagulation established. iii) Unstable angina and non-ST-segment-elevation myocardial infarction 1 mg/kg every 12 hours, usually for 2 - 8 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
539	Enoxaparin Sodium 40 mg Injection	B01AB05520 P5002XX	A*	i) Prevention of Deep Vein Thrombosis(DVT) especially in perioperative and high risk surgical cases ii) Treatment of DVT iii) Unstable angina and non Q wave Myocardial Infarction	i) Prophylaxis for DVT especially in surgical patients: moderate risk, 20 mg SC approximately 2 hours before surgery then 20 mg every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic surgery, medical patients, 40mg every 24 hours for at least 6 days until patient ambulant, max 14 days. ii) Treatment of DVT or pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5 days and until adequate oral anticoagulation established. iii) Unstable angina and non-ST-segment-elevation myocardial infarction 1 mg/kg every 12 hours, usually for 2 - 8 days
540	Enoxaparin Sodium 60 mg Injection	B01AB05520 P5003XX	A*	i) Prevention of Deep Vein Thrombosis(DVT) especially in perioperative and high risk surgical cases ii) Treatment of DVT iii) Unstable angina and non Q wave Myocardial Infarction	i) Prophylaxis fo DVT especially in surgical patients: moderate risk, 20 mg SC approximately 2 hours before surgery then 20 mg every 24 hours for minimum 7 - 10 days, high risk (eg orthopaedic surgery, medical patients, 40mg every 24 hours for at least 6 days until patient ambulant, max 14 days. ii) Treatment of DVT or pulmonary embolism, 1.5 mg/kg every 24 hours, usually for 5 days and until adequate oral anticoagulation established. iii) Unstable angina and non-ST-segment-elevation myocardial infarction 1 mg/kg every 12 hours, usually for 2 - 8 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
541	Entacapone 200 mg Tablet	N04BX02000 T1001XX	A	Parkinson's Disease. An adjunct to standard levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson's disease and end of dose motor fluctuations, who cannot be stabilised on those combinations	200 mg to be taken with each daily dose of levodopa/dopa-decarboxylase inhibitor. Max 2g daily. May be taken with or without food
542	Entecavir 0.5 mg Tablet	J05AF10000T 1001XX	A*	First line treatment of Chronic Hepatitis B in patients who satisfy the criteria for treatment and require long-term therapy or have a very high baseline viral load	0.5-1mg once daily. Renal Dose Adjustment: 0.5-1mg every 48hours (30-49ml/min); 0.5-1mg every 72hours (10-29ml/min); 0.5mg-1mg every 5-7 days (<10ml/min; HD or CAPD).
543	Eperisone HCl 50 mg Tablet	M03BX09110 T1001XX	A	Myotonic symptoms associated with cervical syndrome, periarthritis of shoulder and lumbago spastic paralysis	50 mg 3 times daily
544	Ephedrine 0.5% w/v Nasal Drops	R01AA03110 D6001XX	A/KK	Decongestion of the upper respiratory tract	2 drops 3 times daily. Maximum use for 1 week
545	Ephedrine HCl 30 mg/ml Injection	R03CA02110 P3001XX	B	Treatment of bronchial spasm in asthma, adjunct to correct haemodynamic imbalances and treat hypotension in epidural and spinal anaesthesia	By IM, SC or IV. Severe, acute bronchospasm : 12.5-25 mg. Further dosage should be determine by patient response. When used as a pressor agent : ADULT 25 - 50 mg SC/IM. If necessary, a second IM dose of 50 mg or an IV dose of 25 mg may be given. Direct IV injection, 10 - 25 mg may be given slowly. Maximum parenteral ADULT dose : 150 mg in 24 hours. CHILD : 3 mg/kg or 100 mg/m2 SC or IV daily, in 4 - 6 divided doses
546	Epirubicin 10 mg Injection	L01DB03110 P4001XX	A*	Breast cancer, Non-Hodgkin's lymphoma, Leukaemia (ALL induction), gastric cancer, ovarian cancer	i) 75 - 90mg/m2 body area injected IV in 3 - 5 min, repeated at 21 day intervals.Higher doses up to 135mg/m2 as single agent and 120mg/m2 as combination (effective in treatment of breast cancer) CHILD: 50 mg/m2 over 6 hours. Schedule depends on protocol.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
547	Epirubicin 50 mg Injection	L01DB03110 P4002XX	A*	Breast cancer, Non-Hodgkin's lymphoma, Leukaemia (ALL induction), gastric cancer, ovarian cancer	i) 75 - 90mg/m2 body area injected IV in 3 - 5 min, repeated at 21 day intervals.Higher doses up to 135mg/m2 as single agent and 120mg/m2 as combination (effective in treatment of breast cancer) CHILD: 50 mg/m2 over 6 hours. Schedule depends on protocol.
548	Erlotinib 100 mg Tablet	L01XE03110T 1003XX	A*	i) As monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with stable disease after 4 cycles of standard platinum-based first-line chemotherapy. ii) For the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Restricted to non-smoker, female, epidermal growth factor receptor (EGFR) positive and Asian patients only	150 mg taken at least one hour before or two hours after the ingestion of food once daily. Reduce in steps of 50 mg when necessary. Continue treatment until disease progression or unacceptable toxicity occurs. May require dose modifications when coadministered with strong CYP3A4 inhibitors or inducers; or in cigarette smoking patients.
549	Erlotinib 150 mg Tablet	L01XE03110T 1002XX	A*	i) As monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with stable disease after 4 cycles of standard platinum-based first-line chemotherapy. ii) For the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. Restricted to non-smoker, female, epidermal growth factor receptor (EGFR) positive and Asian patients only.	150 mg taken at least one hour before or two hours after the ingestion of food once daily. Reduce in steps of 50 mg when necessary. Continue treatment until disease progression or unacceptable toxicity occurs. May require dose modifications when coadministered with strong CYP3A4 inhibitors or inducers; or in cigarette smoking patients.
550	Ertapenem 1 g Injection	J01DH03520 P4001XX	A*	i) Patient with confirm ESBL producing gram-negative infection. ii) Empiric treatment for severe community acquired pneumonia or other infections when Pseudomonas aeruginosa is not suspected.	ADULT: 1 g once daily. CHILD 3 month to 12 years: 15 mg/kg twice daily. Not to exceed 1 g/ day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
551	Erythromycin Ethylsuccinate 200 mg/5 ml Suspension	J01FA01238F 2101XX	B	Treatment of susceptible bacterial infections	Child: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.
552	Erythromycin Ethylsuccinate 400 mg Tablet	J01FA01238T 1001XX	B	Treatment of susceptible bacterial infections	Adult 400 mg 6 hrly or 800 mg 12 hrly. Max: 4 g/day. Childn 30-50 mg/kg in divided doses. Childn 2-8 yr 1 g/day in divided doses in severe cases. Infant & childn ≤2 yr 500 mg/day in divided doses.
553	Erythromycin Ethylsuccinate 400 mg/5 ml Suspension	J01FA01238F 2102XX	B	Treatment of susceptible bacterial infections	Child: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.
554	Erythromycin Lactobionate 500 mg Injection	J01FA01129P 3001XX	A*	Only for treatment of i) certain forms of meningitis ii) septicaemia not responding to usual antibiotics iii) mycoplasma pneumonia iv) infection with gram-positive organisms (e.g. tetanus, streptococcal infection) associated with Penicillin allergy, only when oral erythromycin cannot be given	Adult & Child: 25 - 50mg/kg /day infusion every 6 hours. Maximum: 4 g/day.
555	Erythromycin Stearate 250 mg Tablet	J01FA01258T 1001XX	B	Infections due to susceptible organism	Child: 30-50 mg/kg daily, increased to twice the usual dose in severe cases. 2-8 yr: 1 g daily in divided doses; <2 yr: 500 mg daily in divided doses.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
556	Erythropoietin Human Recombinant 10,000 IU/ml Injection	B03XA01000 P5005XX	A*	i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy	i) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose
557	Erythropoietin Human Recombinant 1000 IU/0.5ml Injection	B03XA01000 P5001XX	A*	i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy	i) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose.
558	Erythropoietin Human Recombinant 2000 IU/0.5ml Injection	B03XA01000 P5002XX	A	i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy	i) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
559	Erythropoietin Human Recombinant 3000 IU/0.3ml Injection	B03XA01000 P5003XX	A*	i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy	i) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to 300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose
560	Erythropoietin Human Recombinant 4000 IU/0.4ml Injection	B03XA01000 P5004XX	A	i) Treatment of anaemia associated with chronic renal failure. Dialysis patients who are haemoglobin less than 8 g or exhibiting symptoms of anaemia although haemoglobin more than 8 g and pre-transplant cases ii) Anaemia in cancer (non-myeloid malignancies) with concomitant chemotherapy	i) ADULT by IV injection over 1-5 minutes, initially 50 units/kg 3 times weekly adjusted according to response in step of 25 units/kg 3 times weekly at interval of at least 4 weeks. CHILD initially as for adult. Maintenance, bodyweight under 10 kg usually 75-150 units/kg 3 times weekly, bodyweight 10-30 kg usually 60-150 units/kg 3 times weekly, bodyweight over 30 kg usually 30-100 units/kg 3 times weekly ii) ADULT by SC injection (max. 1 ml per injection site), initially 150 units/kg 3 times weekly, increased if appropriate rise in haemoglobin not achieved after 4 weeks to

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					300 units/kg 3 times weekly. Discontinue if inadequate response after 4 weeks at higher dose.
561	Escitalopram 10 mg Tablet	N06AB10124 T1001XX	A*	i) Major depression ii) Treatment of panic disorder with or without agoraphobia	i) 10 mg once daily; may be increased to max 20 mg daily. ii) Panic disorder with or without agoraphobia :Initially 5 mg for the first week, thereafter increased to 10 mg daily. Max 20 mg daily, ELDERLY initially half the adult dose, lower maintenance dose may be sufficient. CHILD and ADOLESCENT under 18 years not recommended
562	Esmolol HCl 10 mg/ml Injection	C07AB09110 P3001XX	A*	Tachycardia and hypertension in perioperative period	By IV infusion usually within range of 50 - 200 mcg/kg/min
563	Esomeprazole 20 mg Tablet	A02BC05000 T1002XX	A*	i)Gastro-oesophageal reflux disease ii)H. pylori eradication	i)20mg daily for 4-8 weeks ii)40mg daily for 10 days in combination with amoxicillin 1g twice daily or clarithromycin 500mg twice daily
564	Esomeprazole 40 mg Injection	A02BC05000 P3001XX	A*	i) Acute erosive/ ulcerative oesophagitis ii) Non -variceal upper gastrointestinal bleed	i) 20- 40 mg once daily for 2-5 days ii) 80 mg by IV bolus followed by 8mg/hour infusion for 72 hours
565	Esomeprazole 40 mg Tablet	A02BC05000 T1001XX	A*	i)Gastro-oesophageal reflux disease ii)H. pylori eradication	i)20mg daily for 4-8 weeks ii)40mg daily for 10 days in combination with amoxicillin 1g twice daily or clarithromycin 500mg twice daily
566	Essential Phospholipids, nicotinamide, cyanocobalamine , tocopheryl, pyridoxine, thiamine, riboflavine capsule	A05BA00924 C1001XX	A/KK	Nutritional supplement in liver disorders	Please refer to product leaflet

No.	Generic Name	MDC	Category	Indication(s)	Dosage
567	Estradiol 1 mg & Estradiol 1 mg with Dydrogesterone 10 mg	G03FB08954 T1001XX	A*	Hormone Replacement Therapy for women with disorders due to natural or surgically induced menopause with intact uterus.	One tablet daily without pill-free interval, starting with 1 mg of Estradiol for first 14 days, followed by 1mg Estradiol with 10 mg Dydrogestrone daily for the next 14 days
568	Estradiol 1 mg & Norethisterone Acetate 0.5 mg Tablet	G03FA01122 T1001XX	A*	Hormone replacement therapy for oestrogen deficiency symptoms in women more than 1 year after menopause and prevention of osteoporosis in post menopausal women	1 tablet per day without interruption
569	Estradiol 1 mg with Dydrogesterone 5 mg Tablet	G03FB08954 T1002XX	A*	i) Hormone replacement therapy for the relief of symptoms due to oestrogen deficiency ii) Prevention of postmenopausal osteoporosis in women with a uterus	One tablet daily, taken continuously without interruption. Should be used only in postmenopausal women more than 12 month after menopause
570	Estradiol Valerate 1 mg Tablet	G03CA03256 T1002XX	A*	Oestrogen replacement therapy - only those who cannot tolerate Premarin	1 mg daily continuously or 21 day regimen with 1 week of tablet free interval
571	Estradiol Valerate 2 mg and Norgestrel 500 mcg with Estradiol Valerate 2 mg Tablet	G03FB01953 T1001XX	B	Pre and post menopausal syndrome, primary and secondary amenorrhea, menstrual irregularities. Deficiency symptoms after oophorectomy or radiological castration for noncarcinomatous disease	Start on the 5th day of menstrual cycle - 1 tab daily for 21 days then stop for 7 days. If patient forgets dose at usual time, it should be taken within following 12 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
572	Etanercept 25 mg Injection	L04AA11000 P4001XX	A*	i) Moderately to severe rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with inadequate response to methotrexate alone. ii) Active polyarticular-course juvenile idiopathic arthritis in children 2-17 years with inadequate response to, or who have proved intolerant of methotrexate. iii) Psoriatic arthritis as monotherapy or in combination with methotrexate in patient's inadequate response to methotrexate alone. iv)Active ankylosing spondylitis in adults v)Moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA	Adult & geriatric dose: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis; 50 mg SC once-weekly for once-weekly dosing or 25 mg SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing. Plaque psoriasis; Initial: 50 mg SC twice weekly, 72 to 96 hours apart; maintain initial dose for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully). Maintenance dose: 50 mg SC once weekly. Paediatric dose (2 to 17 years): Juvenile idiopathic arthritis; 0.8 mg/kg (max. 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg (max. 25 mg/dose) SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
573	Etanercept 50 mg Injection	L04AB01000 P4002XX	A*	i) Moderately to severe rheumatoid arthritis as monotherapy or in combination with methotrexate in patients with inadequate response to methotrexate alone. ii) Active polyarticular-course juvenile idiopathic arthritis in children 2-17 years with inadequate response to, or who have proved intolerant of methotrexate. iii) Psoriatic arthritis as monotherapy or in combination with methotrexate in patients inadequate response to methotrexate alone. iv) Active ankylosing spondylitis in adults v) Moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA	Adult & geriatric dose: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis; 50 mg SC once-weekly for once-weekly dosing or 25 mg SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing. Plaque psoriasis; Initial: 50 mg SC twice weekly, 72 to 96 hours apart; maintain initial dose for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully). Maintenance dose: 50 mg SC once weekly. Paediatric dose (2 to 17 years): Juvenile idiopathic arthritis; 0.8 mg/kg (max. 25 mg/dose) SC once weekly for once-weekly dosing or 0.4 mg/kg (max. 25 mg/dose) SC twice weekly (individual doses should be separated by 72 to 96 hours) for twice-weekly dosing.
574	Ethambutol HCl 200 mg Tablet	J04AK02110T 1001XX	B	Tuberculosis	Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.
575	Ethambutol HCl 400 mg Tablet	J04AK02110T 1002XX	B	Tuberculosis	Adult: 15-25mg/kg daily (max 1200mg) or 50mg/kg biweekly (max2000mg). Children: 15-25mg/kg daily or 50 mg/kg twice weekly.
576	Ether Solvent	N01AA01000 L9901XX	C	To remove adhesive plaster from the skin	Dose depending on the route and procedure
577	Ethinylestradiol 20 mcg & Drospirenone 3 mg Tablet	G03AA12954 T1002XX	A*	i)Oral contraception ii)Treatment of acne vulgaris in women seeking oral contraception. iii) Treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception.	1 tab daily for 28 consecutive days starting on 1st day of menstrual bleeding.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
578	Ethinylestradiol 20 mcg & Gestodene 75 mcg Tablet	G03AA10954 T1001XX	A/KK	Oral contraception	1 tablet to be taken daily for 21 executive days starting on the first day of menses. Each subsequent pack is started after a 7 days tablet free interval.
579	Ethinylestradiol 20 mcg & Levonorgestrel 100 mcg Tablet	G03AA07954 T1002XX	A/KK	i)Prevention of pregnancy ii)Treatment of moderate acne vulgaris not controlled by conventional therapy (e.g topical preparations and oral antibiotics) in post-menarchal, premenopausal women more than or 14 years who accept contraception.	Beginning on day 1 of cycle, 1 tablet daily for 21 days followed by 7 tablet-free days.
580	Ethionamide 250 mg Tablet	J04AD03000T 1001XX	A*	As second-line therapy in the treatment of Multi Drug Resistant Tuberculosis only in combination with other efficacious agents and only when therapy with isoniazid, rifampicin, or other first-line agents has failed.	ADULT: 15-20mg/kg daily, in divided doses if necessary; maximum dose 1g/day. CHILD: 10-20mg/kg in 2-3 divided doses or 15mg/kg/24hrs as a single daily dose.
581	Ethosuximide 250 mg/5 ml Syrup	N03AD01000 L9001XX	B	Absence seizures	ADULT: Initially, 500 mg daily. Increased by 250 mg at intervals of 4-7 days to usual dose of 1-1.5 g daily. Maximum: Up to 2 g, under strict supervision. CHILD: Greater than or equal to 6 years: Same as adult dose; less than 6 years: Initially, 250 mg daily. Increased gradually to usual dose of 20 mg/kg daily. Maximum: Children greater than or equal to 6 years: Same as adult dose; less than 6 years: Up to 1 g
582	Ethyl Chloride 100ml Spray	N01BX01000 A4001XX	C	For minor surgical procedures including lancing boils, incision and drainage of small abscesses, pain due to athletic injuries and pain due to injection administration	Spray to affected area at a distance of about 30cm until a fine white film is produced

No.	Generic Name	MDC	Category	Indication(s)	Dosage
583	Etomidate 20 mg/10 mg Injection	N01AX07000 P3001XX	A*	Induction of general anaesthesia for haemodynamically unstable patients	Adult: 300mcg/kg given slowly over 30-60 seconds into a large vein in the arm. Child: Up to 30% more than the standard adult dose. Elderly: 150-200 mcg/kg, subsequently adjusted according to effects.
584	Etonogestrel 68 mg Implant	G03AC08000 P1001XX	A/KK	Contraception	A single implant inserted subdermally and can be left in place for three years. The implant can be removed at any time but not later than three years after the date of insertion.
585	Etoposide 100 mg/5 ml Injection	L01CB01000P 3001XX	A*	i) For treatment of children with solid tumours, juvenile myelomonocytic leukemia (JMML) and Langerhan cell histiocytosis ii) Leukaemia, lymphoma iii) Testicular cancer, lung cancer, gestational trophoblastic disease, gastric cancer, sarcoma	i) CHILD: 60-120 mg/m2/day by IV for 3 - 5 days every 3 - 6 weeks depending on protocols ii) Maintenance or palliative chemotherapy for elderly acute myeloid leukemia, consolidation therapy for acute lymphoblastic leukemia, stem cell mobilization (Refer to protocol) iii) 100 mg/m2 by IV every other day for 3 doses repeated every 3-4 weeks
586	Etoposide 50mg capsule	L01CB01000 C1003XX	A*	Treatment of small cell lung cancer and malignant lymphomas	Normal adult dose is 175mg-200mg daily for 5 consecutive days orally, followed by recession (withdrawal) interval of 3 weeks. Repeat administration as necessary. Increase or reduce dose as appropriate, according to the particular disease or symptoms.
587	Etoricoxib 120 mg Tablet	M01AH0500 0T1002XX	A*	i)Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute gouty arthritis iii)Acute pain	i) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					shortest possible duration of treatment)
588	Etoricoxib 60 mg Tablet	M01AH0500 0T1003XX	A*	i)Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute gouty arthritis iii)Acute pain	i) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)
589	Etoricoxib 90 mg Tablet	M01AH0500 0T1001XX	A*	i)Acute and chronic treatment of signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) ii)Acute gouty arthritis iii)Acute pain	i) OA: 60 mg once daily. RA: 90 mg once daily ii & iii) Acute gouty arthritis and acute pain: 120 mg once daily (Given the exposure to COX-2 inhibitors, doctors are advised to use the lowest effective dose for the shortest possible duration of treatment)
590	Everolimus 0.25mg tablet	L04AA18000 T1001XX	A*	Indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant in combination with ciclosporin for microemulsion and corticosteroids.	An initial dose regimen of 0.75 mg b.i.d., which is recommended for the general kidney and heart transplant population. The daily dose of everolimus should always be given orally in two divided doses (b.i.d.).
591	Everolimus 0.75mg tablet	L04AA18000 T1003XX	A*	Indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant in combination with ciclosporin for microemulsion and corticosteroids.	An initial dose regimen of 0.75 mg b.i.d., which is recommended for the general kidney and heart transplant population. The daily dose of everolimus should always be given orally in two divided doses (b.i.d.).

No.	Generic Name	MDC	Category	Indication(s)	Dosage
592	Exemestane 25 mg Tablet	L02BG06000 T1001XX	A*	Treatment of post-menopausal women with advanced breast cancer whose disease has progressed following tamoxifen and non-steroidal aromatase inhibitors	25 mg once daily
593	Ezetimibe 10 mg & Simvastatin 20 mg Tablet	C10BA02000 T1001XX	A*	Primary hypercholesterolemia	Usual starting dose: 10/20 mg/day
594	Ezetimibe 10 mg Tablet	C10AX09000 T1001XX	A*	i) Co-administration with statins for patients who have chronic heart disease or are chronic heart disease equivalent or familial hypercholesterolaemia with target LDL-C not achieved by maximum dose of statins ii) Monotherapy in patients with documented biochemical intolerance to statins	10 mg once daily. Not recommended for children less than 10 years old
595	Factor IX Injection	B02BD04000 P9901XX	A	Prevention and control of bleeding in patients with factor IX deficiency due to haemophilia B	Dose varies according to the patient and the circumstances of the bleeding. i) Mild haemorrhage: initial dose of 30 units/kg body weight. ii) Moderate haemorrhage: initial dose of 50 units/kg iii) Major haemorrhage/surgery: Initial dose of 75 - 100 units/kg. Half of these doses may be repeated after 18-24 hrs if necessary.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
596	Factor IX, Factor II, Factor VII and Factor X In Combination Injection	B02BD01000 P4001XX	A*	i) Treatment and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors, such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required. ii) Treatment and perioperative prophylaxis of bleeding in congenital deficiency of any of the vitamin K dependent coagulation factors only if purified specific coagulation factor product is not available.	Amount and frequency of administration should be calculated on an individual patient basis. Individual dosage requirements can only be identified on the basis of regular determinations of the individual plasma levels of the coagulation factors of interest or on the global tests of the prothrombin complex levels (INR, Quick's test) and a continuous monitoring of the clinical condition of the patient. An approximate calculation is as follows: Required dose (IU) = body weight (kg) x desired factor rise (IU/dl or % of normal) x reciprocal of the estimated recovery, i.e. Factor II = 53 Factor VII = 59 Factor IX = 77 Factor X = 56 As product may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation.
597	Factor VIIa (Recombinant) eptacog alfa (activated) 100 KIU (2 mg) Injection	B02BD08000 P4005XX	A*	Treatment of bleeding episodes and prevention of excessive bleeding in connection with surgery in patients with inherited or acquired haemophilia with inhibitors to coagulation factors VIII or IX	Initially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-5 minutes, followed by 3-6 KIU (60-120 mcg)/kg body weight depending on type & severity of haemorrhage or surgery performed. Dosing interval: initially 2-3 hour to obtain haemostasis and until clinically improved. If continued therapy is needed, dose interval can be increased successively to every 4, 6, 8 or 12 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
598	Factor VIIa (Recombinant) eptacog alfa (activated) 50 KIU (1 mg) Injection	B02BD08000 P4004XX	A*	Treatment of bleeding episodes and prevention of excessive bleeding in connection with surgery in patients with inherited or acquired haemophilia with inhibitors to coagulation factors VIII or IX	Initially 4.5 KIU (90 mcg)/kg body weight IV bolus over 2-5 minutes, followed by 3-6 KIU (60-120 mcg)/kg body weight depending on type & severity of haemorrhage or surgery performed. Dosing interval: initially 2-3 hour to obtain haemostasis and until clinically improved. If continued therapy is needed, dose interval can be increased successively to every 4, 6, 8 or 12 hours
599	Factor VIII (Human blood coagulation factor) & Von Willebrand factor Injection	B02BD06000 P4002XX	A*	i)The treatment and prophylaxis of haemorrhage or surgical bleeding in Von Willebrand Disease (VWD) when 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) treatment alone is ineffective or contraindicated. ii)The treatment and prophylaxis of bleeding associated with factor VIII deficiency due to haemophilia A.	i. Von Willebrand Disease: Spontaneous Bleeding Episodes: Initially, factor VIII 12.5-25 IU/kg and ristocetin cofactor 25-50 IU/kg followed by factor VIII 12.5 IU/kg and ristocetin cofactor 25 IU/kg subsequently every 12-24 hrs. Minor Surgery: Factor VIII 30 IU/kg and ristocetin cofactor 60 IU/kg daily. Major Surgery: Initially, factor VIII 30-40 IU/kg and ristocetin cofactor 60-80 IU/kg followed by factor VIII 15-30 IU/kg and ristocetin cofactor 30-60 IU/kg subsequently every 12-24 hrs. Prophylaxis: Factor VIII 12.5-20 IU/kg and ristocetin cofactor 25-40 IU/kg 3 times weekly. ii. Hemophilia A therapy: Minor haemorrage: 10-15 IU/kg every 12-24 hours. Moderate to severe haemorrhage: 15-40 IU/kg every 8 to 24 hours. Minor surgery: Loading dose 20-30 IU/kg, maintenance dose 15-30 IU/kg. Major surgery: Loading dose 40-50 IU/kg, maintenance dose 10-40 IU/kg. Prophylaxis: 25-40

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					IU/kg three times weekly As product may differ from one to another, it is strongly advised to refer to the manufacturer (product insert) in regards to dosing calculation.
600	Factor VIII (Recombinant) Octocog Alfa 250 IU Injection	B02BD02000 P4001XX	A*	i)Control and prevention of bleeding episodes in adults and children (0-16 years) with hemophilia A. ii)Surgical prophylaxis in adults and children with hemophilia A. iii)Routine prophylactic treatment to reduce the frequency of bleeding episodes and the risk of joint damage in children with no pre-existing joint damage. Not indicated fot the treatment of von willebrand's disease.	The dosage and duration of treatment should be individualised and taking into account the severity of factor VIII deficiency, location and extent of bleeding and patient's clinical condition. Dose can be calculated by using: i. Required dose (IU) = body weight (kg) x desired factor VIII rise (IU/dl or % of normal) x 0.5 (IU/kg) or ii. Expected factor VIII rise (% of normal) = 2 x (dose administered)/ bodyweight (kg) Dose administered should be titrated to patient's clinical response
601	Factor VIII (Recombinant) Octocog Alfa 500 IU Injection	B02BD02000 P4002XX	A*	i)Control and prevention of bleeding episodes in adults and children (0-16 years) with hemophilia A. ii)Surgical prophylaxis in adults and children with hemophilia A. iii)Routine prophylactic treatment to reduce the frequency of bleeding episodes and the risk of joint damage in children with no pre-existing joint damage. Not indicated for the treatment of von willebrand's disease.	The dosage and duration of treatment should be individualised and taking into account the severity of factor VIII deficiency, location and extent of bleeding and patient's clinical condition. Dose can be calculated by using: i. Required dose (IU) = body weight (kg) x desired factor VIII rise (IU/dl or % of normal) x 0.5 (IU/kg) or ii. Expected factor VIII rise (% of normal) = 2 x (dose administered)/ bodyweight (kg) Dose administered should be titrated to patient's clinical response.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
602	Factor VIII Inhibitor Bypassing Activity Injection	B02BD03000 P4001XX	A	i) Treatment and prophylaxis of hemorrhages in hemophilia A and B patients with inhibitors. ii) Treatment and prophylaxis of hemorrhages in non-hemophilic patients who have developed inhibitors to Factors VIII, IX and XI. iii) Treatment of patients with acquired inhibitors to Factors X and XIII. iv) In the combination with Factor VIII concentrate for a long-term therapy to achieve a complete and permanent elimination of the Factor VIII inhibitor so as to allow for regular treatment with Factor VIII concentrate as in patients without inhibitor.	As a general guideline, a dose of 50 to 100IU/kg body weight is recommended, not exceeding an individual dose of 100IU/kg bw and a maximum daily dose of 200IU/kg bw.
603	Factor VIII Injection	B02BD02999 P9901XX	A	Prevention and control of bleeding in patients with factor VIII deficiency due to classical haemophilia A	Dose varies according to the patient and the circumstances of the bleeding. i) Mild to moderate: Usually a single dose of 10-15units/kg. ii) More serious haemorrhage/minor surgery: Initially 15-25 units/kg followed by 10-15 units/kg every 8 - 12 hours if required iii) Severe haemorrhage/major surgery: Initial: 40 - 50 units/kg followed by 20 - 25 units/kg every 8-12 hrs.
604	Fat Emulsion 10% for IV Infusion Injection	B05BA02000 P6001XX	A	Source of lipid in patients needing IV nutrition	Dose to be individualised. ADULT usual lipid requirement 2-3 g/kg/day. INFANT 0.5 - 1 g/kg/day
605	Fat Emulsion 20% for IV Infusion Injection	B05BA02000 P6002XX	A	Source of lipid in patients needing IV nutrition	Dose to be individualised. ADULT usual lipid requirement 2-3 g/kg/day. INFANT 0.5-1 g/kg/day
606	Felodipine 10 mg Tablet	C08CA02000 T1002XX	A/KK	Hypertension	Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the morning
607	Felodipine 5 mg Tablet	C08CA02000 T1001XX	A/KK	Hypertension	Initiate at 5 mg once daily. Usual dose, 5 - 10 mg once daily in the morning

No.	Generic Name	MDC	Category	Indication(s)	Dosage
608	Fenofibrate 145 mg tablet	C10AB05000 T1002XX	A/KK	As second line therapy after failed gemfibrozil in patients: i) Hypercholesterolemia and hypertriglyceridemia alone or combined [type IIa,IIb,III and V dysplipidemias] in patients unresponsive to dietary and other non-pharmacological measures especially when there is evidence of associated risk factors ii) Treatment of secondary hyperlipoproteinemias if hyperlipoprotenemia persists despite effective treatment of underlying disease iii) Dyslipidemia in Type 2 Diabetes Mellitus	145mg once daily, with or without food
609	Fentanyl 12mcg/h Transdermal Patch	N02AB03136 M7005XX	A*	As a second line drug in the management of chronic severe cancer pain not responding to non-narcotic analgesic. Not to be used in opiod naive patients.The use is to be restricted to pain specialists, palliative medicine specialists and oncologists	ADULT and CHILD over 2 years previously treated with a strong opioid analgesic, initial dose based on previous 24-hour opioid requirement (consult product literature). If necessary dose should be adjusted at 72-hour intervals in steps of 12-25 mcg/hr
610	Fentanyl 25 mcg/h Transdermal Patch	N02AB03136 M7001XX	A*	As a second line drug in the management of chronic cancer pain. The use is to be restricted to pain specialists, palliative medicine specialists and oncologists.	Patients who have not previously received a strong opioid analgesic, initial dose, one 25 mcg/hour patch to be replaced after 72 hours. Patients who have received a strong opioid analgesic, initial dose based on previous 24 hours opioid requirement (oral morphine sulphate 90 mg over 24 hours = one 25 mcg/hour patch). Not recommended in children.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
611	Fentanyl 50 mcg/h Transdermal Patch	N02AB03136 M7002XX	A*	As a second line drug in the management of chronic cancer pain. The use is to be restricted to pain specialists, palliative medicine specialists and oncologists	Patients who have not previously received a strong opioid analgesic, initial dose, one 25 mcg/hour patch to be replaced after 72 hours. Patients who have received a strong opioid analgesic, initial dose based on previous 24 hours opioid requirement (oral morphine sulphate 90 mg over 24 hours = one 25 mcg/hour patch). Not recommended in children.
612	Fentanyl Citrate 50 mcg/ml Injection	N01AH01136 P3001XX	A	Short duration analgesia during pre-medication induction and maintenance of anaesthesia, and in the immediate post-operative period.	Dose should be individualized according to age, body weight, physical status, underlying pathological conditions and type of surgery and anaesthesia. ADULT: Premedication: IM 50 - 100 mcg, 30 - 60 mins prior to surgery. Adjunct to general anaesthesia: Induction IV 50 - 100mcg, repeat 2 - 3 mins intervals until desired effect is achieved. IV/IM 25 - 50mcg in elderly and poor risk patients. Maintenance: IV/IM 25 - 50mcg. Adjunct to regional anaesthesia: IM/slow IV 50 - 100mcg when additinal analgesia is required. Post-operatively (recovery room): IM 50 - 100mcg for pain control, tachypnoea and emergency delirium. May be repeated in 1- 2 hours as needed. CHILD (2 - 12 years): Induction & maintenance: 2 - 3 Mcg/kg.
613	Ferric Ammonium Citrate 800 mg/10 ml	B03AB06136 L2101XX	C	Prevention and treatment of iron-deficiency anaemias	CHILD up to 1 year 5 ml, 1 - 5 years 10 ml, taken well diluted with water

No.	Generic Name	MDC	Category	Indication(s)	Dosage
	Paediatric Mixture				
614	Ferrous controlled release 500 mg, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12, Vitamin C, Niacinamide, Calcium Pantothenate, Folic Acid 800 mcg Tablet	B03AE10903 T1001XX	A/KK	Anemia due to iron deficiency, megaloblastic anemia where there is an associated deficiency of Vitamin C and Vitamin B-complex particularly in pregnancy. In primary health clinic, the indication is restricted to anemia due to iron deficiency in pregnant women ONLY.	One tablet daily
615	Ferrous Fumarate 200 mg Tablet	B03AA02138 T1001XX	C+	Prevention and treatment of iron-deficiency anaemias	Adult: Usual dose range: Up to 600 mg daily. May increase up to 1.2 g daily if necessary. Child: As syrup containing 140 mg(45 mg iron)/5ml. Preterm neonate: 0.6-2.4 ml/kg daily; up to 6 years old: 2.5-5ml twice daily
616	Filgrastim (G-CSF) 30 MU/ml Injection	L03AA02000 P3001XX	A*	i) Reduction in the duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy except chronic myeloid leukemia and myelodysplastic syndrome ii) Haemopoeitic stem cell transplantation (HSCT)/stem cell harvesting	i) Adult: SC or IV 5 mcg/kg/day. Initiation: 24 - 72 hours after chemotherapy. Duration: Until a clinically adequate neutrophil recovery is achieved (absolute neutrophil count of at least 1 x 109/L on 2 consecutive days) ii) Refer to protocol
617	Filgrastim 30 MU in 0.5 ml Injection	L03AA02000 P5001XX	A*	i) Reduction in the duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy except chronic myeloid leukemia and myelodysplastic syndrome ii) Haemopoeitic stem cell transplantation (HSCT)/stem cell harvesting	i) ADULT: 5mcg/kg/day by SC or IV. Initiation: 24 - 72 hours after chemotherapy. Duration: Until a clinically adequate neutrophil recovery is achieved (absolute neutrophil count of at least 1 x 109/L on 2 consecutive days) ii) Refer to protocol

No.	Generic Name	MDC	Category	Indication(s)	Dosage
618	Finasteride 5 mg Tablet	G04CB01000 T1001XX	A*	Treatment and control of benign prostatic hyperplasia	5 mg a day as a single dose. Clinical responses occur within 12 weeks - 6 months of initiation of therapy. Long-term administration is recommended for maximal response
619	Fingolimod 0.5mg Capsule	L04AA27110 C1001XX	A*	Treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability	0.5mg orally once daily
620	Flavoxate HCl 100 mg Tablet	G04BD02110 T1001XX	A	Urinary frequency and incontinence, dysuria, urgency, bladder spasm due to catheterisation	ADULT: 200 mg 3 times daily. CHILD under 12 years not recommended
621	Flecainide Acetate 100 mg Tablet	C01BC04122 T1001XX	A*	i) Sustained monomorphic ventricular tachycardias ii) Preexcited atrial fibrillation associated with Wolff-Parkinson White Syndrome iii) Reciprocating Atrio-Ventricular tachycardias (AVT) associated with Wolff-Parkinson White Syndrome iv) Supraventricular tachycardias due to Intra-Atrio Ventricular Nodul Reentry	Ventricular arrhythmias: 100 mg twice daily, maximum 400 mg/day (usually reserved for rapid control or in heavily built patients), reduced after 3 - 5 days if possible. Supraventricular arrhythmias: 50 mg twice daily, increased if required to maximum of 150 mg twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
622	Fluconazole 100 mg Capsule	J02AC01000C 1002XX	A	i) Oropharyngeal candidiasis, atrophic oral candidiasis associated with dentures, other candidal infections of mucosa ii) Tinea pedis, corporis, cruris, versicolor and dermal candidiasis iii) Invasive candidal & cryptococcal infections (including meningitis) iv) Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary therapy v) Prevention of fungal infections in immunocompromised patients considered at risk as a consequence of HIV infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant	i) Oropharyngeal candidiasis: 50 - 100 mg daily for 7 - 14 days (Maximum 14 days) except in severely immunocompromised patients, treatment can be continued for longer periods. Atrophic oral candidiasis associated with dentures: 50 mg daily for 14 days. Other candidal infections of mucosa: 50 - 100 mg daily for 14 - 30 days. CHILD: 3 - 6 mg/kg on first day then 3 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) ii) 50 mg daily for 2 - 4 weeks, maximum 6 weeks iii) 400 mg initially then 200 - 400 mg daily for 6 - 8 weeks. CHILD: 6 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 -4 weeks old) iv) 100 - 200 mg daily v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
623	Fluconazole 2 mg/ml Injection	J02AC01000P9901XX	A	i) Oropharyngeal candidiasis, atrophic oral candidiasis associated with dentures, other candidal infections of mucosa ii) Tinea pedis, corporis, cruris, versicolor and dermal candidiasis iii) Invasive candidal& cryptococcal infections (including meningitis) iv) Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary therapy v) Prevention of fungal infections in immunocompromised patients considered at risk as a consequence of HIV infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant	i) 50 - 100 mg daily for 7 - 14 days (Maximum 14 days) except in severely immunocompromised patients, treatment can be continued for longer periods. Atrophic oral candidiasis associated with dentures: 50 mg daily for 14 days. Other candidal infections of mucosa: 50 - 100 mg daily for 14 - 30 days. CHILD: 3 - 6 mg/kg on first day then 3 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) ii) 50 mg daily for 2 - 4 weeks, maximum 6 weeks iii) 400 mg initially then 200 - 400 mg daily for 6 - 8 weeks. CHILD: 6-12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) iv) 100 - 200 mg daily v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
624	Fluconazole 50 mg Capsule	J02AC01000C 1001XX	A	i) Oropharyngeal candidiasis, atrophic oral candidiasis associated with dentures, other candidal infections of mucosa ii) Tinea pedis, corporis, cruris, versicolor and dermal candidiasis iii) Invasive candidal & cryptococcal infections (including meningitis) iv) Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary therapy v) Prevention of fungal infections in immunocompromised patients considered at risk as a consequence of HIV infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant	i) Oropharyngeal candidiasis: 50 - 100 mg daily for 7 - 14 days (Maximum 14 days) except in severely immunocompromised patients, treatment can be continued for longer periods. Atrophic oral candidiasis associated with dentures: 50 mg daily for 14 days. Other candidal infections of mucosa: 50 - 100 mg daily for 14 - 30 days. CHILD: 3 - 6 mg/kg on first day then 3 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old) ii) 50 mg daily for 2 - 4 weeks, maximum 6 weeks iii) 400 mg initially then 200 - 400 mg daily for 6 - 8 weeks. CHILD: 6 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 -4 weeks old) iv) 100 - 200 mg daily v) 50 - 400 mg daily. CHILD: 3 - 12 mg/kg daily (every 72 hours in NEONATE up to 2 weeks old, every 48 hours in NEONATE 2 - 4 weeks old)
625	Flucytosine 2.5 g/250 ml Injection	J02AX01000P 9901XX	A*	Treatment of systemic fungal infection	ADULT: 100 - 200 mg/kg daily in 4 divided doses by IV infusion over 20 - 40 minutes not more than 7 days
626	Flucytosine 500 mg Tablet	J02AX01000T 1001XX	A*	Only for the treatment of fungal meningitis	ADULT: 50 - 150 mg/kg/day in 4 divided doses
627	Fludarabine Phosphate 10 mg Tablet	L01BB05162T 1001XX	A*	B-cell chronic lymphocytic leukemia who have not responded to or whose disease had progressed during or after treatment with at least one standard alkylating-agent containing regimen	40 mg /m2 given daily for 5 consecutive days every 28 days. Courses may be repeated every 28 days, usually for up to 6 cycles. Duration of treatment depends on treatment

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					success and tolerability of the drug
628	Fludarabine Phosphate 50 mg Injection	L01BB05162 P4001XX	A*	B-cell chronic lymphocytic leukaemia who have not responded to or whose disease had progressed during or after treatment with at least one standard alkylating-agent containing regimen	25 mg/m2 daily for 5 consecutive days every 28 days. May be administered up to the achievement of a maximal response (usually 6 cycles) and then the drug should be discontinued. Reduce dose by up to 50% in patients with mild to moderate renal impairment (30-70ml/min)
629	Fludrocortisone Acetate 0.1 mg Tablet	H02AA02122 T1001XX	A	As an adjunct to glucocorticoids in the management of primary adrenocortical insufficiency in Addison's disease and treatment of salt-losing adrenogenital syndrome	Adrenocorticoid insufficiency (chronic): ADULT 1 tablet daily. Salt-losing adrenogenital syndrome: ADULT 1 - 2 tablets daily. CHILD and INFANT 0.5 - 1 tablet daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
630	Flumazenil 0.1 mg/ml Injection	V03AB25000 P3001XX	B	i) Diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose ii) Reversal of sedation following anaesthesia with benzodiazepine	i) Initial, 0.2 mg IV over 30 seconds; if desired level of consciousness not obtained after an additional 30 seconds, give dose of 0.3 mg IV over 30 seconds; further doses of 0.5 mg IV over 30 seconds may be given at 1-minutes intervals if needed to maximum total dose of 3 mg; patients with only partial response to 3 mg may require additional slow titration to a total dose of 5 mg; if no response 5 minutes after receiving total dose of 5 mg, overdose is unlikely to be benzodiazepine and further treatment with flumazenil will not help ii) 0.2 mg IV over 15 seconds; if desired level of consciousness is not obtained after waiting 45 seconds, a second dose of 0.2 mg IV may be given and repeated at 60-seconds intervals as needed (up to a maximum of 4 additional times) to a maximum total dose of 1 mg; most patients respond to doses of 0.6 to 1 mg; in the event of resedation, repeated doses may be given at 20-minutes intervals if needed; for repeat treatment, no more than 1 mg (given as 0.5 mg/minute) should be given at any one time and no more than 3 mg should be given in any one hour

No.	Generic Name	MDC	Category	Indication(s)	Dosage
631	Flunarizine HCl 5 mg Capsule	N07CA03110 C1001XX	B	i) Migraine prophylaxis ii) Maintenance treatment of vestibular disturbances and of cerebral and peripheral disorders	i) ADULT: 5 - 10 mg daily preferably at night. ELDERLY more than 65 years: 5 mg at night. Maintenance 5-day treatment at the same daily dose ii) 5 - 10 mg at night. If no improvement after 1 month, discontinue treatment
632	Fluorescein 1 mg Ophthalmic Strip	S01JA01520 M9901XX	B	Diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature	Moisten tip with tear fluid from lower fornix, sterile water or ophthalmic solution and gently stroke across the conjunctiva
633	Fluorescein Sodium 10% in 5 ml Injection	S01JA01520P 3001XX	A	Diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature	500 mg IV
634	Fluorometholone 0.1% Ophthalmic Suspension	S01BA07000 D2001XX	A*	Treatment of steroid responsive ocular inflammation	1-2 drops qds. During the initial 24-48 hr, dose may be increased to 2 drops 2 hrly.
635	Fluorouracil 1 g/20 ml Injection	L01BC02000P 4002XX	A*	Cancers of gastro-intestinal tract, breast and pancreas, head and neck. Ophtalmological indication: trabeculectomy	500 - 600 mg/m2 IV in combination with other cytotoxic agents, repeated every 3 weeks or 300 - 450 mg/m2 IV slow bolus daily for 5 days in combination with biological response modifiers, repeated every 4 weeks or 3000 - 3750 mg/m2 as a continuous infusion over 5 days in combination with a platinum compound every 3 to 4 weeks
636	Fluorouracil 100 mg Tablet	L01BC02000T 1001XX	A	Colorectal cancer	15 mg/kg (max: 1 g/day), may be given once weekly for maintenance. Max: 1 g/week.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
637	Fluorouracil 50 mg / ml in 5 ml Injection	L01BC02000P 4001XX	A*	Cancers of gastro-intestinal tract, breast and pancreas, head and neck. Ophtalmological indication: trabeculectomy	Intravenous Infusion: 15 mg/kg bodyweight (to a maximum of 1 g daily) diluted in 300-500mL of 5% glucose given over a period of 4 hours. 12 mg/kg bodyweight daily for 3 consecutive days. Providing there are no signs of toxic effects, the patient may then be given 6mg/kg I.V. on the 5th, 7th and 9th days. If after the 9th day there is still no sign of toxicity, the patient may be placed on maintenance therapy. Maintenance Therapy: 5 - 10mg/kg bodyweight by I.V. injection once a week.
638	Fluoxetine HCl 20 mg Capsule	N06AB03110 C1001XX	A	i) Depression ii) Obsessive-compulsive disorder	i) 20 mg once daily increased after 3 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily max 80 mg once daily (ELDERLY max 60 mg once daily). ii) Initially 20 mg once daily increased after 2 weeks if necessary, usual dose 20 - 60 mg (ELDERLY 20 - 40 mg) once daily, max 80 mg (ELDERLY max 60 mg) once daily, discontinue if no improvement within 10 weeks. CHILD and ADOLESCENT under 18 years are not recommended
639	Flupenthixol Decanoate 20mg/ml Injection	N05AF01135 P2001XX	B	Chronic psychoses	By deep IM, initial test dose of 5-20 mg, then after at least 7 days. 20 - 40 mg repeated at intervals of 2 - 4 weeks. Maximum 400 mg weekly. Usual maintenance dose 50 mg every 4 weeks to 300 mg every 2 weeks. ELDERLY, initially quarter to half adult dose. CHILD not recommended. Deep IM recommended. Not for IV

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					use.
640	Fluphenazine Decanoate 25 mg/ml Injection	N05AB02135 P3001XX	B	Long term management of psychotic disorders	By deep IM : Test dose 12.5 mg (6.25 mg in ELDERLY), then after 4-7 days 12.5 mg-100 mg repeated at intervals of 14-35 days, adjusted according to response. CHILD not recommended
641	Flutamide 250 mg Tablet	L02BB01000T 1001XX	A*	Metastatic prostatic carcinoma	250 mg 3 times daily
642	Fluticasone Furoate 27.5 mcg/dose Nasal Spray	R01AD08139 A4101XX	A*	Treatment of nasal symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing) and ocular symptoms (itching/burning, tearing/watering, and redness of the eye) of seasonal and perennial allergic rhinitis.	Adults/Adolescents (≥12 years) : 1-2 sprays (27.5 mcg/spray) in each nostril once daily. Children (2-11 years) : 1-2 sprays (27.5 mcg/spray) in each nostril once daily
643	Fluticasone Propionate 125 mcg/dose Inhaler	R03BA05133 A2101XX	B	Prophylactic treatment for asthma	ADULT and CHILD more than 16 years i) Mild asthma : 100 mcg - 250 mcg twice daily ii) Moderate asthma : 250 - 500 mcg twice daily iii) Severe asthma : 500 mcg - 1000 mcg twice daily. Alternatively, the starting dose of fluticasone dipropionate may be gauged at half the total daily dose of beclomethasone dipropionate or equivalent administered by inhalation. CHILD 4 - 11 years, 50 mcg twice daily (maximum 100 mcg twice daily), CHILD 1-4 years, 50-100mcg microgram twice daily
644	Fluvoxamine 100 mg Tablet	N06AB08253 T1002XX	B	Depression	For depression, initially 50 - 100 mg daily in the evening, increased if necessary to 300 mg daily (over 150 mg in divided doses); usual maintenance dose 100 mg daily. CHILD and ADOLESCENT under 18 years not recommended

No.	Generic Name	MDC	Category	Indication(s)	Dosage
645	Fluvoxamine 50 mg Tablet	N06AB08253 T1001XX	B	Depressive disorder	For depression, initially 50 - 100 mg daily in the evening, increased if necessary to 300 mg daily (over 150 mg in divided doses); usual maintenance dose 100 mg daily. CHILD and ADOLESCENT under 18 years not recommended
646	Folic Acid 5 mg Tablet	B03BB01000 T1001XX	C+	i) For the prevention and treatment of folate deficiency states ii) For the prevention of neural tube defect in the foetus	i) ADULT initially 10-20mg mg daily for 14 days or until haematopoietic response obtained. Daily maintenance: 2.5 mg-10mg .CHILD up to 1 year:250 mcg/kg daily; 1 to 5 years:2.5mg/day;6-12 years: 5mg/day ii) 5 mg daily starting before pregnancy and continued through the first trimester
647	Follitropin Alpha (Recombinant Human FSH) 300 IU/0.5 ml Injection	G03GA05000 P3002XX	A*	i) Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate ii) Stimulation of follicular development for intra-uterine cycles iii) Stimulation of follicular development in assisted reproductive technology in the management of infertility	i) 75 - 150 IU daily, should commence within the first 7 days of the menstrual cycle and increased by 37.5 IU or 75 IU at 7 or 14 days interval. Max daily dose 225 IU ii) 150 - 225 IU daily commencing on days 2 or 3 of the cycle. Max daily dose 450 IU
648	Follitropin Alpha (Recombinant Human FSH) 75 IU Injection	G03GA05000 P3001XX	A*	i) Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate ii) Stimulation of follicular development for intra-uterine cycles iii) Stimulation of follicular development in assisted reproductive technology in the management of infertility	i) 75 - 150 IU daily should commence within the first 7 days of the menstrual cycle and increased by 37.5 IU or 75 IU at 7 or 14 days interval. Max daily dose 225 IU ii) 150 - 225 IU daily commencing on days 2 or 3 of the cycle. Max daily dose 450 IU

No.	Generic Name	MDC	Category	Indication(s)	Dosage
649	Follitropin Beta (Recombinant Human FSH) 300 IU Injection	G03GA06000 P3002XX	A*	Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate. Stimulation of follicular development for intra-uterine insemination cycles and assisted reproductive technology in the management of infertility.	To be individualized. Give in multiples of 50 IU. Starting dose can be 50 IU - 200 IU daily. It can be a step-up regime or a step-down, depending on the protocol and the ovarian response
650	Follitropin Beta (Recombinant Human FSH) 50 IU Injection	G03GA06000 P3001XX	A*	Infertility treatment in anovulatory women who have been unresponsive to treatment with clomiphene citrate. Stimulation of follicular development for intra-uterine insemination cycles and assisted reproductive technology in the management of infertility.	To be individualized. Give in multiples of 50 IU. Starting dose can be 50 IU - 200 IU daily. It can be a step-up regime or a step-down, depending on the protocol and the ovarian response
651	Fondaparinux Sodium 12.5 mg/ml Injection in Prefilled Syringe	B01AX05520 P5002XX	A*	i) Treatment of acute Deep Vein Thrombosis (DVT). ii) Treatment of Pulmonary Embolism (PE)	The recommended dose to be administered by SC injection once daily is: 5mg for body weight less than 50kg, 7.5mg for body weight 50 to 100kg, 10mg for body weight greater than 100kg. Treatment should be continued for at least 5 days and until adequate oral anticoagulation is established (INR 2 to 3). Concomitant treatment with vitamin K antagonists should be initiated as soon as possible, usually within 72 hours. The usual duration of treatment is 5 to 9 days
652	Fondaparinux Sodium 2.5 mg/0.5 ml Injection	B01AX05520 P5001XX	A*	i) Prevention of venous thromboembolic events (VTE) in orthopedic surgery (e.g. hip fracture, major knee or hip replacement surgery), abdominal surgery in patients at risk of thromboembolic complication. ii) Treatment of unstable angina or non-ST segment elevation myocardial infarction [UA/NSTEMI] in patients for whom urgent invasive management (PCI) is not indicated. iii) Treatment of ST segment elevation myocardial	i) 2.5 mg once daily given by SC, administered 6 hr following surgical closure provided homeostasis has been established. Usual duration of therapy is 5 to 9 days; for hip fracture patients, an extended course of up to 24 days is recommended. ii) ADULT more than 18 years: 2.5 mg once daily given by SC, initiated as soon as possible after diagnosis and

No.	Generic Name	MDC	Category	Indication(s)	Dosage
				infarction (STEMI) in patients managed with thrombolytics or are not receiving other forms of reperfusion therapy	continued for up to 8 days or until hospital discharge. If patient needs to undergo PCI, unfractionated heparin to be administer as per local practice protocol, taking into account the patient's bleeding risk and time of last dose of fondaparinux. Fondaparinux may be restarted no earlier than 2 hr after sheath removal. iii) ADULT more than 18 years: 2.5 mg once daily; first dose to be given IV (directly through an existing IV line or as infusion in 25 or 50 ml of 0.9% saline over 1-2 min), subsequent doses to be given SC. Treatment to be initiated as soon as diagnosis is made and continued up to a max of 8 days or until hospital discharge, whichever comes earlier. If patient needs to undergo non-primary PCI, unfractionated heparin to be admin as per local practice protocol, taking into account the patient's bleeding risk and time of last dose of fondaparinux. Fondaparinux may be restarted no earlier than 3 hr after sheath removal
653	Formoterol Fumarate Dihydrate 4.5 mcg /dose Inhaler	R03AC13138 A2101XX	A*	i) Moderate persistent and severe persistent asthma ii) COPD	i) ADULT and ELDERLY : 6 - 12 mcg (1 - 2 puff) once - twice daily, maximum daily dose 8 puff. CHILD over 6 years : 2 puff once - twice daily ii) ADULT and ELDERLY : 2 puff once - twice daily, maximum 4 puff once or twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
654	Formoterol Fumarate Dihydrate 9 mcg/dose Turbuhaler	R03AC13138 A2102XX	A*	i) Moderate persistent and severe persistent asthma ii) COPD	i) ADULT and ELDERLY: 1 puff once - twice daily, maximum daily dose 4 - 6 puff. CHILD over 6 years : 1 puff once - twice daily, maximum dose : 2 puff daily ii) ADULT and ELDERLY : 1 puff, once - twice daily, maximum dose : 2 - 4 puff daily
655	Framycetin Sulphate 0.5%, Dexamethasone 0.05% and Gramicidin 0.005% Ear Drops	S01CA01991 D1001XX	A/KK	Otitis externa	Apply 2 - 3 drops 3 to 4 times daily
656	Frusemide 10 mg/ml Injection	C03CA01000 P3001XX	B	Pulmonary oedema	Initially 20 -40 mg IM or slow IV (rate not exceeding 4 mg/min). CHILD: 0.5 - 1.5 mg/kg. Max: 20 mg daily
657	Frusemide 40 mg Tablet	C03CA01000 T1001XX	B	Pulmonary oedema	ADULT: Initial 40 - 80 mg on morning if required, can be increased to a max of 1 g/day in certain cases especially in chronic renal failure. CHILD : 1 - 3 mg/kg daily
658	Fuller's Earth Powder	V03AB00000 F2101XX	C	Adsorbent in pesticide poisoning	Adult: 100-150g every 2-4 hours. Child: 1-2g/kg. (100g of Fuller's Earth is mixed with 200ml water. Repeat until Fuller's Earth is seen in stool (normally between 4-6 hours)
659	Fusafungine 1% Nasal Spray	R02AB03000 A4101XX	A	Local antibiotic, anti-inflammatory treatment of infectious and inflammatory syndromes of the respiratory mucosa	ADULT : 1 oral or 1 nasal inhalation 4 hourly, withdraw if no improvement after 7 days. CHILD : 1 oral or 1 nasal inhalation 6 hourly, withdraw if no improvement after 7 days
660	Fusidate, Sodium 250 mg Tablet	J01XC01520T 1001XX	A*	Treatment of infections caused by susceptible organisms especially Staphylococcal infections including Methicillin Resistant Staphylococcus aureus (MRSA)	ADULT: 500 mg 3 times daily, skin and soft tissue infection: 250 - 500 mg twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
661	Fusidic Acid 1% Eye Drops	S01AA13000 D2001XX	A	For staphylococcal infections	1 drop in conjunctival sac 12 hourly. To be continued for 2 days after the eye appears normal. On the first day of treatment, may be applied more frequently: 1 drop 4 hourly. Surgical prophylaxis : 1 drop every 12 hours, 24 - 48 hours before operation
662	Fusidic Acid 2% Cream	D06AX01000 G1001XX	A	Skin infections caused by staphylococci, streptococci, corynebacterium minutissumun and other sodium fusidate-sensitive organisms	Apply to affected area 2 - 3 times daily
663	Fusidic Acid 2% in Betamethasone Valerate 0.1% Cream	D07CC01948 G1001XX	A/KK	Inflammatory dermatosis where bacterial infection is likely to occur eg atopic eczema, discoid eczema, stasis eczema, seborrhoic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus	Uncovered lesion- Apply 2 to 3 times daily. Covered lesions- Less frequent applications may be adequate
664	Fusidic Acid 50 mg/ml Suspension	J01XC01000L 8001XX	A*	Treatment of infections caused by staphylococcal especially Methicillin Resistant Staphylococcus aureus (MRSA)	ADULT: 15 ml 3 times daily. CHILD 1 - 5 years: 5 ml 3 times daily; 5 - 12 years: 10 ml 3 times daily. INFANT : 1 ml/kg body weight daily in 3 - 4 divided doses
665	Fusidic Acid 500 mg Injection	J01XC01520P 4001XX	A*	Treatment of severe staphylococcal infections especially Methicillin Resistant Staphylococcus aureus (MRSA). To be used in combination therapy only	ADULT: 500 mg 3 times daily diluted to 250 - 500 ml infused slowly over 2 hours. Maximum: 2 g daily. CHILD and INFANT : 20 mg/kg/day divided into 3 equal doses infused slowly over 2 - 4 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
666	Gabapentin 100 mg Tablet	N03AX12000 T1002XX	A*	i) Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs ii) Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult more than 18 years	ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administering 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS on day 3. Thereafter, then dose may be increased in 3 equally divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided dose. Effective dose: CHILD 3 to less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day
667	Gabapentin 300 mg Capsule	N03AX12000 C1001XX	A*	i) Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs ii) Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult more than 18 years	ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administered 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS on day 3. Thereafter, may be increased in 3 equally divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided doses. Effective dose: CHILD 3 to less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
668	Gabapentin 600 mg Tablet	N03AX12000 T1001XX	A*	i) Add-on therapy for intractable partial epilepsy, refractory to standard anti-epileptic drugs ii) Treatment of various types of neuropathic pain, both peripheral (which includes diabetic neuropathy, post-herpetic neuralgia, trigeminal neuralgia) in adult over 18 years	ADULT & CHILD > 12 yrs: 900-3600mg/day. Therapy may be initiated by administered 300mg TDS on day 1, or by titrating the dose as: 300mg once on day 1, 300mg BD on day 2, 300mg TDS on day 3. Thereafter, may be increased in 3 equally divided doses up to max 3600mg/day.CHILD 3-12 yr: Initially 10-15 mg/kg/day in 3 divided doses. Effective dose: CHILD 3 to less than 5 yrs: 40mg/kg/day in 3 divided doses, CHILD 5-12 yrs: 25-35mg/kg/day in 3 divided doses ii) ADULT: 900mg/day in 3 equally divided doses. Max 3600mg/day
669	Gadobenate Dimeglumine Injection Solution	V08CA08996 P3001XX	A*	i) MRI of the liver for the detection of focal liver lesions in patients with known or suspected primary liver cancer (e.g. Hepatocellular carcinoma) or metastatic disease; ii) MRI of the brain and spine where it improves the detection of lesion and provides diagnostic information additional to that obtained with unenhanced MRI; iii) Contrast-enhanced MR-angiography where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease in patients with suspected or known vascular disease of the abdominal or peripheral arteries.	i) MRI of liver: 0.05ml/kg body weight. This corresponds to 0.1ml/kg of the 0.5M solution ii) MRI of brain & spine: 0.1mmol/kg body weight. This corresponds to 0.2ml/kg of the 0.5M solution iii) MRA: 0.1mmol/kg body weight. This corresponds to 0.2ml/kg of the 0.5M solution

No.	Generic Name	MDC	Category	Indication(s)	Dosage
670	Gadobutrol 1 mmol/ml injection	V08CA09000 P3001XX	A*	In adults, adolescents and children aged 2 years and older with diagnostic difficulty especially in patients with renal impairment for: i) Contrast enhancement in cranial and spinal magnetic resonance imaging (MRI). ii) Contrast enhanced MRI of liver or kidneys in patients with high suspicion or evidence of having focal lesion to classify these lesions as benign or malignant. iii)Contrast enhancement in Magnetic Resonance Angiography (CE-MRA).	A single intravenous injection of 0.1mmol/kg (equivalent to 0.1 ml/kg body weight). Max: 0.3 mmol/kg (equivalent to 0.3 ml/kg body weight)
671	Gadopentetate Dimeglumine 469 mg/ml	V08CA01000 P3001XX	A	i) Cranial and spinal magnetic resonance imaging ii) Whole body magnetic resonance imaging	The usual dose in adults, children, and neonates is 0.2 mL/kg (0.1mmol/kg) intravenously. For cranial and spinal imaging, a further dose of 0.2 mL/kg (0.1mmol/kg) may be given within 30 minutes if necessary; in adults this second dose may be 0.4 mL/kg (0.2mmol/kg). For whole body imaging in adults and children over 2 years, a dose of 0.4 mL/kg (0.2 mmol/kg) may be needed in some cases to produce adequate contrast and in special circumstances a dose of 0.6 mL/kg (0.3 mmol/kg) may be used in adults
672	Gadoterate Meglumine (Gadoteric Acid) 0.5 mmol/ ml Injection	V08CA02254 P3001XX	A	High risk patients undergoing Magnetic Resonance Imaging for cerebral and spinal disease, diseases of the vertebral column and other whole body pathology	The recommended dose is 0.1mmol/kg (equivalent to 0.2 mL/kg in adults, children and infants. In angiography, depending on the results of the examination being performed, a second injection may be administered during the same session if necessary

No.	Generic Name	MDC	Category	Indication(s)	Dosage
673	Gadoxetic acid disodium 0.25 mmol/ml solution for injection (10ml pre-filled syringe)	V08CA10520 P3001XX	A*	For use in adults for the enhancement of magnetic resonance imaging (MRI) of focal liver lesions	0.1ml/kg body weight (equivalent to 25 µmol per kg body weight). Not recommended for patients younger than 18 years
674	Gamma Benzene Hexachloride 0.1 % Lotion	P03AB02100 L6001XX	C	Scabies	Apply lotion to entire body from neck down for 8 to 12 hours, then rinse
675	Gamma Benzene Hexachloride 0.1% in Oil Solution	P03AB02100 L9901XX	C	Head lice	Apply a sufficient quantity of shampoo onto clean, dry hair; generally 1 ounce is sufficient, no more than 2 ounces should be used. Work the shampoo into hair thoroughly and allow to remain on hair for 4 minutes. Add small quantities of water and massage until a good lather forms. Rinse thoroughly and towel dry briskly
676	Gamma Benzene Hexachloride 1% Cream	P03AB02100 G1002XX	A/KK	Only for scabies in adult	Scabies Adult: Apply a thin layer of 1% topical preparation onto all skin areas from the neck to toes. Completely wash off from the body with warm water after 8-12 hr.
677	Ganciclovir Sodium 50 mg/ ml Injection	J05AB06520P 3001XX	A*	Treatment of cytomegalovirus (CMV) disease in immunocompromised patients, prevention of CMV disease during immunosuppressive therapy following organ transplantation	Initial: 5 mg/kg infused over 1 hour 12 hourly for 14 - 21 days (CMV retinitis treatment) or 7 - 14 days (CMV disease prevention). Long term maintenance: 6 mg/kg daily for 5 days/week or 5 mg/kg daily for 7 days/week
678	Ganirelix 0.25 mg/0.5 ml Injection	H01CC01000 P2001XX	A*	Prevention of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for assisted reproduction technique	Given by SC 0.25 mg once daily, starting on day 6 of ovarian stimulation and continued until ovulation induction

No.	Generic Name	MDC	Category	Indication(s)	Dosage
679	Gefitinib 250 mg tablet	L01XE02000T1001XX	A*	For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously failed chemotherapy, and who have activating mutation of epidermal growth factor receptor (EGFR). Restricted to non-smoker, female, EGFR positive and Asian patients only.	250mg tablet once a day, taken with or without food
680	Gemcitabine HCl 1 g Injection	L01BC05110P4002XX	A*	i) Locally advanced or metastatic non-small cell lung cancer ii) Locally advanced or metastatic pancreatic cancer iii) In combination with carboplatin in the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed more than six months, following platinum-based therapy iv) In combination with paclitaxel for treatment of patients with metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated	i) Alone or with cisplatin: 1000 mg/m2 day 1 & 8 every 3 weeks or 1000 mg/m2 day 1, day 8, day 15 every 4 weeks ii) Initially 1000 mg/m2 weekly for 7 weeks followed by 1 week rest. Subsequent cycles 1000 mg/ m2 weekly for 3 weeks followed by 1 week rest iii) Gemcitabine 1000 mg/m2 as 30 minutes IV infusion day 1 & 8 of each 21-day cycle followed by carboplatin on day 1 to attain a target AUC of 4 mg/ml/minute iv) 1250 mg/m2 on days 1 and 8 of each 21-day cycle with paclitaxel 175 mg/m2 given as a 3-hour infusion before gemcitabine on day 1 of each 21-day cycle

No.	Generic Name	MDC	Category	Indication(s)	Dosage
681	Gemcitabine HCl 200 mg Injection	L01BC05110P 4001XX	A*	i) Locally advanced or metastatic non-small cell lung cancer ii) Locally advanced or metastatic pancreatic cancer iii) In combination with carboplatin in the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed more than six months, following platinum-based therapy iv) In combination with Paclitaxel, for treatment of patients with metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated	i) Alone or with cisplatin: 1000 mg/m2 day 1 & 8 every 3 weeks or 1000 mg/m2 day 1, day 8, day 15 every 4 weeks ii) Initially 1000 mg/m2 weekly for 7 weeks followed by 1 week rest. Subsequent cycles 1000 mg/ m2 weekly for 3 weeks followed by 1 week rest iii) Gemcitabine 1000 mg/m2 as 30 minutes IV infusion day 1 & 8 of each 21-day cycle followed by carboplatin on day 1 to attain a target AUC of 4 mg/ml/minute iv) 1250 mg/m2 on days 1 and 8 of each 21-day cycle, with paclitaxel 175 mg/m2 given as a 3-hour infusion before gemcitabine on day 1 of each 21-day cycle
682	Gemeprost (Prostagladin E1 Synthetic Analogue) 1 mg Pessary	G02AD03000 S1001XX	A	Inducing abortion in the first trimester	Cervical dilatation: 1 pessary 3 hourly before surgery to a max of 5 pessaries over 24 hours
683	Gemfibrozil 300 mg Capsule	C10AB04000 C1001XX	A/KK	Treatment of hyperlipoprotinaemias (TYPES IIA, IIB, III, IV, V)	ADULT: 1200 mg/day in 2 divided doses, 30 minutes before breakfast and dinner. Dose range from 0.9-1.5 g daily
684	Gentamicin 0.1% Cream	D06AX07183 G1001XX	A*	For localised infections	Apply 2 - 3 times daily
685	Gentamicin 0.3% Eye Drops	S01AA11183 D2001XX	A/KK	Broad spectrum antibiotic in superficial eye infections and also for Pseudomonas aeruginosa	1 - 2 drops every 4 hours, in severe infection dosage may be increased up to 2 drops every hour
686	Gentamicin 0.3% Eye Ointment	S01AA11183 G5101XX	A/KK	Conjunctivitis, blepharitis, blepharo-conjunctivitis, keratitis, keratoconjunctivitis, episcleritis, dacrocystitis, corneal ulcers, styes and infected eye socket	Apply into the conjunctival sac 3 - 4 times daily
687	Gentamicin 3% Fortified Eye Drops	S01AA11183 D2002XX	A	Broad spectrum antibiotic in superficial eye infections and also for Pseudomonas aeruginosa	Dose according to the needs of the patient

No.	Generic Name	MDC	Category	Indication(s)	Dosage
688	Gentamicin 7.5 mg Beads	J01GB03183P1001XX	A	Treatment of chronic osteomyelitis of post-traumatic, post-operative or hematogenous origin	7.5 - 22.5 mg chains to fill affected cavity
689	Gentamicin Sulphate 10 mg/ml Injection	J01GB03183P3002XX	B	Infections due to susceptible organisms	ADULT: 3 - 5 mg/kg/day 8 hourly IM or IV. CHILD up to 2 weeks: 3mg/kg every 12 hours; 2 weeks - 12 years: 2 mg/kg 8 hourly
690	Gentamicin Sulphate 40 mg/ml Injection	J01GB03183P3003XX	B	Infections due to susceptible organisms	ADULT: 3 - 5 mg/kg/day 8 hourly IM or IV. CHILD up to 2 weeks: 3mg/kg every 12 hours; 2 weeks - 12 years: 2 mg/kg 8 hourly
691	Gentamicin Sulphate and Betamethasone Disodium Phosphate Eye Drops	S01CA05990D2001XX	A/KK	Inflammatory and allergic conditions involving superficial eye structures and when bacterial infection is present : conjunctivitis, blepharitis, keratitis, episcleritis, dacryocystitis, hordeolum, meibomianitis, injuries involving anterior segment of the eye	2 drops 3 - 4 times daily
692	Gentamicin Sulphate and Betamethasone Disodium Phosphate Eye Ointment	S01CA05990G5101XX	A	Inflammatory and allergic conditions involving superficial eye structures and when bacterial infection is present : conjunctivitis, blepharitis, keratitis, episcleritis, dacryocystitis, hordeolum, meibomianitis, injuries involving anterior segment of the eye	Thin coating of ointment 3 - 4 times daily
693	Glibenclamide 5 mg Tablet	A10BB01000T1001XX	B	Diabetes mellitus type 2. Restriction : Use only in patient under 65 years old	Range: 2.5 - 15 mg daily (with or immediately after breakfast). Initially 2.5 mg daily increasing by 2.5 mg required for metabolic control. Max: 20mg daily.
694	Gliclazide 30 mg Modified Release Tablet	A10BB09000T5002XX	B	Diabetes mellitus type 2	Initially, 30mg daily at breakfast time, may increase in successive steps to 60, 90 or 120mg daily at 1 month intervals. Max daily dose: 120mg
695	Gliclazide 60 mg Modified Release Tablet	A10BB09000T5001XX	B	Diabetes mellitus type 2	Initially, 30mg daily at breakfast time, may increase in successive steps to 60, 90 or 120mg daily at 1 month intervals (except in patients whose blood glucose level was not

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					reduced after 2 weeks of treatment). Max daily dose: 120mg
696	Gliclazide 80 mg Tablet	A10BB09000 T1001XX	B	Diabetes mellitus type 2	Initially 40-80mg daily. A single dose should not exceed 160mg and when higher doses are required, a twice daily split dosage is advised and should be divided. Maximum daily dose: 320mg. For elderly, starting dose should be 40mg twice daily.
697	Glucagon (Lyophilised) 1 mg/ml Injection	H04AA01000 P4001XX	B	Management of hypoglycaemia	Adult, children > 20kg: 1mg by SC, IM or IV. Children < 20kg : 0.5mg. If patient does not respond within 10 minutes, administer IV glucose. Repeat in 20 minutes if necessary.
698	Glutaraldehyde Solution 2%	V07AV00000 L9905XX	A	2% formulation - High level disinfection for heat sensitive equipments such as endoscopes	20 minutes or more immersion is recommended for endoscopes before the session and between patients after thorough cleaning based on manufacturer recommendation
699	Glycerin	A06AX01000 L5001XX	C+	As a lubricant and osmotic dehydrating agent	Apply to area when required
700	Glycerin 25% and Sodium Chloride 15% Enema	A06AG20921 G2001XX	C+	Constipation	1 enema as required
701	Glyceryl Trinitrate 0.5 mg Sublingual Tablet	C01DA02221 T1001XX	C	Prophylaxis and treatment of angina and left ventricular failure	0.5-1 mg sublingually may be repeated every 5 minutes until relief is obtained. Seek physician if the pain persists after a total of 3 tablets in a 15 minutes period.
702	Glyceryl Trinitrate 5 mg/ml Injection	C01DA02221 P3001XX	A	Prophylaxis and treatment of angina, left ventricular failure. Not for direct IV injection.	Initial 5 mcg/min delivered via infusion pump. Subsequent titration must be adjusted to clinical situation with dose increment becoming more cautious as partial response is seen.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
703	Glyceryl Trinitrate Aerosol Spray 400mcg (metered dose)	C01DA02221 A1001XX	B	Prophylaxis and treatment of angina and left ventricular failure	At the onset of an attack, one or two metered sprays should be administered on or under the tongue. A spray maybe repeated approximately every 5 minutes as needed. No more than 3 metered sprays are recommended within 15 minute period. If chest pain persists after a total of 3 sprays, prompt medical attention is recommended. Aerosol may be used prophylactically 5 to 10 minutes before engaging in activities that might precipitate an acute attack
704	Glycine 1.5% Irrigating Solution	B05CX03000 H3001XX	A	Bladder irrigation during genitourinary surgery	The dosage depends on the extent of the procedure and its duration
705	Glycopyrrolate 200 mcg/ml Injection	A03AB02320 P3001XX	A*	i) To reduce secretions (respiratory tract) for certain types of surgery ii) Reversal of neuromuscular block in patients where atropine is contraindicated	i) Pre-op: 4mcg/kg via IM administration 30-60 mins before procedure. Intraoperative: 0.1 mg via IV administration, repeat at 2-3 min intervals when needed. Max: 400mcg/dose. ii) 0.2 mg by IV for each 1 mg of neostigmine or 5 mg pyridostigmine
706	Glycopyrronium 50mcg, Inhalation Powder Hard Capsules	R03BB06320 A2001XX	A/KK	For maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). COPD diagnosis is confirmed by spirometry.	One capsule daily. The recommended dose is the inhalation of the content of one capsule once daily using inhaler. It is recommended to be administered, at the same time of the day each day. No relevant use of glycopyrronium in pediatric population (<18 years) for COPD.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
707	Golimumab 50mg (0.5ml) solution for injection in a pre-filled syringe	L04AB06000 P5001XX	A*	i) Rheumatoid arthritis (RA): In combination with methotrexate (MTX), is indicated for: - The treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to DMARD therapy including MTX has been inadequate. - The treatment of active, severe and progressive rheumatoid arthritis in adult patients not previously treated with MTX. ii) Psoriatic arthritis (PsA): Golimumab alone or in combination with MTX, is indicated for: The treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. iii) Ankylosing spondylitis (AS): Golimumab(used alone) is indicated for: The treatment of active ankylosing spondylitis in adult patients when the response to conventional therapy has been inadequate.	i) Rheumatoid arthritis 50mg given as a subcutaneous injection once a month, on the same date each month. ii) Psoriatic arthritis 50mg given as a subcutaneous injection once a month, on the same date each month. iii) Ankylosing spondylitis 50mg given as a subcutaneous injection once a month, on the same date each month.
708	Goserelin 10.8 mg Depot Injection	L02AE03000P 2002XX	A	Prostate cancer,endometriosis,leiomyoma uteri and assissted reproduction,breast cancer in premenopausal and perimenopausal women suitable for hormonal manipulation	One 10.8mg depot injected subcutaneously into the anterior abdominal wall, every 12 weeks.
709	Goserelin 3.6 mg Depot Injection	L02AE03000P 2001XX	A	Prostate cancer,endometriosis,leiomyoma uteri and assissted reproduction,breast cancer in premenopausal and perimenopausal women suitable for hormonal manipulation	3.6 mg depot injection every 28 days
710	Granisetron HCl 1 mg Tablet	A04AA02110 T1001XX	A	Prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy	ADULT 1 mg twice daily or 2 mg once daily with the first dose to be administered within 1 hour prior to cytostatic therapy and can be given for up to 1 week following radiotherapy. Maximum 9 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
711	Granisetron HCl 1 mg/ml Injection	A04AA02110 P3001XX	A	i) Prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy ii) Post-operative nausea and vomiting	i) ADULT 1-3 mg as an IV bolus not less than 30 seconds; maximum 9 mg/day. CHILD over 2 years; single dose of 10-40 mcg/kg as an IV infusion; maximum 3 mg/day ii) ADULT 1 mg by slow IV injection over 30 seconds prior to induction of anaesthesia
712	Griseofulvin (Ultramicrosize 125 mg = 250 mg Microsize) Tablet	D01BA01000 T1001XX	B	Dermatophyte infections of the skin, scalp, hair and nails, where topical therapy has failed or inappropriate	ADULT: 500 mg daily up to 1 g daily in divided doses, 2-8 wk in hair and skin infections, 6 mth in fingernail infections and 12 mth or more for toenail infections. CHILD: 10 mg/kg daily in divided doses or as a single dose
713	Haemodialysis Concentrate with Acetate	B05ZA00908 H1001XX	A	For acute renal failure, chronic renal failure, overhydration, intoxication, adjustment of acid-base and electrolyte balance	Dose depending on clinical cases
714	Haemodialysis Concentrate with Bicarbonate	B05ZA00908 H1002XX	A	For acute renal failure, chronic renal failure, overhydration, intoxication, adjustment of acid-base and electrolyte balance	Dose depending on clinical cases
715	Haemophilus Influenza Type B Conjugate Vaccine Injection (Single Dose)	J07AG01000 P4001XX	C	Immunisation of infants against Haemophilus Influenzae Type B	0.5 ml IM
716	Haloperidol 1.5 mg Tablet	N05AD01000 T1001XX	B	Schizophrenia and other psychoses	Adult: 0.5-5 mg bid/tid, may increase up to 100 mg daily in severe or resistant cases. Usual maintenance: 3-10 mg daily. Child: >3 yr: Initially, 25-50 mcg/kg daily in 2 divided doses, increased gradually if necessary. Max: 10 mg/day.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
717	Haloperidol 5 mg Tablet	N05AD01000 T1002XX	B	Schizophrenia and other psychoses	Adult: 0.5-5 mg bid/tid, may increase up to 100 mg daily in severe or resistant cases. Usual maintenance: 3-10 mg daily. Child: >3 yr: Initially, 25-50 mcg/kg daily in 2 divided doses, increased gradually if necessary. Max: 10 mg/day.
718	Haloperidol 5 mg/ml Injection	N05AD01000 P3001XX	B	Acute psychoses and mania	ADULT: IM or IV , 2 mg - 10 mg then every 4 - 8 hours according to response to total maximum 18 mg daily. Use in child is not recommended
719	Heparin 1000 units/ml Injection	B01AB01520 P3001XX	B	i) Prophylaxis and treatment of venous thrombosis and pulmonary embolism. ii) Treatment of myocardial infarction and arterial embolism. iii) Prevention of clotting in arterial and heart surgery and for prevention of cerebral thrombosis	i) By IV injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every 12 hours (laboratory monitoring on daily basis essential to adjust dose). Small adult or child, lower loading dose then, 15-25 units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC injection. ii) As i), for unstable angina and acute peripheral arterial occlusion. iii) Prophylaxis in general surgery, by SC injection, 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted dose regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected

No.	Generic Name	MDC	Category	Indication(s)	Dosage
720	Heparin 5000 units/ml Injection	B01AB01520 P3002XX	B	i) Prophylaxis and treatment of venous thrombosis and pulmonary embolism. ii) Treatment of myocardial infarction and arterial embolism. iii) Prevention of clotting in arterial and heart surgery and for prevention of cerebral thrombosis	i) By IV injection, loading dose of 5000 units (10,000 units in severe pulmonary embolism) followed by continuous infusion of 15-25 units/kg/hr. By SC injection (for DVT) of 15,000 units every 12 hours (laboratory monitoring on daily basis essential to adjust dose). Small adult or child, lower loading dose then, 15-25 units/kg/hr by IV infusion, or 250 units/kg every 12 hours by SC injection. ii) As i), for unstable angina and acute peripheral arterial occlusion. iii) Prophylaxis in general surgery, by SC injection, 5000 units 2 hour before surgery, then every 8-12 hours for 7 days or until patient is ambulant, during pregnancy (with monitoring), 5000-10000 units every 12 hours. An adjusted dose regimen may be used for major orthopaedic surgery or low molecular weight heparin may be selected
721	Heparin Sodium 50 units in Sodium Chloride Injection	B01AB01930 P3001XX	B	To maintain patency of peripheral venous catheters	Flush with 5 ml (50 units) every 4 hours or as required
722	Hepatitis A, Inactivated Vaccine 160 antigen units Injection	J07BC02000P 5001XX	A	Vaccination against hepatitis A especially in those at risk of exposure to hepatitis A virus such as: i) Visitors ii) Chronic hepatitis B and C patient iii) Those requiring vaccination against hepatitis A	0.5 ml per injection. ADULT and CHILD more than 15 years: A single primary dose followed by a booster dose 6 - 12 months later. CHILD 2 - 15 years: A single primary dose followed by a booster dose 6 - 12 months later

No.	Generic Name	MDC	Category	Indication(s)	Dosage
723	Hepatitis B Immunoglobulin (Human) Injection	J06BB04000P3001XX	A	i) For post-exposure prophylaxis of hepatitis B ii) Prophylaxis against recurrence of hepatitis B infection in chronic hepatitis B post liver transplantation	i) Adults: Recommended Dose: 1000-2000 IU IM and if necessary, the dose should be increased or repeated. Children: Inject 32-48 IU/kg of body weight, should be administered within 7 days after exposure to HBsAg (preferably within 48 hrs). Neonates: Recommended Initial Dose: 100-200 IU. The 1st dose should be administered within 5 days after birth (preferably within 48 hrs) and booster dose should be 32-48 IU/kg body weight. The booster dose should be administered between 2 and 3 months after the 1st administration. ii) Different regimens depending on hepatitis B virus (HBV) DNA positivity
724	Hepatitis B Vaccine Injection	J07BC01000P4001XX	C+	Immunisation against infections caused by Hepatitis B virus	ADULTS over 20 years: 10mcg/dose. ADOLESCENT 11 - 19 years: 5 mcg/dose. NEWBORN and CHILD up to 10 years: 2.5 mcg/dose. INFANTS born to HBsAg positive mothers: 3 doses of 0.5 ml each. Second dose to be given after 1 month and booster dose after 6 months
725	Homatropine 2% Eye Drops	S01FA05330D2003XX	B	i) Mydriasis and cycloplegia for refraction ii) Treatment of anterior segment inflammation	i) Adult: Instill 1 or 2 drops of 2% solution immediately before the procedure, repeat at 5-10-minute intervals if necessary. Child: Instill 1 drop of 2% soln immediately before the procedure, repeat at 10-min intervals if necessary. ii) Adult: Instill 1-2 drops of 2% bd-tds up to every 3-4 hr as needed. Child: 3 mth- 2 yr: instill 1 drop of 0.5% soln once daily or on alternate

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					days. >2 yr: instill 1 drop of 1% or 2% soln bd.
726	Human Albumin Injection	B05AA01000 P3001XX	B	i) Acute hypovolemic shock ii) Hypoproteinaemia iii) Neonatal hyperbilirubinaemia	i) ADULT 25 g. CHILD 0.6 g/kg body weight ii) Maximum daily dose is 2g iii) 1 g/kg before exchange transfusion. Dose is given at rate of 1 ml of 25% solution per minute
727	Human Normal Globulin Injection	J06BA02000P 3001XX	A	i) Hypogammaglobulinaemia and other deficiency states ii) Severe refractory idiopathic thrombocytopenia purpura (platelet less than 20,000) with internal bleeding, particularly central nervous system iii) Septicaemia in immunocompromised patients or patients not responding to antibiotics iv) Chronic lymphocytic leukaemia not responding to conventional therapy	i) 50 mg/kg body weight daily for 5 days, then 25 - 50 mg/kg weekly for maintenance according to the severity of the condition ii) 400 mg/kg daily for 5 days with a further dose of 400 mg/kg as required iii) Septicaemia in immunocompromised patients or patients not responding to antibiotics iv) 250 mg/kg per month Dose varies depending on brand used
728	Human Papillomavirus (Types 16, 18) Vaccine Injection	J07BM02000 P3001XX	C+	For the prevention of cervical cancer due to papilloma virus. To be used as part of the public health program only	Given by IM into deltoid region. ADULT and CHILD 10 - 25 years, 3 doses of 0.5 mL, at 0, 1 and 6 months
729	Human Papillomavirus (Types 6, 11, 16, 18) Vaccine Injection	J07BM01000 P3001XX	C+	For the prevention of cervical cancer due to papilloma virus. To be used as part of the public health program only	Given by IM into deltoid region or higher anterolateral thigh. ADULT and CHILD 9 - 26 years, 3 doses of 0.5 mL, at 0, 2 and 6 months
730	Hydralazine HCl 20 mg Injection	C02DB02110 P3001XX	B	Hypertensive crisis in pregnancy	i) Slow IV injection, ADULT: 5-10 mg diluted with 10ml sodium chloride 0.9%. May be repeated after 20-30 minutes if necessary. ii) IV infusion 200-300 mcg/minutes. Maintenance dose 50-150 mcg/minutes

No.	Generic Name	MDC	Category	Indication(s)	Dosage
731	Hydrochlorothiazide 25 mg Tablet	C03AA03000 T1001XX	B	Diuretic, hypertension	ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily
732	Hydrochlorothiazide 50 mg Tablet	C03AA03000 T1002XX	B	Diuretic, hypertension	ADULT: Diuretics; 25-200 mg daily. Hypertension 12.5-25 mg daily CHILD: Oedema and hypertension; Adjunct; 1 to 2 mg/kg ORALLY daily in single or two divided doses; Children 2-12 years old MAX dose, not to exceed 100 mg ORALLY daily; Infants less than 6 months old, may require doses up to 3 mg/kg ORALLY daily in two divided doses, Infants up to 2 yrs old: MAX dose, not to exceed 37.5 mg ORALLY daily
733	Hydrocortisone 1% & Neomycin 0.5% Cream	D07CA01952 G1001XX	B	Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses	Apply to affected part 2-3 times daily (occasionally may cause sensitisation to Neomycin)
734	Hydrocortisone 1% Cream	D07AA02000 G1001XX	B	Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses	Apply sparingly to affected area 2 - 3 times daily until condition improve, then reduce frequency
735	Hydrocortisone 1% Ointment	D07AA02000 G5001XX	B	Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses	Apply sparingly to affected area 2 - 3 times daily until condition improve, then reduce frequency

No.	Generic Name	MDC	Category	Indication(s)	Dosage
736	Hydrocortisone 10 mg Tablet	H02AB09000 T1001XX	B	Glucocorticoid replacement therapy in primary or secondary adrenal insufficiencies and long term management of congenital adrenal hyperplasia in children	ADULT: 20 - 30 mg daily in divided doses. CHILD: 10 - 30 mg daily in divided doses
737	Hydrocortisone Enema 0.1%	A07EA02000 G2001XX	B	Adjunctive treatment for ulcerative colitis and proctitis	ADULT 100 mg 1-2 times/day for 2-3 weeks. If used for longer than 3 weeks, taper treatment over 2-3 weeks
738	Hydrocortisone Sodium Succinate 100 mg Injection	H02AB09520 P4001XX	C	Conditions responsive to systemic or local glucocorticoid injection therapy especially in emergencies	Initially 100 - 500 mg IV over 30 seconds to more than 10 minutes. Dose may be repeated at intervals of 2, 4 or 6 hours
739	Hydrogen Peroxide 1.5% Ear Drops	S02AA06241 D1001XX	C	To soften impacted ear wax	Instill 1 - 2 drops into the ear as required (leave for a few minutess)
740	Hydrogen Peroxide 20 volume Solution	D08AX01241 L9901XX	C	Skin disinfection, particularly cleansing and deodorising wounds and ulcers	Hydrogen Peroxide 6% (=approx. 20 vol) shall be dispensed. For cleansing wounds: 1.5% to 6% solution apply 2-3 times daily or when nescessary. As a mouthwash: rinse the mouth for 2-3 minutes with 15ml of hydrogen peroxide 6% diluted in half a tumblerful of warm water 2-3 times daily. Disinfecting cleaned equipment: immersion for 30 minutes in 6% solution. As ear drop for removal of wax: hydrogen peroxide 6% diluted with 3 parts of water preferably just before use
741	Hydroxychloroquine Sulphate 200 mg Tablet	P01BA02183 T1001XX	A	i) SLE and mixed connective tissue disease for skin, joint and serosa ii) Second line therapy for acute rheumatoid arthritis	i) Initially 400 mg daily in divided dose. Maintenance : 200 - 400 mg daily ii) ADULT : 400 - 600 mg daily. Maintenance: 200 - 400 mg daily. CHILD : up to 6.5 mg/kg daily (maximum 400mg daily)
742	Hydroxyethyl Cellulose Jelly	V07AY00250 G4001XX	B	For lubricating purpose	Apply sufficiently for lubricating purpose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
743	Hydroxyethyl Starch 6% Injection	B05AA07000 P9901XX	B	Therapy and prophylaxis of hypovolaemia and shock in connection with surgery trauma, infections and burns	ADULT daily dose up to 20 ml/kg/day. Normally 500-1500 ml. The rate of infusion may approach 20 ml/kg/hour in acute haemorrhagic shock, slower rates in burns and septic shock. CHILD under 10 years do not exceed 15 ml /kg/hour.
744	Hydroxyprogesterone Caproate 250 mg/ml Injection	G03DA03128 P2001XX	A	Habitual and threatened abortion	250 - 500 mg once weekly by IM injection
745	Hydroxyurea 500 mg Capsule	L01XX05000C 1001XX	A	i)Solid tumours ii) Chronic myelocytic leukaemia and myeloproliferative disease iii)Severe psoriasis eg. Extensive plaque psoriasis, erythrodermic psoriasis, pustular psoriasis -as third line therapy.	i) Intermittent therapy: 80 mg/kg orally as a single dose every 3rd day. Continuous therapy: 20 - 30 mg/kg orally as a single dose dly. Concomitant therapy with irradiation: 80 mg/kg orally as a single dose every 3rd day.(administration of hydroxyurea should be started at least 7 days before initiation of irradiation and continued during radiotherapy as well). ii)Continuous therapy (20 - 30 mg/kg orally as a single dose daily, therapy should be interrupted if the white blood cell count drops below 2500/mm3, or the platelet count below 100,000/mm3. iii) 500 mg tds.
746	Hydroxyzine HCl 25 mg Tablet	N05BB01110 T1001XX	A	Allergic pruritus	Initially 25 mg at night, increased if necessary up to 25 mg 3-4 times daily. ADULT and CHILD more than 10 years : 50 - 75 mg; 6 - 10 years: 25 - 50 mg; 1 - 5 years: 12.5 - 25 mg; to be taken daily in divided doses
747	Hyoscine Hydrobromide 400 mcg/ml	A04AD01330 P3001XX	B	To reduce oral secretions before surgery	200-600 mcg given as SC or IM 60 minutes before induction of anaesthesia.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
	Injection				CHILD: 15 mcg/kg
748	Hyoscine N-Butylbromide 1 mg/ml Liquid	A03BB01320 L5001XX	B	Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system	ADULT 40mg 4 times a day. CHILD 6-12 years old: 10mg 3 times a day.
749	Hyoscine N-Butylbromide 10 mg Tablet	A03BB01320 T1001XX	B	Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system	ADULT 40mg 4 times a day. CHILD 6-12 years old: 10mg 3 times a day.
750	Hyoscine N-Butylbromide 20 mg/ml Injection	A03BB01320 P3001XX	B	Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system	20 mg IM/IV repeated after 30 min if needed. Max: 100 mg daily.
751	Hypromellose 0.3% Eye Drops	S01XA20000 D2002XX	B	Tear deficiency, ophthalmic lubricant; for relief of dry eyes and eye irritation	1 - 2 drops several times a day
752	Hypromellose 0.3%, Carbomer 980 Ophthalmic Gel	S01KA02000 G3201XX	B	Symptomatic relief of severe dry eye conditions and as lens lubricant during ophthalmic diagnostic procedures	Instill 1-2 drops in affected eye(s) as needed
753	Ibandronic Acid 150 mg Tablet	M05BA06000 T1003XX	A*	Treatment of postmenopausal osteoporosis to reduce the risk of fracture. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk.	150 mg once monthly
754	Ibuprofen 200 mg Tablet	M01AE01000 T1001XX	B	Pain and inflammation in rheumatic disease	Dosage: ADULT: 200 - 400 mg 3 times daily after food, maximum 3.2 g daily. CHILD: 30-50 mg/kg body weight daily in divided doses, maximum 2.4g daily. Lowest effective dose for the shortest possible duration.
755	Ichthammol Glycerin 10% Ear Drops	S02AA30000 D1001XX	C	Ear wick for otitis externa with oedema	2 - 3 drops 3 - 4 times daily and in ear wick for otitis externa

No.	Generic Name	MDC	Category	Indication(s)	Dosage
756	Idarubicin 10 mg Injection	L01DB06110 P4002XX	A*	i) Acute promyelocytic leukaemia ii) Relapse Acute myeloid leukemia (with sibling match) iii) Acute myeloid leukemia, acute lymphoblastic leukemia (salvage therapy)	i) Induction phase: 12 mg/m2 IV slow bolus on Days 3, 5 and 7. Consolidation phase, month 1: 12 mg/m2 IV on Days 1 and 2. Repeat monthly for 3 courses ii) 12 mg/m2 D1-3 iii) 12 mg/m2 D1-3 as part of FLAG-IDA regimen. Children: 10mg/m2 IV daily for 3 days
757	Idarubicin 5 mg Injection	L01DB06110 P4001XX	A*	i) Acute promyelocytic leukaemia ii) Relapse Acute myeloid leukemia (with sibling match) iii) Acute myeloid leukemia, acute lymphoblastic leukemia (salvage therapy)	i) Induction phase: 12 mg/m2 IV slow bolus on Days 3, 5 and 7. Consolidation phase, month 1: 12 mg/m2 IV on Days 1 and 2. Repeat monthly for 3 courses ii) 12 mg/m2 D1-3 iii) 12 mg/m2 D1-3 as part of FLAG-IDA regimen. Children: 10mg/m2 IV daily for 3 days
758	Idursulfase 2 mg/ml Injection	A16AB09000 P3001XX	A*	Hunter syndrome (Mucopolysaccharidosis II, MPS II).	0.5 mg/kg of body weight administered every week as an intravenous infusion.
759	Ifosfamide 1 g Injection	L01AA06000 P4001XX	A*	i) Solid tumours ii) Leukaemia iii) Lymphoma	i) 1.2 - 2.4 g/m2/day for 3 - 7 days as a 30 - 120 minutes infusion. Alternatively, can also be given as a single high dose, eg. 5 g/m2 in a 24 hour infusion. Cycles may be repeated every 3 - 4 weeks ii) CHILD: 400 - 3000 mg/m2/day for 3 - 5 days according to protocol iii) Refer to protocols
760	Imatinib Mesylate 100 mg Tablet	L01XE01196T 1001XX	A*	i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kit	i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day ii) ADULT : 400mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
761	Imatinib Mesylate 400 mg Tablet	L01XE01196T 1002XX	A*	i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kit	i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day ii) ADULT : 400mg/day
762	Imiglucerase 400 IU Injection	A16AB02000 P4002XX	A*	Non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: - anemia, after exclusion of other causes, such as iron deficiency - thrombocytopenia - bone disease, after exclusion of other causes, such as Vitamin D deficiency - hepatomegaly or splenomegaly	Dosage should be individualized to each patient. Initial dosages range from 2.5 units/kg of body weight 3 times a week to 60 units/kg once every 2 weeks. Administered by intravenous infusion over 1-2 hours.
763	Imipenem 500 mg and Cilastatin 500 mg Injection	J01DH51961 P4002XX	A*	Severe infections caused by susceptible pathogens especially useful in infections involving ESBL organisms. Not to be used for prophylaxis	Based on type or severity of infection, susceptibility of pathogen(s) and patient condition including body weight and renal function. ADULT: 1 - 2 g/day in 3 - 4 divided doses. Maximum: 4 g/day or 50 mg/kg/day. Infusion rate: less than 500 mg dose: over 20 - 30 minutes, more than 500 mg: dose over 40 - 60 minutes. CHILDREN: ≥ 40kg body weight should receive adult doses. CHILDREN AND INFANTS: <40kg body weight should receive 15mg/kg at six hour intervals. The total daily dose should not exceed 2g.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
764	Imipramine HCl 25 mg Tablet	N06AA02110 T1001XX	B	Depression	Initially up to 75 mg daily in divided doses increased gradually to 150 - 200 mg (up to 300 mg in hospital patients); up to 150 mg may be given as a single dose at bedtime. ELDERLY initially 10 mg daily; increased gradually to 30 - 50 mg daily; CHILD is not recommended
765	Imiquimod 5 % w/w Cream	D06BB10000 G1001XX	A*	Treatment of external genital and perianal warts or condyloma acuminata in adults	Apply to affected area at bedtime for 3 times a week for up to 16 weeks; leave on skin for 6-10 hours
766	Immunoglobulin Tetanus Human 250 Units/Vial Injection	J06BB02000P 3001XX	B	Passive immunization against tetanus	Prophylaxis of tetanus: IM 250 units. Treatment of tetanus: IM 30 - 300 units/kg
767	Indacaterol Maleate 150 mcg Inhalation Capsule	R03AC18253 C9901XX	A*	Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).	Once-daily inhalation of the content of one 150/300 microgram capsule. Maximum dose is 300 microgram once-daily.
768	Indacaterol Maleate 300 mcg Inhalation Capsule	R03AC18253 C9902XX	A*	Maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).	Once-daily inhalation of the content of one 150/300 microgram capsule. Maximum dose is 300 microgram once-daily.
769	Indinavir Sulfate 400 mg Capsule	J05AE02183C 1001XX	A*	i) Post-exposure prophylaxis (PEP) among healthcare workers in high-risk HIV occupational exposure ii) For therapy as part of combination antiretroviral treatment on adult HIV patients ie Highly Active Anti-Retroviral Therapy (HAART)	ADULT: 800 mg every 8 hours. CHILD (investigational): 500 mg/m2 every 8 hours (patients with smaller body surface area (BSA) may require lower doses of 300 - 400 mg/m2 every 8 hours). Dosage may vary depending on types of combination therapy used.
770	Indomethacin 100 mg Suppository	M02AA23000 S2001XX	B	Pain and inflammation in rheumatic arthritis	Adult: As supp: 100 mg to be inserted at night and repeated in the morning if necessary.
771	Indomethacin 25 mg Capsule	M01AB01000 C1001XX	B	Pain and inflammation in rheumatic disease	50 - 200 mg daily in divided doses, with food. Child not recommended.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
772	Infliximab 100 mg Injection	L04AB02000 P4001XX	A*	i) Rheumatoid arthritis (moderate to severe), in combination with methotrexate ii) Ankylosing spondylitis in patients with active disease despite treatment with methotrexate iii) Crohn's Disease in patients who have an inadequate response to conventional therapies. iv) Fistulizing Crohn's Disease in patients who have an inadequate response to conventional therapies v) Ulcerative Colitis in patients who have an inadequate response to conventional therapies	i) Rheumatoid arthritis: ADULT over 18 years old: 3 mg/kg at 0, 2, 6 weeks, then every 8 weeks; May increase to 10 mg/kg or increase dosing frequency to 4 weekly for patients with incomplete response. Discontinue if no response by 12 weeks of initial infusion or after dose adjustment ii) Ankylosing spondylitis: ADULT over 18 years: 5 mg/kg IV over 2 hour given at week 0, 2, and 6 then every 6-8 weeks. Discontinue if no response by 6 weeks of initial infusion. iii), iv) & v)5 mg/kg given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter
773	Influenza Vaccine (Inactivated, trivalent) Injection (containing 3 strains, two type A subtypes, of which one must include pandemic A (H1N1) and one Type B subtype)	J07BB02963P 3001XX	B	Prophylaxis of influenza for frontliners (KKM staff and essential services personnel) and in high risk groups	CHILD 6-35 months: Single dose of 0.5 ml IM or deep SC; 3-8 years: 1-2 doses of 0.5 ml IM ADULT & CHILD more than 9 years: Single dose of 0.5 ml IM
774	Influenzae Vaccine (Inactivated,Trivalent) Type A (H1N1) 15 mcg, Type A (H3N2) 15 mcg & Type B 15 mcg Haemagglutinin Injection	J07BB02963P 5002XX	B	Prevention of influenza and influenza related complications in high risk adult patients, in particular individuals who have chronic cardiovascular, pulmonary, metabolic or renal disease, or who are immunocompromized and elderly patients	19 to 59 years: Single dose of 0.1ml 9mcg/strain intradermally. ≥ 60 years: Single dose of 0.1ml 15mcg/strain intradermally

No.	Generic Name	MDC	Category	Indication(s)	Dosage
775	Influenzae Vaccine (Inactivated,Trivalent) Type A (H1N1) 9 mcg, Type A (H3N2) 9 mcg & Type B 9 mcg Haemagglutinin Injection	J07BB02963P5001XX	B	Prevention of influenza and influenza related complications in high risk adult patients, in particular individuals who have chronic cardiovascular, pulmonary, metabolic or renal disease, or who are immunocompromized and elderly patients	18 to 59 years: Single dose of 0.1ml 9mcg/strain intradermally. ≥ 60 years: Single dose of 0.1ml 15mcg/strain intradermally
776	Insulin Aspart 100 IU/ml Injection	A10AB05000P3001XX	A*	Diabetic Type 1 and 2 in patients that still experienced hypoglycaemia with use of human insulin	Dose to be individualised. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight
777	Insulin Aspart 30% and Protaminated Insulin Aspart 70% 100 U/ml Injection	A10AD05000P3001XX	A/KK	Diabetic type 1 and 2 in patients that still experienced hypoglycaemia with use of human insulin	Dose to be individualised. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight
778	Insulin Detemir 100 IU/ml Injection in Prefilled syringe/cartridge	A10AE05000P5001XX	A*	i)Type 1 Diabetes patients on basal bolus regimen, whom experience hypoglycemia with conventional insulin, to be used in combination with rapid or short-acting insulin. ii)Type 2 Diabetes patients on oral anti-diabetics and basal insulin regimen or basal bolus insulin regimen whom experience hypoglycemia with conventional basal insulin.	Individualized dose given via SC once or twice daily. Initiate at a dose of 10IU or 0.1-0.2IU/kg. For twice daily dosing, the evening dose can be administered either with the evening meal, at bedtime, or 12 hours after the morning dose.
779	Insulin Glargine 300IU/3ml Prefilled Pen for Injection	A10AE04000P5001XX	A/KK	i) Diabetes mellitus type I in adults and child over 6 years ii) Diabetes mellitus type II in adult	ADULT and CHILD over 6 years: individualised dose given by SC, once daily at the same time every day. Adult patients who are insulin naïve may be initiated with 10IU daily.
780	Insulin Glulisine 100u/ml solution for injection in pre-filled pen 3ml	A10AB06000P5001XX	A*	Treatment of adults, adolescents and children 6 years or older with diabetes mellitus, where treatment with insulin is required.	Glulisine should be given shortly (0-15 min) before or soon after meals. Apidra should be used in regimens that include an intermediate or long acting insulin or basal insulin analogue and can be used with oral hypoglycaemic agents. The dosage of Apidra should be

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					individually adjusted.
781	Insulin Lispro 100 IU/ml Injection in Prefilled syringe/cartridge	A10AB04000 P5001XX	A*	i) As initial therapy in children with Type 1 diabetes ii)Type 1 diabetes patients on basal bolus regimen, not controlled or experience hypoglycaemia with conventional insulin, to be used in combination with long-acting insulin iii)Type 2 diabetes patients on basal bolus or premixed regimen, not controlled or experience hypoglycaemia with conventional insulin, to be used in combination with intermediate-acting insulin or long-acting insulin iv)Patients with diabetes in pregnancy with poor postprandial control or experience hypoglycaemia with conventional short-acting insulin	Dose to be individualized. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight, given within 15 minutes before meal.
782	Insulin Lispro 25% & Insulin Lispro Protamine 75% 100 IU/ml Injection in Prefilled syringe/cartridge	A10AD04000 P5001XX	A*	Patients with Type 2 diabetes whom experience hypoglycemia with the use of human premixed insulin.	Dose to be individualized. The average daily insulin requirement is between 0.5 to 1.0 units/kg body weight
783	Insulin Recombinant Neutral Human Short Acting 100 IU/ml Injection in 10ml vial	A10AB01000 P3001XX	B	Diabetes mellitus	Dose to be individualised. The average daily insulin requirement is between 0.3-1.0 units/kg body weight/day. Daily insulin requirement may be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.
784	Insulin Recombinant Neutral Human Short-acting 100IU/ml Penfill and Refill	A10AB01000 P5001XX	B	Diabetes mellitus	Dose to be individualised. The average daily insulin requirement is between 0.3-1.0 units/kg body weight/day. Daily insulin requirement may be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
785	Insulin Recombinant Synthetic Human Intermediate-Acting 100IU/ml in Vial for Injection	A10AC01000 P3001XX	B	Diabetes mellitus	Dose to be individualised. The daily insulin requirement is usually between 0.3 and 1.0IU/kg /day
786	Insulin Recombinant Synthetic Human Premixed 100IU/ml in Vial for Injection	A10AD01000 P3001XX	B	Diabetes mellitus	Dose to be individualised. The average daily insulin requirement is between 0.3-1.0 units/kg body weight/day. Daily insulin requirement may be higher in patients with insulin resistance, and lower in patients with residual, endogenous insulin production.
787	Insulin Recombinant Synthetic Human, Intermediate-Acting 100 IU/ml Penfill and Refill	A10AC01000 P5001XX	B	Insulin dependent diabetes mellitus, non insulin dependent diabetes unresponsive to treatment to diet or oral hypoglycaemics, hyperkalaemia to assure proper utilisation of glucose and reduce glucosuria in non diabetic patients receiving parenteral nutrition	Dose to be individualised. The daily insulin requirement is usually between 0.3 and 1.0IU/kg /day
788	Insulin Recombinant Synthetic Human, Premixed 100 IU/ml Penfill and Refill	A10AD01000 P5001XX	B	Insulin dependent diabetes mellitus, non insulin dependent diabetes unresponsive to treatment to diet or oral hypoglycaemics, hyperkalaemia to assure proper utilisation of glucose and reduce glucosuria in non diabetic patients receiving parenteral nutrition	Dose to be individualised. The average daily insulin requirement is between 0.5-1.0 units/kg body weight

No.	Generic Name	MDC	Category	Indication(s)	Dosage
789	Interferon Alfa - 2a 3 MIU Injection	L03AB04000 P3001XX	A*	For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's Sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinoma	i) Initial: 3 MIU SC daily. If intolerant, 1.5 MIU daily or 3 MIU 3 times a week or 1.5 MIU 3 times a week. Maintenance: 1.5-3 MIU SC 3 times a week ii) Patient > 18 years: 3 MIU daily (days 1-3), 6 MIU daily (days 4-6), 9 MIU daily (days 7-84) iii) Patient > 18 years: Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times a week iv) 2.5-5 MIU/m2 SC 3 times a week for 4-6 months. CHILD: up to 10 MIU/m2 BSA v) Monotherapy: Initial: 3 - 6 MIU SC 3 times a week for 6 months. Maintenance: 3 MIU 3 times a week for an additional 6 months. vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 MIU 3 times a week for 1 week, then 9 MIU 3 times a week for 1 week, then 18 MIU 3 times a week thereafter for 3-12 months SC
790	Interferon Alfa-2b 18 MIU Multidose Injection Pen	L03AB05000 P5001XX	A	For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinoma	i) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 - 9 MIU 3 - 5 times a week or daily depending on response iii) Patient more than 18 years. Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 million IU 3 times/week for 1 week,

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					then 9 million IU 3 times/week for 1 week, then 18 million IU 3 times/week thereafter for 3-12 month SC or IM
791	Interferon Alfa-2b 30 MIU Multidose Injection Pen	L03AB05000 P5002XX	A	For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinoma	i) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 - 9 MIU 3 - 5 times a week or daily depending on response iii) Patient more than 18 years. Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 million IU 3 times/week for 1 week, then 9 million IU 3 times/week for 1 week, then 18 million IU 3 times/week thereafter for 3-12 month SC or IM
792	Interferon Alpha - 2a 4.5 MIU Injection	L03AB04000 P3002XX	A*	For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's Sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinoma	i) 2 MIU SC or IM 3 times a week ii) Patient more than 18 years: 3 - 9 MIU 3 - 5 times a week or daily depending on response iii) Patient more than 18 years. Initially escalating dose to 18-36 MIU SC/IM for 10-12 weeks. Maintenance: up to 36 MIU 3 times weekly iv) 2.5-5 MIU/m2 SC 3 times weekly for 4-6 month. CHILD: up to 10 MIU/m2 BSA v) 3 MIU for 12 months vi) As an adjunct to cytotoxic chemotherapy: An escalating dose of 3 million IU 3 times/week for 1 week, then 9 million IU 3 times/week for 1 week, then

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					18 million IU 3 times/week thereafter for 3-12 month SC or IM
793	Interferon Alpha 2b 3 MIU Injection	L03AB05000 P3001XX	A*	For the treatment of i) Hairy cell leukaemia ii) Chronic myelogenous leukaemia iii) AIDS related Kaposi's sarcoma iv) Chronic hepatitis B v) Chronic hepatitis C vi) Advanced renal cell carcinoma	i) 2 MIU/m2 SC or IM 3 times a week ii) 4 - 5 MIU/m2 SC daily. Treatment must be discontinued after 8 to 12 weeks of treatment if at least a partial haematological remission or a clinically meaningful cytoreduction has not been achieved iii) Patient > 18 years : 30 MIU/m2 SC or IM three times a week until disease progression or maximal response has been achieved after 16 weeks of treatment. iv) 5 MIU daily or 10 MIU three times a week for 16 weeks. CHILD : 3 MIU/m2 three times a week for the first week of therapy followed by dose escalation to 6 MIU/m2 (maximum of 10MIU) three times a week SC for a total duration of 16 to 24 weeks v) 3 MIU SC or IM 3 times a week.
794	Interferon beta - 1b 250mcg (8MIU) Injection	L03AB08000 P4001XX	A*	i)Relapsing-remitting multiple sclerosis (RRMS): Reduction of frequency and degree of severity of clinical relapses in ambulatory patients characterized by at least two attacks of neurological dysfunction over the preceding two year period, followed by complete or incomplete recovery ii)Secondary progressive multiple sclerosis (SPMS):Reduction of frequency and severity of clinical relapses and for slowing the progression of disease	0.25 mg (8 MIU) by SC injection every other day
795	Interferon Beta-1a 22 mcg	L03AB07000 P5001XX	A*	Multiple sclerosis of the relapsing remitting type with 2 or more relapses within the last 2 years	22 mcg 3 times weekly

No.	Generic Name	MDC	Category	Indication(s)	Dosage
796	Interferon Beta-1a 44 mcg	L03AB07000 P5002XX	A*	Multiple sclerosis of the relapsing remitting type with 2 or more relapses within the last 2 years	44 mcg 3 times weekly
797	Iodamide Injection	V08AA03000 P3001XX	A	For hysterosalpingography	According to the procedure and route of administration
798	Iodine and Potassium Iodide Solution	H03CA00200 L9901XX	B	i) Pre-operative treatment of thyrotoxicosis ii) Thyrotoxicosis crisis	i) 1 ml daily in divided doses ii) 2 - 3 ml daily
799	Iodixanol 320 mg I/ml Injection	V08AB09000 P3001XX	A	X-ray contrast medium for cardioangiography, cerebral angiography, peripheral arteriography, abdominal angiography, urologaphy, venography, CT enhancement, lumbar, thoracic and cervical myelography	Depending on type of examination
800	Iohexol Injection	V08AB02000 P3001XX	A	X-ray contrast medium for use in adults and children for cardioangiography, arteriography, urography, phlebography and CT-enhancement. Lumbar, thoracic, cervical myelography and computed tomography of the basal cisterns, following subarachnoid injection. Arthrography, endoscopic retrograde pancreatography (ERCP), herniography, hysterosalpingography, sialography and studies of the gastrointestinal tract	Dose depending on the route and procedure
801	Iopamidol 30.62 g in 50 ml Injection	V08AB04000 P3001XX	A	i) Neuroradiology : myeloradiculography, cisternography and ventriculography ii) Angiograph : cerebral arteriography, thoracic aortography, abdominal aortography, angiocardiography, selective visceral arteriography, peripheral arteriography, venography, digital subtraction angiography (DSA), DSA of cerebral arteries, DSA of peripheral arteries, DSA of abdominal arteries iii) Urography : intravenous urography iv) Contrast enhancement in CT Scanning, arthrography, fistulography	For angiography and cardiac cases- dose depending on the route and procedure. For selected vascular examination - bottles of 30 ml and 100 ml; dose depending on the route and procedure

No.	Generic Name	MDC	Category	Indication(s)	Dosage
802	Iopromide 300mg injection (623 mg of iopromide with 300 mg of iodine per mL)	V08AB05000 P3001XX	A	i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt	Dose depending on the route and procedure
803	Iopromide 370mg injection (769 mg of iopromide with 370 mg of iodine per mL)	V08AB05000 P3002XX	A	i) For angiography, urography, aortography and the visualization of body cavities ii) Contrast enhancement during computerized tomography iii) To check functioning of a dialysis shunt	Dose depending on the route and procedure
804	Ipratropium Bromide 0.0125% Nebulising Solution (125 mcg/ml)	R03BB01320 A3001XX	B	Only for treatment of : i) Patients with ischaemic heart disease who develop extrasystole with salbutamol or terbutaline ii) Patients with chronic bronchitis who have airway obstruction and who do not respond to salbutamol or terbutaline. Reversible airways obstruction, particularly in chronic obstructive pulmonary disease	ADULT: 500 mcg up to 4 times daily. CHILD 5 - 12 years : 125 - 250 mcg up to 4 times daily, 12 years : 250 - 500 mcg up to 4 times daily
805	Ipratropium Bromide 0.025% Nebulising Solution (250 mcg/ml)	R03BB01320 A3002XX	B	Only for treatment of : i) Patients with ischaemic heart disease who develop extrasystole with salbutamol or terbutaline ii) Patients with chronic bronchitis who have airway obstruction and who do not respond to salbutamol or terbutaline. Reversible airways obstruction, particularly in chronic obstructive pulmonary disease	ADULT: 500 mcg up to 4 times daily. CHILD 5 - 12 years : 125 - 250 mcg up to 4 times daily, 12 years : 250 - 500 mcg up to 4 times daily
806	Ipratropium Bromide 0.5 mg and Salbutamol 2.5 mg per UDV	R03AK04320 A3001XX	B	Management of reversible bronchospasm associated with obstructive airway diseases	Acute attacks: 1 unit dose vial. In severe cases not relieved by 1 unit dose vial, 2 unit dose vials may require, patient should consult a doctor immediately. Maintenance : 1 unit dose vial 3 - 4 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
807	Ipratropium Bromide 20 mcg and Fenoterol 50 mcg/dose Inhaler	R03AK03986 A2101XX	B	Management of symptoms in chronic obstructive airway disorders with reversible bronchospasm such as bronchial asthma and chronic bronchitis with or without emphysema	ADULT & CHILD more than 6 years; Acute asthma 2 puffs. Severe cases: if breathing has not noticeably improved after 5 mins, 2 further puffs may be taken. Intermittent and long-term treatment 1-2 puffs for each administration, up to max 8 puffs/day (average: 1-2 puffs three times daily)
808	Ipratropium Bromide 20 mcg and Salbutamol base 100 mcg/dose Inhalation	R03AK04320 A1001XX	B	Management of reversible bronchospasm associated with obstructive airway diseases	ADULT and ELDERLY: 2 inhalations 4 times daily. Maximum: 12 inhalations daily. CHILD under 12 years not recommended
809	Ipratropium Bromide 20 mcg/dose Nebuliser solution	R03BB01320 A1001XX	B	Only for treatment of : i) Patients with chronic bronchitis who have airway obstruction and who do not respond to Salbutamol or Terbutaline ii) Patients with ischaemic heart disease who develop extrasystole with Salbutamol or Terbutaline	20 - 40 mcg 3 - 4 times daily. In the early treatment, up to 80 mcg 3 - 4 times daily. CHILD up to 6 years : 20 mcg 3 times daily, 6 - 12 years : 20 - 40 mcg 3 times daily
810	Irbesartan 150 mg and Hydrochlorothiazide 12.5 mg Tablet	C09DA04000 T1003XX	A/KK	Hypertension in patients who cannot tolerate ACE inhibitors because of cough	1 tablet daily
811	Irbesartan 150 mg Tablet	C09CA04000 T1001XX	A/KK	Hypertension, diabetic nephropathy (in patients who cannot tolerate ACE inhibitors because of cough)	150 mg to 300 mg daily
812	Irbesartan 300 mg & Hydrochlorothiazide 12.5 mg Tablet	C09DA04000 T1001XX	A/KK	Hypertension in patients who cannot tolerate ACE inhibitors because of cough	1 tablet daily
813	Irbesartan 300 mg Tablet	C09CA04000 T1002XX	A/KK	Hypertension, diabetic nephropathy (in patients who cannot tolerate ACE inhibitors because of cough)	150 mg to 300 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
814	Irinotecan HCl Trihydrate 20 mg/ml Injection	L01XX19110P 3002XX	A*	Only for patients with colorectal cancer who: i) have relapsed within 6 months after the end of adjuvant chemotherapy with 5-fluorouracil-based regime ii) have progressive disease despite 5-fluorouracil chemotherapy for advanced disease iii) good performance status (WHO of 2 or less) The treatment must be given in a tertiary oncology centre or have clearance in writing by an oncologist	In combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an IV infusion over 90 mins followed by infusion with folinic acid and 5-fluorouracil. In monotherapy (for previously treated patients): 350 mg/m2 administered as an intravenous infusion over 90 minutes period once every 3 weeks
815	Irinotecan HCl Trihydrate 40 mg/2 ml Injection	L01XX19110P 3001XX	A*	Only for patients with colorectal cancer who: i) have relapsed within 6 months after the end of adjuvant chemotherapy with 5-fluorouracil-based regime ii) have progressive disease despite 5-fluorouracil chemotherapy for advanced disease iii) good performance status (WHO of 2 or less) The treatment must be given in a tertiary oncology centre or have clearance in writing by an oncologist	In combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an IV infusion over 90 mins followed by infusion with folinic acid and 5-fluorouracil. In monotherapy (for previously treated patients): 350 mg/m2 administered as an intravenous infusion over 90 minutes period once every 3 weeks
816	Iron (III)-hydroxide polymaltose complex (IPC) 100mg iron and 0.35mg folic acid chewable tablet	B03AD04250 T2001XX	A/KK	Treatment of latent and manifest iron deficiency and prevention of iron and folic acid deficiency before, during after pregnancy (during lactation)	Dosage and duration of therapy are dependent upon the extent of iron deficiency. Manifest iron deficiency: 1 chewable tablet two to three times daily until a normalization of the hemoglobin value is achieved. Afterwards the therapy should be continued with 1 chewable tablet daily at least until the end of pregnancy to replenish the iron stores. Latent iron deficiency and prevention of iron and folic acid deficiency: 1 chewable tablet daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
817	Iron Dextran 50 mg Fe/ml Injection	B03AC06000 P3001XX	B	Severe iron deficiency anaemia	An initial test dose of 0.5 ml should be given over the desired route. For severe iron deficiency anaemia, 1-2 ml daily given by deep IM. Dosage is individualized according to total iron deficit
818	Iron Sucrose 100 mg/5 ml Injection	B03AC02250 P3001XX	A/KK	Dialysis patients on erythropoietin therapy, second and third trimester pregnancy and post partum anaemia patients with iron deficiency: i) who are not responsive to oral iron therapy ii) who may be at risk of allergic reactions to iron dextran injection	Individualised dosage. ADULT and ELDERLY: Cumulative dose is to be administered in single doses of 100 - 200 mg of iron 2 - 3 times weekly depending on Hb level. By IV drip infusion, slow IV injection or directly into the venous limb of the dialyser. Total cumulative dose: 1000 mg
819	Isoflurane Liquid	N01AB06000 L5001XX	B	i) Induction and ii) Maintenance of anaesthesia	i) Induction- Initiate at a concentration of 0.5 % ii) Maintenance- 1 - 2.5 % in oxygen or nitrous oxide mixture. 0.5 - 0.75 % with oxygen and nitrous oxide for Caesarian section
820	Isoniazid 100 mg Tablet	J04AC01000T 1001XX	B	i) Tuberculosis ii)Tuberculous meningitis	i) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg biweekly (max 1200mg)
821	Isoniazid 400 mg Tablet	J04AC01000T 1002XX	B	i) Tuberculosis ii)Tuberculous meningitis	i) & ii) ADULT 5-8mg/kg daily (Max 300mg) or 15-20mg/kg biweekly (max 1200mg)
822	Isoprenaline HCl 0.2 mg/ml Injection	C01CA02110 P3001XX	B	Complete heart block (third-degree artrioventricular block) not responding to atropine, while waiting for cardiac pacing	If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose 5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					response
823	Isoprenaline HCl 1 mg/5 ml Injection	C01CA02110 P3002XX	B	Complete heart block (third-degree artrioventricular block) not responding to atropine, while waiting for cardiac pacing	If given as IM: Initially 0.2 mg (1 ml of 1:5000 solution), followed by 0.02-1 mg depending on clinical response. If given as SC: 0.2 mg (1 ml of 1:5000 solution), followed by 0.15-0.2 mg depending on clinical response. If given as IV : 1-2 mg in 500 ml of dextrose 5%, infused at a rate of 0.5-2 ml/min while the patient's EKG is being monitored. The dose should be titrated to produce the desired clinical response
824	Isosorbide Dinitrate 1 mg/ml Injection	C01DA08221 P3001XX	A	Treatment for angina pectoris and left ventricular failure	2-10 mg/hour IV infusion after dilution, higher doses up to 20 mg/hour may be required
825	Isosorbide Dinitrate 10 mg Tablet	C01DA08221 T1001XX	B	Prophylaxis and treatment for: i) Angina ii) Left ventricular failure	i) 30 - 120 mg daily in divided doses ii) 40 - 160 mg, up to 240 mg if required
826	Isosorbide Mononitrate 50 mg SR Capsule	C01DA14221 C2001XX	A	Prophylaxis and treatment of angina pectoris	50 mg daily
827	Isosorbide-5-Mononitrate 30 mg SR Tablet	C01DA14221 T5001XX	A	Prophylaxis and treatment of angina pectoris	Initiate at 30 mg for 1st 2-4 days to avoid headache. Usual dose: 60 mg once daily, may be increased to 120 mg once daily
828	Isosorbide-5-Mononitrate 60 mg SR Tablet	C01DA14221 T5002XX	A	Prophylaxis and treatment of angina pectoris	60mg once daily, increase to 120 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
829	Isotretinoin 10 mg Capsule	D10BA01000 C1001XX	A*	Only for treatment of i) Severe nodulo-cystic acne ii) Acne conglobata iii) Acne fulminans iv) Severe acne vulgaris failing conventional treatment.	0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; the maximum recommended dose is 2mg/kg of body weight per day. After about 4 weeks, therefore, dosage for the maintenance treatment should be adjusted within the range 0f 0.1-1mg/kg daily to meet individual need. Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re-starting treatment.
830	Isotretinoin 20 mg Capsule	D10BA01000 C1002XX	A*	Only for treatment of i) Severe nodulo-cystic acne ii) Acne conglobata iii) Acne fulminans iv) Severe acne vulgaris failing conventional treatment WARNING: THIS DRUG IS TERATOGENIC	0.5-1 mg/kg of body weight per day (in two divided doses) for 15 to 20 weeks; the maximum recommended dose is 2mg/kg of body weight per day. After about 4 weeks, therefore, dosage for the maintenance treatment should be adjusted within the range 0f 0.1-1mg/kg daily to meet individual need. Treatment usually lasts a total of 16 weeks. There should be an interval of at least 8 weeks before re-starting treatment.
831	Itopride HCl 50 mg Tablet	A03FA00110 T1001XX	A*	Treatment of gastrointestinal symptoms of functional, non-ulcer dyspepsia (chronic gastritis) i.e sensation of bloating, early satiety, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting	50 mg 3 times daily before meal

No.	Generic Name	MDC	Category	Indication(s)	Dosage
832	Itraconazole 10 mg/ml Oral Solution	J02AC02000L 9901XX	A*	Treatment of: i) oral and/or oesophageal candidiasis ii) fluconazole resistant and/or oesophageal candidiasis	i) 200 mg daily for 1 week. If no response after 1 week, continue treatment for another week ii) 100 - 200 mg twice daily for 2 weeks. If no response after 2 weeks, continue treatment for another 2 weeks. The 400 mg daily dose should not be used for more than 14 days if there are no signs of improvement
833	Itraconazole 100 mg Capsule	J02AC02000C 1001XX	A/KK	i) Dermatomycosis including pityriasis versicolor ii) Oral candidiasis iii) Palmar tinea manus and plantar tinea pedis iv) Fingernail onychomycosis v) Toenail onychomycosis vi) Vulvovaginal candidiasis	i) 200 mg once daily for 7 days ii) 100 mg daily for 15 days iii) 200 mg twice daily for 7 days iv) 200mg twice daily for 1 week per month for 2 months v) 200 mg twice daily for 1 week per month for 3 months vi)200 mg morning and evening for 1 day or 200 mg once daily for 3 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
834	Ivabradine 5 mg Tablet	C01EB17110 T1001XX	A*	i) Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contraindication or intolerance to beta blockers ii) Treatment of coronary artery disease. Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. Ivabradine is indicated: - in patients unable to tolerate or with a contraindication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm. Treatment of chronic heart failure. Ivabradine is indicated in chronic heart failure NYHA II to IV class with sinus rhythm and whose heart rate is ≥75bpm, in combination with standard beta-blocker therapy or when beta- blocker therapy is contraindicated or not tolerated.	Initial dose 5 mg twice daily. May increase dose after 3-4 weeks to 7.5 mg twice daily depending on response. ELDERLY, initial dose 2.5 mg twice daily and titrate to a maximum of 7.5 mg twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
835	Ivabradine 7.5 mg Tablet	C01EB17110 T1002XX	A*	i) Symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contraindication or intolerance to beta blockers ii) Treatment of coronary artery disease. Symptomatic treatment of chronic stable angina pectoris in coronary artery disease patients with normal sinus rhythm. Ivabradine is indicated: - in patients unable to tolerate or with a contraindication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose and whose heart rate is > 60 bpm. Treatment of chronic heart failure. Ivabradine is indicated in chronic heart failure NYHA II to IV class with sinus rhythm and whose heart rate is ≥75bpm, in combination with standard beta-blocker therapy or when beta- blocker therapy is contraindicated or not tolerated.	Initial dose 5 mg twice daily. May increase dose after 3-4 weeks to 7.5 mg twice daily depending on response. ELDERLY, initial dose 2.5 mg twice daily and titrate to a maximum of 7.5 mg twice daily
836	Kanamycin 1 g Injection	J01GB04183P 4001XX	A*	i) Treatment of gonorrhoea and neonatal meningitis ii) Treatment of TB patients who require reserved second line drugs but have no pre-existing renal complications	i) ADULT: 1 - 2 g daily IM in 1 - 2 equally divided doses. CHILD: 30 - 50 mg/kg/day in 1 - 2 divided doses ii) ADULT: 2 g daily IM in 2 equally divided doses twice a week or 1 g once daily 3 days a week
837	Ketamine 10 mg/ml Injection	N01AX03110 P3001XX	B	Sole anaesthetic for short procedures or induction of anaesthesia in certain types of patients (e.g in shock states)	IV Initially, 1-4.5 mg/kg IV, a dose of 2 mg/kg produces anesth for 5-10 mins. IM Initially, 6.5-13 mg/kg IM, a dose of 10 mg/kg produces anesth for 12-25 mins.
838	Ketamine 50 mg/ml Injection	N01AX03110 P3002XX	B	Sole anaesthetic for short procedures or induction of anaesthesia in certain types of patients (e.g in shock states)	IV Initially, 1-4.5 mg/kg IV, a dose of 2 mg/kg produces anesthesia for 5-10 mins. IM Initially, 6.5-13 mg/kg IM, a dose of 10 mg/kg produces anesthesia for 12-25 mins.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
839	Ketoconazole 2% Shampoo	D01AC08000 L5201XX	A/KK	Resistant dandruff only	Apply twice weekly for 2 - 4 weeks. Prophylaxis: Once every 1 - 2 weeks
840	Ketoconazole 200 mg Tablet	J02AB02000T 1001XX	A/KK	i) Pityriasis versicolor ii) Systemic mycosis (other skin mycoses) iii) Nail infections	i) 200 mg with meal once daily for 10 days ii) 200 - 400 mg daily for 4 weeks - 6 months iii) 200 - 400 mg daily for 6 - 12 months.
841	Ketoprofen 2.5% Gel	M02AA10000 G3001XX	A	As a short term treatment for traumatic lesions, sprains, tendinitis, oedema, bruises	Apply onto affected areas 2-4 times daily up to 10 days.
842	Ketoprofen 200 mg Slow Release Capsule	M01AE03000 C2002XX	A/KK	Pain and inflammation in rheumatic disease	200mg in the morning or evening. Should be taken with food: Take immediately after meals.
843	Ketoprofen 30 mg Transdermal Plaster	M02AA10000 M7001XX	A	Treatment of signs & symptoms of arthritis deformans, periarthritis humero-scapularis, tendinitis, peritendinitis, sore muscle, swelling, pain resulting from trauma (eg. contusion, distorsion, sprain).	Apply 1 plaster to the affected area twice daily
844	Ketoprofen 50 mg/ml Injection	M01AE03000 P3001XX	A*	To be used only in treatment of acute inflammatory conditions	By deep IM into gluteal muscle, 50-100 mg every 4 hours. Maximum 200 mg in 24 hours for up to 3 days. Child not recommended
845	Ketorolac Tromethamine 0.5% Eye drops	S01BC05239 D2001XX	A	i) Ocular itching due to allergic conjunctivitis ii) Prophylaxis and reduction of inflammation and associated symptoms following ocular surgery	Prophylaxis and reduction of inflammation and associated symptoms following ocular surgery: 1 drop 3 times daily starting 24 hours pre-operatively and continuing up to 3 weeks post-operatively.
846	Ketorolac Tromethamine 30 mg/ml Injection	M01AB15239 P3001XX	A*	Short term management of moderate to severe postoperative pain	ADULT: 60mg as a single dose via IM inj or 30mg as a single IV dose. Alternatively, 30mg every 6 hr via IM or IV admin up to a max of 120mg daily.
847	Labetalol HCl 100 mg Tablet	C07AG01110 T1001XX	B	Hypertension (including in pregnancy)	ADULT: 100 mg (50 mg in elderly) daily with food, increased at intervals of 14 days to usual dose of 200 mg twice daily, up to 800 mg twice daily (3 - 4 divided doses if higher dose). Max:

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					2.4 g daily
848	Labetalol HCl 200 mg Tablet	C07AG01110 T1002XX	B	Hypertension (including in pregnancy)	ADULT: 100 mg (50 mg in elderly) daily with food, increased at intervals of 14 days to usual dose of 200 mg twice daily, up to 800 mg twice daily (3 - 4 divided doses if higher dose). Max: 2.4 g daily
849	Labetalol HCl 5 mg/ml Injection	C07AG01110 P3001XX	B	Hypertension crisis	ADULT: 20mg injected slowly for at least 2 min, followed by 40-80mg dose every 10 min, if necessary upto 300 mg. Patient should remain supine during and 3 hr after the procedure.
850	Lactobacillus acidophilus 100 million viable cells and estriol 0.03mg vaginal tablet	G03CC06953 T1001XX	A/KK	i)Atrophic vaginitis due to estrogen deficiency during menopause and post-menopause, or as co-medication to systemic hormone replacement therapy ii)Restoration of the Lactobacillus flora after local and/or systemic treatment with anti-infective agents or chemotherapeutic agents	Atrophic vaginitis: 1 vaginal tablet daily for 6-12 days followed by a maintenance dose of 1 vaginal tablet for 1-2 days per week Restoration therapy: 1-2 vaginal tablet daily for 6-12 days Administration The vaginal tablets should be inserted deeply into the vagina in the evenings before bedtime. In cases of a very dry vagina, vaginal tablet can be moistened with 1 or 2 drops of water before insertion into the vagina. ?During menstruation, treatment should be interrupted and resumed afterwards Should not use vaginal douches or rinses during treatment
851	Lactulose 3.35 g/5 ml Liquid	A06AD11000 L5001XX	C+	i) Constipation ii) Hepatic encephalopathy	i) ADULT 15 ml twice daily adjusted to patient's need. CHILD 0.5 ml/kg/dose once or twice daily ii) 30-50 ml 3-4 times daily, dose adjusted to produce 2-3 soft stools daily. CHILD 1 ml/kg/dose 3-4 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
852	Lamivudine 10 mg/ml Oral Solution	J05AF05000L9901XX	A*	HIV infection in combination with other antiretroviral agents	ADULT: 150 mg twice daily or 300 mg once daily. INFANT under 1 month: 2 mg/kg twice daily. CHILD 3 month or over: 4 mg/kg twice daily. Maximum 300 mg daily
853	Lamivudine 100 mg Tablet	J05AF05000T1001XX	A*	Management of chronic hepatitis B infection associated with evidence of hepatitis B viral replication and active liver inflammation	Adult: 100 mg once daily. For patients with concomitant HIV infection: 300 mg once daily or in 2 divided doses. Child: >2 yr: 3 mg/kg once daily. Max: 100 mg/day.
854	Lamivudine 150 mg Tablet	J05AF05000T1002XX	A/KK	HIV infection in combination with other antiretroviral agents	ADULT: 150 mg twice daily or 300 mg once daily. INFANT under 1 month: 2 mg/kg twice daily. CHILD 3 month or over: 4 mg/kg twice daily. Maximum 300 mg daily
855	Lamotrigine 100 mg Tablet	N03AX09000T1002XX	A	i) Adjunctive or monotherapy for partial seizures and generalised tonic-clonic seizures not satisfactorily controlled with other antiepileptic drugs ii) Prevention of mood episodes in adult 18 years and above with bipolar disorder, predominately by preventing depressive episodes	i) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg daily
856	Lamotrigine 25 mg Dispersible/Chewable Tablet	N03AX09000T2001XX	A	Add-on therapy in intractable partial seizures	25 mg daily - 50 mg twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
857	Lamotrigine 5 mg Dispersible/Chewable Tablet	N03AX09000T2002XX	A	Management of seizures in children aged 2 - 12 years	a) Add-on therapy in patients not taking Valproate: week 1 and 2: 2 mg/kg/day twice daily, week 3 and 4: 5 mg/kg/day twice daily. Maintenance: 5 - 15 mg/kg/day twice daily b) Add-on therapy in patients taking Valproate or other anti-epileptic drugs, week 1 and 2: 0.2 mg/kg/day as a single dose (children less than 25 kg may take 5 mg on alternate days), week 3 and 4: 0.5 mg/kg/day as a single dose. Maintenance dose: 1 -5 mg/kg/day once daily or twice daily
858	Lamotrigine 50 mg Tablet	N03AX09000T1001XX	A	i) Adjunctive or monotherapy for partial seizures and generalised tonic-clonic seizures not satisfactorily controlled with other antiepileptic drugs ii) Prevention of mood episodes in adult 18 years and above with bipolar disorder, predominately by preventing depressive episodes	i) Up to 200 mg daily in single or divided dosage ii) 25- 200 mg daily
859	Lansoprazole 30 mg Tablet	A02BC03000T1001XX	A*	i) Peptic ulcer disease ii) Reflux oesophagitis iii) Zollinger-Ellison Syndrome iv) For eradication of Helicobacter pylori in combination with antibiotic	i) 30mg daily in the morning for up to 4 weeks (duodenal ulcer) or up to 8 weeks (gastric ulcer). Maintenance: 15mg/day.ii) 30mg OD in the morning for up to 8 weeks if not healed. Maintenance: 15mg OD. iii) Initially 60mg OM & adjust as required. Daily doses >120mg should be given in 2 divided doses. iv) 30 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily , amoxicillin 1 g twice daily or metronidazole 400 mg twice daily) for 1-2 weeks

No.	Generic Name	MDC	Category	Indication(s)	Dosage
860	Lanthanum Carbonate 1000mg Chewable Tablet	V03AE03130 T2004XX	A*	Phosphate binding agent for the treatment of hyperphosphataemia in dialysis patients with sustained hypercalcaemia of more than three months and secondary hyperparathyroidism	Initial: 750 to 1500 mg/day in divided doses with meals then titrate in increments of 750 mg/day at intervals of 2 to 3 weeks. Maintenance: 1500-3000 mg/day in divided doses. Max: 3750 g/day
861	Laronidase 2.9 mg/5ml Injection	A16AB05000 P3001XX	A*	Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms	0.58 mg/kg of body weight administered once-weekly as an intravenous infusion
862	L-Asparaginase 10,000 IU Injection	L01XX02000P 3001XX	A*	i) Acute lymphoblastic leukemia ii) Non-hodgkin's lymphoma	i) 5,000 iu/m2 for 10 days during induction, 10,000 iu/m2 also used with high dose methotrexate rescue in consolidation phase of acute lymphoblastic leukemia ii) CHILD: 5,000 - 25,000 iu/m2 per dose depending on protocol
863	Latanoprost 0.005% and timolol maleate 0.5% eye drops	S01ED51990 D2004XX	A*	For reduction of Intraocular Pressure (IOP) in patients with Open-angle Glaucoma (OAG) and Ocular Hypertension (OH) who are insufficiently responsive to topical beta-blocker.	1 drop in the affected eye(s) once daily
864	Latanoprost 0.005% Eye Drops	S01EE01000 D2001XX	A*	Reduction of elevated intraocular pressure in patients with open-angle glaucoma	The recommended dosage is one drop (1.5 µg) in the affected eye(s) once daily in the evening. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart
865	Leflunomide 10 mg Tablet	L04AA13000 T1001XX	A*	i) Persistent active rheumatoid arthritis ii) Active psoriatic arthritis	Loading dose: 100 mg once daily for 3 days. Maintenance: 10-20 mg once daily
866	Leflunomide 20 mg Tablet	L04AA13000 T1002XX	A*	i) Persistent active rheumatoid arthritis ii) Active psoriatic arthritis	Loading dose: 100 mg once daily for 3 days. Maintenance: 10-20 mg once daily.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
867	Lenalidomide 10 mg Capsule	L04AX04000 C1002XX	A*	In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy	Recommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle
868	Lenalidomide 15 mg Capsule	L04AX04000 C1003XX	A*	In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy	Recommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle
869	Lenalidomide 25 mg Capsule	L04AX04000 C1004XX	A*	In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy	Recommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle
870	Lenalidomide 5 mg Capsule	L04AX04000 C1001XX	A*	In combination with dexamethesone is indicated for the treatment of multiple myeloma patients who have received at least one prior therapy	Recommended starting dose: 25 mg once daily on days 1 to 21 of repeated 28 day cycle with dexamethasone 40 mg once daily on days 1 to 4, 9 to 12 and 17 to 20 of each 28 day cycle for the first 4 cycles of therapy, thereafter dexamethasone 40 mg once daily on day 1 to 4 every 28 day cycle

No.	Generic Name	MDC	Category	Indication(s)	Dosage
871	Letrozole 2.5 mg Tablet	L02BG04000 T1001XX	A*	i) Treatment of hormone responsive metastatic or locally advance breast cancer after failure of tamoxifen ii) Adjunct for node positive postmenopausal women with early breast cancer (positive or unknown oestrogen or positive progesterone receptor status / receptor status) who have received 5 years of adjuvant tamoxifen therapy	2.5 mg once daily
872	Leucovorin Calcium (Calcium Folinate) 15 mg Tablet	V03AF03390 T1001XX	A	Treatment of folic acid antagonist overdose	15 mg every 6 hours for the next 48 - 72 hours
873	Leucovorin Calcium (Calcium Folinate) 3 mg Injection	V03AF03237 P3001XX	A	i) Biochemical modulator for 5-Fluorouracil in the treatment of colorectal cancer ii) As rescue for high dose methotrexate iii) Megaloblastic anaemias due to deficiency of folic acid	i) 200mg/m2 by slow IV injection over a minimum 3 minutes, followed by 5-Fluorouracil or 20mg/m2 IV followed by 5-Fluorouracil. In both cases, treatment is repeated daily for 5 days; may repeat at 4-week intervals for 2 courses then 4- to 5-week intervals ii) 15 mg (approximately 10mg/m2) every 6 hours for 10 doses, starting 24 hours after the beginning of the methotrexate infusion iii) Up to 1 mg daily
874	Leucovorin Calcium (Calcium Folinate) 50 mg Injection	V03AF03237 P3002XX	A	i) Biochemical modulator for 5-Fluorouracil in the treatment of colorectal cancer ii) As rescue for high dose methotrexate iii) Gestational trophoblastic disease	i) 200mg/m2 by slow IV injection over a minimum 3 minutes, followed by 5-Fluorouracil or 20mg/m2 IV followed by 5-Fluorouracil. In both cases, treatment is repeated daily for 5 days; may repeat at 4-week intervals for 2 courses then 4- to 5-week intervals ii) 15 mg (approximately 10mg/m2) every 6 hours for 10 doses, starting 24 hours after the beginning of the methotrexate infusion iii) 6 - 12 mg exactly 30 hours after each dose of methotrexate.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					In EMA-CO regime for high risk gestational trophoblastic disease, use 30 mg IM
875	Leuprolide Acetate 11.25 mg Injection	L02AE02122P5002XX	A*	i) Endometriosis ii) Hormonal therapy in advanced prostate cancer	11.25 mg every 3 months
876	Leuprolide Acetate 3.75 mg Injection	L02AE02122P5001XX	A*	i) Endometriosis ii) Hormonal therapy in advanced prostate cancer	i) 3.75 mg monthly for 3 - 6 months ii) 3.75 mg IM or SC injection monthly
877	Levetiracetam 100 mg/ml Injection	N03AX14000P3001XX	A*	i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of age. To be initiated when conventional IV antiepileptic drugs failed to achieve control, or oral form is temporarily not feasible in seizure emergencies	i) ADULTS and ADOLESCENT (from 16 years): Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 weeks depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12 to 17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2 to 4 weekly. CHILD (4 to 11 years) and ADOLESCENT (12 to 17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
878	Levetiracetam 100 mg/ml Oral Solution	N03AX14000 L9901XX	A*	As adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy	CHILD: 4-11 years and adolescent (12-17 years) less than 50 kg: Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg two times daily twice weekly
879	Levetiracetam 250 mg Tablet	N03AX14000 T1001XX	A*	i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of age	i) Monotherapy ADULTS and ADOLESCENT (from 16 years) : Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 week depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
880	Levetiracetam 500 mg Tablet	N03AX14000 T1002XX	A*	i) Monotherapy therapy in the treatment of partial onset seizures with or without secondary generalization in patients from age 16 years of age with newly diagnosed epilepsy ii) Adjunctive treatment in partial onset seizures with or without secondary generalization in adults and children from 4 years of age with epilepsy; juvenile myoclonic epilepsy and idiopathic generalized tonic clonic epilepsy from 12 years of age	i) Monotherapy ADULTS and ADOLESCENT (from 16 years) : Starting dose: 250 mg twice daily, Increase dose to 500 mg twice daily after 2 week. Dose can be further increased by 250 mg twice daily every 2 week depending upon the clinical response. Max: 1500 mg twice daily. ii) ADULT more than 18 years and ADOLESCENT (12-17 years) more than or equal to 50 kg: Initially 500 mg twice daily may be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increments or decrements 2-4 weekly. CHILD (4-11 years) and ADOLESCENT (12-17 years) less than 50 kg : Initially 10 mg/kg twice daily, may be increased up to 30 mg/kg twice daily. Dose changes should not exceed increments or decrements of 10 mg/kg twice daily every 2 weeks. CHILD more than or equal to 50 kg: Adult dose
881	Levobupivacaine 5mg/ml Injection	N01BB10110 P3001XX	A	Production of local or regional anesthesia for surgery and obstetrics, and for postoperative pain management	Surgical anesthesia : Lumber epidural : 10 - 20 ml (50 - 150 mg) , caesarean section : 15 - 30 ml (75 - 150 mg), intrathecal: 3 ml (15 mg), peripheral nerve block : 1 - 40 ml, ilioinguinal/iliohypogastric block. CHILD : 0.25 - 0.5 ml/kg (1.25-2.5 mg/kg)
882	Levocetirizine Dihydrochloride 5 mg Tablet	R06AE09110 T1001XX	A*	Symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and chronic idopathic urticaria	Children above 6 years and adults: 5 mg orally once daily (Swallow whole, do not chew/crush).

No.	Generic Name	MDC	Category	Indication(s)	Dosage
883	Levodopa 100 mg and Benserazide 25 mg Dispersible Tablet	N04BA02977 T4001XX	A*	Parkinson's Disease	Initially 1 cap tds. Max initial dose: 6 caps/day. Patients previously on immediate-release Levodopa/Benserazide preparations: Initially dose should substitute every 100mg of Levodopa with 1 controlled-released cap, given at same dosage frequency as before. Increase every 2-3 days.
884	Levodopa 100 mg and Carbidopa 25 mg Tablet	N04BA02000 T1001XX	B	Parkinson's disease	Patients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previously being taken
885	Levodopa 100 mg, Benserazide 25 mg HBS capsule	N04BA02977 C1001XX	B	Parkinson's Disease	Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed levodopa 1000-1200 mg/benserazide 250-300 mg per day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
886	Levodopa 100 mg, Carbidopa 25 mg and Entacapone 200 mg Tablet	N04BA03977 T1002XX	A*	Idiopathic Parkinson's disease	The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using 1 of the 4 available tablet strengths (50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapone). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum dose, for the strengths of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10 tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg equal to carbidopa 375 mg/day. Therefore, using a maximum recommended daily dose of carbidopa 375 mg, the maximum daily dose of 200/50/200 mg is 7 tablets per day. The maximum total daily levodopa dose administered should not exceed 1500 mg.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
887	Levodopa 150 mg, Carbidopa 37.5 mg and Entacapone 200 mg Tablet	N04BA03977 T1003XX	A*	Idiopathic Parkinson's disease	The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using 1 of the 4 available tablet strengths (50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapone). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum dose, for the strengths of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10 tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg equal to carbidopa 375 mg/day. Therefore, using a maximum recommended daily dose of carbidopa 375 mg, the maximum daily dose of 200/50/200 mg is 7 tablets per day. The maximum total daily levodopa dose administered should not exceed 1500 mg.
888	Levodopa 200 mg, Benserazide 50 mg Tablet	N04BA02977 T1001XX	B	Parkinson's Disease	Initial: 100/25 mg 1-2 times/day, increase every 3-4 days until therapeutic effect, optimal dosage: 400/100 mg to 800/200 mg/day divided into 4-6 doses. Dose: 200/50 mg used only when maintenance therapy is reached and not to exceed

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					levodopa 1000-1200 mg/benserazide 250-300 mg per day
889	Levodopa 200 mg, Carbidopa 50 mg & Entacapone 200 mg Tablet	N04BA03977 T1004XX	A*	Idiopathic Parkinson's disease	The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using 1 of the 4 available tablet strengths (50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapone). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum dose, for the strengths of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10 tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg equals carbidopa 375 mg/day. Therefore, using a maximum recommended daily dose of carbidopa 375 mg, the maximum daily dose of 200/50/200 mg is 7 tablets per day. The maximum total daily levodopa dose administered should not exceed 1500 mg.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
890	Levodopa 250 mg and Carbidopa 25 mg Tablet	N04BA02000 T1002XX	B	Parkinson's disease	Patients not receiving Levodopa before, initially 100 - 125 mg 3 - 4 times daily adjusted according to response. Maintenance: 0.75 - 2 g in divided doses. In patients previously treated with Levodopa the dose should be about 20 - 25% of the dose previous being taken
891	Levodopa 50 mg, Carbidopa 12.5 mg & Entacapone 200 mg Tablet	N04BA03977 T1001XX	A*	Idiopathic Parkinson's disease	The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using 1 of the 4 available tablet strengths (50/12.5/200mg, 100/25/200mg, 150/37.5/200mg or 200/50/200mg levodopa/carbidopa/entacapone). Patients should be instructed to take only 1 tablet/dose administration. While the experience with total daily dosage >200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum dose, for the strengths of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg, is 10 tablets/day. Ten (10) tablets of the strength 150/37.5/200 mg equal to carbidopa 375 mg/day. Therefore, using a maximum recommended daily dose of carbidopa 375 mg, the maximum daily dose of 200/50/200 mg is 7 tablets per day. The maximum total daily levodopa dose administered should not

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					exceed 1500 mg.
892	Levofloxacin 250 mg Tablet	J01MA12000 T1001XX	A*	Community acquired pneumonia	500 mg daily for 7 - 14 days
893	Levofloxacin 500 mg Injection	J01MA12000 P3001XX	A*	Community Acquired Pneumonia	500 mg daily for 7 - 14 days
894	Levofloxacin 500 mg Tablet	J01MA12000 T1002XX	A*	Community acquired pneumonia	500 mg daily for 7 - 14 days
895	Levonorgestrel 1.5 mg Tablet	G03AC03000 T1001XX	A*	Emergency contraception within 72 hours of unprotected sexual intercourse for the female victim of sexual violence to prevent unwanted pregnancy	1.5 mg as a single dose as soon as possible after coitus [preferably within 12 hours but no later than after 72 hours]
896	Levonorgestrel 150 mcg and Ethinyloestradiol 30 mcg Tablet	G03AA07954 T1001XX	C+	Contraception	1 tablet daily for 21 days from first day of the cycle, followed by 7 tab free days
897	Levonorgestrel 52 mg Intrauterine System	G02BA03000 P1001XX	A*	i) Contraception (Initial release rate of 20 mcg/24 hours). ii) Idiopathic menorrhagia	i) & ii):One unit intrauterine device to be inserted into the uterine cavity within 7 days of the onset of menstruation or immediately after first trimester abortion. Postpartum insertion should be postponed until 6 weeks after delivery.Can be inserted at any time of amenorrheic woman. One unit IUD is effective for 5 years
898	Levothyroxine Sodium 100 mcg Tablet	H03AA01520 T1001XX	B	Hypothyroidism	Start at low dose and increase at 2-4 weeks interval. Adult: Initially, 50-100 mcg/day may increase by 25-50 mcg at approximately 3 to 4 weeks intervals until the thyroid deficiency is corrected. Maintenance: 100-200 mcg/day. CHILD; 0 - 3 months: 10 - 15 mcg/kg/day; 3 - 6 months: 8 - 10 mcg/kg/day; 6 - 12 months: 6 - 8 mcg/kg/day; 1 - 5 years: 5 - 6 mcg/kg/day; 6 - 12 years: 4 - 5 mcg/kg/day; more than 12

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					years: 2 -3 mcg/kg/day
899	Levothyroxine Sodium 25 mcg Tablet	H03AA01152 T1003XX	B	Hypothyroidism	Start at low dose and increase at 2-4 weeks interval. Usual recommended dose for i) Treatment of benign euthyroid goitre: 75-200mcg. ii) Prophylaxis of relapse after surgery for euthyroid goitre: 75-200mcg iii) Substitution therapy in hypothyroidism: ADULT Initially, 25-50mcg/day. Maintenance: 100-200mcg/day. CHILDREN Initially 12.5-50mcg/day, Maintenance: 100-150mcg/m2 body surface area iv) Concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism: 50-100mcg v) Suppression therapy in thyroid cancer: 150-300mcg
900	Levothyroxine Sodium 50 mcg Tablet	H03AA01520 T1002XX	B	Hypothyroidism	Start at low dose and increase at 2-4 weeks interval. Usual recommended dose for i) Treatment of benign euthyroid goitre: 75-200mcg. ii) Prophylaxis of relapse after surgery for euthyroid goitre: 75-200mcg iii) Substitution therapy in hypothyroidism: ADULT Initially, 25-50mcg/day. Maintenance: 100-200mcg/day. CHILDREN Initially 12.5-50mcg/day, Maintenance: 100-150mcg/m2 body surface area iv) Concomitant supplementation during anti-thyroid drug treatment of hyperthyroidism: 50-100mcg v) Suppression therapy in thyroid cancer:

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					150-300mcg
901	Lidocaine 25mg and Prilocaine 25mg Cream	N01BB52974 G1001XX	A	Used for painless venepunctures, radial artery cannulations before extradural/spinal and other regional blocks in children above 1 year old and adults. Also used in chronic renal failure patients for insertion of A-V fistulas and shunts for haemodialysis.	Apply a thick layer under occlusive dressing at least 1 hour before the procedure
902	Lidocaine Medicated Plaster 5% w/w	N01BB02110 M6001XX	A*	Indicated for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN). Restrictions: i) For elderly patients with polymedication status whom certain treatment was contraindicated or not tolerated. ii)Prescribed by pain specialist only.	1 patch /day (Adults & elderly. Cover the painful area once daily for up to 12 hr w/in 24-hr period. Subsequent plaster-free interval: At least 12 hr. Not more than 3 plasters should be used at the same time)
903	Lignocaine 10 % w/w Spray	N01BB02110 A4001XX	B	For surface anaesthesia in dental practice, in otorhinolaryngology and paracentesis	Spray to affected part
904	Lignocaine 2 % with Adrenaline (1:80,000) Injection	N01BB52974 P3001XX	B	For local anaesthesia including infiltration, nerve and plexus blocks	By infiltration: 0.5 - 1 ml; not to exceed 7 mg/kg body weight
905	Lignocaine 2% Jelly	N01BB02110 G4001XX	B	Use for endotracheal tubes and instruments, painful procedures in the ear, nose and throat, burns, wounds, abrasions, lacerations; catheterisation of the male and female urethra and for symptomatic treatment of cystitis and urethritis	Apply to affected area 10 mins before catheterization, etc
906	Lignocaine 2% Viscous Solution	N01BB02110 L5001XX	A	For post-tonsilectomy, sore throat, dumping syndrome, hiccough, reflux vomiting, painful lesions of the mouth, cardiospasm, instrumentation of the respiratory and digestive tract	As 2% soln: For pain: 300 mg rinsed and ejected for mouth and throat pain; or gargled and swallowed if necessary for pharyngeal pain. Not to be used more frequently than every 3 hr. Max (topical oral soln): 2.4 g/day.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
907	Lignocaine 2% with Chlorhexidine 0.05% Gel	N01BB52974 G3001XX	B	To provide local anaesthesia and lubrication during catheterization, exploration by sound and other endourethral operations and examinations, cytoscopy and symptomatic treatment of painful cystitis and urethritis	Adult Male Instil 20 mL slowly into the urethra until it reaches external sphincter, proximal to the prostrate. Subsequently, apply compression at the corona for several mins. Fill the length of the urethra w/ the remaining gel. Sounding procedure or cytoscopy Instill 40 mL (in 3-4 portions) into the insertion area then allow 5-10 mins for anaesth to take effect. Adult Female Prior to urological procedure, instill 5-10 mL in small portions to fill the whole urethra & allow anaesth to take effect in 3-5 mins.Childn <12 yr Up to 6 mg/kg.
908	Lignocaine 4 % Solution	N01BB02110 L5002XX	B	For anaesthesia of mucous membranes of the oropharyngeal, tracheal and bronchial areas eg. in laryngoscopy and bronchoscopy	Bronchoscopy, 2 - 3 ml with suitable spray; biopsy in mouth, 3 - 4 ml with suitable spray or swab (with adrenaline if necessary); maximum 7.5 ml
909	Lignocaine HCl (Lidocaine) 100 mg/ml Injection	C01BB01110 P3002XX	B	Ventricular tachycardia and ventricullar fibrillation. To be diluted before use	50-100 mg IV as a bolus, repeated after 5 minutes if necessary. Maintenance : 1-4 mg/min by IV infusion under ECG monitoring
910	Lignocaine HCl (Lidocaine) 2% Injection	N01BB02110 P3001XX	B	Local anesth by infiltration IV regional anesthesia and nerve block. Emergency management of ventricular arrhythmias particularly after myocardial infarction and cardiac surgery	Local anesthesia : ADULT Maximum: 100 mg; CHILD Maximum: 3 mg/kg Cardiac arrhythmias : ADULT 50-100 mg IV. Maximum: 200-300 mg/hour; CHILD Loading dose: 0.5-1 mg/kg IV repeated if necessary up to 3-5 mg/kg followed by a continuous infusion of 10-50 mcg/kg/min
911	Lignocaine HCl (Lidocaine) 20 mg/ml Injection	C01BB01110 P3001XX	B	Ventricular tachycardia and ventricullar fibrillation. To be diluted before use	50-100 mg IV as a bolus, repeated after 5 minutes if necessary. Maintenance : 1-4 mg/min by IV infusion under ECG monitoring

No.	Generic Name	MDC	Category	Indication(s)	Dosage
912	Lignocaine HCl 1% Injection	N01BB02110 P3002XX	C+	Local or regional anaesthesia for episiotomy repairs	According to patients weight and nature of procedures, maximum 200mg. For most obstetric procedures, the preparation is diluted to 0.5%, which gives the maximum effect with the least toxicity. [lignocaine 1%, 1 part and normal saline or sterile distilled water, 1 part]
913	Lignocaine HCl 5% and Phenylephrine HCl 0.5% Nasal Spray	N01BB02984 A4101XX	A*	Preparation of nasal mucosa for surgery (eg. Cautery to Little?s area), aid the treatment of acute nose bleeds and removal of foreign bodies from the nose, topical anaesthesia of the pharynx prior to direct or indirect laryngoscopy, topical anaesthesia and local vasoconstriction prior to endoscopy of the upper airways	Adults and children over 12 years : 5 squirts per nostril. Children: 8 to 12 years 3 squirts per nostril, 4 to 8 years 2 squirts per nostril, 2 to 4 years 1 squirt per nostril. Doses are to be administered once only.
914	Lignocaine, Aluminium Acetate, Zinc Oxide and Hydrocortisone Ointment	C05AX03931 G5001XX	A/KK	Anorectal pain, pruritis, inflammation and irritation	Apply once or twice daily. Not for prolonged use
915	Lignocaine, Aluminium Acetate, Zinc Oxide and Hydrocortisone Suppository	C05AX03931 S2001XX	B	Anorectal pain, pruritis, inflammation and irritation	1 suppository to be used once or twice daily. Not for prolonged use
916	Linagliptin 5 mg tablet	A10BH05000 T1001XX	A*	Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HBA1c is more than 9%.	Adults: 5 mg once daily. When linagliptin is added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly.
917	Linezolid 2 mg/ml Injection	J01XX08000P 3001XX	A*	MRSA patient with severe sepsis requiring intensive care and not clinically responding to vancomycin	ADULT: 600 mg twice daily for 10 - 14 days. CHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					daily
918	Linezolid 20 mg/ml Suspension	J01XX08000L8001XX	A*	MRSA patients with severe sepsis requiring intensive care and not clinically responding to vancomycin	CHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily
919	Linezolid 600 mg Tablet	J01XX08000T1001XX	A*	MRSA patient with severe sepsis requiring intensive care and not clinically responding to vancomycin.	ADULT: Above 12 years 600 mg every 12 hours for 10-14 days. CHILD: 10 mg/kg 3 times daily. PREMATURE NEONATES less than 7 days: 10 mg/kg twice daily
920	Liquid Paraffin	A06AA01000L5001XX	C	Constipation	ADULT 10-30 ml daily at night but should not be taken immediately before going to bed. CHILD not recommended
921	Lithium Carbonate 300 mg Tablet	N05AN01121T1001XX	A	i) Prophylaxis and treatment of acute mania and hypomania episodes ii)Prophylaxis of manic depression in bipolar illness or bipolar depression and recurrent depression	Dose depends on the preparation used. Doses should be adjusted to produce a serum-lithium concentration of 0.4-1 mmol/l.
922	Loperamide 2 mg Capsule	A07DA03110C1001XX	B	Adjunct to rehydration in acute diarrhoea in adult also in chronic diarrhoea in adult	Acute diarrhoea: ADULT: 4 mg stat, followed by 2 mg after each unformed stool (up to 5 days). Usual 6- 8 mg daily. Max: 16 mg daily. Chronic diarrhoea: Initially 4-8 mg daily in divided doses, adjust according to response. Max: 16 mg daily
923	Lopinavir 200 mg and Ritonavir 50 mg Tablet	J05AE06964T1001XX	A*	As second line protease inhibitor if intolerant to indinavir/ ritonavir as part of HAART regimen	Adult: (Therapy-naive patients) 400/100 mg bd or 800/200 mg once daily; (Therapy-experienced patients): 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Children >40 kg or w/ BSA >1.4 m2 as adult dose.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
924	Lopinavir/Ritonavir Oral Solution	J05AE06964L9901XX	A	Management of patients with asymptomatic and symptomatic (early or advanced) HIV Infection with CD4 cell counts <50 cubic mm	Tab Adult Therapy-naive patients 400/100 mg bd or 800/200 mg once daily. Therapy-experienced patients 400/100 mg bd. Concomitant therapy (efavirenz, nevirapine, amprenavir, fosamprenavir or nelfinavir) 400/100 mg bd. Can be used w/ no dose adjustment. Childn >40 kg or w/ BSA >1.4 m2 Adult dose. Oral Soln Childn 6 mth-12 yr, 15-40 kg 10/2.5 mg/kg bd; 7 to <15 kg 12/3 mg/kg bd. Max: 5 mL bd in childn >40 kg. W/ efavirenz or nevirapine 15-45 kg 11/2.75 mg/kg bd; 7 to <15 kg 13/3.25 mg/kg.
925	Loratadine 1 mg/ml Syrup	R06AX13000L9001XX	A	Allergic rhinitis, chronic urticaria and other allergic dermatological disorders	ADULT and CHILD over 6 years : 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily
926	Loratadine 10 mg Tablet	R06AX13000T1001XX	B	Allergic rhinitis and allergic dermatoses	ADULT and CHILD over 6 years 10 mg once daily. CHILD 2 - 6 years: 5 mg once daily
927	Loratadine 5 mg and Pseudoephedrine Sulphate 120 mg Tablet	R01BA52988T1001XX	A/KK	For treatment of allergic rhinitis and allergic dermatoses	ADULT and CHILD over 12 years 1 tablet twice daily
928	Lorazepam 1 mg Tablet	N05BA06000T1001XX	A/KK	i) Severe anxiety ii) Insomnia	i) 1 - 4 mg increase to 10 mg daily in divided doses. ELDERLY (or delibitated) half adult dose ii) 1 - 2 mg at bedtime Not recommended in children

No.	Generic Name	MDC	Category	Indication(s)	Dosage
929	Losartan 50 mg Tablet	C09CA01500 T1001XX	A/KK	Patients intolerant of ACE inhibitors, only in the treatment of i) Hypertensive patient with left ventricular hypertrophy ii) Hypertension in diabetics with proteinuria or nephropathy	Hypertension: Usual starting and maintenance dose: 50 mg once daily. Maximum increasing the dose to 100 mg once daily. Patients with intravascular volume-depletion starting dose of 25 mg once daily. Renal protection in Type 2 diabetic patients with proteinuria and hypertension, starting dose: 50 mg once daily, may be increased to 100 mg once daily based on blood pressure response
930	Losartan Potassium 100 mg & Hydrochlorothiazide 25 mg Tablet	C09DA01935 T1004XX	A*	Hypertension in patients who cannot tolerate ACE inhibitors because of cough, hypertensive patient with left ventricular hypertrophy	Fixed dose combination is not indicated for initial therapy. i. Usual starting & maintenance dose: 1 tab of losartan & HCTZ 50/12.5 mg once daily. May be increased to 2 tab of losartan & HCTZ 50/12.5 mg or 1 tab of losartan & HCTZ 100/25mg once daily if blood pressure remains uncontrolled after about 3 weeks of combination therapy with losartan & HCTZ 50/12.5mg. Max: 1 tab of losartan & HCTZ 100/25mg once daily or 2 tab of Losartan & HCTZ 50/12.5 mg once daily. ii. Usual starting dose: 50 mg losartan once daily, may be titrated with a combination of losartan 50mg & HCTZ 12.5 mg, maybe substituted with losartan 100mg & HCTZ 12.5mg, followed by losartan 100 mg & HCTZ 25 mg once daily.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
931	Losartan Potassium 100 mg and Hydrochlorothiazide 12.5 mg Tablet	C09DA01935 T1003XX	A*	Hypertension in patients who cannot tolerate ACE inhibitors because of cough, hypertensive patient with left ventricular hypertrophy	Fixed dose combination is not indicated for initial therapy. i. Usual starting & maintenance dose: 1 tab of losartan & HCTZ 50/12.5 mg once daily. May be increased to 2 tab of losartan & HCTZ 50/12.5 mg or 1 tab of losartan & HCTZ 100/25mg once daily if blood pressure remains uncontrolled after about 3 weeks of combination therapy with losartan & HCTZ 50/12.5mg. Max: 1 tab of losartan & HCTZ 100/25mg once daily or 2 tab of Losartan & HCTZ 50/12.5 mg once daily. ii. Usual starting dose: 50 mg losartan once daily may be titrated with a combination of losartan 50mg & HCTZ 12.5 mg, maybe substituted with losartan 100mg & HCTZ 12.5mg, followed by losartan 100 mg & HCTZ 25 mg once daily.
932	Losartan Potassium 100 mg Tablet	C09CA01500 T1002XX	A/KK	Patients intolerant of ACE inhibitors, only in the treatment of: i) Hypertensive patient with left ventricular hypertrophy ii)Hypertension in diabetics with proteinuria or nephropathy	Usual starting dose: 50 mg once daily. May be increased to 100 mg once daily.
933	Losartan Potassium 50 mg and Hydrochlorothiazide 12.5 mg Tablet	C09DA01935 T1001XX	A/KK	Hypertension in patients who cannot tolerate ACE inhibitors because of cough, hypertensive patient with left ventricular hypertrophy	1 tablet once daily, may increase to maximum dose losartan 100 mg/ hydrochlorothiazide 25 mg once daily
934	Magnesium Sulphate 45% Paste	D11AX05183 G6001XX	C	Inflammatory skin conditions such as boils and carbuncles	Apply under dressing

No.	Generic Name	MDC	Category	Indication(s)	Dosage
935	Magnesium Sulphate 50% Injection	B05XA05183 P3001XX	C	i)Treatment and prophylaxis of acute hypomagnesaemia ii) Prevention and treatment of life-threatening seizures in the treatment of toxemias of pregnancy (pre-eclampsia and eclampsia)	i) Mild hypomagnesemia (ADULT): 1gm magnesium sulphate (8mEq) IM every 6 hours for 4 doses. Severe hypomagnesemia (ADULT): 0.25 g/kg IM over 4 hours. Alternative dose of 5g may be given by slow intravenous infusion over 3 hours ii) Toxemia of pregnancy: An initial intravenous dose of 4gm of magnesium sulphate is recommended. Followed by an intramuscular dose of 4-5gm into each buttock. This may be followed by a dose of 4-5gm into alternate buttocks every 4 hours as needed. Alternatively, the initial dose IV dose may be followed by an infusion of 1-2gm/hr
936	Magnesium Trisilicate Mixture	A02AA10912 L2101XX	C	Heartburn, dyspepsia	10-20 ml 3-4 times daily before meals
937	Magnesium Trisilicate Tablet	A02AA10912 T1001XX	C	Heartburn, dyspepsia	ADULT 1-2 tablet to be chewed up to 6 times a day before meals. CHILD over 6 years one tablet to be taken 3-4 times a day
938	Magnesium, Aluminium Hydroxide and Simethicone Suspension	V07AB00900 L8001XX	C	As a buffering agent for reconstituting didanosine powder for oral administration so as to prevent acid degradation of didanosine which is used for the treatment of paediatric patients (more than 6 months old) with symptomatic HIV infection	DDI should be mixed with water and diluted with the appropriate dose of antacids to a final concentration of 10 mg per ml
939	Malathion 1 % Shampoo	P03AX03000 L5201XX	C+	Lice infestation	Wet hair, apply shampoo and work up lather. Leave for 15 minutes and rinse, comb. Repeat if necessary after 7 - 9 days

No.	Generic Name	MDC	Category	Indication(s)	Dosage
940	Mannitol 10% Injection (10 g/100 ml)	B05BC01000 P3001XX	A	Cerebral oedema	0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age
941	Mannitol 20% Injection (20 g/100 ml)	B05BC01000 P3002XX	A	Cerebral oedema	0.25- 2 g/kg IV of a 15% to 25% solution over 30-60 minutes. Safety and efficacy not established in children under 12 years of age
942	Measles and Rubella Virus Vaccine Live, Attenuated (Freeze-dried) 10 doses/vial	J07BD52963P 4002XX	C	For active immunization against measles and rubella in infants, children, adolescents and young adults at risk. Immunization of susceptible non-pregnant adolescent and adult females is indicated if certain precautions are observed. The vaccine can be safely and effectively given simultaneously with DTP, DT, TT, Td, BCG, Polio Vaccine (OPV and IPV), Haemophilus influenza type B, Hepatitis B, Yellow fever vaccine and vitamin A supplementation.	The vaccine should be reconstituted only with the diluent supplied (sterile water for injection) using a sterile syringe and needle. With gentle shaking the dried cake is easily dissolved. After reconstitution the vaccines should be used immediately. A single dose of 0.5ml should be administered by deep SC injection into the anterolateral aspect of upper thigh in infants and upper arm in older children. If the vaccines are not used immediately then it should be stored in the dark at 20C and 80C for no longer than 6 hours.
943	Measle's Vaccine Injection (10 doses)	J07BD01000P 4001XX	C+	Prophylaxis against measles and to prevent development of infection (if given within 72 hours of contact)	By SC or IM injection, 0.5 ml as a single dose at 12 - 15 months of age
944	Measles, Mumps and Rubella (MMR) Vaccine Injection (Single Dose)	J07BD52963P 4001XX	C+	For immunisation of children against measles, mumps and rubella	Subcutaneous or by intramuscular injection, 0.5 ml
945	Mebeverine HCl 135 mg Tablet	A03AA04110 T1002XX	B	Irritable bowel syndrome	135 mg 3 times daily
946	Meclozine HCl 25 mg and Pyridoxine 50 mg Tablet	R06AE55919 T1001XX	B	Nausea and vomiting of pregnancy	1 - 2 tablet 2 - 3 times daily in severe cases

No.	Generic Name	MDC	Category	Indication(s)	Dosage
947	Mecobalamin 500 mcg Tablet	M09AX00000 T1001XX	B	Peripheral neuropathies	1 tablet 3 times daily. The dosage should be adjusted according to age of patient and severity of symptoms
948	Medroxyprogesterone Acetate 10 mg Tablet	G03DA02122 T1002XX	B	i) Secondary amenorrhoea ii) Abnormal uterine bleeding due to hormonal imbalance	i) 5-10 mg daily for 5-10 days started anytime during cycle ii) 5-10 mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum secretory transformation 10 mg daily for 10 days from day 16 of the cycle
949	Medroxyprogesterone Acetate 100 mg Tablet	L02AB02122 T1002XX	A	Breast carcinoma, endometrial carcinoma, renal carcinoma	200-500 mg orally daily
950	Medroxyprogesterone Acetate 5 mg Tablet	G03DA02122 T1001XX	B	i) Secondary amenorrhoea ii) Abnormal uterine bleeding due to hormonal imbalance	i) 5-10 mg daily for 5-10 days started anytime during cycle ii) 5-10 mg daily for 5-10 days on day 16-21 of menstrual cycle. Optimum secretory transformation 10 mg daily for 10 days from day 16 of the cycle
951	Medroxyprogesterone Acetate 50 mg/ml Injection	G03AC06122 P3001XX	B	Prevention of pregnancy and to provide long term contraception	150mg to be administered once every 3 month
952	Medroxyprogesterone Acetate 500 mg Tablet	L02AB02122 T1001XX	A	Breast carcinoma, endometrial carcinoma, renal carcinoma	200-500 mg orally daily
953	Mefenamic Acid 250 mg Capsule	M01AG01000 C1001XX	B	Mild to moderate pain	ADULT: 250 - 500 mg 3 times daily after meals. CHILD over 6 months: 6.5 - 25 mg/kg daily 3 - 4 times daily for not longer than 7 days except in juvenile arthritis
954	Mefenamic Acid 250 mg Tablet	M01AG01000 T1001XX	B	Mild to moderate pain	ADULT: 250 - 500 mg 3 times daily after meals. CHILD over 6 months: 6.5 - 25 mg/kg daily 3 - 4 times daily for not longer than 7 days except in juvenile arthritis

No.	Generic Name	MDC	Category	Indication(s)	Dosage
955	Mefloquine HCl 250 mg Tablet	P01BC02110 T1001XX	A*	For multi-drug resistant cases of malaria only	Treatment of malaria: ADULT and CHILD 25 mg/kg usually given over 2-3 days. Prophylaxis of malaria: ADULT 250 mg once a week. CHILD over 5 kg : 5 mg/kg once a week; prophylaxis should start 1-3 weeks before departure and continue for 4 weeks after last exposure
956	Meloxicam 7.5 mg Tablet	M01AC06000 T1001XX	A/KK	Only for patients not responding to other NSAIDs in the treatment of i) painful osteoarthritis ii) rheumatoid arthritis	i) Initially 7.5 mg daily. May be increased to 15 mg daily ii) initially 15 mg daily. May be reduced to 7.5 mg daily. Maximum 15 mg daily. Child under 12 years not recommended
957	Melphalan 2 mg Tablet	L01AA03000 T1001XX	A	i) Multiple myeloma ii) Neuroblastoma, rhabdomyosarcoma iii) Recurrent neuroblastoma (palliative)	i) 8 - 10 mg/m2 for 4 days every 4 weeks ii) 10 - 35 mg/m2 once every month For dose regimes, refer to protocols
958	Melphalan 50 mg Injection	L01AA03000 P4001XX	B	High dose conditioning therapy for stem cell transplantation in multiple myeloma	200 mg/ m2 IV infusions in divided doses for Day 1 to day 3 followed by IV infusions of autologous stem cells
959	Memantine HCl 10 mg Tablet	N06DX01110 T1001XX	A*	As monotherapy or as adjunctive therapy with cholinesterase inhibitors for the symptomatic treatment of patients with moderate to severe Alzheimer's disease.	Adult Initially 5 mg/day on the 1st week, 5mg twice a day on the 2nd week, then 15 mg/day (10mg in the morning and 5mg in the evening) on the 3rd week. From the 4th week on, continue treatment with maintenance dose of 20 mg/day (10mg twice a day). Max: 20 mg/day.
960	Memantine HCl 20 mg Tablet	N06DX01110 T1002XX	A*	As monotherapy or as adjunctive therapy with cholinesterase inhibitors for the symptomatic treatment of patients with moderate to severe Alzheimer's disease.	Adult Initially 5 mg/day on the 1st week, 5mg twice a day on the 2nd week, then 15 mg/day (10mg in the morning and 5mg in the evening) on the 3rd week. From the 4th week on, continue treatment with maintenance dose of 20

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					mg/day (10mg twice a day). Max: 20 mg/day.
961	Meningococcal A, C, Y, W 135 Vaccine Injection	J07AH04000 P4001XX	B	Immunisation against meningococcal diseases caused by Neisseria meningitis Group A, Group C, Group Y or Group W-135	Prophylaxis: 0.5 ml intramuscular injection.
962	Menotrophin 150 IU Injection (Follicle Stimulating Hormone 150 IU and Luteinizing Hormone 150 IU)	G03GA02954 P4002XX	A*	Treatment of infertility where clomifene has fail or stimulation of follicle growth as part of an assisted reproductive technology (ART)	SC or IM injection according to patients response
963	Menotrophin 75 IU Injection (Follicle Stimulating Hormone 75 IU and Luteinizing Hormone 75 IU)	G03GA02954 P4001XX	A*	Treatment of infertility where clomifene has fail or stimulation of follicle growth as part of an assisted reproductive technology (ART)	SC or IM Injection according to patient's response
964	Menotrophin, Highly Purified 75 IU Injection (Follicle Stimulating Hormone 75 IU and Luteinizing Hormone 75 IU)	G03GA02954 P4003XX	A*	Anovulation in women who have been unresponsive to treatment with clomiphene citrate or stimulation of follicle growth as part of an assisted reproductive technology (ART)	The recommended initial dose of MENOPUR is 75-150 IU daily. The subsequent dosing should be adjusted according to individual patient response. Adjustments in dose should not be made more frequently than every 7 days. The recommended dose increment is 37.5 IU per adjustment and should not exceed 75 IU. The maximum daily dose should not be higher than 225 IU.
965	Menthol 1.6% in Industrial Methylated Spirit Inhalation	R01AX30000 A9901XX	C	Decongestion of the upper respiratory tract	As directed for local use
966	Mepivacaine HCl 2% with Adrenaline (1:100,000) Injection	N01BB53974 P3001XX	B	For local anaesthesia including infiltration and nerve blocks	Adult: Single site in the jaw: 36 mg (1.8ml). Entire oral cavity: 180 mg (9 ml). Max: 400 mg (20 ml) per single dental procedure

No.	Generic Name	MDC	Category	Indication(s)	Dosage
967	Mepivacaine HCl 3% Injection	N01BB03110 P3001XX	B	For dental local anaesthesia including infiltration and nerve blocks on patients in whom adrenalin might be contraindicated	Adult: Single site in the jaw: 54 mg (1.8 ml). Entire oral cavity: 270 mg (9 ml). Max: 400 mg (13.3 ml) per single dental procedure
968	Mercaptopurine 50 mg Tablet	L01BB02000T 1001XX	A	i) Langerhan's cell histocytosis ii) Acute lymphoblastic leukaemia iii) Acute promyelocytic leukaemia APML (maintenance)	"Leukaemia adults: 2.5mg/kg or 80-00mg/m2 p.o per day, given as a single dose. To be increased at the end of 4 weeks, If necessary, up to 5mg/kg p.o per day. Maintainance dosage is 1.5mg/kg -2.5mg/kg p.o per day Children age 5 and older: Induction: 2.5mg/kg/day p.o once daily. Maintanance dose: 1.5mg/kg -2.5mg.kg p.o once daily or 70-100mg/m2 p.o once daily."
969	Meropenem 1 g Injection	J01DH02000 P4002XX	A*	i. Emperical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti-virals or antifungal agent ii. Septicaemia iii. Serious infections in renal impaired patients	ADULT: 0.5g - 1g 8 hourly CHILD: (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used
970	Meropenem 500 mg Injection	J01DH02000 P4001XX	A*	i. Emperical treatment for presume infections in patients (adult and children) with febrile neutropenia, used as monotherapy or in combination with anti-virals or antifungal agent ii. Septicaemia iii. Serious infections in renal impaired patients	ADULT: 0.5g - 1g 8 hourly CHILD: (aged 3 months and over): 10-40mg/kg 8 hourly, if body weight over 50kg, adult dosage should be used

No.	Generic Name	MDC	Category	Indication(s)	Dosage
971	Mesalazine 1 g Suppository	A07EC02259 S2002XX	A	Inflammatory bowel disease of ulcerative colitis and Crohn's disease.	Ulcerative colitis: 1 g suppository insert rectally once daily at bedtime. The dose may be increased to 500 mg 3 times daily if the response is inadequate after 2 weeks of therapy. To achieve maximum benefit, it is recommended that the suppository be retained in the rectum for a minimum of 1 to 3 hours or longer. The usual course of therapy, depending upon response, may last from 3 to 6 weeks. CHILD not recommended
972	Mesalazine 250 mg Suppository	A07EC02259 S2001XX	A	Inflammatory bowel disease of ulcerative colitis and Crohn's disease.	Ulcerative colitis: 1 g suppository insert rectally once daily at bedtime. The dose may be increased to 500 mg 3 times daily if the response is inadequate after 2 weeks of therapy. To achieve maximum benefit, it is recommended that the suppository be retained in the rectum for a minimum of 1 to 3 hours or longer. The usual course of therapy, depending upon response, may last from 3 to 6 weeks. CHILD not recommended
973	Mesalazine 250mg MR Tablet	A07EC02259 T1001XX	A	Inflammatory bowel disease of ulcerative colitis and Crohn's disease.	ADULT: 250 - 500 mg 3 - 4 times daily for 3 - 6 weeks. CHILD up 2 years with Crohn's disease: 20 - 30 mg/daily in divided doses
974	Mesalazine 500mg MR Tablet	A07EC02259 T1002XX	A	Inflammatory bowel disease of ulcerative colitis and Crohn's disease.	ADULT: 250 - 500 mg 3 - 4 times daily for 3 - 6 weeks. CHILD up 2 years with Crohn's disease: 20 - 30 mg/daily in divided doses
975	Mesalazine 6.67% w/w Enema	A07EC02259 G2001XX	A	Inflammatory bowel disease of ulcerative colitis and Crohn's disease.	60 ml (4g) at bedtime, retained overnight, approximately 8 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
976	Mesna 100 mg/ml Injection	V03AF01520 P3001XX	A	For prevention of urotoxic effects of oxazaphosphorines e.g. ifosfamide and cyclophosphamide	IV injection at a dosage of 20% of the corresponding oxazaphosphorine dose at the times 0 hour (concurrently with the oxazaphosphorine), 4 hours and 8 hours thereafter. CHILD: Dose given at greater frequency (e.g. 6 times) and a shorter intervals (e.g. 3 hours)
977	Metformin 500 mg and Glibenclamide 2.5 mg Tablet	A10BD02926 T1001XX	B	As second-line therapy when diet, exercise and initial treatment with sulphonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes mellitus	Initial dose:1.25 mg/250 mg ORALLY once daily; titrate in increments of 1.25 mg/250 mg per day every 2 weeks,2.5 mg/500 mg to 5 mg/500 mg ORALLY twice daily; titrate in increments of 5 mg/500 mg up to MAX 20 mg/2000 mg once daily
978	Metformin 500 mg and Glibenclamide 5 mg Tablet	A10BD02926 T1002XX	B	As second-line therapy when diet, exercise and initial treatment with sulphonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes mellitus	Initial dose:1.25 mg/250 mg ORALLY once daily; titrate in increments of 1.25 mg/250 mg per day every 2 weeks,2.5 mg/500 mg to 5 mg/500 mg ORALLY twice daily; titrate in increments of 5 mg/500 mg up to MAX 20 mg/2000 mg once daily
979	Metformin HCl 500 mg Extended Release Tablet	A10BA02110 T5001XX	A/KK	Diabetes mellitus who experienced gastrointestinal side effects with normal metformin	500 mg once daily. Maximum dose 2000 mg once daily with evening meal
980	Metformin HCl 500 mg Tablet	A10BA02110 T1001XX	B	Diabetes mellitus	Initial: 500mg orally twice daily with food. Maintenance: Titrate in 500mg increments weekly, doses up to 2000 mg daily may be divided into 2 equal doses.
981	Metformin HCl 750 mg Extended Release Tablet	A10BA02110 T5003XX	A/KK	Diabetes mellitus who experienced gastrointestinal side effects with normal metformin	500 mg once daily. Maximum dose 2000 mg once daily with evening meal

No.	Generic Name	MDC	Category	Indication(s)	Dosage
982	Methadone 5mg/ml Syrup	N07BC02110 L9001XX	A/KK	Detoxification treatment of narcotic addiction	Initial 10-20mg per day, increasing by 10-20mg per day until there are no signs of withdrawal or intoxication. Usual dose 40-60mg/day
983	Methotrexate 2.5 mg Tablet	L01BA01000 T1001XX	A	i) Acute lymphoblastic leukaemia and acute promyelocytic leukemia (maintenance) ii) Extensive plaque psoriasis, erythrodermic psoriasis, pustular psoriasis, Reiter's syndrome, connective tissue disease	i) ADULT: 20 mg/m2 weekly. CHILD: 20 - 30 mg/m2 weekly according to protocol ii) Relapsed acute lymphoblastic leukaemia (ALL): 100 mg/m2/day for 5 days 6 weekly according to protocol iii) Dose used by dermatologist: 5 - 25 mg weekly. Liver biopsy after cumulative dose of 1.5 gram and repeat liver biopsy with additional gram received. Maximum cumulative dose is 4 gram. Monitor full blood count (FBC), renal and liver function iv) Rheumatoid arthritis, psoriatic arthropathy: dose used by rheumatologist: 2.5 mg/week orally starting dose, increasing to 7.5 - 20 mg/weekly
984	Methotrexate 50 mg Injection	L01BA01520 P3001XX	A	i) Solid tumours ii) Gestational trophoblastic disease iii) Acute leukaemia/lymphomas iv) Rheumatoid arthritis, psoriatic arthropathy, severe/erythrodermic psoriasis	i) 50 mg/m2 once every 2 - 3 weeks in combination with other drugs ii) 50 mg IV Day 1, 3, 5, 9 every 3 weeks. For high risk gestational trophoblastic disease, use 100 mg/m2 as part of EMA-CO regime iii) High dose regimes: 500 - 3000 mg/m2 per dose may be used, employing the 500 mg preparations. CHILD: Central nervous system prophylaxis for acute leukaemia 2 gm/m2 over 24 hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks. Relapse acute

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					lymphoblastic leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. The 500 mg strength is not for intrathecal (IT) use. Dosage for intrathecal treatment and prophylaxis in leukaemia: less than 1 year: 5 mg, 1 - 2 years: 7.5 mg, 2 - 3 years: 10 mg, more than 3 years: 12.5 mg. IT preparation must be clearly stated/verified. ENSURE THAT PREPARATION IS SUITABLE FOR INTRATHECAL USE iv) Dose used by rheumatologist: 10 - 15 mg IM injection or oral weekly. Dose used by dermatologist: 10 - 25 mg IM injection weekly

No.	Generic Name	MDC	Category	Indication(s)	Dosage
985	Methotrexate 500 mg/20 ml Injection	L01BA01520 P3002XX	A	i) Solid tumours ii) Gestational trophoblastic disease iii) Acute leukaemias, lymphomas	i) 50 mg/m2 once every 3 weeks in combination with other drugs (for this dose, use the 50 mg preparation) ii) 50 mg IV Day 1, 3, 5, 9 every 3 weeks. For high risk gestational trophoblastic disease, use 100 mg/m2 as part of EMA-CO regime iii) High dose regimes: 500 - 3000 mg/m2 per dose may be used, employing the 500 mg preparations. CHILD: Central nervous system prophylaxis for acute leukaemia 2 gm/m2 over 24 hours with folinic acid rescue, 3 doses for B-cell lineage. 4 doses for T-lineage all every 3 weeks. Relapse acute lymphoblastic leukaemia (ALL): 1 gm/m2 over 36 hours with folinic acid rescue every 3 weeks for 9 doses, maintenance: 50 mg/m2 every 2 weeks. B-cell lymphoma: 3 gm/m2 over 3 hours with folinic acid rescue for three doses. Methotrexate level monitoring recommended when using high dose regimens. THE 500 MG STRENGTH IS NOT FOR INTRATHECAL USE
986	Methoxsalen 1% Lotion	D05AD02000 L6001XX	A	Repigmenting agent in vitiligo in conjuction with controlled doses of UVA or sunlight	Apply 0.1% lotion to area to be exposed to the UVA light (need to dilute the 1% lotion to 0.1% lotion, otherwise the skin will burn)
987	Methoxsalen 10 mg Capsule	D05BA02000 C1001XX	A	Protection before exposure to sunlight, psoriasis and vitiligo	0.2 - 0.6 mg/kg/body weight. For repigmentation of larger lesions (greater than 6 cm sq): 20 mg/day 2 hours before exposure. Take with food or milk

No.	Generic Name	MDC	Category	Indication(s)	Dosage
988	Methoxy Polyethylene Glycol-epoetin Beta 100 mcg/0.3 ml Injection in Prefilled Syringe	B03XA03000 P5001XX	A*	Treatment of anaemia associated with chronic renal failure in the following circumstances: i) Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii) Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii) Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.	Non Erythropoiesis Stimulating Agent (ESA)-treated patients: 0.6mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients: 120-360 mcg once monthly or 60-180 mcg every two weeks.
989	Methoxy Polyethylene Glycol-epoetin Beta 120 mcg/0.3 ml Injection in Prefilled Syringe	B03XA03000 P5005XX	A*	Treatment of anaemia associated with chronic renal failure in the following circumstances: i) Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii) Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii) Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.	Non Erythropoiesis Stimulating Agent (ESA)-treated patients: 0.6mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients: 120-360 mcg once monthly or 60-180 mcg every two weeks.
990	Methoxy Polyethylene Glycol-epoetin Beta 150 mcg/0.3 ml Injection in Prefilled Syringe	B03XA03000 P5006XX	A*	Treatment of anaemia associated with chronic renal failure in the following circumstances: i) Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii) Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issue	Non Erythropoiesis Stimulating Agent (ESA)-treated patients: 0.6mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks

No.	Generic Name	MDC	Category	Indication(s)	Dosage
991	Methoxy Polyethylene Glycol-epoetin Beta 200 mcg/0.3 ml Injection in Prefilled Syringe	B03XA03000 P5007XX	A*	Treatment of anaemia associated with chronic renal failure in the following circumstances: i) Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii)Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii) Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.	Non Erythropoiesis Stimulating Agent (ESA)-treated patients: 0.6mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients: 120-360 mcg once monthly or 60-180 mcg every two weeks.
992	Methoxy Polyethylene Glycol-epoetin Beta 50 mcg/0.3 ml Injection in Prefilled Syringe	B03XA03000 P5002XX	A*	Treatment of anaemia associated with chronic renal failure in the following circumstances: i) Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii) Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii) Patients who require 2 or more erythropoietin injections per week and where compliance is an issue.	Non Erythropoiesis Stimulating Agent (ESA)-treated patients: 0.6mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks
993	Methoxy Polyethylene Glycol-epoetin Beta 75 mcg/0.3 ml Injection in Prefilled Syringe	B03XA03000 P5004XX	A*	Treatment of anaemia associated with chronic renal failure in the following circumstances: i) Patients who require 2 or more subcutaneous erythropoietin injections per week and need to travel to obtain the injections. ii) Patients who are on high doses of subcutaneous erythropoietin injections eg. 6000 units or more per time and require more than 1 injection of conventional erythropoietin per time. iii)Patients who require 2 or more erythropoietin injections per week and where compliance is an issue	Non Erythropoiesis Stimulating Agent (ESA)-treated patients: 0.6mcg/kg, once every two weeks (IV or SC). When the Hb is >11g/dl, administration can be reduced to once monthly using the dose equal to twice the previous two weekly dose. ESA-treated patients : 120-360 mcg once monthly or 60-180 mcg every two weeks

No.	Generic Name	MDC	Category	Indication(s)	Dosage
994	Methyl Salicylate 25% Ointment	M02AC00260 G5001XX	C+	Relief of minor aches and pains of muscles and joints associated with simple backache, arthritis and rheumatic conditions.	To be massage well to the affected area, 3 - 4 times daily.
995	Methylcellulose 1% with 50 mg Vitamin C Eye Drops	S01XA00990 D2001XX	B	To be used only for i) Post-operative cases with dry eye ii) Unconscious patients in critical care unit (CCU) with exposure keratitis	1 to 4 times daily depending on severity of cases
996	Methyldopa 250 mg Tablet	C02AB01110 T1001XX	B	Hypertension	Adult: 250 mg 2 - 3 times daily, gradually increased at intervals of 2 or more days, maximum; 3 g/day. Elderly: initially 125 mg twice daily, increased gradually, maximum; 2 g daily. Child: Initially, 10 mg/kg or 300 mg/m2 daily in 2-4 divided doses; increase as necessary. Max: 65 mg/kg, 2 g/m2 or 3 g daily, whichever is least.
997	Methylene Blue 1% Injection	V03AB17100 P3001XX	B	For treatment of idiopathic and drug-induced methaemoglobinemia	Adult and children: 1 to 2 mg/kg (0.1 to 0.2 mL/kg of a 1% solution) IV very slowly over 5 minutes. This dosage can be repeated if necessary after one hour.
998	Methylphenidate HCl 10 mg Tablet	N06BA04110 T1001XX	A	Attention deficit hyperactivity disorder (ADHD)	CHILD over 6 years, initially 5 mg 1 - 2 times daily, increased if necessary at weekly intervals by 5 - 10 mg daily to maximum of 60 mg daily in divided doses; discontinue if no response after 1 month, also suspend periodically to assess child's condition (usually finally discontinued during or after puberty)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
999	Methylphenidate HCl 18 mg Extended-release Tablet	N06BA04110 T5002XX	A*	Attention deficit hyperactivity disorder (ADHD)	CHILD over 6 years: Individualize dosage, to be taken once daily in the morning. Dose may be adjusted in increments to a maximum of 54 mg/day, at weekly interval. Patient new to methylphenidate: starting dose 18 mg once daily; adults 18mg or 36mg once daily. Patient currently using methylphenidate: 18 - 36 mg. Maximum 54 mg/day. Discontinue if no response after 1 month
1000	Methylphenidate HCl 20 mg LA Capsule	N06BA04110 C2003XX	A*	Attention deficit hyperactivity disorder (ADHD)	20 mg once daily to be taken in the morning. Dosage be adjusted in increments to a maximum of 60 mg/day
1001	Methylphenidate HCl 36 mg Extended-release Tablet	N06BA04110 T5003XX	A*	Attention deficit hyperactivity disorder (ADHD)	CHILD over 6 years: Individualize dosage, to be taken once daily in the morning. Dose may be adjusted in increments to a maximum of 54 mg/day, at weekly interval. Patient new to methylphenidate: starting dose 18 mg once daily; adults 18mg or 36mg once daily. Patient currently using methylphenidate: 18 - 36 mg. Maximum 54 mg/day. Discontinue if no response after 1 month
1002	Methylphenidate HCl 40mg LA Capsule	N06BA04110 C2002XX	A*	Attention deficit hyperactivity disorder (ADHD)	20 mg once daily to be taken in the morning. Dosage be adjusted in increments to a maximum of 60 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1003	Methylprednisolone Acetate 40mg injection	H02AB04134 P3001XX	A*	i) Intramuscular administration: anti-inflammatory treatment, treatment of hematological and oncological disorders, endocrine disorders ii) Intrasynovial, periarticular, intrabursal or soft tissue administration: Indicated as adjunctive therapy for short term administration in : Synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, post-traumatic osteoarthritis iii) Intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, psoriatic plaques, lichen simplex chronicus (neurodermatitis) *Restricted to patients experiencing side effects with triamcinolone acetonide	i. Intramuscular route a) Asthma: may be used in place of a short burst of oral steroids in vomiting or non-adherent patients. The recommended dose is 80-120mg intramuscularly as a one-dose b) Adrenogenital syndrome: 40mg every two weeks c) Rheumatoid arthritis (maintenance): 40-120mg weekly d) Dermatologic lesions (acute severe dermatitis, chronic contact dermatitis, seborrheic dermatitis): 40-120mg weekly for 1-4 weeks ii. Intraarticular route Recommended dose is 4 to 80 milligrams, depending upon the size of the joint. Injections may be repeated at intervals of 1 to 5 or more weeks in chronic cases iii.Intralesional route 20 to 60 milligrams methylprednisolone acetate injected into the lesion
1004	Methylprednisolone Sodium Succinate 0.5 g Injection	H02AB04520 P4001XX	A	Suppression of inflammatory and allergic disorders, cerebral oedema, immunosuppression treatment of haematological and oncological disorders, treatment of shock states and endocrine disorders	15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for up to 48 hours
1005	Methylprednisolone Sodium Succinate 1 g Injection	H02AB04520 P4002XX	A	Suppression of inflammatory and allergic disorders, cerebral oedema, immunosuppression treatment of haematological and oncological disorders, treatment of shock states and endocrine disorders	15 - 30 mg/kg daily. Large doses may be repeated 4 - 6 hourly for up to 48 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1006	Metoclopramide HCl 1 mg/ml Syrup	A03FA01110 L9001XX	B	i) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting ii) Promote bowel transit during diagnostic procedures	i) CHILD over 5 years: 2.5 - 5 ml 3 times daily. 3 - 5 years 2 ml 2 - 3 times daily. 1 - 3 years: 1 ml 2 - 3 times daily. Under 1 year: 1 ml 2 times daily ii) Single dose given 10 minutes before examination. CHILD over 5 years: 2.5 - 5 ml. Between 3 - 5 years: 2 ml. Under 1 year: 1 ml
1007	Metoclopramide HCl 10 mg Tablet	A03FA01110 T1001XX	B	i) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting ii) Promote bowel transit during diagnostic procedures	i) ADULT over 20 years: 10 mg 3 times daily. ADULT between 12 - 20 years: 5 mg 3 times daily. CHILD under 12 years: 0.12 mg/kg/dose 6 - 12 hourly ii) Single dose 5 - 10 minutes before examination; ADULT and CHILD over 15 years: 10 - 20 mg; CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly
1008	Metoclopramide HCl 5 mg/ml Injection	A03FA01110 P3001XX	B	i) Dyspepsia, flatulence, hiatus hernia, peptic ulceration, reflux oesophagitis, gastritis, duodenitis, cholelithiasis, nausea, vomiting ii) Promote bowel transit during diagnostic procedures	i) ADULT over 20 years: 10 mg 3 times daily. ADULT between 12 - 20 years: 5 mg 3 times daily. CHILD under 12 years: 0.12 mg/kg/dose 6 - 12 hourly ii) Single dose 5 - 10 minutes before examination; ADULT and CHILD over 15 years: 10 - 20 mg; CHILD less than 15 years: 0.12 mg/kg/dose 6 - 12 hourly
1009	Metolazone 2.5 mg Tablet	C03BA08000 T1002XX	A*	Oedema in congestive cardiac failure, nephrotic syndrome and impaired renal function	Adult: 5-10 mg daily, increased if necessary to 20 mg daily. Max: 80 mg in 24 hr. Elderly: Initially, 2.5 mg/day or every other day. Should be taken with food. Take after breakfast.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1010	Metoprolol Tartrate 100 mg Tablet	C07AB02123 T1002XX	B	Hypertension, angina, myocardial infarction, arrhythmias	Hypertension: Initially 100 mg to maximum 400 mg daily, Angina: 50 mg - 100 mg in 2 - 3 times daily. Myocardial infarction: 200 mg daily in divided doses. Arrythmias: 50 mg - 300 mg in 2 - 3 times daily
1011	Metoprolol Tartrate 50 mg Tablet	C07AB02123 T1001XX	B	Hypertension, angina, myocardial infarction, arrhythmias	Hypertension: Initially 100 mg to maximum 400 mg daily, Angina: 50 mg - 100 mg in 2 - 3 times daily. Myocardial infarction: 200 mg daily in divided doses. Arrythmias: 50 mg - 300 mg in 2 - 3 times daily
1012	Metronidazole 0.5 g Suppository	P01AB01000 S2001XX	B	Anaerobic infection	Anaerobic infections Adult: As a 1-g suppository 8 hrly for 3 days, then 12 hrly. Substitute oral therapy as soon as possible. May be unsuitable for initiating therapy in severe infections. Child: <1 yr: 125 mg; 1-5 yr: 250 mg; 5-10 yr: 500 mg. All doses to be given 8 hrly for 3 days, then 12 hrly thereafter. May be unsuitable for initiating therapy in severe infections. Prophylaxis of postoperative anaerobic bacterial infections Adult: 1 g 8 hrly starting 2 hr before surgery.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1013	Metronidazole 200 mg Tablet	P01AB01000 T1001XX	B	Anaerobic infection	Anaerobic bacterial infections Adult: Initially, 800 mg followed by 400 mg 8 hly for about 7 days. Other recommended doses: 500 mg 8 hrly or 7.5 mg/kg 6 hrly (max: 4 g in 24 hr). Child: 7.5 mg/kg 8 hrly. Elderly: Use lower end of adult dose recommendations. Do not admin as a single dose. Prophylaxis of postoperative anaerobic bacterial infections Adult: 400 mg by mouth 8 hrly in the 24 hr prior to surgery followed postoperatively by IV or rectal admin until oral therapy is possible. Other sources recommend that oral doses be initiated only 2 hr prior to surgery and that number of doses for all admin routes be limited to a total of 4. Elderly: Dose reduction may be necessary. Tab: Should be taken with food.
1014	Metronidazole 200 mg/5 ml Suspension	P01AB01000 L8001XX	B	Anaerobic infection	CHILD: 7.5 mg/kg 3 times daily for 7 days
1015	Metronidazole 500 mg/100 ml Injection	J01XD01000P 9901XX	A	Anaerobic infections	ADULT: 500 mg IV infusion 8 hourly. CHILD: 7.5 mg/kg body weight every 8 hours. Neonates: 15mg/kg LD, followed by 7.5mg/kg every 12 hourly. 1 month to 18 years: 7.5mg/kg (maximum 500mg) every 8 hours.
1016	Miconazole 2% Cream	D01AC02221 G1001XX	B	i) Fungal infections: Tinea pedis, Tinea corporis, Tinea capitis and other dermatophyte infections caused by Trichophyton and Epidermophyton species ii) Antifungal agent that has been in various candida infections including vaginal candidiasis	Apply sparingly and rub gently onto affected area 1-2 times daily continuing for 14 days after lesions have healed

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1017	Miconazole Nitrate 2% Powder	D01AC02221 F2001XX	A	Skin infections caused by dermatophytes or Candida	Dust powder over infected area 1 - 2 times daily
1018	Midazolam 5 mg/5 ml Injection	N05CD08110 P3001XX	A	Pre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor procedures	Usual sedative range 2.5 - 7.5 mg (about 70 mcg/kg by IV injection over 30 seconds). Premedication by IM injection 70 - 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2 mg/kg/hour
1019	Midazolam 5 mg/ml Injection	N05CD08110 P3002XX	A	Pre-operative sedation, induction of general anaesthesia, premedication and sedation in ICU and sedation for minor procedures	Usual sedative range 2.5 - 7.5 mg (about 70mcg/kg by IV injection over 30 seconds). Premedication by IM injection 70 - 100 mcg/kg 30 -60 minutes before surgery; ELDERLY: 1 - 1.5 mg/kg. Induction: Induction by slow IV infusion 200 - 300 mcg/kg (ELDERLY 100 - 200 mcg/kg. CHILD over 7 years 150 - 200 mcg/kg); Maximum: 0.35mg/kg. Sedation in ICU 0.03 - 0.2 mg/kg/hour
1020	Midazolam 7.5 mg Tablet	N05CD08253 T1001XX	A/KK	Pre and post-operative sedation	ADULT: Usually 7.5 - 15 mg at bedtime; or for premedication, 30 - 60 minutes before the procedure. For ELDERLY, debilitated or impaired liver/kidney function: 7.5 mg
1021	Minocycline 100 mg Capsule	J01AA08110C 1002XX	A*	As second-line treatment for leprosy only	100 mg daily 6 - 18 months
1022	Minocycline 50 mg Capsule	J01AA08110C 1001XX	A*	As second-line treatment for leprosy only	100 mg daily 6 - 18 months

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1023	Minoxidil 5 mg Tablet	C02DC01000 T1001XX	A*	Severe hypertension	ADULTS and CHILD above 12 years old: Initially 5 mg daily in single or divided doses (elderly 2.5 mg). May increase by 5 - 10 mg daily at intervals of 3 or more days until optimum control is achieved. Maximum 50 mg daily
1024	Mirtazapine 15 mg Orodispersible Tablet	N06AX11000 T4001XX	A*	Major depression	Initially 15 mg daily at bedtime increased according to response up to 45 mg daily as a single dose at bedtime or in 2 divided doses. CHILD and ADOLESCENT under 18 years not recommended
1025	Mirtazapine 30 mg Orodispersible Tablet	N06AX11000 T4002XX	A*	Major depression	Initially 15 mg daily at bedtime increased according to response up to 45 mg daily as a single dose at bedtime or in 2 divided doses. CHILD and ADOLESCENT under 18 years not recommended
1026	Mitomycin C 0.002% Eye Drops	S01AX00000 D2003XX	A	Pterygium, conjunctival tumour, glaucoma surgery	1 - 2 drops several times a day
1027	Mitomycin C 0.02% Eye Drops	S01AX00000 D2001XX	A	Pterygium, conjunctival tumour, glaucoma surgery	1 - 2 drops several times a day
1028	Mitomycin C 0.04% Eye Drops	S01AX00000 D2002XX	A	Pterygium, conjunctival tumour, glaucoma surgery	1 - 2 drops several times a day
1029	Mitomycin-C 10 mg Injection	L01DC03000 P4001XX	A*	i) Gastrointestinal, lung, breast, cervical cancers ii) Bladder tumours iii) Opthalmological conditions: conjunctival squamous neoplasia, squamous cell carcinoma of conjunctiva, trabeculectomy chronic lymphocytic leukaemia, chronic myelogenous leukaemia. Gastric, colorectal, lung cancer	i) 10 - 20 mg/m2 body surface area (BSA) given as a single dose through a running IV infusion repeated every 6 - 8 weeks. The whole schedule may be repeated depending on the bone marrow ii) 10 - 40 mg daily or every other day (intravesical) iii) 0.4 mg topically as a single application for opthalmological conditions, duration: 1 to 3 minutes

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1030	Mitoxantrone 20 mg/10ml Injection	L01DB07110 P3001XX	A*	Acute leukaemia, elderly patients with acute myeloid leukaemia (AML), relapsed/resistant acute leukaemia, non-Hodgkin's lymphoma (NHL)	10 - 12 mg/m2 IV daily for 3 days, in combination with other cytotoxic agents. Refer to protocol. CHILD: 5 - 10 mg/m2 daily for 3 - 5 days according to protocol. Treatment of acute leukaemia, ADULT: 8 - 12 mg/m2/day once daily for 4 - 5 days. CHILD more than 2 years: same as adult dose. CHILD 2 years: 0.4 mg/kg/day once daily for 3 - 5 days
1031	Mixed Gas-Gangrene Antitoxin 25,000 units/5 ml Injection	J06AA05000P 3001XX	B	Mixed gas-gangrene	Prophylactic: 25,000 units IM or IV. Therapeutic: Not less than 75,000 units IV
1032	Moclobemide 150 mg Tablet	N06AG02000 T1001XX	A*	Treatment of depressive syndrome	Initially 300 mg daily in divided doses. Gradually to increase up to 600 mg daily in divided doses depending on response. Usual range 150 - 600 mg daily. Not recommended in children
1033	Modified Fluid Gelatin 4% Injection	B05AA06905 P9901XX	B	For primary volume replacement in hypovolaemia, peri-operative stabilization of the circulation, haemodilution, extracorporeal circulation (haemodialysis and heart-lung machine)	ADULT 500 - 1500 ml given as IV infusion
1034	Modified Polypeptides (Polygeline) 3.5% Injection	B05AA10905 P9901XX	B	For primary volume replacement in hypovolaemia, peri-operative stabilization of the circulation, haemodilution, extracorporeal circulation (haemodialysis and heart-lung machine)	Administered by intravenous infusion only. Total dosage and rate of infusion depend upon the amount of blood loss and hemodynamic parameters. The usual dose is 500 to 1000 milliliters (mL), with total dosage not to exceed 2500 mL daily
1035	Molgramostim 300 mcg Injection	L03AA03000 P4002XX	A*	i) As secondary prophylaxis and therapeutic use against chemotherapy induced leucopenia according to clinician's discretion ii) Haemopoietic stem cell	SC or IV 250 mcg/m2/day. Initiation: 24 to 72 hours after chemotherapy. Duration: Until a clinically adequate neutrophil

No.	Generic Name	MDC	Category	Indication(s)	Dosage
				transplantation (HSCT)	recovery is achieved
1036	Mometasone Furoate 0.1% Cream	D07AC13139 G1001XX	A*	Steroid responsive dermatosis and vitiligo. Used where a potent steroid is required for short duration not more than 6 weeks	Apply thin layer to the affected skin areas once daily until the lesion heals or for duration of 3 weeks whichever is sooner.Massage gently and thoroughly until the medication disappears.
1037	Mometasone Furoate 50 mcg Aqueous Nasal Spray	R01AD09139 A4101XX	A*	Allergic rhinitis	ADULT and CHILD over 12 years: 100 mcg/day (2 sprays) to each nostril once daily. Maximum 200 mcg (4 sprays) once daily. Reduce to 50 mcg (1 spray) once daily when control achieved. CHILD 6 - 12 years old: 50 mcg (1 spray) to each nostril once daily
1038	Monobasic Sodium Phosphate 48%, Dibasic Sodium Phosphate 18%	A06AG01162 L5001XX	A	Bowel cleansing prior to colonoscopy, radiological examination or bowel surgery	45 ml diluted with half a glass (120 ml) of water, followed by one full glass (240 ml) of water to be taken depending on the time of the procedure. For morning procedure, 45 ml dilute with half glass of water should be taken at 7 am and the second 45 ml at 7 pm on the day before the procedure. For afternoon procedure, the first dose should be taken at 7 pm on the day before and the second dose at 7 am on the day of the procedure. Solid food must not be taken during the preparation period; clear fluids or water can be taken liberally. Not recommended for use in children
1039	Montelukast Sodium 10 mg Tablet	R03DC03520 T1001XX	A/KK	Chronic treatment of asthma and relief of symptoms of seasonal allergic rhinitis for children more than 15 years and adults	CHILD more than 15 years and ADULT: 10 mg daily at bedtime

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1040	Montelukast Sodium 4 mg Oral Granules	R03DC03520 F1001XX	A*	Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma	12 months - 5 years: 1 packet of 4mg oral granules daily at bedtime
1041	Montelukast Sodium 5 mg Tablet	R03DC03520 T2001XX	A*	Asthmatics, not controlled on high dose inhaled corticosteroids more than 1600 mcg/day and with co-morbid allergic disorders. Chronic treatment of asthma	CHILD 6 - 14 years: One 5 mg chewable tablet daily at bedtime
1042	Morphine HCl 10 mg/5 ml Solution	N02AA01110 L9901XX	B	For use in management of moderate to severe pain especially that associated with neoplastic disease	5 - 20 mg or more regularly every 4 hours in terminal pain
1043	Morphine Sulphate 10 mg Controlled Release Tablet	N02AA01183 T5001XX	A	Prolonged relief of severe pain associated with neoplastic disease; assists in procuring sleep where sleeplessness is due to pain or shock	10 - 60 mg 12 hourly intervals, depend upon the severity of the pain. Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly.
1044	Morphine Sulphate 10 mg Immediate Release Tablet	N02AA01183 T6002XX	A*	Relief of moderate to severe pain (cancer patient)	5-10 mg every four hours. The dose may be increased according to needs
1045	Morphine Sulphate 10 mg Suppository	N02AA01183 S2001XX	A*	Relief of severe chronic pain (cancer patient)	15 - 30 mg regularly every 4 hours
1046	Morphine Sulphate 10 mg/ml Injection	N02AA01183 P3001XX	B	For moderate to severe pain especially that associated with neoplastic disease	ADULT: 10 - 20 mg/kg or more SC or IM every 4 hours in terminal pain. CHILD: Up to 1 month: 0.15 mg/kg body weight; 1 - 12 months: 0.2 mg/kg body weight; 1 - 5 years: 2.5 - 5 mg ; 6 - 12 years: 5 - 10 mg
1047	Morphine Sulphate 20 mg Suppository	N02AA01183 S2002XX	A*	Relief of severe chronic pain (cancer patient)	15 - 30 mg regularly every 4 hours
1048	Morphine Sulphate 30 mg Controlled Release Tablet	N02AA01183 T5002XX	A	Prolonged relief of severe pain associated with neoplastic disease; assists in procuring sleep where sleeplessness is due to pain or shock	10 - 60 mg 12 hourly intervals, depend upon the severity of the pain
1049	Morphine Sulphate 30 mg Suppository	N02AA01183 S2003XX	A*	Relief of severe chronic pain (cancer patient)	15 - 30 mg regularly every 4 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1050	Morphine Sulphate 5 mg Immediate Release Tablet	N02AA01183 T6001XX	A*	Relief of moderate to severe pain (cancer patient)	5-10 mg every four hours. The dose may be increased according to needs
1051	Morphine Sulphate 60 mg Controlled Release Tablet	N02AA01183 T5003XX	A	Prolonged relief of severe pain associated with neoplastic disease; assists in procuring sleep where sleeplessness is due to pain or shock	10 - 60 mg 12 hourly intervals, depend upon the severity of the pain. Children (more than 1 year of age) with severe cancer pain: 0.2 - 0.8mg/kg 12 hourly.
1052	Moxifloxacin 0.5% Ophthalmic Solution	S01AX22110 D2001XX	A*	Treatment of conjunctivitis caused by susceptible organism	CHILD more than 1 year and ADULT: 1 drop to affected eye(s) 3 times daily for 7 days
1053	Moxifloxacin 400 mg Injection	J01MA14110 P3001XX	A*	Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae.	IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days
1054	Moxifloxacin 400mg Tablet	J01MA14110 T1001XX	A*	Second line therapy for Severe Community Acquired Pneumonia (CAP) patients with co-morbidity or with recent antibiotic therapy, suspected infections of resistant pathogens including Streptococcus pneumoniae, Haemophilus influenzae & Mycoplasma pneumoniae.	IV or Oral: 400 mg once daily. The recommended total treatment duration for sequential administration (intravenous followed by oral therapy) is 7 to 14 days
1055	Multivitamin Drops	A11BA00901 D5001XX	B	For prevention and treatment of vitamin deficiencies	INFANT less than 1 year: 1 ml daily
1056	Multivitamin Injection	A11BA00901 P3001XX	B	For prevention and treatment of vitamin deficiencies	Initially 2 - 4 pairs IV 4 - 8 hourly, reduce to 1 pair IV daily. For less serious cases, 1 pair IV 1 - 2 times daily or based on individual requirements
1057	Multivitamin Syrup	A11BA00901 L9001XX	C+	For prevention and treatment of vitamin deficiencies	CHILD 5 ml daily or based on manufacturer
1058	Multivitamin Tablet	A11BA00901 T1001XX	B	For prevention and treatment of vitamin deficiencies	1 - 2 tablets daily or based on individual requirements

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1059	Mupirocin 2% Cream	D06AX09000 G1001XX	A	Skin infection by Staphylococcus aureus (including MRSA), Staphylococcus epidermidis and beta-haemolytic streptococcus	Adults and child over 1 year, apply up to 3 times daily for up to 10 days
1060	Mupirocin 2% Ointment	D06AX09000 G5001XX	A	For MRSA infections only	ADULT and CHILD: Apply up to three times daily for up to 10 days
1061	Mycophenolate Mofetil 250 mg Capsule	L04AA06236 C1001XX	A*	i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis resistant or intolerant to cyclophosphamide therapy	i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day
1062	Mycophenolate Mofetil 500 mg tablet	L04AA06236 T1002XX	A*	i) Prophylaxis of acute organ rejection in patients receiving allogenic renal, cardiac and hepatic transplant ii) Used with steroids for induction and maintenance of severe lupus nephritis resistant or intolerant to cyclophosphamide therapy	i) Renal transplant rejection: ADULT: 1 g twice daily. CHILD (3 months and older): 600 mg/m(2)/dose, twice daily; maximum daily dose, 2 g/10 mL. Cardiac transplant rejection: 1.5 g twice daily. Hepatic transplant rejection: 1.5 g twice daily ii) Induction phase: 2 - 3 g/day for up to 6 months. Maintenance phase: dose gradually tapers to 1 g/day
1063	Mycophenolate Sodium 180mg Tablet	L04AA06520 T1001XX	A*	Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids	720 mg twice daily
1064	Mycophenolate Sodium 360mg Tablet	L04AA06520 T1002XX	A*	Prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplant in combination with ciclosporin and corticosteroids	720 mg twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1065	Nalbuphine HCl 10 mg/ml Injection	N02AF02110 P3001XX	B	Perioperative analgesia, for relief of moderate to severe pain	10 - 20 mg SC, IM or IV every 3 - 6 hours
1066	Naloxone HCl 0.02 mg/ml Injection	V03AB15110 P3001XX	B	For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage	0.005 - 0.01 mg/kg body weight repeated at intervals of 2 - 3 minutes according to the patient's needs by IM, IV or SC
1067	Naloxone HCl 0.4 mg/ml Injection	V03AB15110 P3002XX	B	For the complete/partial reversal of narcotic depression including respiratory depression induced by opioids such as natural and synthetic narcotics. Diagnosis of suspected acute opioids overdosage	Initially 0.4 - 2 mg IV repeated at intervals of 2 - 3 minutes according to patient's needs
1068	Naltrexone HCl 50 mg Tablet	N07BB04110 T1001XX	A	Adjunct in relapse prevention treatment in detoxified formerly opioid-dependant patients	Initial 25 mg may be increased to 50 mg. Maintenance: 350 mg weekly; administered as 50 mg daily. Dosing interval may be lengthened to improve compliance; 100 mg on alternate days or 150 mg every third day
1069	Nandrolone Decanoate 25 mg/ml Injection	A14AB01135 P3001XX	A	Anabolic therapy	ADULT: 25 - 50 mg every 3 weeks by IM. CHILD over 2 years: 25 - 50 mg every 3 to 4 weeks
1070	Naproxen 250 mg Tablet	M01AE02000 T1001XX	A/KK	i) Rheumatic arthritis, osteoarthritis and ankylosing spondylitis ii) Acute gout iii) Muscular skeletal disorder, dysmenorrhoea	i) 0.5 - 1 g daily in 2 divided doses ii) 750 mg initially then 250 mg 8 hourly iii) 500 mg initially then 250 mg every 6 - 8 hour as required
1071	Naproxen Sodium 275 mg Tablet	M01AE02520 T1001XX	A	i) Rheumatic arthritis, osteoarthritis and alkylosing spondylitis ii) Acute gout iii) Muscular skeletal disorder and dysmenorrhoea	550 mg- 1100 mg in two divided doses
1072	Neomycin 0.5% Cream	D06AX04256 G1001XX	B	Infections of the skin due to susceptible organisms	Apply sparingly to affected area up to 3 times daily (For short term use, 1 - 2 weeks)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1073	Neomycin 0.5% in Betamethasone 17-Valerate 0.01% Cream	D07CC01947 G1001XX	B	Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo	Apply sparingly to affected area 2 - 3 times daily. (May cause sensitisation to neomycin. Use with caution)
1074	Neomycin 0.5% in Betamethasone 17-Valerate 0.01% Ointment	D07CC01947 G5001XX	B	Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo	Apply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to Neomycin. Use with caution)
1075	Neomycin 0.5% in Betamethasone 17-Valerate 0.1% Cream	D07CC01947 G1002XX	A	Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo	Apply sparingly to affected area 2 - 3 times daily (May cause sensitisation to neomycin. Use with caution)
1076	Neomycin 0.5% in Betamethasone 17-Valerate 0.1% Ointment	D07CC01947 G5002XX	A	Treatment of the following conditions where bacterial infection is present or likely to occur: eczemas, prurigo nodularis, psoriasis (excluding widespread plaque psoriasis), neurodermatoses, anal and genital intertrigo	Apply sparingly to affected area 2 to 3 times daily. (May cause sensitisation to neomycin. Use with caution)
1077	Neomycin 0.5% Ointment	D06AX04256 G5001XX	B	Infections of the skin due to susceptible organisms	Apply sparingly to affected area up to 3 times daily (For short term use, 1- 2 weeks)
1078	Neomycin with Polymyxin B Sulphate and Gramicidin Eye Drops	S01AA30990 D2001XX	A	Eye infections that require a broad spectrum antibiotic	1 - 2 drops in the affected eye 2 - 4 times daily. In severe infections : 1 - 2 drops every 15 - 30 minutes

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1079	Neostigmine Methylsulphate 2.5 mg/ml Injection	N07AA01183P3002XX	B	i) Myasthenia gravis ii) Reversal of non-depolarising neuromuscular blockade	i) ADULT: 1 - 2.5 mg at suitable intervals by SC, IM or IV. Usual total daily dose 5 - 20 mg. CHILD: 200 - 500 mcg at suitable intervals throughout the day. NEONATE: 50 - 250 mcg every 4 hours ii) By IV injection over 1 minute, 50 - 70 mcg/kg (maximum 5 mg) after or with atropine sulphate 0.6 - 1.2 mg
1080	Netilmicin Sulphate 100 mg/2 ml Injection	J01GB07183P3002XX	A	Systemic infections	ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
1081	Netilmicin Sulphate 150 mg/2 ml Injection	J01GB07183P3003XX	A	Systemic infections	ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
1082	Netilmicin Sulphate 50 mg/2 ml Injection	J01GB07183P3001XX	A	Systemic infections	ADULT: 4 - 6.5 mg/kg/day IM or IV in 2 - 3 equally divided doses for 7 - 14 days. Maximum: 7.5 mg/kg/day. CHILD: 5 - 7.5 mg/kg/day 8 - 12 hourly depending on gestation and age. Maximum: 7.5 mg/kg/day
1083	Nevirapine 200 mg Tablet	J05AG01000T1001XX	A/KK	Treatment of HIV-1 infection in combination with other antiretroviral agents	Combined with other antiretrovirals: 200 mg once daily for the 1st 14 days; up to 200 mg twice daily if rash does not develop. Re-introduce at a lower dose for the 1st 14 days if treatment is interrupted for >7 days,necessitate

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					reintroduction at a lower dose for the first 14 days.
1084	Nicotine 10 mg/ 16 hour Transdermal Patch	N07BA01000 M7005XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mg patch daily for another 2 weeks. Apply to dry non-hairy skin site. Application limited to 16 hours in a 24-hr period in each case. Review at 3 months.
1085	Nicotine 14mg/24 hour Transdermal Patch	N07BA01000 M7002XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Apply 1 patch daily for 24 hours as in the product leaflet
1086	Nicotine 15 mg/ 16 hour Transdermal Patch	N07BA01000 M7006XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mg patch daily for another 2 weeks. Apply to dry non-hairy skin site. Application limited to 16 hours in a 24-hr period in each case. Review at 3 months.
1087	Nicotine 2 mg Gum	N07BA01000 M9901XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1088	Nicotine 21mg/24 hour Transdermal Patch	N07BA01000 M7003XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Apply 1 patch daily for 24 hours as in the product leaflet.
1089	Nicotine 4 mg Gum	N07BA01000 M9902XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Smokes ≤ 20 sticks/day, chew 2mg gum. Smokes ≥ 20 sticks/day,chew 4 mg gum. (MAX 24 pieces /day for up to 12 week.)
1090	Nicotine 5 mg/ 16 hour Transdermal Patch	N07BA01000 M7004XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Adult over 18 years old: 15 mg patch on waking (usually in the morning) and remove 16 hours later (usually at bedtime) for 8 weeks, then 10 mg patch daily for 2 weeks followed by one 5 mg patch daily for another 2 weeks. Apply to dry non-hairy skin site. Application limited to 16 hours in a 24-hr period in each case. Review at 3 months.
1091	Nicotine 7mg/24 hour Transdermal Patch	N07BA01000 M7001XX	A/KK	For the treatment of tobacco dependence by relieving nicotine withdrawal symptoms, thereby facilitating smoking cessation in smokers motivated to quit.	Apply 1 patch daily for 24 hours as in the product leaflet.
1092	Nicotinic Acid 50 mg Tablet	A11HA01000 T1001XX	B	For prophylaxis and treatment of Vitamin B3 deficiency	Prophylactic: 15 - 30 mg daily. Therapeutic: 50 - 250 mg daily. Maximum single dose: 200 mg. Maximum dose in 24 hours: 800 mg
1093	Nicotinic Acid 500 mg Tablet	C10AD02000 T1001XX	B	Hyperlipidaemia	100 - 200 mg 3 times daily, gradually increased over 2 - 4 weeks to 1 - 2 g 3 times daily with or after meals. CHILD: 100 - 250 mg/day in 3 divided doses with meals increase 100 mg/day weekly or 250 mg/day every 2 - 3 weeks as tolerated. Maximum: 10 mg/kg/day
1094	Nifedipine 10 mg Capsule	C08CA05000 C1001XX	B	Hypertension	10 - 30 mg 3 times daily. Maximum: 120 - 180 mg per day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1095	Nifedipine 10 mg Tablet	C08CA05000 T1001XX	B	Hypertension	Initial dose of 10 mg twice daily. Usual range 10 - 30 mg 3 times daily. Maximum: 120 - 180 mg per day. Elderly: Dose reduction may be necessary.
1096	Nilotinib 150mg capsule	L01XE08110T 1001XX	A*	For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in the chronic phase (CP).	300mg twice daily. Dose adjustments or modifications:For neutropenia & thrombocytopenia
1097	Nilotinib 200 mg Capsule	L01XE08110C 1001XX	A*	Treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in adults who: i) Failed imatinib ie no cytogenic response and no haematological response by 12 months ii) Have molecular resistance to Imatinib as shown by molecular mutation studies iii) Are intolerant to Imatinib	400 mg twice daily, 12 hours apart. No food should be taken two hours before and 1 hour after taking the dose
1098	Nimodipine 10 mg/50 ml Infusion Solution	C08CA06000 P9901XX	A*	Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin	IV infusion of 1 mg/hour for a period of 2 hours (about 15 mcg/kg/hour). IV therapy should be started no later than 4 days after haemorrhage & continue for up to 10 - 14 days
1099	Nimodipine 30 mg Tablet	C08CA06000 T1001XX	A*	Prophylaxis & treatment of ischaemic neurological deficits caused by cerebral vasospasm following subarachnoid haemorrhage of aneurysmal origin	360 mg daily in divided doses for 7 days
1100	Nitrazepam 5 mg Tablet	N05CD02000 T1001XX	B	Epilepsy (infantile spasms)	5 - 10 mg at bedtime. ELDERLY or debilitated 2.5 - 5 mg. CHILD not recommended. Increasing slowly according to response

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1101	Nitrofurantoin 100 mg Tablet	J01XE01000T 1002XX	B	Uncomplicated lower urinary tract infections	Acute uncomplicated urinary tract infections Adult: 50-100 mg 4 times daily for 7 days. Dual-release preparation: 100 mg bid. Child: >3 mth and older children: 3 mg/kg daily in 4 divided doses. Prophylaxis of uncomplicated urinary tract infections Adult: 50-100 mg at bedtime. Child: >3 mth and older children: 1 mg/kg once daily.
1102	Nonacog alfa 1000 IU injection	B02BD09000 P4003XX	A*	Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)	Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
1103	Nonacog alfa 2000 IU injection	B02BD09000 P4004XX	A*	Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)	Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
1104	Nonacog alfa 250 IU injection	B02BD09000 P4001XX	A*	Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)	Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					to 4 days.
1105	Nonacog alfa 500 IU injection	B02BD09000 P4002XX	A*	Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)	Number of factor IX units required = body weight (kg) x desired factor IX increase (% or units/dL) x reciprocal of observed recovery (units/kg per units/dL). Average dose for secondary prophylaxis for previously treated adult patients (PTP) was 40 units/kg (range 13 to 78 units/kg) at intervals of 3 to 4 days
1106	Noradrenaline Acid Tartrate (Norepinephrine Bitartrate) 1 mg/ml Injection	C01CA03123 P3001XX	A	Septic shock and shock where peripheral vascular resistance is low	Infuse and titrate to desired pressure response. Range: 0.05 - 0.5 mcg/kg/minute
1107	Norethisterone 0.35 mg Tablet	G03AC01000 T1001XX	C+	Contraception	1 tablet daily starting on the first day of the menstrual bleeding
1108	Norethisterone Enanthate 200 mg/ml Injection	G03AC01257 P3001XX	B	Contraception	By deep IM injection only. First injection is within first 5 days of the cycle. The next 3 injections are given at 8 weeks interval after which the injection interval should be extended to 12 weeks
1109	Norfloxacin 0.3% Eye Drops	S01AX12000 D2001XX	A*	Superficial infections of the eye (Pseudomonas aeruginosa and MRSA) and its adnexae	ADULT and CHILD more than 1 year: 1-2 drops 4 times daily. First day : 1 - 2 drops two hourly during waking hours (depending on severity)
1110	Nystatin 100,000 units/g Cream	D01AA01000 G1001XX	C	Prevention and treatment of cutaneous infections caused by Candida albicans	Apply liberally to affected area twice daily or as required. After lesion has disappeared continue treatment for 10 days to prevent relapses. Nail infection: Cut nails as short as possible. Apply cream once daily until growth of new nail has set in

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1111	Nystatin 100,000 units/g Ointment	D01AA01000 G5001XX	C	Prevention and treatment of cutaneous or mucocutaneous infections caused by Candida albicans	Apply liberally to affected area twice daily or as required. After lesion has disappeared continue treatment for 10 days to prevent relapses. Nail infection: Cut nails as short as possible. Apply cream once daily until growth of new nail has set in
1112	Nystatin 100,000 units/ml Suspension	A07AA02000 L8001XX	B	Prevention and treatment of candidiasis of the skin and mucous membranes, protection against candidas overgrowth during antimicrobial /corticosteroid therapy and as selective decontamination regimens	NEWBORN: 50,000-100,000 units daily. CHILD up to 5 years: 100,000 -500,000 units 6 hourly. CHILD up to 6-12 years and ADULT: 500,000-1,000,000 units 3 to 4 times daily
1113	Nystatin 500,000 units Tablet	A07AA02000 T1001XX	B	Prevention and treatment of candidiasis of the skin and mucous membranes, protection against candidas overgrowth during antimicrobial /corticosteroid therapy and as selective decontamination regimens	ADULT: 500,000 -1,000,000 units 6 hourly, according to severity of infections. CHILD: 100,000-500,000 units 6 hourly
1114	Octreotide 0.05 mg/ml Injection	H01CB02122 P3002XX	A	i) Acromegaly ii) Treatment of patients with symptoms associated with gastro-entero-pancreatic endocrine tumours iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, GRFomas, insulinomas iv) Prevention of complications following pancreatic surgery v) Emergency management of bleeding gastro-eosophageal varices in patients with cirrhosis	i, ii and iii) Initially 0.005 - 0.1 mg SC 1 - 2 times daily, increase gradually up to 0.1 - 0.2 mg 3 times daily iv) 0.1 mg 3 times daily for 7 consecutive days, starting on the day of operation, at least 1 hour before laparotomy v) 25 mcg/hour for 5 days by continous IV infusion

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1115	Octreotide 0.1 mg/ml Injection	H01CB02122 P3001XX	A	i) Acromegaly ii) Treatment of patients with symptoms associated with gastro-entero-pancreatic endocrine tumours iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, GRFomas, insulinomas iv) Prevention of complications following pancreatic surgery v) Emergency management of bleeding gastro-eosophageal varices in patients with cirrhosis	i, ii and iii) Initially 0.005 - 0.1 mg SC 1 - 2 times daily, increase gradually up to 0.1 - 0.2 mg 3 times daily iv) 0.1 mg 3 times daily for 7 consecutive days, starting on the day of operation, at least 1 hour before laparotomy v) 25 mcg/hour for 5 days by continous IV infusion
1116	Octreotide Acetate 20 mg Injection	H01CB02122 P2001XX	A*	i) Adjunctive treatment for active acromegaly (second/third line therapy in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor). ii) Treatment of symptoms associated with functional gastro-entero-pancreatic endocrine tumours. iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, Glucagonomas, Gastrinomas/Zollinger-Ellison syndrome, Insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy, GRFomas.	10 - 30 mg every 4 weeks as deep intragluteal injection

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1117	Octreotide Acetate 30 mg Injection	H01CB02122 P2002XX	A*	i) Adjunctive treatment for active acromegaly (second/third line therapy in whom surgery or radiotherapy is inappropriate or ineffective- based on level of growth hormone and high IGF-1 and residual pituitary tumor). ii) Treatment of symptoms associated with functional gastro-entero-pancreatic endocrine tumours. iii) Carcinoid tumours with features of the carcinoid syndrome, VIPomas, Glucagonomas, Gastrinomas/Zollinger-Ellison syndrome, Insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy, GRFomas.	10 - 30 mg every 4 weeks as deep intragluteal injection
1118	Ofloxacin 0.3% Otic Solution	S02AA00000 D1001XX	A/KK	Acute otitis media with tympanostomy tubes, chronic suppurative otitis media with perforated tympanic membranes and otitis externa	CHILD: 1 - 12 years: 5 drops twice daily for 10 days. ADULT and CHILD over 12 years: 6 - 10 drops twice daily and remain in the ear about 10 minutes
1119	Ofloxacin 100 mg Tablet	J01MA01000 T1001XX	A	i) As second-line treatment of leprosy ii) As second-line treatment for tuberculosis and multidrug resistant tuberculosis (MDR-TB) iii) Sequential therapy for UTI and pyelonephritis	i) 400 mg/day ii) 400 mg twice daily iii) 200 mg twice daily
1120	Ofloxacin 200 mg Injection	J01MA01000 P4001XX	A	Sequential therapy for UTI and pyelonephritis	200 mg IV twice daily for 3 - 5 days followed with 200 mg tablet twice daily for 3 - 5 days as maintenance dose (if necessary)
1121	Olanzapine 10 mg Disintegrating Tablet	N05AH03000 T4002XX	A*	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1122	Olanzapine 10 mg Tablet	N05AH03000 T1002XX	A*	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
1123	Olanzapine 5 mg Tablet	N05AH03000 T1001XX	A*	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
1124	Olanzapine 5mg Disintegrating Tablet	N05AH03000 T4001XX	A*	i) Acute and maintenance treatment of schizophrenia and other psychoses where positive and or negative symptoms are prominent ii) Short-term use for acute mania episodes associated with Bipolar 1 disorder	i) 5 - 10 mg once daily, increase to 10 mg once daily within 5 - 7 days, adjust by 5 - 10 mg/day at 1 week intervals, maximum 20 mg/day ii) 10 - 15 mg once daily, increase by 5 mg/day at intervals of not less than 24 hours. Maintenance 5 - 20 mg/day; maximum 20 mg/day
1125	Olive Oil Ear Drops	S02DC00000 D1001XX	C	Impacted wax softener	3 - 4 drops 3 - 4 or as directed
1126	Olopatadine hydrochloride ophthalmic solution 0.2%	S01GX09110 D2002XX	A*	Temporary prevention of ocular itching due to allergic conjunctivitis	One drop in each affected eye once a day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1127	Omalizumab 150 mg (powder and solvent for solution)	R03DX05000 P3001XX	A*	i) For adults and adolescents (≥12 years), for severe persistent allergic asthma whose symptoms are inadequately controlled with inhaled corticosetroids ii) For Children (6 to <12 years of age): As add-on therapy to improve asthma control with severe persistent allergic asthma who have positive skin test or in vitro reactivity to a perennial aero allergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta 2 agonist	i) Adult & adolescent ≥12 yr, 150-375 mg SC every 2-4 wk, according to body wt & baseline serum total IgE level.. For subcutaneous administration only. Do not administer by the intravenous or intramuscular route. ii) Appropriate dose and dosing frequency of omalizumab is determined by baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to initial dosing, patients should have their IgE level determined for their dose assignment. Based on these measurements 150-375mg in 1 -3 injections may be needed for each administration. Patients whose baseline IgE levels or body weight in kilograms are outside the limits of the dosing table should not be given omalizumab. For subcutaneous administration only.
1128	Omeprazole 10 mg Capsule	A02BC01000 C1001XX	A/KK	Only for : i)Reflux oesophagitis ii)For eradication of Helicobacter pylori infection iii)Benign peptic ulcer not responding to conventional therapy iv)Zollinger-Ellison Syndrome	i) 20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks ii) 20 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily or metronidazole 400 mg twice daily) for 1 - 2 weeks iii) 20 mg once daily for 4 - 6 weeks iv) ADULT: 20 - 120 mg once daily adjusted according to the patient's response. CHILD 0.4 - 0.8 mg/kg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1129	Omeprazole 20 mg Capsule	A02BC01000 C1002XX	A/KK	Only for : i)Reflux oesophagitis ii)For eradication of Helicobacter pylori infection iii)Benign peptic ulcer not responding to conventional therapy iv)Zollinger-Ellison Syndrome	i) 20 - 80 mg 1 - 2 times daily up to 8 - 12 weeks ii) 20 mg twice daily in combination with any of the 2 antibiotics (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily or metronidazole 400 mg twice daily) for 1 - 2 weeks iii) 20 mg once daily for 4 - 6 weeks iv) ADULT: 20 - 120 mg once daily adjusted according to the patient's response. CHILD 0.4 - 0.8 mg/kg/day
1130	Omeprazole 40 mg Injection	A02BC01000 P4001XX	A*	i) Reflux oesophagitis, eradication of H. Pylori infection, benign peptic ulcer not responding to conventional therapy, Zollinger-Ellison Syndrome ii) Endoscopically confirmed peptic ulcer	i) 40 mg IV once daily when oral therapy is inappropriate ii) 40- 160 mg by IV in single or divided doses
1131	Ondansetron 2 mg/ml Injection	A04AA01110 P3001XX	A	i)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii)Postoperative nausea and vomiting	i)8 mg given by IV infusion over 15 minutes or by IM immediately before treatment followed by 8 mg orally every 12 hours for up to 5 days. CHILD 5 mg/m2 body surface IV over 15 minutes immediately before chemotherapy followed by 4 mg orally every 12 hours for up to 5 days ii)Prevention : 4 mg given by IV at induction of anaesthesia. CHILD over 2 years, 100mcg/kg (max 4mg) by slow IV before, during or after induction of anaesthesia. Treatment of postoperative: 4 mg by IM or slow. CHILD over 2 years 100 mcg/kg (maximum 4mg) by slow IV

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1132	Ondansetron 4 mg Tablet	A04AA01110 T1001XX	A	i)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii) Postoperative nausea and vomiting	i)8 mg 1 - 2 hours before treatment then 8 mg every 12 hours for up to 5 days. CHILD, treatment by infusion followed by 4 mg by mouth every 12 hours for up to 5 days ii)Prevention of postoperative nausea and vomiting, 16 mg 1 hour before anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg at intervals of 8 hours for a further 2 doses
1133	Ondansetron 8 mg Tablet	A04AA01110 T1002XX	A	i)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii) Postoperative nausea and vomiting	i)8 mg 1 - 2 hours before treatment then 8 mg every 12 hours for up to 5 days. CHILD, treatment by infusion followed by 4 mg by mouth every 12 hours for up to 5 days ii)Prevention of postoperative nausea and vomiting, 16 mg 1 hour before anaesthesia or 8 mg 1 hour before anaesthesia followed by 8 mg at intervals of 8 hours for a further 2 doses
1134	Ondansetron 8 mg/4ml Injection	A04AA01110 P3002XX	A	i)Prevention of nausea and vomiting induced by chemotherapy and radiotherapy ii)Postoperative nausea and vomiting	i)8 mg given by IV infusion over 15 minutes or by IM immediately before treatment followed by 8 mg orally every 12 hours for up to 5 days. CHILD 5 mg/m2 body surface IV over 15 minutes immediately before chemotherapy followed by 4 mg orally every 12 hours for up to 5 days ii)Prevention : 4 mg given by IV at induction of anaesthesia. CHILD over 2 years, 100mcg/kg (max 4mg) by slow IV before, during or after induction of anaesthesia. Treatment of postoperative: 4 mg by IM or slow. CHILD over 2 years 100 mcg/kg (maximum 4mg)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					by slow IV
1135	Oral Rehydration Salt	A07CA00905 F2101XX	C	Replacement of fluid and electrolytes loss in diarrhoea	ADULT: 200 - 400 ml (1 - 2 sachets) for every loose motion. CHILD: 200 ml (1 sachet) for every loose motion. In severe dehydration 100 ml/kg for 3 - 4 hours. INFANT: 1 - 1.5 times their usual feed volume (50 ml per stool for small infant)
1136	Orphenadrine 100 mg Tablet	M03BC01110 T1001XX	A	Painful muscle spasm	Initially 150 mg daily in divided doses. Maximum: 400 mg daily
1137	Ortho-phthalaldehyde 0.55% Solution	V07AV00000 L9909XX	A	High level disinfectant for sensitive endoscopes or semi-critical reusable medical devices	Manual reprocessing, at least 12 minute immersion time at room temperature (20 degree celcius) is required. Automatic endoscope reprocessor, at least 5 minute immersion time at a minimum of 25 degree celcius is required
1138	Oxaliplatin 50 mg Injection	L01XA03000 P4001XX	A*	Only for patients with colorectal cancer who: i) have relapsed within 6 months after the end of adjuvant chemotherapy with 5-fluorouracil-based regime ii) have progressive disease despite 5-fluorouracil chemotherapy for advanced disease iii) good performance status (WHO of 2 or less). The treatment must be given in a tertiary oncology centre or have clearance in writing by an oncologist	85 mg/m2 IV repeated every 2 weeks
1139	Oxybutynin Chloride 5 mg Tablet	G04BD04110 T1001XX	A*	For the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (ie urgency, frequency, urinary leakage, urge incontinence, dysuria)	ADULT: Initially 5 mg 2 - 3 times daily increased if necessary to maximum 5 mg 4 times daily. ELDERLY: Initially 2.5 - 3 mg twice daily, increased to 5 mg twice daily according to response and tolerance. CHILD over 5 years, neurogenic bladder instability: 2.5 - 3 mg twice daily increased to 5 mg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					twice daily to maximum 3 times daily.
1140	Oxycodone HCl 10 mg Immediate Release Capsules	N02AA05110 C1002XX	A*	i)As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain ii)As a step-down analgesic drug in post-operative procedures (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)	Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses
1141	Oxycodone HCl 10 mg Prolonged Release Tablet	N02AA05110 T5001XX	A*	Management of moderate to severe chronic cancer pain non-responsive to morphine (in accordance with WHO step-wise ladder of chronic pain management) [Initiated by Chronic Pain Specialist only]	ADULT, ELDERLY and CHILDREN more than 18 years, opioid-naive patients: 10 mg 12 hourly. Renal or hepatic impairment: 5 mg 12 hourly. Titrate dose carefully, as frequently as once a day if necessary, to achieve pain relief
1142	Oxycodone HCl 20 mg Immediate Release Capsules	N02AA05110 C1003XX	A*	i)As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain ii)As a step-down analgesic drug in post-operative procedures (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)	Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses
1143	Oxycodone HCl 20 mg Prolonged Release Tablet	N02AA05110 T5002XX	A*	Management of moderate to severe chronic cancer pain non-responsive to morphine (in accordance with WHO step-wise ladder of chronic pain management) [Initiated by Chronic Pain Specialist only]	ADULT, ELDERLY and CHILDREN more than 18 years, opioid-naïve patients: 10 mg 12 hourly. Renal or hepatic impairment: 5 mg 12 hourly. Titrate dose carefully, as frequently as once a day if necessary, to achieve pain relief
1144	Oxycodone HCl 40 mg Prolonged Release Tablet	N02AA05110 T5003XX	A*	Management of moderate to severe chronic cancer pain non-responsive to morphine (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)	Initially, 10 mg every 12 hours, increased if necessary according to severity of pain, usual max. 200 mg every 12 hours, but some patients may require higher doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1145	Oxycodone HCl 5 mg Immediate Release Capsules	N02AA05110 C1001XX	A*	i)As a second line drug in the management of opioid responsive, moderate to severe chronic cancer pain ii)As a step-down analgesic drug in post-operative procedures (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)	Initially 5 mg every 4 to 6 hours, increased if necessary according to severity of pain, usual max. 400 mg daily, but some patients may require higher doses
1146	Oxycodone Hydrochloride 10 mg/ml Injection	N02AA05110 P3001XX	A*	For the treatment of moderate to severe pain in patients with cancer and post-operative pain. For the treatment of severe pain requiring the use of a strong opioid.	Adults over 18 years: The following starting doses are recommended. A gradual increase in dose may be required if analgesia is inadequate or if pain severity increases. IV Bolus: Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for injections. Administer a bolus dose of 1 to 10 mg slowly over 1-2 minutes. Doses should not be administered more frequently than every 4 hours. IV Infusion: Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for injections. A starting dose of 2 mg/hour is recommended. IV PCA: Dilute to 1 mg/ml in 0.9% saline, 5% dextrose or water for injections. Bolus doses of 0.03 mg/kg should be administered with a minimum lock-out time of 5 minutes. SC Bolus: Use as 10 mg/ml concentration. A starting dose of 5 mg is recommended, repeated at 4-hourly intervals as required. SC Infusion: Dilute in 0.9% saline, 5% dextrose or water for injections if required. A starting dose of 7.5 mg/day is recommended in opioid naïve patients, titrating gradually according

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					to symptom control. Cancer patients transferring from oral oxycodone may require much higher doses (see below). Transferring patients between oral and parenteral oxycodone: The dose should be based on the following ratio: 2 mg of oral oxycodone is equivalent to 1 mg of parenteral oxycodone. It must be emphasised that this is a guide to the dose required.Inter-patient variability requires that each patient is carefully titrated to the appropriate dose.
1147	Oxycodone Hydrochloride 10mg and Naloxone Hydrochloride Dihydrate 5mg Tablet	N02AA55900 T1002XX	A*	The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipatio. For pain specialist only	Adults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1148	Oxycodone Hydrochloride 10mg Controlled Release Tablet	N02AA05110 T5301XX	A*	Management of moderate to severe chronic cancer pain non-responsive to morphine in accordance with WHO step-wise ladder of chronic pain management. (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)	Adults, elderly and children over 12 years: Usual starting dose for opioid-naive patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives, muscle relaxants or other CNS medicines) is 10mg 12 hourly. The dose should then be carefully titrated with longitudinal patient monitoring, assessing whether the pain is opioid responsive and providing the patient significant pain relief. Patients with renal or hepatic impairment: The recommended adult starting dose should be reduced by 1/3 to 1/2, and each patient should be titrated to adequate pain control according to their clinical situation.
1149	Oxycodone Hydrochloride 20mg and Naloxone Hydrochloride Dihydrate 10mg Tablet	N02AA55900 T1003XX	A*	The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipatio. For pain specialist only	Adults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1150	Oxycodone Hydrochloride 20mg Controlled Release Tablet	N02AA05110 T5302XX	A*	Management of moderate to severe chronic cancer pain non-responsive to morphine in accordance with WHO step-wise ladder of chronic pain management. (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)	Adults, elderly and children over 12 years: Usual starting dose for opioid-naive patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives, muscle relaxants or other CNS medicines) is 10mg 12 hourly. The dose should then be carefully titrated with longitudinal patient monitoring, assessing whether the pain is opioid responsive and providing the patient significant pain relief. Patients with renal or hepatic impairment: The recommended adult starting dose should be reduced by 1/3 to 1/2, and each patient should be titrated to adequate pain control according to their clinical situation.
1151	Oxycodone Hydrochloride 40mg and Naloxone Hydrochloride Dihydrate 20mg Tablet	N02AA55900 T1004XX	A*	The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipation. For pain specialist only	Adults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1152	Oxycodone Hydrochloride 40mg Controlled Release Tablet	N02AA05110 T5303XX	A*	Management of moderate to severe chronic cancer pain non-responsive to morphine in accordance with WHO step-wise ladder of chronic pain management (Initiated by palliative medicine physicians, oncologists, anaesthesiologists, haematologists and pain specialists only)	Adults, elderly and children over 12 years: Usual starting dose for opioid-naive patients or patients presenting with moderate to severe pain uncontrolled by weaker opioids (especially if they are receiving concurrent sedatives, muscle relaxants or other CNS medicines) is 10mg 12 hourly. The dose should then be carefully titrated with longitudinal patient monitoring, assessing whether the pain is opioid responsive and providing the patient significant pain relief. Patients with renal or hepatic impairment: The recommended adult starting dose should be reduced by 1/3 to 1/2, and each patient should be titrated to adequate pain control according to their clinical situation.
1153	Oxycodone Hydrochloride 5 mg and Naloxone Hydrochloride Dihydrate 2.5mg Tablet	N02AA55900 T1001XX	A*	The management of moderate to severe chronic pain unresponsive to non-narcotic analgesics. The opioid antagonist naloxone in the fixed combination is added to counteract and/or prevent opioid-induced constipation. For pain specialist only	Adults and paediatric patients from 18 years of age: The usual starting dose for opioid-naïve patients or patients presenting with moderate to severe chronic pain uncontrolled by weaker opioids is one tablet 10mg/5mg at 12 hourly intervals, or one tablet 5mg/2.5mg 12-hourly for patients with mild hepatic impairment and patients with renal impairment. The dose should then be cautiously titrated, as frequently as every 1-2 days if necessary, to achieve pain relief.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1154	Oxymetazoline HCl 0.01% Nasal Drops	R01AA05110 D6003XX	A*	Acute cold, paranasal sinusitis, syringitis, otitis media.	Newborn (up to 4 weeks): 1 drop. Infant (1 - 12 month): 1 - 2 drop. Doses to be given twice or three times daily
1155	Oxymetazoline HCl 0.025% (Paediatric) Nasal Drops	R01AA05110 D6001XX	A/KK	Acute colds, paranasal sinusitis and otitis media	1 - 2 drops twice daily in each nostril for child more than 1 year
1156	Oxymetazoline HCl 0.025% (Paediatric) Nasal Spray	R01AA05110 A4101XX	A	Acute colds, paranasal sinusitis and otitis media	2 - 3 sprays into each nostril twice daily for child more than 1 year
1157	Oxymetazoline HCl 0.05% (Adult) Nasal Drops	R01AA05110 D6002XX	A/KK	Acute colds, paranasal sinusitis and otitis media	1 - 2 drops twice daily in each nostril
1158	Oxymetazoline HCl 0.05% (Adult) Nasal Spray	R01AA05110 A4102XX	A	Acute colds, paranasal sinusitis and otitis media	2 - 3 sprays into each nostril twice daily, maximum 6 sprays per nostril/day
1159	Oxymetholone 50 mg Tablet	A14AA05000 T1001XX	A	Anaemias caused by the administration of myelotoxic drugs, treatment of AIDS-wasting syndrome	ADULT and CHILD: 1 - 5 mg/kg daily in one daily dose. Usual effective dose 1 - 2 mg/kg/day, given for a minimum trial of 3 - 6 months because response may be delayed
1160	Oxytetracycline with Polymyxin B Sulphate Eye Ointment	S01AA30947 G5101XX	B	Conjunctivitis, dacryocystitis, blepharoconjunctivitis, keratitis, trachoma, blepharitis, pre-op prophylaxis against infection	Apply into the conjunctival sac 4 times daily
1161	Oxytocin 10 units/ml Injection	H01BB02000 P3001XX	B	Induction of labour	IV: 0.5 - 1 milliunits/minute; gradually increase dose in increments of 1 - 2 milliunits/minute until desired contraction pattern is established; dose may be decreased after desired frequency of contractions is reached and labor has progressed to 5 - 6 cm dilation
1162	Oxytocin 5 units & Ergometrine Maleate 0.5 mg/ml Injection	G02AC01900 P3001XX	C+	i) Prevention and treatment of post partum haemorrhage ii) Management of third stage of labour	i) 1 ml IM may be repeated after 2 hours. Should not exceed 3 ml within 24 hours ii) For routine management of third stage of labour, 1 ml IM following delivery of the anterior shoulder or

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					immediately after delivery of the child
1163	Paclitaxel 100 mg/16.6 ml Injection	L01CD01000 P3002XX	A*	i) Treatment of recurrent breast cancer, after failure of anthracycline-based chemotherapy ii) Primary adjuvant therapy in advanced ovarian cancer in combination with cisplatin iii) Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in chemonaive patients in combination with platinum compounds	i) 175 mg/m2 IV over 3 hours every 3 weeks ii) 175 mg/m2 IV over 3 hour followed by cisplatin 75 mg/m2 in every 3 weeks or 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks iii) 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks
1164	Paclitaxel 30 mg/5 ml Injection	L01CD01000 P3001XX	A*	i) Treatment of recurrent breast cancer, after failure of anthracycline-based chemotherapy ii) Primary adjuvant therapy in advanced ovarian cancer in combination with cisplatin iii) Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in chemonaive patients in combination with platinum compounds	i) 175 mg/m2 IV over 3 hours every 3 weeks ii) 175 mg/m2 IV over 3 hour followed by cisplatin 75 mg/m2 in every 3 weeks or 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks iii) 135 mg/m2 IV over 24 hours followed by cisplatin 75 mg/m2 every 3 weeks
1165	Paliperidone 100 mg Prolonged Release Injection	N05AX13000 P2004XX	A*	Second or third line treatment of acute and maintenance treatment of schizophrenia in adults	Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq (this can be increased or decreased based on individual patient's tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle
1166	Paliperidone 150 mg Prolonged Release Injection	N05AX13000 P2005XX	A*	Second or third line treatment of acute and maintenance treatment of schizophrenia in adults	Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq (this can be increased or decreased based on individual patient's tolerability and/or efficacy). These monthly maintenace dose can be administered in

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					either the deltoid or gluteal muscle
1167	Paliperidone 3 mg Extended Released Tablet	N05AX13000 T5001XX	A*	Second or third line treatment of schizophrenia	ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min
1168	Paliperidone 50 mg Prolonged Release Injection	N05AX13000 P2002XX	A*	Second or third line treatment of acute and maintenance treatment of schizophrenia in adults	Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq (this can be increased or decreased based on individual patient's tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle
1169	Paliperidone 6 mg Extended Released Tablet	N05AX13000 T5002XX	A*	Second or third line treatment of schizophrenia	ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min
1170	Paliperidone 75 mg Prolonged Release Injection	N05AX13000 P2003XX	A*	Second or third line treatment of acute and maintenance treatment of schizophrenia in adults	Initiation: Deltoid IM 150 mg eq on Day1, followed by deltoid IM 100 mg eq on one week later. Maintenance: Monthly dose of 75 mg eq (this can be increased or decreased based on individual patient's tolerability and/or efficacy). These monthly maintenace dose can be administered in either the deltoid or gluteal muscle

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1171	Paliperidone 9 mg Extended Released Tablet	N05AX13000 T5004XX	A*	Second or third line treatment of schizophrenia	ADULT 6 mg once daily in the morning, adjusted if necessary; usual range 3 -12 mg daily. Renal impairment (creatinine clearance between 10-50 mL/min) 3 mg once daily. Avoid if creatinine clearance less than 10mL/min
1172	Palivizumab 100mg Injection	J06BB16000P 3001XX	A*	For the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in paediatric patients at high risk of RSV disease	15 mg/kg IM once a month during season of RSV risk
1173	Pamidronate Disodium 30 mg Injection	M05BA03520 P3001XX	A*	Hypercalcaemia of malignancy (tumour -induced hypercalcaemia)	Dose depends on the initial serum calcium levels. Doses range from a single infusion of 30 - 90 mg
1174	Pamidronate Disodium 90 mg Injection	M05BA03520 P3002XX	A*	Hypercalcaemia of malignancy (tumour -induced hypercalcaemia)	Dose depends on the initial serum calcium levels. Doses range from a single infusion of 30 - 90 mg
1175	Pancreatin 150 mg Capsule	A09AA02000 C1001XX	A/KK	Treatment of pancreatic exocrine insufficiency due to conditions such as cystic fibrosis, chronic pancreatitis and non-pancreatic diseases	Initially 1 - 2 capsules with each meal. May increase to 5 - 15 capsules daily
1176	Pancuronium Bromide 2 mg / ml Injection	M03AC01320 P3001XX	B	Muscle relaxant as an adjunct to general anaesthesia	ADULT: Initially 50 - 100 mcg/kg IV, then 10 - 20 mcg/kg as required. CHILD > 2 YEARS: Initially 60 - 100 mcg/kg then 10 - 20 mcg/kg. Intensive care, by IV, 60 mcg/kg every 60 - 90 minutes
1177	Pantoprazole 40 mg Injection	A02BC02000 P3001XX	A*	Bleeding peptic ulcer and acute stress ulceration	40 mg twice daily until oral administration can be resumed. CHILD not recommended

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1178	Pantoprazole 40 mg Tablet	A02BC02000 T1001XX	A*	i) Helicobacter pylori eradication ii) Peptic ulcer disease iii) Erosive and non-erosive reflux oesophagitis (GERD and NERD) iv) Zollinger-Ellison Syndrome v) Prevention of NSAID induced gastropathy	i) 40 mg twice daily in combination with any of the 2 antibiotics (Clarithromycin 500 mg twice daily, Amoxicillin 1 g twice daily or Metronidazole 400 mg twice daily) for 1-2 weeks ii) 40 mg daily for 2 - 4 weeks iii) 20 - 40 mg daily on morning for 4 weeks iv) Initially 80 mg daily, dose can be titrated up or down as needed. v) 20 mg daily. CHILD not recommended
1179	Papaverine HCl 120 mg/10ml Injection	A03AD01110 P3002XX	A	Relief of cerebral and peripheral ischaemia associated with arterial spasm and myocardial ischaemia complicated by arrhythmias	ADULT: 30 - 120 mg may be repeated every 3 hours as necessary. CHILD: 6 mg/kg daily in 4 divided doses
1180	Paracetamol 10mg/ml in 100ml Solution for IV Infusion	N02BE01000 P3101XX	A	Mild to moderate pain and pyrexia	Body Weight (BW) ≤ 10kg: 7.5mg/kg, max: 30mg/kg BW >10kg to ≤ 33kg: 15mg/kg, max 60mg/kg not exceeding 2g BW >33kg to ≤ 50kg: 15mg/kg, max 60mg/kg not exceeding 3g BW >50kg (with risk of hepatotoxicity): 1g, max 3g BW >50kg (without risk of hepatotoxicity): 1g, max 4g OR as in the product leaflet
1181	Paracetamol 120 mg/5 ml Syrup	N02BE01000 L9001XX	C+	Mild to moderate pain and pyrexia	CHILD: up to 1 year: 60 - 120 mg. 1 - 5 years: 120 - 240 mg. 6 - 12 years: 240 - 480 mg per dose. Repeat every 4 - 6 hours when necessary. Maximum of 4 doses in 24 hours
1182	Paracetamol 125 mg Suppository	N02BE01000 S2002XX	C+	Symptomatic relief of fever and post operative pain for paediatric cases	CHILD 1 - 5 years: 125 - 250 mg; 6 - 12 years: 250 - 500 mg; 3 - 11 months: 80 mg inserted every 4 - 6 hours if necessary, maximum 4 doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1183	Paracetamol 250 mg Suppository	N02BE01000 S2001XX	B	Symptomatic relief of fever and post operative pain for paediatric cases	CHILD 1 - 5 years : 125 - 250 mg; 6 - 12 years : 250 - 500 mg; 3 - 11 months : 80 mg inserted every 4 - 6 hours if necessary, maximum 4 doses in 24 hours. INFANTS under 3 months should not be given Paracetamol unless advised by doctor; a dose of 10 mg/kg (5 mg/kg if jaundiced) is suitable
1184	Paracetamol 500 mg Tablet	N02BE01000 T1001XX	C+	Mild to moderate pain and pyrexia	ADULT: 500 - 1000 mg every 4 - 6 hours, maximum of 4 g daily
1185	Paradichlorobenzene, Turpentine Oil and Chlorbutol Ear Drops	S02DA30900 D1001XX	B	Occlusion or partial occlusion of the external auditory meatus by soft wax or wax plug	Instill 5 drops into the ears
1186	Paraffin Mole Alba (White Soft Paraffin)	D02AC00000 G5001XX	C	Xerosis and ichthyosis	Apply to the affected area
1187	Paraffin Mole Flava	D02AC00000 G5002XX	C	Xerosis and ichthyosis	Apply to the affected area
1188	Paraldehyde Injection	N05CC05000 P3001XX	C	Status epilepticus	The usual intramuscular dose of paraldehyde for status epilepticus is 0.15 to 0.3 milliliter/kilogram, a moderate additional dose (0.05 milliliter/kilogram) may be necessary. The dose may be repeated in 2 to 6 hours and no more than 5 milliliters should be administered in one site
1189	Parecoxib Sodium 40mg Injection	M01AH0452 0P3001XX	A*	Management of post operative pain in the immediate post operative setting only	40 mg followed by 20 or 40 mg every 6 to 12 hours, as required. Use limited to two days only with a maximum dose of 80 mg/day. Reduce the initial dose by 50% in elderly less than 50 kg
1190	Pazopanib Hydrochloride 200 mg Tablet	L01XE11110T 1001XX	A*	For treatment of advanced and/or metastatic renal cell carcinoma (RCC)	Recommended dose is 800 mg ORALLY once daily. Should be taken without food (at least one hour before or two hours after meal). The dose should not

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					exceed 800 mg.
1191	Pazopanib Hydrochloride 400 mg Tablet	L01XE11110T 1002XX	A*	For treatment of advanced and/or metastatic renal cell carcinoma (RCC)	Recommended dose is 800 mg ORALLY once daily. Should be taken without food (at least one hour before or two hours after meal). The dose should not exceed 800 mg.
1192	Pefloxacin 400 mg Injection	J01MA03196 P3001XX	A	Infections due to gram-positive and gram-negative pathogens	Administered as a slow (one hour) intravenous perfusion, after diluting the contents of the 400 mg in 250 ml 5% glucose (two perfusions daily, morning and evening)
1193	Pefloxacin 400 mg Tablet	J01MA03000 T1001XX	A	i) Infections due to gram-positive and gram-negative pathogens ii) Uncomplicated UTI, chancroid gonococcal urethritis	ADULT i) 800 mg/day in 2 divided doses ii) 800 mg stat
1194	Pegfilgrastim Pre-filled Syringe 6 mg/0.6 ml (10 mg/ml)	L03AA13000 P5001XX	A*	Reduction in the duration of neutropenia, the incidence of febrile neutropenia and the incidence of infection as manifested by febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)	Adults (≥18 years): One 6 mg dose (a single pre-filled syringe) of pegfilgrastim for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy. Renal impairment: Pharmacokinetics of pegfilgrastim is not expected to be affected by renal impairment. Hepatic impairment: Pharmacokinetics of pegfilgrastim is not expected to be affected by hepatic impairment. Paediatric population: Insufficient data to recommend the use of pegfilgrastim in children and adolescents under 18 years of age.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1195	Peginterferon Alfa-2b 80 mcg Injection	L03AB10000 P5002XX	A*	Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis B	i) Combination therapy with Ribavirin: ADULT: SC 1.5 mcg/kg/week CHILD and ADOLESCENT (3-17 yr): SC 60 mcg/m2/week for 24-48 weeks Monotherapy: ADULT: SC 1 mcg/kg/week for 24 weeks to 1 year ii) SC 1.0 - 1.5 mcg/kg once weekly for 52 weeks
1196	Peginterferon Alpha-2a 135 mcg Prefilled Syringe	L03AB11000 P5002XX	A*	i) Chronic hepatitis C usually in combination with ribavirin (Important to establish hepatitis C virus (HCV) genotype and viral load where combination treatment is advocated) ii) For the treatment of both HbeAg-positive and HbeAg-negative chronic hepatitis B with compensated liver disease and evidence of viral replication who are not responding or tolerating oral antiviral therapy (Initiated by Hepatologist and Gasteroenterologist only)	i) 180 mcg weekly SC with ribavirin 800 mg daily for 24 weeks in patients in genotype 2 and 3 and 180 mcg weekly SC with ribavirin (1000 - 1200 mg) for 48 weeks for those with genotype 1 and 4. 135 mg dose may be used for patients who cannot tolerate the 180 mcg dose ii) 180 mcg weekly SC for 48 weeks
1197	Peginterferon Alpha-2a 180 mcg Prefilled Syringe	L03AB11000 P5001XX	A*	i) Chronic hepatitis C usually in combination with ribavirin (Important to establish hepatitis C virus (HCV) genotype and viral load where combination treatment is advocated) ii) For the treatment of both HbeAg-positive and HbeAg-negative chronic hepatitis B with compensated liver disease and evidence of viral replication who are not responding or tolerating oral antiviral therapy (Initiated by Hepatologist and Gasteroenterologist only)	i) 180 mcg weekly with ribavirin 800 mg daily for 24 weeks in patients in genotype 2 and 3 and 180 mcg weekly with ribavirin (1000 - 1200 mg) for 48 weeks for those with genotype 1 and 4. 135 mg dose may be used for patients who cannot tolerate the 180 mcg dose ii) 180 mcg subcutaneously once a week for 48 weeks
1198	Pegylated Interferon Alpha-2b 100 mcg Injection	L03AB10000 P5003XX	A*	Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis B	i) Monotherapy: SC at a dose of 0.5 or 1 mcg/kg once weekly for at least 6 months. Combination therapy: 1.5mcg/kg/week SC in combination with ribavirin capsules. ii) 1-1.5 mcg/kg once weekly for at least 24 weeks and up to 52

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					weeks.
1199	Pegylated Interferon Alpha-2b 120 mcg Injection	L03AB10000 P5004XX	A*	Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis B	i) Monotherapy: SC at a dose of 0.5 or 1 mcg/kg once weekly for at least 6 months. Combination therapy: 1.5mcg/kg/week SC in combination with ribavirin capsules. ii) 1-1.5 mcg/kg once weekly for at least 24 weeks and up to 52 weeks.
1200	Pegylated Interferon Alpha-2b 150 mcg Injection	L03AB10000 P5005XX	A*	Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis B	i) Monotherapy: SC at a dose of 0.5 or 1 mcg/kg once weekly for at least 6 months. Combination therapy: 1.5mcg/kg/week SC in combination with ribavirin capsules. ii) 1-1.5 mcg/kg once weekly for at least 24 weeks and up to 52 weeks.
1201	Pegylated Interferon Alpha-2b 50 mcg Injection	L03AB10000 P5001XX	A*	Treatment of: i) Chronic Hepatitis C ii) Chronic Hepatitis B	i) Monotherapy: SC at a dose of 0.5 or 1 mcg/kg once weekly for at least 6 months. Combination therapy: 1.5mcg/kg/week SC in combination with ribavirin capsules. ii) 1-1.5 mcg/kg once weekly for at least 24 weeks and up to 52 weeks.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1202	Pegylated Liposomal Doxorubicin HCl 20 mg/vial	L01DB01110 P3003XX	A*	i) For patients with platinum-resistant ovarian cancer where the disease relapses within 6 months after completion of the initial platinum-based chemotherapy ii) For patients with platinum-sensitive ovarian cancer where the disease responds to first-line platinum-based therapy but relapses 12 months or more after completion of the initial platinum based chemotherapy. As third line therapy for very selected patients. (Gyne Oncology Specialist only)	50 mg/m2 IV every 4 weeks for as long as the disease does not progress & patient continues to tolerate treatment.For doses <90 mg: dilute in 250 ml Dextrose 5 % in Water. For doses >90 mg: dilute in 500 ml Dextrose 5 % in Water. To minimize the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. Renal impairment: No dose adjustment required in patients with creatinine clearance 30-156 ml/min, no pharmacokinetic data are available in patients with creatinine clearance of less than 30 ml/min. Hepatic impairment: At initiation of therapy: Bilirubin 1.2 - 3.0 mg/dl, the first dose is reduced by 25 %, Bilirubin > 3.0 mg/dl, the first dose is reduced by 50 %.
1203	Pemetrexed Disodium 100 mg Injection	L01BA04016 P3002XX	A*	In combination with Cisplatin for the 2nd line treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) other than predominantly squamous cell histology	Initial therapy 500 mg/m(2) IV over 10 minutes on day 1, followed 30 minutes later by cisplatin 75 mg/m(2) infused IV over 2 hours; repeat cycle every 21-days. Prior chemotherapy : 500 mg/m(2) IV, as a single-agent, over 10 minutes on day 1 of each 21-day cycle
1204	Pemetrexed Disodium 500 mg Injection	L01BA04016 P3001XX	A*	In combination with Cisplatin for the 2nd line treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) other than predominantly squamous cell histology	Initial therapy 500 mg/m (2) IV over 10 minutes on day 1, followed 30 minutes later by cisplatin 75 mg/m(2) infused IV over 2 hours; repeat cycle every 21-days. Prior chemotherapy : 500 mg/m(2) IV, as a single-agent, over 10 minutes on day 1 of each 21-day cycle

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1205	Pentamidine Isethionate 300 mg Injection	P01CX01198 P3001XX	A*	Only for the treatment of pneumonia due to Pneumocytosis carinii	4 mg/kg once daily by slow IV infusion for at least 14 days
1206	Pentoxifylline 400 mg Tablet	C04AD03000 T1001XX	A/KK	Peripheral vascular disease	400 mg 2 - 3 times daily
1207	Peracetic Acid and Hydrogen Peroxide	V07AV00000 L9906XX	A	High level disinfectant or sterilant for heat labile endoscopes	Immersion time based on manufacturer recommendation
1208	Perindopril 4 mg and Indapamide 1.25 mg Tablet	C09BA04900 T1001XX	A/KK	Essential hypertension, for patients whose blood pressure is insufficiently controlled by perindopril alone.	One tablet daily, preferably taken in the morning and before a meal.
1209	Perindopril 4 mg Tablet	C09AA04000 T1001XX	B	i) Hypertension ii) Congestive heart failure iii) Stable coronary artery disease	i) 4 mg as single dose, may be increased to a single 8 mg dose. ELDERLY: Start treatment with 2 mg dose. In renal insufficiency, dose should be adapted according to creatinine clearance ii) Single starting oral dose of 2 mg should be increased to a single 4 mg once BP acceptability has been demonstrated iii) 4 mg once daily for 2 weeks, may be increased to 8 mg once daily. ELDERLY: 2 mg once daily for 1 week, then 4 mg once daily for the following week, may be increased up to 8 mg once daily
1210	Perindopril 8 mg Tablet	C09AA04000 T1002XX	B	i) Hypertension ii) Congestive heart failure iii) Stable coronary artery disease	i) 4 mg as single dose, may be increased to a single 8 mg dose. ELDERLY: Start treatment with 2 mg dose. In renal insufficiency, dose should be adapted according to creatinine clearance ii) Single starting oral dose of 2 mg should be increased to a single 4 mg once BP acceptability has been demonstrated iii) 4 mg once daily for 2 weeks, may be increased to 8 mg once daily. ELDERLY: 2 mg once daily for 1 week, then 4 mg once daily for the following

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					week, may be increased up to 8 mg once daily
1211	Peritoneal Dialysis Solution (1.5% Dextrose 5 Litres)	B05DB00908 H2001XX	B	For chronic renal disease requiring dialysis and for acute renal failure	Dose depending on clinical cases
1212	Peritoneal Dialysis Solution (4.25% Dextrose, 2 Litres)	B05DB00908 H2002XX	B	For chronic renal disease requiring dialysis and for acute renal failure	Dose depending on clinical cases
1213	Peritoneal Dialysis with 7.5% Icodextrin Solution	B05DB00908 H2003XX	A*	As a once replacement for a single glucose exchange as part of a continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) regimen for the treatment of chronic renal failure, particularly for patients who have lost ultra filtration on glucose solutions	Administered as a single daily exchange for the long dwell in continuous ambulatory peritoneal dialysis or automated peritoneal dialysis. The recommended dwell time is 8 to 16 hours
1214	Permethrin 5% w/v Lotion	P03AC04000 L6001XX	A*	Treatment of scabies	Apply thoroughly to all body parts. Leave on for 8 - 14 hours. Not recommended for children less than 2 years old
1215	Perphenazine 4 mg Tablet	N05AB03000 T1001XX	B	Schizophrenia and other psychoses	ADULT: Initially 4 mg 3 times daily adjusted according to response, maximum 24 mg daily. ELDERLY: 1/4 to 1/2 adult dose. CHILD not recommended
1216	Pethidine HCl 100 mg/2 ml Injection	N02AB02110 P3002XX	B	For relief of moderate to severe pain (medical and surgical), pre-anaesthetic medication and obstetrical analgesia	ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
1217	Pethidine HCl 50 mg/ml Injection	N02AB02110 P3001XX	B	For relief of moderate to severe pain (medical and surgical), pre-anaesthetic medication and obstetrical analgesia	ADULT: 0.5 - 2 mg/kg SC or IM every 3 - 4 hours if necessary. CHILD: by IM 0.5 - 2 mg/kg. Up to 1 year : 1- 2 mg/kg weight IM, 1 - 5 years : 12.5 - 25 mg IM, 6 - 12 years: 25 - 50 mg IM
1218	Phenobarbitone 30 mg Tablet	N03AA02000 T1002XX	B	Epilepsy	ADULT: 60 - 180 mg daily on. CHILD: Up to 8 mg/kg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1219	Phenobarbitone Sodium 200 mg/ml Injection	N03AA02520 P3001XX	B	Status Epilepticus	ADULT: 10 mg/kg IV at a rate of not faster than 100 mg/minute. Initial maximum dose does not exceeding 1 gm. Daily maintenance of 1 - 4 mg/kg/day. CHILD: 10 - 20 mg/kg/dose loading dose, followed by repeated doses at 10 mg/kg/dose (strictly in ICU setting). Maintenance 5 - 8 mg/kg/day
1220	Phenol 80% w/w Liquid	D08AE03000 L5001XX	C	As disinfectant	Use in various dilutions
1221	Phenoxybenzamine HCl 100 mg/2 ml Injection	C04AX02110 P3001XX	A*	Hypertensive episodes associated with phaeochromocytoma	1 mg/kg daily over at least 2 hours into large vein. Do not repeat within 24 hours.
1222	Phenoxymethyl Penicillin 125 mg Tablet	J01CE02500T 1001XX	C	i) Treatment or prophylaxis of infections caused by susceptible organisms ii) Prophylactic, rheumatic fever	i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day
1223	Phenoxymethyl Penicillin 125 mg/5 ml Syrup	J01CE02500F 2101XX	C	Treatment or prophylaxis of infections caused by susceptible organisms	CHILD: Up to 1 year: 62.5 mg 6 hourly; 1 - 5 years: 125 mg 6 hourly; 6 - 12 years: 250 mg 6 hourly
1224	Phenoxymethyl Penicillin 250 mg Tablet	J01CE02500T 1002XX	C	i) Treatment or prophylaxis of infections caused by susceptible organisms ii) Prophylactic, rheumatic fever	i) ADULT: 500 - 750 mg 6 hourly.CHILD; up to 1 year: 62.5 mg, 1 - 5 years: 125 mg, 6 - 12 years: 250 mg 6 hourly ii) ADULT: 125 - 250 mg twice daily. CHILD: 25 - 50 mg/kg in divided doses every 6 - 8 hours. Maximum: 3 g/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1225	Phenylephrine HCl 2.5% Eye Drops	S01FB01110 D2001XX	B	For pupillary dilation in uveitis, for refraction without cyclopegic. For fundoscopy and other diagnostic procedures	Mydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution, repeated in one hour if necessary. Chronic mydriasis: 1 drop of a 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior synechiae (treatment) or synechiae, posterior (prophylaxis): 1 drop of a 2.5% or 10% solution, repeated in one hour if necessary, not to exceed three times a day. Treatment may be continued the following day, if necessary
1226	Phenylephrine HCl 10% Eye Drops	S01FB01110 D2002XX	B	For pupillary dilation in uveitis, for refraction without cyclopegic. For fundoscopy and other diagnostic procedures	Mydriasis and vasoconstriction: 1 drop of 2.5% or 10% solution, repeated in one hour if necessary. Chronic mydriasis: 1 drop of a 2.5% or 10% solution 2 - 3 times a day. Uveitis with posterior synechiae (treatment) or synechiae, posterior (prophylaxis): 1 drop of a 2.5% or 10% solution, repeated in one hour if necessary, not to exceed three times a day. Treatment may be continued the following day, if necessary
1227	Phenytoin Sodium 100 mg Capsule	N03AB02520 C1002XX	B	Epilepsy	ADULT and CHILD more than 6 years: 300-400 mg/day in 3 - 4 divided doses before meals. Maximum: 600 mg/day. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1228	Phenytoin Sodium 125 mg/5ml Suspension	N03AB02520 L8001XX	B	Epilepsy	ADULT: Patients with no previous treatment may be started on 1 teaspoonful or 5 mL (125 milligrams) 3 times daily. It is then individualized to the patient. An increase to 5 teaspoonfuls (625 milligrams) may be made if necessary. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day. Children over 6 years and adolescents may require the minimum adult dose (300mg/day).
1229	Phenytoin Sodium 30 mg Capsule	N03AB02520 C1001XX	B	Epilepsy	ADULT and CHILD more than 6 years: 300-400 mg/day in 3 - 4 divided doses before meals. Maximum: 600 mg/day. CHILD: Initially 5 mg/kg/day in 2 - 3 divided doses. Maintenance: 4 - 8 mg/kg/day. Maximum: 300 mg/day
1230	Phenytoin Sodium 50mg/ml Injection	N03AB02520 P3001XX	B	Status epilepticus	i) Status epilepticus: ADULT 10 - 15 mg/kg by slow IV. Maximum 50 mg/minute. Maintenance: 100 mg orally/IV every 6 - 8 hours. CHILD 15 - 20 mg/kg by slow IV. Maximum: 1 - 3 mg/kg/minute ii) Neurosurgery 100 - 200 mg IM approximately at 4 hourly interval
1231	Phosphate Solution containing Sodium Acid Phosphate 1.936 g /15 ml	B05XA09902 L5001XX	A	For supplemental ionic phosphorus for correction of hypophosphataemia	According to the needs of the patient
1232	Phyllanthus Niruri Extract 250 mg Capsule	HA05BA5999 C1001XX	A/KK	Liver tonic	2 capsules to be taken orally, 3 times a day, before or after meals
1233	Pilocarpine 1% Eye Drops	S01EB01110 D2001XX	B	Miotics in chronic open-angle glaucoma	1 drop 1 - 4 times a day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1234	Pilocarpine 2% Eye Drops	S01EB01110 D2002XX	B	Miotics in chronic open-angle glaucoma	1 drop 1 - 4 times a day
1235	Pilocarpine 4% Eye Drops	S01EB01110 D2003XX	B	Miotics in chronic open-angle glaucoma	1 drop 1 - 4 times a day
1236	Piperacillin 4 g & Tazobactam 500 mg Injection	J01CR05961P 3001XX	A*	Febrile neutropenia, lower respiratory tract infection and severe sepsis	Adult and children more than 12 years: 4.5g 6 hourly, for neutropenia adult and children more than 50kg: 4.5g 6 hourly. Children less than 50kg: 90mg/kg 6 hourly
1237	Piperacillin Sodium 4 g Injection	J01CA12520P 4002XX	A	Infections due to Pseudomonas aeruginosa	ADULT: 100 - 150 mg/kg IM/IV in divided doses. Increase to 200 - 300 mg/kg in severe infections & at least 16 g in life-threatening infections. Single dose over 2 g: IV route only. Maximum: 24 g/day. CHILD: 50-75 mg/kg/dose every 6 - 8 hourly
1238	Piracetam 1 g Injection	N06BX03000 P3001XX	A*	Treatment of cerebral functional impairment	30 - 160 mg/kg/day orally or parenterally 2 times daily or 3 to 4 times daily. Maximum: 24 g/day
1239	Piracetam 1.2 g Tablet	N06BX03000 T1001XX	A*	Mild cognitive impairment, post concussional head syndrome, head injury disorder, chronic vertigo and myoclonus	Initially 7.2 g daily in 2 - 3 divided doses, increased according to response by 4.8 g daily every 3 - 4 days to maximum of 20 g daily. CHILD under 16 years not recommended
1240	Piracetam 20% Solution	N06BX03000 L5001XX	A*	Children with learning disability, progressive myoclonic epilepsy and hypoxia	30 - 160 mg/kg/day orally. To be given 2 times daily or 3 - 4 times daily. Maximum 24 g/day
1241	Piribedil 50 mg Tablet	N04BC08000 T5001XX	A*	Parkinson disease	As monotherapy: 150 - 250 mg as 3 - 5 divided doses daily. As combination with L-dopa therapy: 50 - 150 mg daily (50 mg per 250 mg of L-dopa)
1242	Piroxicam 10 mg Capsule	M01AC01000 C1001XX	A/KK	i) Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis ii) Acute musculoskeletal disorders iii) Acute gout	i) 20 mg daily, maintenance 10 - 30 mg daily, in single or divided doses ii) 40 mg daily in single or divided doses for 2 days, then 20 mg daily for 7 - 14 days iii) 40 mg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					initially, then 40 mg daily in single or divided doses for 4 - 6 days
1243	Pizotifen 0.5 mg Tablet	N02CX01253 T1001XX	B	Prophylactic treatment of vascular headache	Starting with 0.5mg daily, the dosage should be progressively increased. The average maintenance dosage is 1.5mg daily in divided doses or as a single dose at night. Max dose: 4.5 mg/day and 3 mg/dose. Child: >2 yr: Up to 1.5 mg daily in divided doses. Max dose: 1 mg/dose.
1244	Pneumococcal Vaccine (Polyvalent)	J07AL01000P 3001XX	A	Prevention of pneumococcal infections in high risk subjects from the age of 2 years including patient with a history of splenectomy or scheduled splenectomy	Primary injection: 1 single injection (0.5 ml) only. Booster: Must not be given within 5 years except in very high risk patient who received the vaccine while under immunosuppressive treatment
1245	Podophyllum 10 - 20% Paint	D06BB04000 L7001XX	B	External anogenital warts	Apply 2 - 3 drops carefully to lesion after protecting surrounding area with vaseline. Wash off after 6 hours or if feel burning sensation and repeat 2 - 3 times weekly or once weekly
1246	Policresulen 360 mg/g Concentrate	G01AX03900 L9901XX	A	Local treatment of cervical and vaginal inflammation and tissue damage eg. discharge due to bacterial, trichomonal and fungal infections, protrusions of endocervical mucosa (erosion), haemostasis following biopsy or excision of uterine polyps	For cauterization, undiluted once or twice weekly whilst for vaginal douches, to be diluted 1 part concentrate to 5 parts of water
1247	Poliomyelitis Oral Live Vaccine (10 Doses)	J07BF02000D 5001XX	C+	Immunisation against poliomyelitis	Two drops (0.1 ml). Primary immunization: 1 oral dose at 3,4 & 5 month of age. Booster doses at 1-4 years & 7 years.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1248	Polycitra Syrup	A12BA02955 L9001XX	C	For treatment of calcium and uric acid stones	The usual dose of potassium citrate is 30 - 60 mEq/day orally in 3 or 4 doses with meals or within 30 minutes after meals. ADULT: 15 ml 3 times daily well diluted with water. CHILD 5-15 ml 3 times daily, after meals and at bedtime.
1249	Polyethylene Glycol /Macrogol 4000 Powder	A06AD15000 F2101XX	A	Bowel cleansing prior to colonoscopy, radiological examination or colonic surgery. Suitable for patients with heart failure or renal failure	1 sachet dissolved in 1 L of water. 2-3 L of oral solution are required. When morning surgery is planned, the oral solution is given in the late afternoon the day prior. If surgery is scheduled in afternoon, the oral solution should be given on the same day for ingestion to be completed three hours before surgery
1250	Polymyxin B Sulphate 10,000 U, Neomycin Sulphate 5 mg and Hydrocortisone 10 mg Ear Drops	S02CA03991 D1001XX	B	Treatment of bacterial infection and inflammation of the external auditory meatus	3 drops 3 - 4 times daily. External auditory meatus and canal to be thoroughly cleansed and dried before each application but soap should not be used as the antibiotics may be inactivated by it
1251	Posaconazole 40mg/ml Oral Suspension	J02AC04000L 8001XX	A*	Prophylaxis of invasive fungal infections in the following adult patients: i. Patient receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections. ii. Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Prophylaxis of invasive fungal infections: 200mg (5ml) three times a day. The duration of therapy is based on recovery from neutropenia or immunosuppression. For patients with acute myelogenous leukemia or myelodysplastic syndromes, prophylaxis with posaconazole should start several days before the anticipated onset of neutropenia and continue 7 days after the neutrophil count rises above 500cell/mm3. Increasing the total daily dose above

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					800mg does not further enhance the exposure to posaconazole.
1252	Potassium Chloride 0.15% w/v & Sodium Chloride 0.9% w/v Injection	A06AD10921 L9902XX	B	Prevention and treatment of potassium, sodium and chloride depletion	Dosage depends on the age, weight, clinical and biological (acid-base balance) conditions of the patient and concomitant therapy. Maximum recommended dose of potassium is 2 to 3 mmol/kg/24hr
1253	Potassium Chloride 1 g/10 ml Injection	B05XA01100 P3001XX	B	For the correction of severe hypokalaemia and when sufficient potassium cannot be taken by mouth	By slow IV infusion depending on the deficit or the daily maintenance requirements. 1 g diluted in 500 ml normal saline or glucose and given slowly over 2 - 3 hours
1254	Potassium Chloride 1 g/15 ml Mixture	A12BA01100 L2101XX	C	Potassium depletion	1 g once or twice daily until serum potassium is restored
1255	Potassium Chloride 600 mg SR Tablet	A12BA01100 T5001XX	B	For the treatment and specific prevention of hypokalaemia	ADULT: 2 - 3 tablets daily. Severe deficiency: 9 - 12 tablets daily or according to the needs of the patient
1256	Potassium Citrate 3 g/10 ml and Citric Acid Mixture	A12BA02955 L2101XX	C	For systemic or urine alkalinization	ADULT: 15-30 ml well diluted with water. CHILD up to 1 year: 2.5 ml 3 times daily; 1 - 5 years: 5 ml 3 times daily; 6 - 12 years: 10 ml 3 times daily. To be taken well diluted with water, after meals and at bedtime.
1257	Potassium Dihydrogen Phosphate Injection	B05XA06170 P3001XX	A	For treatment of hypophosphataemia	Up to 10mmol phosphate administered over 12 hours
1258	Potassium Iodide Mixture	H03CA00200 L2101XX	B	Pre-operative management of hyperthyroidism and thyrotoxicosis	ADULT and CHILD: 50 - 250 mg 3 times daily
1259	Potassium Permanganate 1:10,000 Solution	D08AX06362 L9901XX	C+	Cleansing and deodorising suppurative eczematous reactions and wounds	As soaks or wet dressing 1 - 3 times daily or as required
1260	Potassium Permanganate 1:20,000 Solution	D08AX06362 L9902XX	C	Cleansing and deodorising suppurative eczematous reactions and wounds	As a bath once to twice daily or as required

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1261	Povidone Iodine 10% (equivalent to 1% iodine) Solution	D08AG02000 L9902XX	B	Skin operation prior to surgery, in cleansing open wounds, as an antiseptic for operative wounds infections	To be applied undiluted in pre-operative skin disinfection and general antisepsis.
1262	Povidone Iodine 7.5% (equivalent to 0.75% iodine) Scrub	D08AG02000 L9901XX	B	As preoperative scrub for hands and skin	Spread 5 ml over both hands and rub thoroughly for about 5 minutes. Rinse thoroughly. Repeat if desired. Pre-operative use on patient: Apply scrub and rub thoroughly for about 5 minutes. Rinse off using a sterile gauze saturated with water
1263	Pralidoxime 25 mg/ml Injection	V03AB04000 P3002XX	B	Antidote in the treatment of organophosphorus insecticide poisoning and in the control of overdosage by anticholinergic drugs used in the treatment of myasthenia gravis	Adult: Used in combination with atropine. Admin atropine via IM/IV inj and repeat as needed until patient shows signs of atropine toxicity. Maintain atropinisation for at least 48 hr. As soon as the effects of atropine are observed, 1-2 g of pralidoxime (chloride, iodide or mesilate) may be given via IM/IV inj. Repeat dose after 1 hr, then every 8-12 hr, if necessary. In severe poisoning, continuous infusion of 200-500 mg/hr may be given, titrated according to response. Alternatively, pralidoxime chloride may be given at an initial dose of 30 mg/kg via IV infusion over 20 minutes or IV inj over 5 minutes, followed by IV infusion at 8 mg/kg/hr. Max: 12 g/24 hr. Child: As mesilate: 20-60 mg/kg. Renal impairment: Dose adjustment may be required.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1264	Pramipexole Dihydrochloride 0.125 mg Tablet	N04BC05110 T1001XX	A*	Treatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa	Dose escalation: 0.125 mg 3 times daily on week 1 then 0.25 mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3. Increase by 0.75 mg at weekly intervals if needed up to maximum of 4.5 mg/day. Patient on levodopa: Reduce dose. Renal impairment: In patient with creatinine clearance < 20ml/min, the daily dose of pramipexole should be started at 0.125 mg daily instead of 0.25mg and the maximum dose should not > 1.5 mg daily
1265	Pramipexole Dihydrochloride 1 mg Tablet	N04BC05110 T1002XX	A*	Treatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa	Dose escalation: 0.125 mg 3 times daily on week 1 then 0.25 mg 3 times daily week 2 then 0.5 mg 3 times daily on week 3. Increase by 0.75 mg at weekly intervals if needed up to maximum of 4.5 mg/day. Patient on levodopa: Reduced dose. Renal impairment: In patient with creatinine clearance < 20ml/min, the daily dose of pramipexole should be started at 0.125 mg daily instead of 0.25mg and the maximum dose should not > 1.5 mg daily
1266	Pramipexole Dihydrochloride Extended Release 0.375mg Tablet	N04BC05110 T5001XX	A	Treatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa	Dose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week 2, 1.5 mg/day on week 3. Increase by 0.75 mg at weekly intervals if needed up to a max of 4.5 mg/day. Patient on l-dopa: reduce dose. Renal Impairment: CrCl 30-50 mL/min Initially 0.375 mg every other day. May be increased by 0.375 mg at weekly intervals to max 2.25 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1267	Pramipexole Dihydrochloride Extended Release 1.5mg Tablet	N04BC05110 T5003XX	A	Treatment for signs and symptoms of advanced idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa	Dose escalation: 0.375 mg/day on week 1, 0.75 mg/day on week 2, 1.5 mg/day on week 3. Increase by 0.75 mg at weekly intervals if needed up to a max of 4.5 mg/day. Patient on l-dopa: reduce dose. Renal Impairment: CrCl 30-50 mL/min Initially 0.375 mg every other day. May be increased by 0.375 mg at weekly intervals to max 2.25 mg/day
1268	Prasugrel HCl 10 mg Tablet	B01AC22110 T1002XX	A*	Co-administered with aspirin, is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndromes who are to be managed with percutaneous coronary intervention (PCI) as follows: STEMI with or without diabetes, UA and NSTEMI with diabetes, age <75yrs old, weight >60kg, without history of TIA stroke and clinically suspected clopidogrel resistance subset. (Only to be used in Cardiology Centre as third line treatment/ adjunctive therapy).	Initiate treatment with a single 60mg oral loading dose. Continue at 10mg/5mg once daily with or without food. Patients should also take aspirin (75 mg - 325 mg) daily.
1269	Pravastatin Sodium 20 mg Tablet	C10AA03520 T1001XX	A/KK	Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy. In health clinics, Pravastatin is restricted to HIV patients on HAART.	10 - 20 mg once daily. Maximum: 40 mg daily
1270	Prazosin HCl 1 mg Tablet	C02CA01110 T1001XX	B	Hypertension	Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1271	Prazosin HCl 2 mg Tablet	C02CA01110 T1002XX	B	Hypertension	Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily
1272	Prazosin HCl 5 mg Tablet	C02CA01110 T1003XX	B	Hypertension	Initially 0.5 mg 2 - 3 times daily, the initial dose on retiring to bed at night; increased to 1 mg 2 - 3 times daily after 3 - 7 days: further increased if necessary to maximum 20 mg daily
1273	Pre/Post Natal Vitamin & Mineral Capsule	A11AA03903 C1001XX	C+	Vitamin and mineral supplement for use during pregnancy and lactation	1 capsule daily or based on individual requirements
1274	Pre/Post Natal Vitamin & Mineral Tablet	A11AA03903 T1001XX	C+	Vitamin and mineral supplement for use during pregnancy and lactation	1 tablet daily or based on individual requirements
1275	Prednisolone 3 mg/5 ml Syrup	H02AB06000 L9001XX	B	i) Replacement therapy for primary and secondary adrenocortical insufficiency ii) Adrenogenital syndrome iii) Other therapy	i) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single daily
1276	Prednisolone 5 mg Tablet	H02AB06000 T1001XX	B	i) Replacement therapy for primary and secondary adrenocortical insufficiency ii) Adrenogenital syndrome iii) Other therapy	i) 5 - 25 mg daily in divided doses ii) 10 - 20 mg/m2 body surface daily in divided doses iii) ADULT: 5 - 60 mg daily. CHILD: 0.5 - 2 mg/kg/day in divided doses every 6 - 8 hours or as a single daily
1277	Pregabalin 150 mg Capsules	N03AX16000 C1002XX	A*	i) Second line treatment of neuropathic pain in patients who do not response to first line drugs ii) Fibromyalgia	i) Initially, 75 mg twice daily. May be increased to 150 mg twice daily after 3-7 days. Max: 600 mg/day after an additional 7-day interval ii) Initially, 75 mg twice daily. May be increased to 150 mg twice daily within 1 week or 225 mg twice daily. Max: 450 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1278	Pregabalin 75 mg Capsule	N03AX16000 C1001XX	A*	i) Second line treatment of neuropathic pain in patients who do not response to first line drugs ii) Fibromyalgia	i) Initially, 75 mg twice daily. May be increased to 150 mg twice daily after 3-7 days. Max: 600 mg/day after an additional 7-day interval ii) Initially, 75 mg twice daily. May be increased to 150 mg twice daily within 1 week or 225 mg twice daily. Max: 450 mg/day
1279	Primaquine 7.5 mg base Tablet	P01BA03162 T1001XX	B	i) Treatment of malaria ii) Prophylaxis together with a schizonticide such as chloroquine	i) 15 mg daily for 14 days, increased to higher doses or longer course if resistance in P.vivax occurs. ii) ADULT: 30 mg once weekly. CHILD: 0.5 mg once weekly Child: 250mcg/kg daily for 14 days. Should be taken with food. Take with meals to avoid GI discomfort.
1280	Primidone 250 mg Tablet	N03AA03000 T1001XX	B	Epilepsy	ADULT: Initially 1 tablet daily in the evening, increasing by 1 tablet every 4 - 7 days to 3 - 4 tablets daily. Maximum dosage: 1.5 g daily in divided doses. CHILD: 6 - 8 years: Up to 1/2 adult dose
1281	Probenecid 500 mg Tablet	M04AB01000 T1001XX	A	Hyperuricemia associated with gout and gouty arthritis (for cases allergic to allopurinol or serum uric acid not controlled by allopurinol alone)	500 mg to 1000 mg twice daily
1282	Procaine Benzylpenicillin Aqueous 3 mega units (3 g) Injection	J01CE09702P 4001XX	B	Treatment of infections due to Penicillin G-sensitive organisms	ADULT: 300,000 - 900,000 units (300 - 900 mg) IM daily. CHILD: Up to 1 year: 150 mg IM daily. 1 - 5 years: 300 mg IM daily. 6 - 12 years: 600 mg IM daily
1283	Procaine Penicillin Fortified 4 MU Injection	J01CE09702P 4002XX	B	Treatment of infections due to Penicillin G-sensitive organisms	ADULT: 300,000 - 900,000 units (300 - 900 mg) IM daily. CHILD: Up to 1 year: 150 mg IM daily. 1 - 5 years: 300 mg IM daily. 6 - 12 years: 600 mg IM daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1284	Procarbazine HCl 50 mg Capsule	L01XB01110 C1001XX	A	Lymphomas	Adult: Monotherapy: Initially, 50 mg/day, increased by 50 mg daily to 250-300 mg daily in divided doses. Continue doses until max response is achieved or appearance of signs of toxicity. Maintenance: 50-150 mg/day or 1-2 mg/kg daily until a cumulative dose of at least 6 g. Combination Therapy: 100 mg/m2 on days 1-14 of each 4- or 6-wk cycle. Child: Initially, 50 mg/m2 daily, up to 100 mg/m2 adjust according to response.
1285	Prochlorperazine Maleate 5mg Tablet	N05AB04253 T1002XX	B	i) Severe nausea and vomiting ii) Vertigo/labyrinthine disorders	Nausea and vomiting Adult: As maleate or mesilate: 20 mg, further doses are given if needed. Recommended buccal dose: As maleate: 3-6 mg bid. Vertigo Adult: As maleate or mesilate: 15-30 mg daily, given in divided doses. May reduce gradually to 5-10 mg daily. Recommended buccal dose: 3-6 mg bid. May be taken with or without food.
1286	Prochlorperazine Mesylate 12.5 mg/ml Injection	N05AB04253 P3001XX	B	i) Severe nausea and vomiting ii) Vertigo/labyrinthine disorders	Deep IM injection, 12.5 mg repeated if necessary after 6 hours and then followed by an oral dose. Not recommended in children
1287	Procyclidine HCl 5 mg/ ml Injection	N04AA04110 P3001XX	B	i) All forms of Parkinson's disease (idiopathic paralysis agitants), post-encephalitis and arteriosclerosis ii) To control troublesome extrapyramidal symptoms induced by neuroleptic drugs including pseudo-parkinsonism, acute dystonic reactions and akathisia	i) Initial dose 2.5mg TDS, increasing by 2.5-5mg/day at intervals of 2 or 3 days until the optimum clinical response is achieved. Usual maintenance dose: 15-30mg/day. Max: 60mg/day ii) Initial dose 2.5mg TDS, increasing by 2.5mg daily until symptoms are relieved. Usual maintenance dose: 10-30mg/day. IV Emergency: 5-10 mg. IM

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					Emergency: 5-10 mg as a single dose, may repeat after 20 mins if needed. Max: 20 mg/day.
1288	Progesterone 100 mg capsule	G03DA04000 C1001XX	A*	Supplementation of the luteal phase	200-300mg daily orally. For supplementation of the luteal phase during in IVF, 400-600mg per day in 2-3 divided doses to be inserted vaginally.
1289	Progesterone 8% Vaginal Gel	G03DA04000 G3001XX	A*	Treatment of infertility due to inadequate luteal phase	90 mg intravaginally daily from day of egg retrieval till pregnancy established
1290	Prolase Tablet	M09AB00000 T1001XX	B	Oedema and inflammation in conjunction with other physical or chemotherapeutic measures	2 tablet 4 times daily
1291	Promethazine HCl 25 mg/ml Injection	R06AD02110 P3001XX	B	Allergic conditions	By deep IM: ADULT: 25 - 50 mg, maximum 100 mg. CHILD: 5 - 10 years : 6.25 - 12.5 mg. By slow IV: 25 - 50 mg in a solution of 2.5 mg/ml in water for injection. Maximum 100 mg
1292	Promethazine HCl 5 mg/5 ml Syrup	R06AD02110 L9001XX	B	Allergic conditions	CHILD 2 - 5 years: 5 - 15 mg daily, 5 - 10 years : 10 - 25 mg daily
1293	Proparacaine HCl 0.5% Ophthalmic Drops	S01HA04110 D2001XX	B	Topical anaesthesia in ophthalmic procedures	Deep anaesthesia:1 or 2 drops in the (eyes) every 5 to 10 minutes for 3 to 5 doses. For minor surgical procedures: instill 1 to 2 drops every 5 to 10 minutes for 1 to 3 doses. Tonometry and/or tonography procedure: 1 to 2 drops in each eye before procedure.
1294	Propiverine HCl 15 mg Tablet	G04BD06110 T1001XX	A*	Treatment of urinary incontinence, urgency and frequency in neurogenic detrusor overactivity (detrusor hyperreflexia) and in idiopathic detrusor overactivity (overactive bladder)	ADULT: 15 mg twice daily to 3 times daily, increase to 4 times daily if required. Max dose: 60 mg daily. CHILD more than 5 years: 0.2 to 0.4 mg/kg per day in 2 divided doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1295	Propofol 10mg/ml (1%) Injection	N01AX10000 P9901XX	A*	Induction & maintenance of general anaesthesia. Sedation of ventilated ICU patients	Adult: Induction: 20- 40 mg by injection or infusion every 10 sec. Usual dose: 1.5-2.5 mg/kg. Maintenance: 4-12 mg/kg/hr or intermittent bolus inj of 20-50 mg. Child: >8 yr: Induction dose of 2.5 mg/kg. Maintenance dose: 9-15 mg/kg/hr by IV infusion or intermittent bolus inj. Elderly: Including neurosurgical and debilitated patients: Infuse at a rate of 20 mg every 10 sec. Maintenance: 3-6 mg/kg/hr. Usual dose needed: 1-1.5 mg/kg. Duration of use: Can be administered for a maximum period of 7 days. Sedation: 0.3 - 4 mg/kg/hour up to 3 days
1296	Propofol 20mg/ml (2%) emulsion for injection of infusion	N01AX10000 P9902XX	A*	Induction & maintenance of general anaesthesia. Sedation of ventilated ICU patients	Adult: IV Induction and maintenance of general anesth Induction: 40 mg every 10 sec. Maintenance: 4-12 mg/kg/hr or intermittent boluses of 20-50 mg. Sedation In diagnostic and surgical procedures: Initial: 6-9 mg/kg/hr by infusion. Maintenance: 1.5-4.5 mg/kg/hr. For ventilated patients: 0.3-4 mg/kg/hr. Monitor lipid concentrations if duration of sedation >3 days.
1297	Propranolol HCl 1 mg/ml Injection	C07AA05110 P3001XX	A	Arrhythmias and thyrotoxicosis crisis	Slow IV injection in a dose of 1 mg over 1 minute, repeated if necessary every 2 minutes until a maximum of 10 mg has been given in conscious patients and 5 mg in patients under anaesthesia. CHILD: 25 - 50 mcg/kg slow IV with

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					appropriate monitoring
1298	Propranolol HCl 10 mg Tablet	C07AA05110 T1001XX	B	Dysrythmias, tachycardia, hypertrophic obstructive cardiomyopathy (For cardiologist only)	10 - 40 mg 3 - 4 times daily
1299	Propranolol HCl 40 mg Tablet	C07AA05110 T1002XX	B	i) Hypertension ii) Angina iii) Myocardial infarct iv) Cardiac arrhythmia v) Portal hypertension vi) Migraine vii) Thyrotoxicosis	i) Initially 80 mg twice daily increased as required to a usual range of 160 - 320 mg daily. CHILD: Initial doses of 1 mg/kg in divided doses, can be increased to 2 - 4 mg/kg/day in divided doses ii) Initial dose of 40 mg 2 - 3 times daily. Maintenance 120 - 240 mg daily iii) 40mg 4 times daily for 2 - 3 days then 80 mg twice daily, beginning 5 - 21 days after infarction iv) 10 - 40 mg 3 - 4 times daily v) Initially 40 mg twice daily. The dose may be increased as required up to 160 mg twice daily vi) Initial prophylaxis dose: 40 mg 2 - 3 times daily. The dose may be increased at weekly intervals up to 160 mg daily vii) Adjunct: 10 - 40 mg 3 - 4 times daily. CHILD: Arrythmias, thyrotoxicosis: 0.25 - 0.5 mg/kg 3 - 4 times daily as required
1300	Propylthiouracil 50 mg Tablet	H03BA02000 T1001XX	B	Hyperthyroidism	ADULT Initially 300-450mg in 8 hourly intervals (can be given up to 600-900mg/daily) until symptoms are controlled in 1-2 months. Maintenance 50-150mg daily for at least 12-18 months. CHILDREN 6-10 years: 50-150mg. CHILDREN > 10 years: 150-300mg daily. All doses are to be given in 3 divided doses daily. Taken with food.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1301	Protamine Sulphate 10 mg/ml Injection	V03AB14183 P3001XX	B	Heparin overdose and following cardiac or arterial surgery or dialysis procedures when required to neutralize the effects of heparin administered during extracorporeal circulation	5 ml slow IV injected over 10 minutes. If administered within 15 minutes of heparin dose, 1 mg will neutralise approximately 100 units of heparin. If longer time has elapsed, less protamine is required. Not more than 50 mg should be injected at any one time. The dose is dependent on the amount and type of heparin to be neutralised, its route of administration and the time elapsed since it was last given and blood coagulation studies.
1302	Protein Free Haemodialysate 10% Jelly	D03AX00000 G4001XX	A	Trophic lesions in patients with arterial occlusive disease and with chronic venous insufficiency, burn injuries, impaired wound healing, decubitus ulcers and skin ulcer caused by irradiation	Apply 3 - 5 times daily
1303	Protein Free Haemodialysate 20% Eye Gel	S01XA20000 G3001XX	A	Eyes disorders e.g. burns, scalds, ulcers, prevention and treatment of radiation dermatitis, traumatic and ischaemic wound	Instill 1 drop 3 - 4 times daily
1304	Protein Free Haemodialysate 5% Ointment	D03AX00000 G5001XX	A	Trophic lesions in patients with arterial occlusive disease and with chronic venous insufficiency, burn injuries, impaired wound healing, decubitus ulcers and skin ulcer caused by irradiation	Apply 3 - 5 times daily
1305	Protein Free Haemodialysate Dental Adhesive Paste	D03AX00000 G6001XX	A	Painful and inflammatory affliction on the oral mucosa, gums and lips, teething pain, denture pressure sores, oral and maxillofacial surgery and dressing after scaling	Apply to lesions 3 - 5 times daily
1306	Pyrantel Pamoate 125 mg Tablet	P02CC01127 T1001XX	C	Intestinal nematodes	ADULT and CHILD: 2 years and older - single dose 10mg/kg body weight once. Maximum 1 g
1307	Pyrantel Pamoate 250 mg Tablet	P02CC01127 T1002XX	C	Intestinal nematodes	ADULT and CHILD: 2 years and older - single dose 10mg/kg body weight once.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					Maximum 1 g
1308	Pyrazinamide 500 mg Tablet	J04AK01000T1001XX	B	Tuberculosis	Adult: 20-40mg/kg daily (max 1500mg) or 50mg/kg biweekly (max 2000mg). Children: 20-30mg/kg daily or 30-40mg/kg thrice weekly.
1309	Pyridostigmine Bromide 60 mg Tablet	N07AA02320T1001XX	B	Myasthenia gravis	ADULT: 30 - 120 mg at suitable intervals throughout the day, total daily dose 0.3 - 1.2 g. CHILD up to 6 years initially 30 mg, 6 - 12 years initially 60 mg, usual total daily dose 30 - 360 mg
1310	Pyridoxine HCl 10 mg Tablet	A11HA02110T1001XX	C+	i)Pyridoxine-dependent convulsions in infant ii)Sideroblastic anaemia iii)B6-deficient anaemia in adult iv) Prophylaxis to peripheral neuritis in isoniazid therapy v) Nausea and vomiting of pregnancy and irradiation sickness	i) INFANT 4 mg/kg daily for short periods ii) 100 - 400 mg daily in divided doses iii) ADULT 20 - 50 mg up to 3 times daily iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 - 100 mg daily
1311	Pyridoxine HCl 50 mg/2 ml Injection	A11HA02110P3001XX	B	i) Pyridoxine-dependent convulsions in infancy ii) Sideroblastic anaemia iii) B6-deficient anaemia in adult iv) Prophylaxis to peripheral neuritis in isoniazid therapy v) Nausea and vomiting of pregnancy and irradiation sickness	i) INFANT 4 mg/kg daily for short periods ii) 100 - 400 mg daily in divided doses iii) ADULT 20 - 50 mg up to 3 times daily iv) Prophylaxis 10 mg daily, therapeutic 50 mg 3 times daily v) 20 - 100 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1312	Quetiapine Fumarate 100 mg Immediate Release Tablet	N05AH04138 T1002XX	A*	i) Schizophrenia ii) Short term treatment of acute manic episodes associated with bipolar I disorder, either monotherapy or adjunct to lithium or divalproex iii) Treatment of depressive episodes associated with bipolar disorder	i) Initial titration schedule over 4 days: 25 mg twice daily on Day 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 - 3 divided doses. Institute further dose adjustments, if indicated, at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii) 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of not more than 200 mg/day. Adjust dose within the range of 200 - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1)
1313	Quetiapine Fumarate 200 mg Extended Release Tablet	N05AH04138 T5002XX	A*	i)Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorder	i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2. Maintenance dose: 400 to 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily. In elderly or hepatic impairment:Start

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					with 50mg/ day, may be increased in increments of 50mg /day to an effective dose.
1314	Quetiapine Fumarate 200 mg Immediate Release Tablet	N05AH04138 T1004XX	A*	i) Schizophrenia ii) Short term treatment of acute manic episodes associated with bipolar I disorder, either monotherapy or adjunct to lithium or divalproex iii) Treatment of depressive episodes associated with bipolar disorder	i) Initial titration schedule over 4 days: 25 mg twice daily on Day 1, increase in steps of 25 - 50 mg 2 to 3 times daily on Days 2 and 3 to reach target dose of 300 - 400 mg daily by Day 4, given in 2 - 3 divided doses. Institute further dose adjustments, if indicated, at intervals of 2 days or more, in steps of 25 - 50 mg twice daily ii) 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) & 400 mg (Day 4). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of not more than 200 mg/day. Adjust dose within the range of 200 - 800 mg/day depending on clinical response and tolerability of the patient. Usual effective dose range: 400 - 800 mg/day iii) 50 mg ORALLY once a day on Day 1, then 100 mg once daily on Day 2, then 200 mg once daily on Day 3, then 300 mg once daily on Day 4 (all doses given at bedtime); patients requiring higher doses should receive 400 mg on Day 5, increased to 600 mg on Day 8 (week 1)
1315	Quetiapine Fumarate 300 mg Extended Release Tablet	N05AH04138 T5003XX	A*	i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorder	i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose: 400 - 800 mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					Recommended daily dose is 300 mg. May be titrated up to 600 mg daily
1316	Quetiapine Fumarate 400 mg Extended Release Tablet	N05AH04138 T5004XX	A*	i) Schizophrenia ii) Moderate to severe manic episodes in bipolar disorder iii) Major depressive episodes in bipolar disorder	i) & ii) 300 mg once daily on Day 1 and 600 mg on Day 2. Maintenance dose 400 - 800mg once daily. Maximum dose: 800 mg daily iii) 50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily
1317	Quetiapine Fumarate 50 mg Extended Release Tablet	N05AH04138 T5001XX	A*	i)Schizophrenia ii)Moderate to severe manic episodes in bipolar disorder iii)Major depressive episodes in bipolar disorder	i) & ii) 300 mg once daily on Day 1 then 600 mg on Day 2. Maintenance dose: 400 to 800 mg once daily. Maximum dose: 800 mg daily. iii)50 mg on Day 1, 100 mg on Day 2, 200 mg on Day 3 and 300 mg on Day 4. Recommended daily dose is 300 mg. May be titrated up to 600 mg daily. In elderly or hepatic impairment: Start with 50mg/ day, may be increased in increments of 50mg /day to an effective dose.
1318	Quinine Dihydrochloride 600 mg/2 ml Injection	P01BC01110 P3001XX	B	Severe and complicated malaria	By slow intravenous infusion (over 4 hours). ADULT: 20 mg/kg followed by 10 mg/kg every 8 hours. CHILD : 20 mg/kg followed by 10 mg/kg every 12 hours, initial dose should be half in patients who have received quinine, quinidine or mefloquine during the previous 12 or 24 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1319	Quinine Sulphate 300 mg Tablet	P01BC01183 T1001XX	B	Severe and complicated malaria	300 - 600 mg daily. Treatment: 1.2 - 2 g daily in divided doses. CHILDS less than 1 year : 100 - 200 mg daily, 1 - 3 years : 200 - 300 mg daily, 4 - 6 years: up to 500 mg daily, more than 7 years : up to 1 g daily. All above doses are given for 7 days in 2 - 3 divided doses
1320	Rabeprazole Sodium 20 mg Tablet	A02BC04520 T1001XX	A*	i) Treatment and maintenance of erosive or ulcerative gastroesophageal reflux disease (GERD) ii) Duodenal ulcers	i) 10-20 mg daily for 4-8 weeks, maintenance 10-20 mg daily ii) 20 mg daily at morning for up to 4-8 weeks
1321	Rabies Human Diploid Cell Vaccine (Lyophilised) Injection	J07BG01000P 4001XX	B	Pre-exposure and post-exposure vaccination against rabies	Prophylaxis: 3 dose (1 ml each) schedule on D0, D7 and D28. Booster dose after every 2 - 3 years. Post exposure prophylaxis: use after attack of a potential rabid animal: 1 dose on D0, D3, D7, D14 and D28. In previously vaccinated individuals 2 doses on D0 and D3
1322	Raloxifene HCl 60 mg Tablet	G03XC01110 T1001XX	A*	Prevention and treatment of post menopausal osteoporosis	1 tablet daily
1323	Raltegravir 400 mg tablet	J05AX08500T 1001XX	A*	Raltgeravir combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in patients who are contraindicated to boosted Protease Inhibitor or who are intolerant to boosted Protease Inhibitor.	400mg administered orally, twice daily with or without food, to be given combination with other antiretroviral agent.
1324	Ramipril 2.5 mg Tablet	C09AA05000 T1001XX	A	i) Hypertension and congestive heart failure ii) Post-myocardial infarction iii) Reducing risk of myocardial infarction, stroke or cardiovascular death in diabetics or patients with increased cardiovascular risks	i) Hypertension: Initially 2.5 mg once daily, increased at intervals of 1 - 2 weeks to maximum 10 mg once daily; Congestive heart failure:Initially 1.25 mg once daily. Max: 10 mg/day ii) Initially 2.5 mg twice daily for 2 days then increased to maximum 5 mg twice daily iii) Initially 1.25 - 2.5 mg once daily, increased to 5

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					mg once daily after 1 week, maximum dose: 10 mg once daily after 3 weeks
1325	Ramipril 5 mg Tablet	C09AA05000 T1002XX	A	i) Hypertension and congestive heart failure ii) Post-myocardial infarction iii) Reducing risk of myocardial infarction, stroke or cardiovascular death in diabetics or patients with increased cardiovascular risks	i) Hypertension: Initially 2.5 mg once daily, increased at intervals of 1 - 2 weeks to maximum 10 mg once daily; Congestive heart failure:Initially 1.25 mg once daily. Max: 10 mg/day ii) Initially 2.5 mg twice daily for 2 days then increased to maximum 5 mg twice daily iii) Initially 1.25 - 2.5 mg once daily, increased to 5 mg once daily after 1 week, maximum dose: 10 mg once daily after 3 weeks
1326	Ranibizumab 10 mg/ ml Injection	S01LA04000P 3001XX	A*	i) Treatment of Neovascular (wet) Age-Related Macular Degeneration (ARMD) ii) Treatment of visual impairment due to diabetic macular edema (DME) iii) Treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO) Note: Indication ii) and iii) approved to be used by retinal specialist only (PFUKKM 1/2015)	0.5 mg (0.05ml) as a single intravitreal Injection.Interval between 2 doses should not be shorter than 1 month, then monitor for visual acuity monthly. Treatment is given monthly & continued until max visual acuity is achieved, confirmed by stable visual acuity for 3 consecutive monthly assessments.
1327	Ranitidine 150 mg Tablet	A02BA02110 T1001XX	B	i) Benign gastric and duodenal ulcer ii) Reflux oesophagitis iii) Non-ulcer dyspepsia iv) Zollinger-Ellison Syndrome	i) 150 mg twice daily (at morning and night) or 300 mg on night for 4-8 weeks. Maintenance: 150-300 mg on night ii) 150 mg twice daily or 300 mg on night for 8-12 weeks iii) 150 mg daily or twice daily iv) 150 mg and may be increased as necessary to 6 g/day
1328	Ranitidine 150 mg/10 ml Syrup	A02BA02110 L9001XX	B	Peptic ulcer disease	CHILD 2-4 mg/kg 2 times daily. Maximum 300 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1329	Ranitidine 25 mg/ml Injection	A02BA02110 P3001XX	B	i) Benign gastric/ duodenal ulceration, reflux oesophagitis, Zollinger Ellison Syndrome ii) Stress ulcer prophylaxis in post-operative and high risk patients	i) ADULT: Slow IV injection of 50 mg diluted to 20 ml and given over at least 2 minutes. May be repeated every 6-8 hours or IV infusion at rate of 25 mg/hour for 2 hours, may be repeated at 6-8 hours intervals or IM. CHILD: 1 mg/kg/dose 6-8 hourly. ii) Initial slow IV injection of 50 mg, then continuous infusion of 125-250 mcg/kg/hour
1330	Ranitidine 300 mg Tablet	A02BA02110 T1002XX	B	i) Benign gastric and duodenal ulcer ii) Reflux oesophagitis iii) Non-ulcer dyspepsia iv) Zollinger-Ellison Syndrome	i) 150 mg twice daily (at morning and night) or 300 mg on night for 4-8 weeks. Maintenance: 150-300 mg on night ii) 150 mg twice daily or 300 mg on night for 8-12 weeks iii) 150 mg daily or twice daily iv) 150 mg and may be increased as necessary to 6 g/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1331	Remifentanil 5 mg Injection	N01AH06110 P4001XX	A*	i) As an analgesic agent for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery. ii)Continuation of analgesia into the immediate post-operative period under close supervision, during transition to longer acting analgesia. iii)Provision of analgesia and sedation in mechanically ventilated intensive care patients.	For IV use only. ADULT: Induction:Bolus infusion: 1µg/kg over 30-60 seconds; Continuous infusion: 0.5-1µg/kg/min; Maintenance: Continuous infusion: 0.025 to 2 µg/kg/min. CHILD (1-12 years of age): Induction: Insufficient data; Neonates: IV infusion 0.4-1.0 mcg/kg/minute depending on the anaesthetic method and adjust according to patient response, supplemental IV inj of 1 mcg/kg dose may be given. 1-12 yr: initially 0.1-1 mcg/kg by IV inj over at least 30 seconds (excluded if not needed), followed by IV infusion 0.05-1.3 mcg/kg/minute depending on the anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion. 12-18 yr: 0.1-1 mcg/kg IV inj over at least 30 seconds (excluded if not needed), followed by IV infusion of 0.05-2 mcg/kg/minute depending on anaesthetic method and adjust according to patient response, supplemental IV bolus inj may be admin during infusion.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1332	Repaglinide 2 mg Tablet	A10BX02000 T1001XX	A*	Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone is inadequate)	OHA naïve patient: Start dose with 0.5mg per meal Patients transferred from another oral hypoglycaemic agent: Start dose with 0.5-1mg per meal In combination with metformin: Start dose as 0.5mg per meal Titrate every 1-2weeks according to blood glucose response. Max single dose: 4mg before each main meal. Max total daily dose: 16mg. Doses to be taken within 30 minutes of meals, 2-4 meals a day
1333	Ribavirin 200 mg Capsule	J05AB04000C 1001XX	A*	For the treatment of chronic hepatitis C (in combination with interferon alfa-2a/2b)	ADULT (more than 18 years old): 50mg/kg/day Recommended: Body weight: ≤ 75kg should receive 1000mg daily as two 200mg capsules in the morning and three 200mg capsules in the evening Body weight: >75kg should receive 1200mg as three 200mg capsules in the morning and three 200mg capsules in the evening Genotype 1,4: 48 weeks Genotype: 24 weeks duration should be individualized in accordance with the baseline characteristics of the disease.
1334	Riboflavine 3 mg Tablet	A11HA04000 T1001XX	C	For prevention and treatment of riboflavine deficiency	CHILD: 2.5-10 mg/day in divided doses. ADULT: 5-30 mg/day in divided doses
1335	Rifampicin 100 mg/5 ml Syrup	J04AB02000L 9001XX	A	Tuberculosis and leprosy	CHILD: 20 mg/kg body weight daily in 1 - 2 doses. Up to 1 year: 10 mg/kg body weight in a single daily dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1336	Rifampicin 150 mg Capsule	J04AB02000C 1001XX	B	i) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitis	i) ADULT: 450 - 600 mg as a single morning dose. CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) 600 mg/day iii) 600 mg twice daily for 2 days
1337	Rifampicin 150 mg, Isoniazid 75 mg & Pyrazinamide 400 mg Tablet	J04AM05000 T1001XX	B	Initial phase (2 months) of tuberculosis treatment	Patient more than or 71 kg: 5 tab/day, 55 -70 kg: 4 tab/day, 38-54 kg: 3 tab/day, 30-37 kg: 2 tab/day. To be taken as a single dose
1338	Rifampicin 150 mg, Isoniazid 75 mg, Pyrazinamide 400 mg & Ethambutol HCl 275 mg Tablet	J04AM06000 T1001XX	B	Treatment of both pulmonary and extrapulmonary tuberculosis, in the intensive treatment phase	ADULT: 30 - 37 kg: 2 tablets daily, 38 - 54 kg: 3 tablets daily, 55 - 70 kg: 4 tablets daily, more than 70 kg: 5 tablets daily
1339	Rifampicin 150mg + Isoniazid 75mg tablet	J04AM02000 T1001XX	B	For pulmonary tuberculosis in which organisms are susceptible in continuation phase treatment for 4 months	30-37kg: 2 tablets once daily, 38-54kg: 3 tablets once daily, 55-70kg: 4 tablets once daily, Above 70kg: 5 tabs once daily
1340	Rifampicin 300 mg Capsule	J04AB02000C 1002XX	B	i) Tuberculosis ii) Leprosy iii) Prophylaxis for meningococcal meningitis	i) Tuberculosis ADULT: Daily doses: 10mg/kg/day Body weight doses: 10-15/kg/day CHILD: 10 - 20 mg/kg body weight daily in 1 - 2 doses. Maximum daily dose : 600mg Directly observed therapy (DOT): 10 mg/kg twice weekly or 3 times/week. Maximum: 600 mg ii) Leprosy: ADULT: 600 mg/day CHILDREN: 10mg/kg iii) Prophylaxis for meningococcal meningitis: ADULT: 600 mg twice daily for 2 days CHILDREN: 10mg/kg twice daily for 2 days INFANT: 5mg/kg twice daily for 2 days"

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1341	Rifampicin, Dapsone & Clofazimine	J04AM02961 T9901XX	B	For the treatment of leprosy and tuberculosis	Rifampicin: 600 mg once monthly, Dapsone: 100 mg daily, Clofazimine: 300 mg once monthly and 50 mg daily (or 100 mg on alternate days)
1342	Ringers Solution (contained sodium chloride, potassium chloride and calcium chloride)	B05XA30905 P6001XX	B	As a source of electrolytes and water for hydration/replenishing of chloride	According to the needs of the patient
1343	Risperidone 1 mg Tablet	N05AX08000 T1001XX	B	Psychoses and schizophrenia	ADULT : 2 mg in 1 - 2 divided doses on first day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweigh risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1 - 2 mg twice daily. Not recommended in children under 15 years
1344	Risperidone 1 mg/ml Oral Solution	N05AX08000 L5001XX	A	Psychoses and schizophrenia	ADULT: 2 mg in 1 - 2 divided doses on 1st day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweighs risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1-2 mg twice daily. Not recommended in children under 15 years

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1345	Risperidone 2 mg Tablet	N05AX08000 T1002XX	B	Psychoses and schizophrenia	ADULT : 2 mg in 1 - 2 divided doses on first day then 4 mg in 1 - 2 divided doses on 2nd day then 6 mg in 1 - 2 divided doses on 3rd day (slower titration appropriate in some patients); usual range 4 - 8 mg daily; dose above 10 mg daily only if benefit outweigh risk (maximum 16 mg daily). Elderly (or in hepatic or renal impairment): initially 0.5 mg twice daily increased in steps of 0.5 mg twice daily to 1 - 2 mg twice daily. Not recommended in children under 15 years
1346	Risperidone 25 mg Injection (Long Acting)	N05AX08000 P3001XX	A*	Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia	25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1347	Risperidone 37.5 mg Injection (Long Acting)	N05AX08000 P3002XX	A*	Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia	25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1348	Risperidone 50 mg Injection (Long Acting)	N05AX08000 P3003XX	A*	Treatment of acute and chronic schizophrenic psychosis and other psychotic conditions, in which positive and negative symptoms are prominent. It also alleviates affective symptoms associated with schizophrenia	25 mg IM every 2 weeks. Dose increments (if required) to 37.5 mg or 50 mg can be considered after a minimum of 4 weeks on each dosage
1349	Ritodrine HCl 50 mg/5 ml Injection	G02CA01110 P3001XX	A	Prevention of preterm labour	IV 0.05 mg/min to be gradually increased by 0.05 mg/min every 10-15 minutes. IM injection: 10 mg 4-6 hourly. Continue treatment for 12-48 hours after ceased contraction

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1350	Ritonavir 100 mg Capsule	J05AE03000C1001XX	A*	Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells or c) Viral load more than 10,000 copies/ml	ADULT: (Single PI) initially 300 mg twice daily, increase by 100 mg twice daily increments to 600 mg twice daily. (Dual PI) Initially 200mg BD, then increase by 100mg BD & reaching 400mg BD within 2 wk.
1351	Ritonavir 80 mg/ml Solution	J05AE03000L9901XX	A*	Progressive or advanced HIV infection in combination with other antiretroviral agents. Criteria for use: a) Clinical AIDS b) CD4 less than 350 cells or c) Viral load more than 10,000 copies/ml	ADULT: 400 - 600 mg twice daily. CHILD: >1 month, initiate at dise of 25mg/m2 twice daily, titrate dose upward every 2-3 days by 50mg/m2 twice daily (maximum dose 600mg twice daily)
1352	Rituximab 10 mg/ml Injection	L01XC02000P3001XX	A*	i) Treatment of patients with relapsed or chemo-resistant low grade or follicular B-cell Non-Hodgkin's lymphoma ii) Adjunctive therapy with combination chemoagents for aggressive Non-Hodgkin Lymphoma iii) Severe active rheumatoid arthritis with inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARDs) including one or more tumour necrosis factor (TNF) inhibitor therapies iv) Maintenance in relapsed/ refractory follicular lymphoma after response to induction therapy	i) 375 mg/m2 BSA administered as an IV infusion through a dedicated line once weekly for 4 weeks ii) Combination with CHOP (cyclophosphamide, doxorubicin, prednisone and vincristine) as 375 mg/m2 BSA on day 1 of each chemotherapy cycle for 8 cycles after IV administration of the glucocorticoid component of CHOP. iii) 1000 mg IV infusion followed by a second 1000 mg IV infusion two weeks later iv) 375mg/m2 BSA once every 3 months until disease progression or for a maximum period of two years.
1353	Rivaroxaban 10 mg Tablet	B01AX06000T1001XX	A*	Prevention of venous thromboembolism in patients undergoing elective hip or knee replacement surgery	10 mg once daily. Initial dose should be taken 6 to 10 hour post-surgery provided that haemostasis has been established. Duration of treatment: Major hip surgery 5 weeks. Major knee surgery 2 weeks

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1354	Rivaroxaban 15 mg Tablet	B01AX06000 T1002XX	A*	i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack. ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults.	i)20mg once daily or 15mg once daily (for patients with moderate renal impairment (creatinine clearance 30-49 ml/min) Dosage: ii) & (iii) 15mg BD for 21 days, followed by 20mg OD.
1355	Rivaroxaban 20 mg Tablet	B01AX06000 T1003XX	A*	i)Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as Congestive heart failure (CHF), hypertension, age ≥ 75 yrs, diabetes mellitus, prior stroke or transient ischaemic attack. ii)Treatment of deep vein thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. iii) Treatment of Pulmonary Embolism (PE), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute PE in adults.	i)20mg once daily or 15mg once daily (for patients with moderate renal impairment (creatinine clearance 30-49 ml/min) Dosage (ii) & (iii)15mg BD for 21 days, followed by 20mg OD.
1356	Rivastigmine 1.5 mg Capsule	N06DA03123 C1001XX	A*	For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1357	Rivastigmine 2 mg/ml Oral Solution	N06DA03123 L9901XX	A*	For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial dose 1.5 mg 2 times daily. May be increased after a minimum of 2 weeks of treatment to 3 mg 2 times daily. Subsequently to 4.5 mg 2 times daily, up to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1358	Rivastigmine 3 mg Capsule	N06DA03123 C1002XX	A*	For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1359	Rivastigmine 4.5 mg Capsule	N06DA03123 C1003XX	A*	For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1360	Rivastigmine 4.6mg/24hr Transdermal Patch	N06DA03123 M7001XX	A*	Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial, 4.6 mg/24 hr patch TOPICALLY once daily; after a minimum of 4 weeks and good tolerability, increase the dose to 9.5 mg/24 hr patch once daily
1361	Rivastigmine 6 mg Capsule	N06DA03123 C1004XX	A*	For psychiatrists and neurologists only. Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial dose 1.5 mg 2 times daily, may increase by 1.5 mg 2 times daily every 2 weeks to maximum of 6 mg 2 times daily. If treatment is interrupted for several days, should be reinitiated at the lowest daily dose
1362	Rivastigmine 9.5 mg/24hr Transdermal Patch	N06DA03123 M7002XX	A*	Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial, 4.6 mg/24 hr patch TOPICALLY once daily; after a minimum of 4 weeks and good tolerability, increase the dose to 9.5 mg/24 hour patch once daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1363	Rivastigmine Transdermal Patch 13.3mg/24 hours	N03DA03123 M7003XX	A*	Mild to moderately severe dementia associated with Alzheimer's or Parkinson's disease	Initial, 4.6mg/24 hours patch TOPICALLY once daily, after a minimum of 4 weeks of treatment and if well tolerated, this increased to 9.5mg/24 hours or 13.3mg/24 hours (individual responses to rivastigmine may vary and some patients may derive additional benefit from higher doses)
1364	Rocuronium Bromide 10 mg/ml Injection	M03AC09320 P3001XX	A*	As an adjunct to general anaesthesia to facilitate endotracheal intubation, to provide skeletal muscle relaxation during surgery and to facilitate mechanical ventilation in adults, children and infants from 3 months of age	Adult: Initially, 600mcg/kg by inj. Higher doses of 1 mg/kg may be used for intubation during rapid sequence induction of anaesthesia. Maintenance: 150 mcg/kg by inj (may reduce to 75-100 mcg/kg if inhalational anaesthesia is used) or by infusion at a rate of 300-600 mcg/kg/hr. Doses should be based on lean body weight for obese patients weighing >30% above the ideal body weight. Child: Infants and children >1 mth: Initially, 600 mcg/kg by inj. Maintenance: 150 mcg/kg by inj or by infusion at a rate of 300-600 mcg/kg/hr, maintenance doses may be required more frequently than in adult patients. Elderly: Reduced maintenance doses: 75-100 mcg/kg. Renal impairment: Initially, 600mcg/kg by inj. Maintenance: 75-100mcg/kg. Hepatic impairment: or biliary tract disease: Initially, 600mcg/kg by inj. Maintenance: 75-100 mcg/kg.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1365	Ropinirole HCl 2 mg Extended Release Tablet	N04BC04110 T5003XX	A*	Treatment of idiopathic Parkinson?s disease. It may be used as monotherapy or in combination with levodopa	ADULT: Initially 2 mg once daily for the 1st week. May be increased by 2 mg at ≥1 week intervals. Max: 24 mg/day. Switching from ropinirole immediate-realease to prolonged-release tablet; dose of ropinirole prolonged release tablet should be based on the total daily dose of ropinirole immediate-release tab the patient was taking. Tablets should be taken at a similar time each day with or without food, must be swallowed whole and must not be chewed, crushed or divided.
1366	Ropinirole HCl 4 mg Extended Release Tablet	N04BC04110 T5004XX	A*	Treatment of idiopathic Parkinson?s disease. It may be used as monotherapy or in combination with levodopa	ADULT: Initially 2 mg once daily for the 1st week. May be increased by 2 mg at ≥1 week intervals. Max: 24 mg/day. Switching from ropinirole immediate-realease to prolonged-release tablet; dose of ropinirole prolonged release tablet should be based on the total daily dose of ropinirole immediate-release tab the patient was taking. Tablets should be taken at a similar time each day with or without food, must be swallowed whole and must not be chewed, crushed or divided.
1367	Ropinirole HCl 0.25 mg Tablet	N04BCO4110 T1001XX	A*	Parkinson disease in younger patients and patients with dyskinesias, especially peak dose dyskinesias	0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24 mg/day. Most patients need 3-9 mg/day
1368	Ropinirole HCl 1 mg Tablet	N04BCO4110 T1002XX	A*	Parkinson disease in younger patients and patients with dyskinesias, especially peak dose dyskinesias	0.25 mg 3 times daily gradually increasing till adequate response obtained up to a maximum of 24

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					mg/day. Most patients need 3-9 mg/day
1369	Ropivacaine HCl 2 mg/ml Injection	N01BB09110 P3001XX	A*	i) Surgical anaesthaesia including obstetrics ii) Acute pain management	Dose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses (max . total dose 150 mg). ii) lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at interval at of least 30 minutes. Labour pain 6-10 ml/hour of 2mg/ml solution
1370	Ropivacaine HCl 7.5 mg/ml Injection	N01BB09110 P3002XX	A*	i) Surgical anaesthaesia including obstetrics ii) Acute pain management	Dose adjusted according to patient physical status and nature of procedure. i) Lumbar epidural: 15-25 ml of 7.5 mg/ml solution; Caesarean section, 15-20 ml of 7.5 mg/ml solution in incremental doses (max . total dose 150 mg). ii) lumbar epidural: 10-20 ml of 2mg/ml solution followed by 10-15 ml of 2 mg/ml solution at interval at of least 30 minutes. Labour pain 6-10 ml/hour of 2mg/ml solution

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1371	Rosiglitazone 4 mg Tablet	A10BG02000 T1002XX	A*	Type 2 diabetes with insulin resistant features. Prescribed to new patients only if inadequate glycaemic control with all other combination of oral antidiabetic medications (such as sulphonylureas, metformin, acarbose or DPPIV inhibitors) and is the only suitable alternative. Use of rosiglitazone in combination with insulin (for new patients) is not recommended. Combined use with insulin should be limited to existing cases with stable glycaemic control and requires close monitoring in view of increased risk of fluid retention, weight gain and hypoglycaemia. In cases of existing use in patients with optimal glycaemic control, rosiglitazone should be continued with close monitoring of cardiovascular, osteoporosis and fracture risk.	4 mg once daily or in 2 divided doses, may be increased to 8 mg/day in 1-2 divided doses after 12 week
1372	Rosuvastatin 10 mg Tablet	C10AA07390 T1002XX	A*	Dyslipidaemia not responsive to atorvastatin 40 mg or equivalent doses of other statins	Initially 5-10 mg once daily increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe hypercholesterolemia with high cardiovascular risk. Patient of Asian origin, patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1373	Rosuvastatin 20 mg Tablet	C10AA07390 T1003XX	A*	Dyslipidaemia not responsive to atorvastatin 40 mg or equivalent doses of other statins	Initially 5-10 mg once daily increased if necessary at intervals of at least 4 weeks to 20 mg once daily, increased after further 4 weeks to 40 mg daily ONLY in severe hypercholesterolemia with high cardiovascular risk. Patient of Asian origin, patients on concomitant ciclosporin/fibrate and patients with risk factors for myopathy/rhabdomyolysis (including personal/family history of muscular disorders/toxicity), the maximum dose should be 20 mg daily
1374	Rotigotine 2 mg per 24 hour Transdermal Patch	N04BC09000 M7001XX	A*	For stage IV Parkinson Disease with peak dyskinesia	A single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.
1375	Rotigotine 4 mg per 24 hour Transdermal Patch	N04BC09000 M7002XX	A*	For stage IV Parkinson Disease with peak dyskinesia	A single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.
1376	Rotigotine 6 mg per 24 hour Transdermal Patch	N04BC09000 M7003XX	A*	For stage IV Parkinson Disease with peak dyskinesia	A single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.
1377	Rotigotine 8 mg per 24 hour Transdermal Patch	N04BC09000 M7004XX	A*	For stage IV Parkinson Disease with peak dyskinesia	A single daily dose should be initiated at 4mg/24 h and then increased in weekly increments of 2mg/24 h to an effective dose up to a maximal dose of 16mg/24 hr.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1378	Rubella Virus Vaccine Injection (Single injection)	J07BJ01000P3001XX	C	Immunization against rubella (German measles)	0.5 ml SC as a a single dose
1379	Ruxolitinib 15mg tablet	L01XE18162T1002XX	A*	For the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Place in therapy: To be used as 3rd line after hydroxyurea and other best available treatment such as danazol and S.C. Interferon	The recommended starting dose is 15 mg twice daily for patients with a platelet count between 100,000/mm3 and 200,000/mm3 and 20 mg twice daily for patients with a platelet count of >200,000/mm3. There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and <100,000/mm3. The maximum recommended starting dose in these patients is 5 mg twice daily and the patients should be titrated cautiously.
1380	Ruxolitinib 20mg tablet	L01XE18162T1003XX	A*	For the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Place in therapy: To be used as 3rd line after hydroxyurea and other best available treatment such as danazol and S.C. Interferon	The recommended starting dose is 15 mg twice daily for patients with a platelet count between 100,000/mm3 and 200,000/mm3 and 20 mg twice daily for patients with a platelet count of >200,000/mm3. There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and <100,000/mm3. The maximum recommended starting dose in these patients is 5 mg twice daily and the patients should be titrated cautiously.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1381	Ruxolitinib 5mg tablet	L01XE18162T 1001XX	A*	For the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Place in therapy: To be used as 3rd line after hydroxyurea and other best available treatment such as danazol and S.C. Interferon	The recommended starting dose is 15 mg twice daily for patients with a platelet count between 100,000/mm3 and 200,000/mm3 and 20 mg twice daily for patients with a platelet count of >200,000/mm3. There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and <100,000/mm3. The maximum recommended starting dose in these patients is 5 mg twice daily and the patients should be titrated cautiously.
1382	Salbutamol 0.5 % Inhalation Solution	R03AC02183 A3001XX	B	Asthma and other conditions associated with reversible airways obstruction	2 ml may be inhaled up to 4 times daily over a period of 3 minutes per inhalation (0.5 ml diluted in 2.5 ml of normal saline by inhalation over 5 to 15 minutes)
1383	Salbutamol 0.5 mg/ml Injection	R03CC02183 P3001XX	A	Asthma and other conditions associated with reversible airways obstruction	500 mcg by SC/IM injection 4 hourly or 250 mcg by slow IV. If required, by IV infusion, initially 5 mcg/min adjusted according to response and heart rate, usually in the range 3 - 20 mcg/min
1384	Salbutamol 100 mcg/dose Inhalation	R03AC02183 A1001XX	B	Asthma and other conditions associated with reversible airways obstruction	ADULT : 100 - 200 mcg up to 3 - 4 times daily. CHILD : 100 mcg increased to 200 mcg if necessary
1385	Salbutamol 2 mg Tablet	R03CC02183 T1001XX	B	Asthma and other conditions associated with reversible airways obstruction	CHILD 2 - 6 years : 1 - 2 mg 3 - 4 times daily, 6 - 12 years : 2 mg 3 - 4 times daily. CHILD over 12 years and ADULT : 2 - 4 mg 3 - 4 times daily
1386	Salbutamol 2 mg/5 ml Syrup	R03CC02183 L9001XX	B	Asthma and other conditions associated with reversible airways obstruction	CHILD 2 - 6 years : 1 - 2 mg 3 - 4 times daily, 6 - 12 years : 2 mg 3 -4 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1387	Salbutamol 200mcg/dose Inhaler	R03AC02183 A2001XX	B	Asthma and other conditions associated with reversible airways obstruction	CHILD : 100 - 200 mcg. Maintenance : 100 - 200 mcg 2 - 4 times daily. ADULT : 100 - 400 mcg. Maitenance : 100 - 400 mcg 2 - 4 times daily
1388	Salbutamol 5 mg/5 ml Injection	R03CC02183 P3002XX	A*	Prevention of uncomplicated premature labour only	Infusions containing 5 mg in 500ml (10 mcg/ml) at the rate of 10 - 45 mcg/min increased at intervals of 10 minutes until evidence of patient response as shown by reduction of strength, frequency or duration of contractions; maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours
1389	Salicylazosulphapyridine (Sulfasalazine) 500 mg Tablet	A07EC01000 T1001XX	A/KK	i) Treatment of inflammatory bowel disease of ulcerative colitis and Crohn's disease ii) Rheumatoid arthritis	i) ADULT, acute attack 1-2 g 4 times daily until remission occurs (if necessary corticosteroids may also be given), reducing to a maintenance dose of 500 mg 4 times daily, CHILD over 2 years, acute attack 40-60 mg/kg daily, maintenance dose 20-30 mg/kg daily ii) ADULT, initially; 0.5-1 g/day, increase weekly to maintenance dose of 2 g/day in 2 divided doses, maximun 3 g/day. CHILD over 6 years, juvenile rheumatoid arthritis: 30-50 mg/kg/day in 2 divided doses up to a maximum of 2 g/day
1390	Salicylic Acid 1 - 2% in Hydrocortisone 1% Ointment	D07XA01952 G5001XX	B	Seborrhoeic capitis	Apply sparingly to affected areas 1-2 times daily
1391	Salicylic Acid 2 - 10% Cream	D01AE12000 G1001XX	C	Seborrhoeic dermatitis, scalp psoriasis and hyperkeratotic skin conditions	Apply sparingly to the affected area 2-3 times daily
1392	Salicylic Acid 2 - 10% Ointment	D01AE12000 G5001XX	C	Seborrhoeic dermatitis, scalp, psoriasis and hyperkeratotic skin	Apply sparingly to the affected area 2-3 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
				disorders	
1393	Salicylic Acid 2 % Lotion	D01AE12000 L6001XX	B	Seborrhoeic dermatitis, scalp, psoriasis and hyperkeratotic skin conditions	Apply sparingly to the affected area 2-3 times daily. Wash with cleanser 2 - 3 times per day
1394	Salicylic Acid 20% Ointment	D01AE12000 G5002XX	C	Plantar warts	Apply daily and protect surrounding skin (eg with soft paraffin or specially designed plaster) ,may need to continue up to 3 months
1395	Salicylic Acid, Starch, Zinc Oxide Paste	D01AE12952 G6001XX	C	Use as a protective or base	Apply the paste liberally and carefully to the lesions twice daily
1396	Salmeterol 25 mcg and Fluticasone Propionate 125 mcg Inhalation	R03AK06989 A2102XX	A*	Regular treatment of reversible obstructive airway diseases including asthma.	ADULT and CHILD more than 12 years : 1 - 2 puff twice daily. CHILD over 4 years : 1 puff twice daily
1397	Salmeterol 25mcg and Fluticasone Propionate 50mcg Inhalation	R03AK06989 A2104XX	A*	Regular treatment of reversible obstructive airway diseases including asthma in children, where use of lower dose of a combination (bronchodilator and inhaled corticosteroids) is appropriate.	ADULT and CHILD more than 12 years : 2 puff twice daily. CHILD over 4 years : 2 puff twice daily No data on use for children aged under 4 years.
1398	Salmeterol 50 mcg and Fluticasone Propionate 250 mcg Inhalation	R03AK06989 A2101XX	A/KK	i) Regular treatment of reversible obstructive airways diseases including asthma ii) For the regular treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema	i) ADULT and CHILD more than 12 years : 1 puff twice daily. ii) For COPD: Dose is one inhalation 50/250mcg to 50/500mcg twice daily.
1399	Salmeterol 50 mcg and Fluticasone Propionate 500 mcg Inhalation	R03AK06989 A2106XX	A*	i) Regular treatment of reversible obstructive airways diseases including asthma ii) Chronic obstructive pulmonary disease including chronic bronchitis and emphysema	i) ADULT and CHILD more than 12 years : 1 puff twice daily ii) ADULT 1 puff twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1400	Saxagliptin 2.5 mg Tablet	A10BH03000 T1001XX	A/KK	i) As add on therapy in type 2 diabetes patients inadequately controlled on metformin monotherapy and high risk of hypoglycaemia, especially elderly patients with co-morbidities. ii) As add on therapy in type 2 diabetes patients inadequately controlled with a sulphonylure and intolerant/contraindicated for metformin therapy iii) As add on therapy in type 2 diabetes patients inadequately controlled on metformin and sulphonylurea combination therapy iv) In patients with renal failure where metformin contraindicated Not to be used in patients with HbA1c > 8% on single/combination OAD, as insulin initiation is preferred.	Recommended starting dose and maintenance dose in patients with normal renal function and mild renal insufficiency (CrCl more than 50 ml/min) is 5 mg once daily. For patients with moderate to severe renal insufficiency (CrCl less than or equal to 50 ml/min) dose is 2.5 mg once daily
1401	Saxagliptin 2.5mg and Metformin HCl 1000mg Extended-Release Tablet	A10BD10926 T1001XX	A	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.	The recommended starting dose of in patients who need 5mg of saxagliptin and who are not currently treated with metformin is 5mg saxagliptin/500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin. In patients treated with metformin, the dose of should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. Patients who need 2.5mg saxagliptin in combination with metformin extended-release may be treated with 2.5mg/1000mg. Patients who need 2.5mg saxagliptin who are either metformin naive or who require a dose of metformin higher than

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					1000mg should use the individual components. Max daily recommended dose is 5mg/2000mg.
1402	Saxagliptin 5 mg Tablet	A10BH03000 T1002XX	A/KK	i) As add on therapy in type 2 diabetes patients inadequately controlled on metformin monotherapy and high risk of hypoglycaemia, especially elderly patients with co-morbidities. ii) As add on therapy in type 2 diabetes patients inadequately controlled with a sulphonylure and intolerant/contraindicated for metformin therapy iii) As add on therapy in type 2 diabetes patients inadequately controlled on metformin and sulphonylurea combination therapy iv) In patients with renal failure where metformin contraindicated Not to be used in patients with HbA1c > 8% on single/combination OAD, as insulin initiation is preferred.	2.5-5mg once daily. Patients with CrCl < 50ml/min, and when coadministered with strong CYP450 3A4/5 inhibitors: 2.5mg OD

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1403	Saxagliptin 5mg and Metformin HCl 1000mg Extended-Release Tablet	A10BD10926 T1002XX	A	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.	The recommended starting dose of in patients who need 5mg of saxagliptin and who are not currently treated with metformin is 5mg saxagliptin/500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin. In patients treated with metformin, the dose of should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. Patients who need 2.5mg saxagliptin in combination with metformin extended-release may be treated with 2.5mg/1000mg. Patients who need 2.5mg saxagliptin who are either metformin naive or who require a dose of metformin higher than 1000mg should use the individual components. Max daily recommended dose is 5mg/2000mg.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1404	Saxagliptin 5mg and Metformin HCl 500 mg Extended-Release Tablet	A10BD10926 T1003XX	A	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.	The recommended starting dose of in patients who need 5mg of saxagliptin and who are not currently treated with metformin is 5mg saxagliptin/500 mg metformin extended-release once daily with gradual dose escalation to reduce the gastrointestinal side effects due to metformin. In patients treated with metformin, the dose of should provide metformin at the dose already being taken, or the nearest therapeutically appropriate dose. Patients who need 2.5mg saxagliptin in combination with metformin extended-release may be treated with 2.5mg/1000mg. Patients who need 2.5mg saxagliptin who are either metformin naive or who require a dose of metformin higher than 1000mg should use the individual components. Max daily recommended dose is 5mg/2000mg.
1405	Selected Plasma Protein 5 g/100 ml Injection	B05AA02000 P3001XX	B	For treatment of shock due to burns, crushing injuries, abdominal emergencies and where there is a predominant loss of plasma fluids and red blood cells, emergency treatment of shock due to haemorrhage and in infants and small children in the initial therapy of shock due to dehydration and infection	ADULT 12.5-25 g (250-500 ml) by IV. CHILD usual dose 33 ml/kg body weight at rate of 5-10 ml/min
1406	Selegiline HCl 5 mg Tablet	N04BD01110 T1001XX	A*	Only for treatment of late stage Parkinsonism with on and off phenomenon	5 mg twice daily at breakfast and lunch. Maximum 10 mg/day

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1407	Selenium Sulphide 2.5% Shampoo	D11AC03180 L5201XX	A/KK	Dandruff, seborrheic dermatitis of scalp	Dandruff: apply 5-10 mL topically twice weekly for 2 weeks, then 1-4 times per month, as needed, leave on for 2-3 min, then rinse thoroughly. Seborrheic dermatitis of scalp: apply 5-10 mL topically twice weekly for 2 weeks, then 1-4 times per month, as needed, leave on for 2-3 min, then rinse thoroughly
1408	Sertraline HCl 50 mg Tablet	N06AB06110 T1001XX	B	Major depression, obsessive-compulsive disorder (OCD), panic disorder	Depression, obsessive-compulsive disorder: 50 mg/day, may increase in steps of 50mg at weekly interval, max:200mg/day. Panic disorder: Initially 25 mg/day. After 1 week, increase dose to 50 mg/day. All dose changes should be made at intervals of more than 1 week, max: 200 mg/day
1409	Sevelamer 800mg Tablet	V03AE02121 T1001XX	A*	Control of hyperphosphatemia in adult patients receiving haemodialysis and peritoneal dialysis. Restriction: Sevelamer carbonate 800mg tablet should be used in context of multiple therapeutic approach which include calcium supplement, 1, 25-hydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.	Starting dose is one or two 800mg tablets three times per day with meals. Adjust by one tablet per meal in two weeks interval as needed to obtain serum phosphorus target (1.13 to 1.78mmol/L).
1410	Sevoflurane Liquid	N01AB08000 L5001XX	A*	To be used only for i) induction and ii) maintenance of anaesthesia	i) Adult: Given via a calibrated vaporiser: Up to 5% v/v with oxygen or a mixture of oxygen and nitrous oxide. Child: Given via a calibrated vaporiser: Up to 7% v/v. ii) Adult: 0.5-3% v/v with or without nitrous oxide. Child: 0.5-3% v/v with or without nitrous oxide.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1411	Sildenafil Citrate 20 mg Film-coated Tablet	G04BE03136 T1004XX	A*	Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.	ADULTS ≥ 18 years: The recommended dose is 20mg three times a day. Tablets should be taken approximately 6 to 8 hours apart with or without food. ELDERLY (≥65 years): Dosage adjustments are not required in elderly patients. Clinical efficacy as measured by 6-minute walk distance could be less in elderly patients. IMPAIRED RENAL FUNCTION: Initial dose adjustments are not required in patients with renal impairment, including severe renal impairment (creatinine clearance <30ml/min). A downward dose adjustment to 20 mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated. IMPAIRED HEPATIC FUNCTION: Initial dose adjustments are not required in patients with hepatic impairment (Child-Pugh class A and B). A downward dose adjustment to 20mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated.
1412	Silver Nitrate 0.5% Lotion	D08AL01221 L6001XX	B	Use as antiseptic	Apply undiluted to affected area for a limited period
1413	Silver Sulfadiazine 1% Cream	D06BA01199 G1001XX	B	Prevention and treatment of infections in severe burns, leg ulcers where infections may prevent healing and for the prophylaxis of infections in skin grafting	Burns: Apply 3 mm thick layer twice daily with sterile applicator. Leg ulcer: apply at least 3 times a week

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1414	Simvastatin 10 mg Tablet	C10AA01000 T1001XX	B	Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy	10 - 20 mg once daily. Maximum: 80 mg daily
1415	Simvastatin 20 mg Tablet	C10AA01000 T1002XX	B	Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy	10 - 20 mg once daily. Maximum: 80 mg daily
1416	Simvastatin 40 mg Tablet	C10AA01000 T1003XX	B	Hypercholesterolaemia and coronary heart disease intolerant or not responsive to other forms of therapy	10 - 20 mg once daily. Maximum: 80 mg daily
1417	Sitagliptin 100 mg Tablet	A10BH01000 T1003XX	A*	Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HbA1c is more than 9%	ADULT over 18 years, 100 mg once daily: 100mg once daily CrCl ≥ 30 to < 50ml/min: 50mg once daily CrCl < 30 ml/min: 25mg once daily
1418	Sitagliptin 25 mg Tablet	A10BH01000 T1001XX	A*	Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HbA1c is more than 9%	ADULT over 18 years, 100 mg once daily: 100mg once daily CrCl ≥ 30 to < 50ml/min: 50mg once daily CrCl < 30 ml/min: 25mg once daily
1419	Sitagliptin 50 mg and Metformin HCl 1000 mg Tablet	A10BD07926 T1003XX	A*	i)Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin ii)Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics	50 mg/500 mg twice daily. The recommended maximum daily dose is 100 mg sitagliptin plus 2000 mg metformin

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1420	Sitagliptin 50 mg and Metformin HCl 500 mg Tablet	A10BD07926 T1001XX	A*	i)Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin ii)Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics	50 mg/500 mg twice daily. The recommended maximum daily dose is 100 mg sitagliptin plus 2000 mg metformin
1421	Sitagliptin 50 mg and Metformin HCl 850 mg Tablet	A10BD07926 T1002XX	A*	i)Type 2 diabetes patients, especially the elderly, with multiple co-morbidities that always experience hypoglycaemia with other antidiabetics who are inadequately controlled on metformin or sitagliptin alone or already being treated with the combination of sitagliptin and metformin ii)Newly diagnosed type 2 diabetes patients with high baseline HbA1c and multiple co-morbidities who may experience hypoglycaemia with other antidiabetics	50 mg/500 mg twice daily. The recommended maximum daily dose is 100 mg sitagliptin plus 2000 mg metformin
1422	Sitagliptin 50 mg Tablet	A10BH01000 T1002XX	A*	Management of diabetes in patients with renal failure where metformin/sulphonylurea is contraindicated/untolerated and elderly with multiple co morbidities that always experience hypoglycemia with other antidiabetic. Not to be used in diabetic patient whose HbA1c is more than 9%	ADULT over 18 years, 100 mg once daily: 100mg once daily CrCl ≥ 30 to < 50ml/min: 50mg once daily CrCl < 30 ml/min: 25mg once daily
1423	Sodium Alginate 1000 mg/10 ml & Potassium Bicarbonate 200 mg/10 ml Suspension	A02BX13915 L8001XX	A*	Treatment of symptoms of gastro-oesophageal reflux eg. acid regurgitation, heartburn, indigestion due to the reflux of stomach contents not responding to conventional antacids or as an addition to PPI when PPI alone fails to control the symptoms	Adult, elderly & children ≥12 year: 5-10 mL.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1424	Sodium and Meglumine Diatrizoate 58-60% Injection	V08AA01993 P3002XX	B	For IV pyelography	Depend on the type of procedure and the degree and extent of contrast required
1425	Sodium Bicarbonate 1 g/15 ml Mixture	A02AH00131 L2102XX	B	i) Relief of discomfort in mild urinary tract ii) Alkalinisation of urine	i) 3 g in every 2 hours until urinary pH exceeds 7 ii) Maintenance of alkaline urine 5-10 g daily
1426	Sodium Bicarbonate 4.2% (0.5 mmol/ml) Injection	B05XA02131 P3001XX	B	For acceleration of excretion in drug intoxication (where excretion of the drug into the urine is accelerated by elevated urine pH) and for acidosis	IV infusion of 2 - 5 mmol/kg body weight over a period of 4 - 8 hours or according to the needs of the patients
1427	Sodium Bicarbonate 5% w/v Ear Drops	S02DC00131 D1001XX	C	To soften the impacted ear wax	2-3 drops 3-4 times daily
1428	Sodium Bicarbonate 8.4% (1 mmol/ml) Injection	B05XA02131 P3002XX	B	For acceleration of excretion in drug intoxication (where excretion of the drug into the urine is accelerated by elevated urine pH) and for acidosis	According to the needs of the patient. In severe shock due to cardiac arrest: 50 ml by IV
1429	Sodium Bicarbonate Mixture (Paediatric)	A02AH00131 L2101XX	C	Heartburn for rapid relief of dyspepsia	CHILD up to 1 year 5 ml; up to 1-5 years 10 ml in 4 to 6 divided doses
1430	Sodium Bicarbonate, Citric Acid, Sodium Citrate and Tartaric Acid - 4 g per sachet	B05CB10955 M4001XX	B	For relieving of discomfort in mild urinary tract infection, symptomatic relief of dysuria to enchance the action to certain antibiotics especially some sulphonamides. In gout as urinary alkalinizers to prevent cystallisation of urates	4 - 8 g (1- 2 sachets) dissolved in a glass of cold water 4 times daily as prescribed
1431	Sodium Bicarbonate, Magnesium Carbonate, Tincture Cardamom Compound Mixture	A02AH00912 L2101XX	C	Heartburn, for rapid relief of dyspepsia	ADULT 10-20 ml 3 times daily
1432	Sodium Biphosphate 16%, Sodium Phosphate 6% Rectal Solution	A06AG01162 G2001XX	A	Bowel cleansing before colonic surgery, colonoscopy or radiological examination to ensure the bowel is free of solid contents. It is not to be used for treatment of constipation	ADULT 133 ml (1 bottle) administered rectally. CHILD more than 2 years half the adult dose (66.6ml)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1433	Sodium Biphosphate 16%, Sodium Phosphate 6% Solution	A06AG01162 L9901XX	A	Bowel cleansing before colonic surgery, colonoscopy or radiological examination to ensure the bowel is free of solid contents. It is not to be used for treatment of constipation	45 ml diluted with half a glass (120 mL) of water, followed by one full glass (240 mL) of water. Timing of doses is dependent on the time of the procedure. For morning procedure, first dose should be taken at 7 a.m. and second at 7 p.m. on day before the procedure. For afternoon procedure, first dose should be taken at 7 p.m. on day before and second dose at 7 a.m. on day of the procedure. Solid food should not be taken during the bowel preparation period. However clear fluids or water can be taken liberally. CHILD under 12 years not recommended
1434	Sodium Chloride 0.18% with Dextrose 10% Injection	B05XA03904 P6001XX	B	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient
1435	Sodium Chloride 0.18% with Dextrose 4.23% Injection	B05XA03904 P6004XX	B	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient
1436	Sodium Chloride 0.45% Injection	B05XA03100 P6001XX	B	For replenishing fluid and for restoring / maintaining the concentration of sodium and chloride ions	100 - 1000 ml by IV or according to the needs of the patient
1437	Sodium Chloride 0.45% with Dextrose 10% Injection	B05XA03904 P6002XX	B	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient
1438	Sodium Chloride 0.45% with Dextrose 5% Injection	B05XA03904 P6005XX	B	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient
1439	Sodium Chloride 0.9% Eye Drops	S01XA03000 D2001XX	C	Irrigation of conjunctival sac	1 - 2 drops every 3 - 4 hours

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1440	Sodium Chloride 0.9% Injection	B05XA03100 P6002XX	C+	For replenishing fluid and for restoring/maintaining the concentration of sodium and chloride ions	100 - 1000 ml by IV or according to the needs of the patient
1441	Sodium Chloride 0.9% with Dextrose 5% Injection	B05XA03904 P6003XX	C+	For replenishing fluid and energy and for restoring or maintaining the concentration of sodium and chloride ions	According to the needs of the patient
1442	Sodium Chloride 20% Injection	B05XA03100 P9902XX	B	Addition of sodium electrolyte in parenteral nutrition bags especially in paediatrics or neonates with restricted fluid allowance	According to the needs of the patient
1443	Sodium Chloride 3% Injection	B05XA03100 P9901XX	B	Acute dilutional hyponatraemia	According to the needs of the patient
1444	Sodium Chromate (Chromium-51) Solution	V09GX00143 L9901XX	A*	Labelling of erythrocytes for the investigation of haemotological disorders	Usual dose range : 10 - 200 microcuries IV by IV injection
1445	Sodium Citrate 0.3 M Solution	B05CB02136 L9901XX	B	Prophylaxis for aspiration pneumonitis (use as an oral solution)	Dose depending on clinical cases. Usually, 30 ml given 10- 60 minutes before anaesthesia prior to elective cesarean surgery is an effective antacid
1446	Sodium Citrate 3.8% Solution	B05CB02136 H3001XX	B	Sterile solution for irrigation or washout of infected bladder	Dose depending on clinical cases
1447	Sodium Citrate, Citric Acid Mixture 3 g/10 ml	B05CB02136 L2101XX	B	Citrates and citric acid solutions are used to correct the acidosis of certain renal tubular disorders to treat metabolic acidosis for long-term urine alkalinization for prevention and treatment of uric acid and calcium kidney stones and as nonparticulate neutralizing buffers	ADULT 10 - 20 ml. CHILD up to 1 year 2.5 ml tds; 1-5 year 5 ml tds; 6-12 years 10 ml tds. To be taken well diluted with water
1448	Sodium Cromoglycate 2% Eye Drops	S01GX01520 D2001XX	A/KK	Prevention and treatment of allergic conjunctivitis including seasonal and perennial allergic conjunctivitis and vernal keratoconjunctivitis	1 or 2 drops 4 times daily
1449	Sodium Dichloroisocyanurate 2.5 g Tablet	V07AV00000 T1001XX	C	Low and medium level disinfectant	50 - 10,000 ppm av chlorine
1450	Sodium Dichloroisocyanurate 5 g Tablet	V07AV00000 T1002XX	C	Low and medium level disinfectant	50 - 10,000 ppm av chlorine

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1451	Sodium Fusidate 2% Ointment	D06AX01520 G5001XX	A	Skin infections caused by staphylococci, streptococci, corynebacterium minutissumun and other sodium fusidate-sensitive organisms	Apply to affected area 2 - 3 times daily
1452	Sodium glycerophosphat e for addition into infusion solution, 20ml vial	B05XA14171 P3001XX	A	Indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirement of phosphate.	Adults: The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20mmol. This can be met by using 10-20ml of sodium glycerophosphate to the infusion solution or to the admixture for which compatibility has been proved. Infants: The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/kg bodyweight/day.
1453	Sodium Hypochlorite Solution	V07AV00000 L9903XX	C	Low-level disinfectant and antiseptic	Antiseptic: less than 0.5%. Disinfectant: 5%
1454	Sodium Iodide (Iodide-131) Injection	V09FX03200 P3001XX	A*	Used in the determination of various thyroid functions	5 - 50 millicuries
1455	Sodium Iodide (Iodine-131) Capsule	V09FX03200 C1001XX	A*	Determination of various thyroid functions	5 - 10 milicuries (5 mCi for whole body scan)
1456	Sodium Iodide (Iodine-131) Capsule (Therapeutic)	V10XA01200 C1001XX	A*	i) Thyrotoxicosis ii) Thyroid carcinoma	i) 2 - 30 millicuries ii) 80 - 300 millicuries
1457	Sodium Iodide (Iodine-131) Solution	V10XA01200 L9901XX	A*	i) Thyrotoxicosis ii) Thyroid carcinoma	i) 5-25 millicuries ii) 30-150 millicuries

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1458	Sodium Nitrite 30 mg/ml Injection	V03AB08220 P3001XX	B	For cyanide poisoning	Adult: 300 mg sodium nitrite IV over 3 minutes followed after 5 minutes with 12.5g sodium thiosulphate IV administered over 10 minutes. CHILD: 4 - 10 mg/kg of sodium nitrite (max: 300 mg) followed by 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses.
1459	Sodium Nitroprusside 10 mg/ml Injection	C02DD01520 P3001XX	A	i) Hypertensive crisis ii) Controlled hypotension during anaesthesia in order to reduce bleeding in surgical procedures	i) By IV infusion, initially 0.5-1.5 mcg/kg/min, then adjusted before increasement of 0.5 mcg/kg/min every 5 mins within range 0.5-8 mcg/kg/min (lower doses in patients already receiving other antihypertensives); stop if marked response not obtained with max dose in 10 minutes. Use only in infusion with 5 % Dextrose IV. ii) By IV infusion, max: 1.5 mcg/kg/min
1460	Sodium Phosphate (Phosphorus-32) Injection	V10XX01162 P3001XX	A*	Polycythemia vera, chronic myeloid and chronic lymphocytic leukaemia and palliative treatment of bone metastases	Initially 5 millicuries, follow if necessary by a dose of not more than 3 or 4 millicurie at intervals of not less than 2 months
1461	Sodium Polystyrene Sulphonate Powder	V03AE01520 F2101XX	A	Treatment and prevention of hyperkalaemia associated with anuria or severe oliguria, in dialysis patients or those on prolonged peritoneal dialysis	ADULT: Oral: 15 g 1 - 4times/day. Rectal: 30 g in 100 ml 2% methylcellulose and 100 ml water as a daily retention enema. Retain for 9 hours followed by non-sodium cleansing enema. CHILD: 1 g/kg in 1 - 4 doses in acute hyperkalemia.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					Maintenance : 0.5 g/kg/daily
1462	Sodium Tetradecyl Sulphate 1 % Injection	C05BB04183 P3001XX	A*	Sclerotherapy of oesophageal varices, haemorrhoids and varicose veins	0.5-2 mL into the submucosal layer at the base of the oesophageal varix or the haemorrhoid; several injections may be given at different sites, max. total injected 10-15 mL of 1% per treatment
1463	Sodium Tetradecyl Sulphate 3 % Injection	C05BB04183 P3002XX	A*	Sclerotherapy of oesophageal varices, haemorrhoids and varicose veins	0.5-2 mL into the submucosal layer at the base of the oesophageal varix or the haemorrhoid, several injections may be given at different sites, max. total injected 10-15 mL of 1% per treatment
1464	Sodium Thiosulphate 10-20% Solution	D01AE00181 L9901XX	C	Fungicides. For the treatment of pityriasis versicolor	Apply to all affected parts of the body and face with a brush after a bath once daily or twice daily or 3 times daily
1465	Sodium Thiosulphate 500 mg/ml Injection	V03AB06181 P3001XX	B	For cyanide poisoning	Adult: To be given after 300 mg of sodium nitrite has been admin over 5-20 min: 12.5 g of sodium thiosulfate (50 ml of a 25% solution or 25 ml of a 50% solution) given over 10 min. Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses. Child: To be given after 4-10 mg/kg of sodium nitrite (max: 300 mg) has been admin: 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). Methaemoglobin concentration should not exceed 30-40%. If symptoms of cyanide toxicity recur, the

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					doses of nitrite and thiosulfate may be repeated after 30 min at half the initial doses.
1466	Sodium Valproate 200 mg Tablet	N03AG01520 T1001XX	B	Epilepsy	ADULT: Initially 600 mg/day in 2 - 3 divided doses; dose may be increased by 200 mg at 3-day intervals to max 2.5 g/day. Usual maintenance dose: 1-2 g/day (20-30 mg/kg/day). CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg 20 mg/kg/day, in severe cases the dose may be increased provided plasma concentration can be monitored
1467	Sodium Valproate 200 mg/5 ml Syrup	N03AG01520 L9001XX	B	Epilepsy	ADULT: Initially 600 mg/day; dose may be increased by 200 mg at 3-day intervals to max 2500 mg/day. Usual maintenance dose: 1000-2000 mg/day (20-30 mg/kg/day). CHILD: More than 20 kg. Initially 400 mg/day with spaced increases until control is achieved (usually 20-30 mg/kg/day), dose may be increased to 35 mg/kg/day. Less than 20 kg, 20 mg/kg/day. Severe cases: 50 mg/kg daily
1468	Sodium Valproate 400 mg Injection	N03AG01520 P4001XX	B	Status epilepticus	ADULT and CHILD above 10 years: 10 to 15 mg/kg/day IV, may increase 5 to 10 mg/kg/week to achieve optimal clinical response (Maximum 60 mg/kg/day or less with a therapeutic range of 50 to 100 mcg/mL)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1469	Solifenacin Succinate 5 mg Tablet	G04BD08000 T1001XX	A*	Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.	5mg od. Dose can be increased to 10mg if necessary.
1470	Somatropin 10 mg (30IU) Injection	H01AC01000 P5002XX	A*	i) Growth failure due to inadequate endogenous growth hormone. ii) Growth failure in girls due to gonadal dysgenesis (Turner syndrome). iii) Growth failure in short children born small gestational age (SGA)	i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM. ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC. iii) 0.035 mg/kg/day or 1 mg/m2/day SC
1471	Somatropin 12 mg (36IU) Injection	H01AC01000 P3002XX	A*	i) Growth failure due to inadequate endogenous growth hormone ii) Growth failure in girls due to gonadal dysgenesis (Turner syndrome) iii) Growth failure in short children born small gestational age (SGA)	i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
1472	Somatropin 5mg (15IU) Injection	H01AC01000 P3004XX	A*	i) Growth failure due to growth hormone insufficiency ii)Growth failure in girls due to gonadal dysgenesis (Turner syndrome) iii)Growth failure in short children born small gestational age(SGA)	i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
1473	Somatropin 8 mg (24IU) Injection	H01AC01000 P3003XX	A*	i) Growth failure due to growth hormone insufficiency ii)Growth failure in girls due to gonadal dysgenesis (Turner syndrome) iii)Growth failure in short children born small gestational age(SGA)	i) 0.7-1 mg/m2/day or 0.025-0.035 mg/kg/day SC/IM ii) 1.4 mg/m2/day or 0.045-0.05 mg/kg/day SC iii) 0.035 mg/kg/day or 1 mg/m2/day SC
1474	Sotalol HCl 160 mg Tablet	C07AA07110 T1002XX	A*	Ventricular tachyarrythmias	Supraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-threatening ventricular arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					Max: 480-640 mg in divided doses.
1475	Sotalol HCl 80 mg Tablet	C07AA07110 T1001XX	A*	Ventricular tachyarrythmias	Supraventricular and ventricular arrhythmias Adult: Initially, 80 mg/day as single or in 2 divided doses, increased gradually every 2-3 days. Usual dose: 160-320 mg/day in 2 divided doses. Life-threatening ventricular arrhythmias Adult: Initially, 80 mg bid, increased gradually every 3 days to 240-320 mg/day in divided doses if needed. Maintenance: 160-320 mg/day in divided doses. Max: 480-640 mg in divided doses.
1476	Spironolactone 25 mg Tablet	C03DA01000 T1001XX	B	Oedema and ascites in cirrhosis of the liver, congestive heart failure	ADULT: 100 - 200 mg daily in divided doses. Increase to 400 mg if required. CHILD: initially 3 mg/kg daily in divided doses
1477	Stavudine 1 mg/ml Solution	J05AF04000L 5001XX	A*	HIV infection, in combination with other antiretrovirals	Infant: 0 - 13 days old: 0.5 mg/kg/dose twice daily. Infant 14 days and older and weighing less than 30 kg: 1 mg/kg twice daily; more than 30 kg and <60kg: 30 mg twice daily
1478	Stavudine 30 mg Capsule	J05AF04000C 1001XX	A/KK	HIV infection, in combination with other antiretrovirals	ADULT more than 60 kg: 40 mg twice daily; less than 60 kg: 30 mg twice daily. CHILD <30kg: 1mg/kg twice daly; >30kg refer to adult dosage
1479	Stavudine 30 mg, Lamivudine 150 mg & Nevirapine 200 mg Tablet	J05AR07964T 1001XX	A/KK	Fixed dose triple therapy for treatment of HIV infection in adults once patients have been stabilized on the maintenance regimen of nevirapine 200 mg twice daily and have demonstrated adequate tolerability to nevirapine	SLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1480	Stavudine 40 mg Capsule	J05AF04000C1002XX	A*	HIV infection, in combination with other antiretrovirals	ADULT more than 60 kg: 40 mg twice daily; less than 60 kg: 30 mg twice daily. CHILD <30kg: 1mg/kg twice daly; >30kg refer to adult dosage
1481	Stavudine 40 mg, Lamivudine 150 mg & Nevirapine 200 mg Tablet	J05AR07964T1002XX	A*	Fixed dose triple therapy for treatment of HIV infection in adults once patients have been stabilized on the maintenance regimen of nevirapine 200 mg twice daily and have demonstrated adequate tolerability to nevirapine	SLN 30: 30-60 kg 1 tablet twice daily. SLN 40 ≥60 kg 1 tablet twice daily
1482	Streptokinase 1,500,000 IU Injection	B01AD01000P4001XX	A*	Acute myocardial infarction, acute pulmonary embolism	Myocardial infarction: 1,500,000 units over 30 - 60 minutes. Pulmonary embolism: 250,000 units by IV infusion over 30 minutes, then 100,000 units every hour for up to 12-72 hours with monitoring of clotting factors
1483	Streptomycin Sulphate 1 g Injection	J01GA01183P4001XX	B	Tuberculosis	ADULT: 15 mg/kg daily; max: 1 g daily. Reduce max daily dose to 500-750 mg in patients >40 yr. As part of an intermittent therapy: 25-30 mg/kg/day 2-3 times/wk; max: 1.5 g/dose. Not >120 g over the course of treatment should be given unless there are no other treatment options. Child: 20-40 mg/kg (max: 1 g) daily or 25-30 mg/kg (max: 1.5 g) 2-3 times wkly.
1484	Strontium Ranelate 2 g Granules	M05BX03000F1001XX	A*	Treatment of postmenopausal osteoporosis to reduce risk of vertebral and hip fractures when biphosphonates are contraindicated or not tolerated	2 g sachet once daily
1485	Succindialdehyde 11% & Dimethoxytetrahydrofuran 3%	V07AV00000L9907XX	A	High level disinfection for endoscopes, ultrasonicprobes, anaesthesia equipment etc	Immersion time is based on manufacturers recommendation

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1486	Sucralfate 1 g Tablet	A02BX02000 T1001XX	A	i) Benign gastric and duodenal ulceration ii) Stress ulcer prophylaxis	i) 2 g twice daily or 1 g 4 times daily for 4-6 weeks or in resistant cases up to 12 weeks (maximum 8 g daily) ii) 1 g 6 times daily (maximum 8 g daily). CHILD not recommended
1487	Sugammadex 100 mg/ml Injection	V03AB35000 P3001XX	A*	Indicated for reversal of neuromuscular blockade induced by rocuronium and vecuronium in selective patient group: obese, elderly, underlying cardiovascular disease. For pediatric population, sugammadex is recommended for routine reversal	2 mg/kg sugammadex is recommended, if spontaneous recovery has occurred up to at least the reappearance of second twitch tension of the train-of-four (T2). 4 mg/kg sugammadex is recommended if recovery has reached at least 1- 2 post-tetanic counts (PTC). For immediate reversal following administration of rocuronium a dose of 16 mg/kg sugammadex is recommended
1488	Sulfadoxine 500 mg and Pyrimethamine 25 mg Tablet	P01BD51981 T1001XX	B	Treatment of Plasmodium falciparum malaria in patients in whom chloroquine resistance is suspected and malaria prophylaxis for travellers to areas where chloroquine-resistant malaria is endemic	Chloroquine resistant falciparum malaria acute attack Adult: Per tab contains pyrimethamine 25 mg and sulfadoxine 500 mg: 2-3 tabs as a single dose. Do not repeat for at least 7 days. Child: Pyrimethamine 25mg + Sulfadoxine 500mg (Tablet): <2 yr (5-10 kg): ? tab as a single dose; 2-5 yr (>10-20 kg): 1 tab as a single dose; 5-10 yr (< 20-30 kg): 1? tab as a single dose; 10-14 yr (> 30-45 kg): 2 tab as a single dose. Do not repeat for at least 7 days. Renal impairment: Dose reduction may be needed. Severe: contra-indicated. Hepatic impairment: Dose reduction may be needed. Severe: contra-indicated.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1489	Sulphamethoxazole 200 mg & Trimethoprim 40 mg/5ml Suspension	J01EE01961L8001XX	B	Infections caused by susceptible pathogens	Mild to moderate infections: more than 2months: 8 - 12mg Trimethoprim/kg/day divided every 12hours. Serious Infections: 15-20mg Trimethoprim/kg/day divided every 6 hours.
1490	Sulphamethoxazole 400 mg & Trimethoprim 80 mg Injection	J01EE01961P3001XX	A	i) Severe or complicated infections when oral therapy is not feasible ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patients	i) ADULT: 960 mg twice daily increased to 1.44 g twice daily in severe infections. CHILD: 36 mg/kg daily in 2 divided doses increased to 54 mg/kg/day in severe infections ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day PO/IV infusion in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg
1491	Sulphamethoxazole 400 mg & Trimethoprim 80 mg Tablet	J01EE01961T1001XX	B	i) Severe or complicated infections due to susceptible infection ii) Treatment and prophylaxis of pneumocystis carinii pneumonia (PCP) in immunocompromised patients	i) ADULT: 1 - 3 tablets twice daily ii) Treatment: ADULT & CHILD over 4 weeks: 120 mg/kg/day in 2 - 4 divided doses for 14 days. Prophylaxis: ADULT: 960 mg once daily or 960 mg on alternate days (3 times a week) or 960 mg twice daily on alternate days (3 times a week). CHILD; 6 weeks - 5 months: 120 mg twice daily on 3 consecutive days or 7 days per week; 6 months - 5 years: 240 mg; 6 - 12 years: 480 mg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1492	Sulphur 2% & Salicylic Acid 2% Cream	D10AB02951 G1001XX	C	Acne vulgaris and seborrhoeic dermatitis	When used in scalp disorders, a small amount of cream should be rubbed gently into the roots of the hair. When used in skin disorders, the cream should be applied sparingly to the affected area. Apply once daily or until noticeable improvement, then once or twice a week
1493	Sulpiride 200 mg Tablet	N05AL01000 T1001XX	B	Acute and chronic schizophrenia, chronic delusional psychoses	200-400 mg twice daily; 800 mg daily in predominantly negative symptoms and 2.4 g daily in mainly positive symptoms. Elderly, lower initial dose; increased gradually according to response. Child under 14 years not recommended
1494	Sumatriptan 100 mg Tablet	N02CC01000 T1002XX	A/KK	Treatment of acute migraine attacks	50 mg per attack and not more than 300 mg daily
1495	Sumatriptan 50 mg Fast Disintegrating Tablet	N02CC01000 T5001XX	A	Treatment of acute migraine attacks	50 mg per attack and not more than 300 mg daily
1496	Sumatriptan 50 mg Tablet	N02CC01000 T1001XX	A/KK	Treatment of acute migraine attacks	50 mg per attack and not more than 300 mg daily
1497	Sumatriptan 6 mg/0.5 ml Injection	N02CC01000 P5001XX	A	Treament of acute migraine attacks and cluster headache	6 mg given by SC as soon as possible after onset. Dose may be repeated once after not less than 1 hour if needed. Max. 12 mg in 24 hours. Child not recommended
1498	Sunscreen 5 - 20% w/w Cream	D02BA02000 G1001XX	B	Photodermatitis	Apply to exposed areas at least 30 minutes prior to solar exposure; reapply after swimming, prolonged perspiration and after 2 hours of continuos sun exposure

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1499	Suxamethonium Chloride 50 mg/ml Inj	M03AB01100 P3001XX	B	Muscle relaxant as an adjunct to anaesthesia	Intravenous: Muscle relaxant in general anaesthesia Adult: As chloride: single dose of 0.3-1.1 mg/kg injected; supplementary doses of 50-100% of the initial dose may be given at 5-10 min intervals. Max dose (repeated IV injection or continuous infusion): 500 mg/hr Child: As chloride: <1 yr: 2 mg/kg; 1-12 yr: 1 mg/kg. Intramuscular: Muscle relaxant in general anaesthesia Adult: As chloride: 3-4 mg/kg. Max total dose: 150 mg Child: As chloride: <1 yr: Up to 4-5 mg/kg; ≥1 yr: Up to 4 mg/kg. Max dose: 150 mg.
1500	Synthetic ACTH (Tetracosactrin Acetate) 250 mcg/ml Injection	H01AA02000 P3001XX	A	Diagnostic test to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiency	Diagnostic test for investigation of adrenocortical insufficiency Adult: As plain preparation: Measure plasma cortisol concentration immediately before and exactly 30 min after IM/IV inj of 250 mcg. Post-inj rise in plasma cortisol concentration ≥200 nmol/l (70 mcg/l) if normal adrenocortical function. As depot preparation (if inconclusive results with plain preparation): Measure plasma cortisol concentration before and exactly 30 min, 1, 2, 3, 4 and 5 hr after an IM inj of 1 mg tetracosactide acetate depot. Adrenocortical function normal if the post-inj rise in plasma cortisol concentration increases 2-fold in 1st hr, and continues to rise steadily. Expected levels in 1st hr: 600-1,250

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					nmol/l, increasing slowly up to 1000-1800 nmol/l by 5th hr. Child: IV 250 mcg/1.73 m2 BSA. Intramuscular
1501	Tacrolimus 0.03% Ointment	D11AH01000 G5002XX	A*	For short-term and intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis in whom the use of alternative, conventional therapies are deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or are intolerant of alternative, conventional therapies	Adult ≥16 years: Apply 0.03% or 0.1% to the affected skin twice daily and rub in gently and completely. Children ≥ 2 years: Apply 0.03% ointment thinly to the affected skin bd and rub in gently and completely. Treatment should be continued for 1 week after clearing of signs & symptoms of atopic dermatitis.
1502	Tacrolimus 0.1% Ointment	D11AH01000 G5001XX	A*	For short-term and intermittent long-term therapy in the treatment of patients with moderate to severe atopic dermatitis in whom the use of alternative, conventional therapies are deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or are intolerant of alternative, conventional therapies	Adult ≥16 years: Apply 0.03% or 0.1% to the affected skin twice daily and rub in gently and completely. Children ≥ 2 years: Apply 0.03% ointment thinly to the affected skin bd and rub in gently and completely. Treatment should be continued for 1 week after clearing of signs & symptoms of atopic dermatitis.
1503	Tacrolimus 0.5 mg Capsule	L04AD02000 C1003XX	A*	i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejection	i) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses
1504	Tacrolimus 1 mg Capsule	L04AD02000 C1001XX	A*	i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejection	i) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses
1505	Tacrolimus 5 mg Capsule	L04AD02000 C1002XX	A*	i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejection	i) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses
1506	Tacrolimus 5mg/ml Injection	L04AD02000 P3001XX	A*	i) Primary immunosuppressant agent for all solid organ transplantation ii) Rescue therapy for rejection	i) 0.2 mg/kg/day in 2 divided doses ii) 0.3 mg/kg/day in 2 divided doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1507	Tamoxifen Citrate 20 mg Tablet	L02BA01136 T1001XX	A	Breast cancer	20 mg in 1-2 divided doses. Max: 40 mg/day
1508	Tamsulosin HCl 400 mcg Extended Release Tablet	G04CA02110 T5001XX	A*	Second line treatment of functional symptoms of benign prostatic hyperplasia (BPH) in patients who do not tolerate first line drugs or when first line drugs are inappropriate or contraindicated	400 mcg once daily
1509	Tar, Coal Tar and Oleyl Alcohol Liquid	D05AA00952 L5001XX	A/KK	Dandruff, seborrhoeic dermatitis and atopic dermatitis	Massage into wet hair, rinse and repeat. Use once or twice weekly
1510	Technetium-99m Sterile Generator	V09CA01000 P3001XX	A*	Sodium pertechnetate is used for scintigraphy or nuclear scan particularly of the brain and thyroid to prepare various technetium-99m labelled injections for selective organ imaging	Technetium-99m as pertechnetate is obtained by elution with a sterile solution of Sodium Chloride 0.9%. The dosage depend on type of scan i) Thyroid scintigraphy: 18.5-80 MBq (0.5-2.2 mCi) Scintigraphy performed 20 minutes after intravenous injection ii) Salivary gland scintigraphy: 40 MBq (1.1 mCi) Scintigraphy performed immediately after intravenous injection and at regular intervals up to 15 minutes iii) Meckel?s diverticulum scintigraphy: 400 MBq (10.8 mCi) Scintigraphy performed immediately after intravenous injection and at regular interval up to 30 minutes iv) Brain scintigraphy: 370-800 MBq (10-22 mCi) Rapid sequential images are taken immediately within the first minute after intravenous administration, static images 1 to 4 hours later. Thyroid and coriod plexus should be blocked to avoid non-specific 99mTc uptake v) Cardiac and vascular

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					scintigraphy: 740-925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by pretreating with a reducing agent. Dynamic images are taken in the first minute after intravenous administration, followed by regular images over 30 minutes vi) Gastrointestinal bleeding: 740-925 MBq (20-25 mCi) Red cells are labeled in vivo or in vitro by pretreating with a reducing agent. Dynamic images are taken in the first minutes after intravenous administration, followed by regular images at appropriate intervals for up to 24 hours vii) Lacrimal duct scintigraphy: 2-4 MBq each eye (50-100 mCi) Drops are instilled into eye and dynamic images are taken over 2 minutes, followed by static images at appropriate intervals over 20 minutes
1511	Tegafur 100 mg & uracil 224 mg Capsule	L01BC53980 C1001XX	A*	Non small cell lung cancer	300-600 mg daily in 2-3 divided doses
1512	Telbivudine 600 mg Tablet	J05AF11000T 1001XX	A*	Treatment of chronic hepatitis B in patients with evidence of viral replication and active liver inflammation	ADULT and CHILD over 16 years: 600 mg once daily. Renal Dose Adjustment: 600mg every 48hours (30-49ml/min), 600 mg every 72hours. (<30ml/min; not requiring dialysis); 600mg every 96 days (ESRD)
1513	Telmisartan 40 mg Tablet	C09CA07000 T1001XX	A/KK	Hypertension in patients who cannot tolerate ACE inhibitors because of cough	40mg - 80mg once daily
1514	Telmisartan 80 mg & Hydrochlorothiazide 12.5 mg Tablet	C09DA07000 T1001XX	A/KK	Hypertension in patients who cannot tolerate ACE inhibitors because of cough	1 tablet daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1515	Telmisartan 80 mg and Amlodipine 10 mg Tablet	C09DB04935 T1002XX	A/KK	Treatment of essential hypertension in adults: i) Replacement therapy:Patients receiving telmisartan and amlodipine from separate tablets may instead receive one tablet containing the same component doses ii) Add on therapy: Patients who blood pressure is not adequately controlled on telmisartan or amlodipine monotherapy iii) Initial therapy: May also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals	Single-pill combination should be taken once daily. Initiate with telmisartan 80mg/amlodipine 5mg one tablet per day. The maximum recommendation dose is telmisartan 80mg/amlodipine 10mg one tablet per day.
1516	Telmisartan 80 mg and Amlodipine 5 mg Tablet	C10BX03935 T1008XX	A/KK	Treatment of essential hypertension in adults: i) Replacement therapy:Patients receiving telmisartan and amlodipine from separate tablets may instead receive one tablet containing the same component doses ii) Add on therapy: Patients who blood pressure is not adequately controlled on telmisartan or amlodipine monotherapy iii) Initial therapy: May also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals	Single-pill combination should be taken once daily. Initiate with telmisartan 80mg/amlodipine 5mg one tablet per day. The maximum recommendation dose is telmisartan 80mg/amlodipine 10mg one tablet per day.
1517	Telmisartan 80 mg Tablet	C09CA07000 T1002XX	A/KK	i)Hypertension in patients who cannot tolerate ACE inhibitors because of cough ii)Reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors	i) 40mg - 80mg once daily ii) 80mg once daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1518	Temozolomide 100 mg Capsule	L01AX03000 C1003XX	A*	In patients with glioblastoma multiforme who fulfill all the following criteria : i. Total /near total resection ii. ECOG/WHO performance status 0-2 iii. Age less than 60 years	Concomitant phase: 75mg/m2 daily with radiotherapy for 42 days, followed by 6 cycle of adjuvant treatment. Adjuvant phase: Additional 6 cycles of adjuvant phase. Cycle 1- 150mg/m2 once daily for 5 days followed by 23 days without treatment. Cycle 2-6 : 200mg/m2 once daily for 5 days per 28-day cycle
1519	Temozolomide 20 mg Capsule	L01AX03000 C1001XX	A*	In patients with glioblastoma multiforme who fulfill all the following criteria : i. total /near total resection ii. ECOG/WHO performance status 0-2 iii. Age less than 60 years	Concomitant phase: 75mg/m2 daily with radiotherapy for 42 days, followed by 6 cycle of adjuvant treatment. Adjuvant phase: Additional 6 cycles of adjuvant phase. Cycle 1- 150mg/m2 once daily for 5 days followed by 23 days without treatment. Cycle 2-6 : 200mg/m2 once daily for 5 days per 28-day cycle
1520	Tenecteplase 10,000 unit (50 mg) Injection	B01AD11000 P4001XX	A*	Acute myocardial reinfarction where streptokinase is contraindicated due to previous streptokinase induced antibodies. [Indicated when antibodies was given more than 5 days and less than 12 months]	Less than 60 kg: 30 mg, 60 - 69 kg: 35 mg, 70 - 79 kg: 40 mg; 80 -90 kg: 45 mg, 90 kg or above: 50 mg. Administer single IV bolus over 5-10 seconds
1521	Tenofovir Disoproxil Fumarate 300 mg & Emricitabine 200 mg Tablet	J05AR03964T 1001XX	A/KK	Treatment of HIV-1 infection in adults in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors).	1 tablet once daily.
1522	Tenofovir Disoproxil Fumarate 300 mg Tablet	J05AF07138T 1001XX	A*	i)Treatment of HIV-1 infected adults in combination with other antiretroviral agents. ii)Use as first line monotherapy for chronic hepatitis B or as a rescue therapy for patients with drug resistance hepatitis B virus (according to resistant profile or treatment guidelines).	300mg once daily. Renal Dose Adjustment: 300mg every 48hours (30-49ml/min); 300mg every 72hours (10-29ml/min); 300mg every 7 days after dialysis (Hemodialysis)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1523	Terazosin HCl 1 mg Tablet	G04CA03110 T1001XX	A/KK	Only for treatment of Benign Prostatic Hyperplasia. Not to be used for treatment of hypertension	Initially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 10 mg once daily
1524	Terazosin HCl 2 mg Tablet	G04CA03110 T1002XX	A/KK	i) Treatment of Benign Prostatic Hyperplasia. ii)Hypertension	i) Initially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 10 mg once daily. ii)Initial: 1mg once daily at bedtime, Maintenance: 1-5mg once (morning or evening) or twice daily. Max: 20-40mg/day
1525	Terazosin HCl 5 mg Tablet	G04CA03110 T1003XX	A/KK	i) Treatment of Benign Prostatic Hyperplasia. ii)Hypertension	i) Initially 1 mg at night, increased in a stepwise fashion to 2 mg, 5 mg or 10 mg once daily. ii) Initial: 1mg once daily at bedtime, Maintenance: 1-5mg once (morning or evening) or twice daily. Max: 20-40mg/day
1526	Terbinafine HCl 250 mg Tablet	D01BA02110 T1001XX	A/KK	Fungal infections especially onchomycosis caused by dermatophytes	250 mg once daily for 6 weeks for fingernails: 12 weeks for toenails
1527	Terbutaline 0.5mg/dose Inhaler	R03AC03183 A2001XX	B	Bronchial asthma, chronic bronchitis, emphysema and other lung diseases where bronchospasm is a complicating factor	ADULT and CHILD more than 12 years: 1 inhalation 6 hourly. Severe cases: Single dose may be increased to 3 inhalations. Maximum 12 inhalation/24 hour. CHILD 3-12 year: 1 inhalation 6 hourly. Severe cases: Single dose may be increased to 2 inhalations. Maximum 8 inhalation/24 hour
1528	Terbutaline Sulphate 0.3 mg/ml Syrup	R03CC03183 L9001XX	B	Asthma and other conditions associated with reversible airways obstruction	CHILD less than 7 years : 75 mcg/kg 3 times daily, 7 - 15 years : 2.5 mg 2 - 3 times daily
1529	Terbutaline Sulphate 0.5 mg/ml Injection	R03CC03183 P3001XX	B	Bronchial asthma, chronic bronchitis, emphysema and other lung diseases where broncoconstriction is a complicating factor	SC, IM or slow IV: 250-500 mcg up to 4 times daily. CHILD 2 - 15 years 10mcg/kg to a maximum of 300 mcg. Continuous IV infusion, as a solution containing 3 - 5 mcg/ml, 1.5 - 5 mcg/minute for 8 - 10 hours; reduce

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					dose for children
1530	Terbutaline Sulphate 10 mg/ml Nebulizer Solution	R03AC03183 A3001XX	B	Asthma and other conditions associated with reversible airways obstruction	ADULT : 5 - 10 mg 2 -4 times daily, additional doses may be necessary in severe acute asthma. CHILD up to 3 years : 2 mg, 3 - 6 years : 3 mg, 6 - 8 years : 4 mg, over 8 years : 5 mg 2 - 4 times daily
1531	Terbutaline Sulphate 2.5 mg Tablet	R03CC03183 T1001XX	B	Asthma and other conditions associated with reversible airways obstruction	ADULT: Initially 2.5 mg 3 times daily for 1 - 2 week, then up to 5 mg 3 times daily. CHILD less than 7 years: 75 mcg/kg 3 times daily, 7 - 15 years: 2.5 mg 2 - 3 times daily
1532	Terlipressin 1mg/5mg Injection	H01BA04000 P4001XX	A*	Acute oesophageal variceal bleeding	2 mg IV bolus over 1 minute. Maintenance: 1 - 2 mg IV bolus 4 - 6 hourly until bleeding is controlled, up to 24 - 36 hours. The maximum daily dosage is 120-150 mcg/kg body weight.
1533	Testosterone 250 mg/ml Injection	G03BA03000 P3001XX	A*	Only for treatment of male infertility, protein deficiency during convalescence after surgery and wasting disorder. In women, supplementary therapy of progressive mammary carcinoma	By IM only. Hypogonadism 250 mg every 2-3 weeks. To maintain an adequate androgenic effect 250 mg every 3-6 weeks. Potency disorders 250 mg every 4 weeks. Male climateric disorders: 250 mg every 3-4 weeks. Repeated 6-8 weeks courses at 2-3 months interval
1534	Tetanus Toxoid Injection	J07AM01000 P3001XX	C+	Immunization against tetanus infection	2 doses of 0.5 mL IM at an interval of 4-8 wk, followed by the 3rd dose 6-12 mth later. Booster: 0.5 mL IM every 10 yr.
1535	Tetracycline HCl 250 mg Capsule	J01AA07110C 1001XX	B	Infections caused by susceptible pathogens	"Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g daily"
1536	Tetracycline HCl 250 mg Tablet	J01AA07110T 1001XX	B	Infections caused by susceptible pathogens	"Adult: 250-500 mg 6 hrly. Max: 4 g/day. Child: ≥12 yr Max: 2 g daily"

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1537	Thalidomide 50 mg Capsule	L04AX02000 C1001XX	A*	First line induction therapy in newly diagnosed multiple myeloma, salvage therapy in relapsed multiple myeloma and maintenance therapy in multiple myeloma (contraindicated for pregnant women; pregnancy test for females in reproductive age group before starting treatment should be done).	50 mg to 200 mg daily
1538	Thallous Chloride (Thallium-201) Injection	V09GX01100 P3001XX	A*	Used in myocardial perfusion scintigraphy, acute myocardial infarction and post-surgical assessment of coronary artery bypass graft patency, muscle perfusion scintigraphy, visualisation of brain and thyroid tumours and metastases	As IV infusion
1539	Theophylline 125 mg Tablet	R03DA04000 T1001XX	B	Reversible airways obstruction, acute severe asthma	ADULT: 125 mg 3 - 4 times daily after food, increased to 250 mg if required. CHILD: 1 - 15 years : 5 mg/kg/dose (up to 600 mg/ day) every 3 - 4 times daily
1540	Theophylline 250 mg Long Acting Tablet	R03DA04000 T5001XX	B	Reversible airways obstruction and acute severe asthma	ADULT: 250 mg 2 times daily. CHILD under 12 years : Up to 10 mg/kg body weight 2 times daily
1541	Theophylline 80 mg/15 ml Syrup	R03DA04000 L9001XX	B	Reversible airways obstruction and acute severe asthma	ADULT : 125 mg 3 - 4 times daily after food, increased to 250 mg if required. CHILD 1 - 15 years : 5 mg/kg/dose (up to 600 mg/day) every 3 - 4 times per day
1542	Thiamine HCl 100 mg/ml Injection	A11DA01110 P3001XX	B	i) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndrome	i) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200- 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose
1543	Thiamine Mononitrate 10 mg Tablet	A11DA01221 T1002XX	C	i) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndrome	i) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200- 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1544	Thiamine Mononitrate 3 mg Tablet	A11DA01221 T1001XX	C	i) For the prevention or treatment of Vitamin B1 deficiency syndromes including beri-beri and peripheral neuritis associated with pellagra ii) Wernicke-Korsakoff Syndrome	i) Mild to chronic deficiency: 10-25 mg daily. Severe deficiency: 200 - 300 mg daily ii) 500 mg every 8 hours for 2 days, followed by 100 mg 2 times daily until patient can take oral dose
1545	Thioguanine 40 mg Tablet	L01BB03000T 1001XX	A	For acute leukaemia and chronic granulocytic leukaemia	Refer to specific protocols. Usually 100 mg/m2 for 5 - 7 days (acute myeloid leukaemia) or up to 2 weeks (chronic myeloid leukaemia for accelerated/ advanced disease). CHILD: 40 - 60 g/m2 daily according to protocol
1546	Thiopental Sodium 500 mg Injection	N05CA19520 P3001XX	B	i) General anaesthesia, induction ii) Anticonvulsant for cases resistant to conventional anticonvulsants in the ICU	i) ADULT : For induction 200 - 400 mg. For repeat injection 3 - 5 mg/kg over 10 - 15 seconds until desired depth of anaesthesia is obtained. Not FDA approved for use in pediatric patients ii) 75 - 125 mg IV single dose; for local-anaesthetic induced convulsion: 125 - 250 mg IV over 10 minutes
1547	Thymol Compound Gargle	A01AD11985 M2001XX	C	For sore throat and minor mouth inflammation	To be gargled 3-4 times daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1548	Thyrotropin alfa 0.9mg/ml Injection	H01AB01000 P3002XX	A*	Thyrogen (thyrotropin alfa) is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.	A two-injection regimen is recommended for thyrotropin administration.The two-injection regimen is thyrotropin 0.9 mg intramuscularly (IM), followed by a second 0.9 mg IM injection 24 hours later. After reconstitution with 1.2 mL Sterile Water for Injection, 1.0 mL solution (0.9 mg thyrotropin alfa) is administered by intramuscular injection to the buttock. For radioiodine imaging or treatment, radioiodine administration should be given 24 hours following the final Thyrogen injection. Diagnostic scanning should be performed 48 hours after radioiodine administration, whereas post-therapy scanning may be delayed additional days to allow background activity to decline.
1549	Tibolone 2.5 mg Tablet	G03CX01000 T1001XX	A*	Treatment of complaints resulting from the natural or surgical menopause & in cases at high risk for breast carcinomas where general hormone replacement therapy is contraindicated	2.5mg daily
1550	Ticagrelor 90 mg Tablet	B01AC24000 T1001XX	A*	a)Patient who failed clopidogrel readmitted to hospital with recurrent atherothrombotic event while patients are on clopidogrel. b) ACS patients with:i) STEMI - going for invasive (PCI), ii) NSTEMI/UA - intermediate to high risk (based on TIMI score). iii) Other complicated ACS cases treated either medically or invasively via PCI or CABG (risk of Stent thrombosis, 3VD etc.)	Initially, 180mg as single dose followed by 90mg bd with maintenance dose of ASA 75-150 mg daily.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1551	Ticlopidine HCl 250 mg Tablet	B01AC05110 T1001XX	A/KK	i) Prevention of thrombotic stroke for patients who are sensitive /intolerant to Acetysalicylic Acid ii) Maintenance of coronary bypass surgery or angioplasty iii) Maintenance of patency of access in patients on chronic haemodialysis	250 mg twice daily taken with food
1552	Timolol Maleate 0.5% Eye Drops	S01ED01253 D2002XX	A	Elevated intraocular pressure, chronic open angle glaucoma	Initially, 1 drop of 0.25% 2 times daily, if clinical response is not adequate, 1 drop of 0.5% 2 times daily
1553	Tinidazole 500 mg Tablet	P01AB02000 T1001XX	B	i) Amoebiasis ii) Urogenital trichomoniasis and giardiasis	i) ADULT : 2 g as a single dose for 2 - 3 days. CHILD 3 years and older : 50 mg/kg daily for 3 days ii) ADULT : 2 g as a single dose (repeated once if necessary). Sexual partners should be treated concomitantly with the same dose. CHILD 6 years and older : single dose of 1 gram
1554	Tinzaparin sodium 10,000 anti-Factor Xa IU/ml Injection in Prefilled syringe/cartridge	B01AB10520 P5001XX	A*	i)Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), not amounting to hemodynamic instability. ii)Prevention of post-operative DVT in patients undergoing general and orthopaedic surgery.	i)Treatment of DVT and PE, in conjunction with warfarin: 175 anti-Factor Xa IU/kg SC once daily for at least 6 days. ii)Thromboprophylaxis in patients with:Moderate risk of thrombosis (general surgery):3,500 anti-Factor Xa IU SC 2 hrs before surgery and postoperatively, 3,500 anti-Factor Xa IU once daily for 7-10 days. High risk of thrombosis (eg. total hip replacement):4,500 anti-Factor Xa IU SC or 50 anti-Factor Xa IU/kg body weight SC 2 hrs before surgery and then once daily until the patients has been mobilized.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1555	Tinzaparin sodium 20,000 anti-Factor Xa IU/ml Injection in Prefilled syringe/cartridge	B01AB10520 P5002XX	A*	i)Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), not amounting to hemodynamic instability. ii)Prevention of post-operative DVT in patients undergoing general and orthopaedic surgery.	i)Treatment of DVT and PE, in conjunction with warfarin: 175 anti-Factor Xa IU/kg SC once daily for at least 6 days. ii)Thromboprophylaxis in patients with:Moderate risk of thrombosis (general surgery):3,500 anti-Factor Xa IU SC 2 hrs before surgery and postoperatively, 3,500 anti-Factor Xa IU once daily for 7-10 days. High risk of thrombosis (eg. total hip replacement):4,500 anti-Factor Xa IU SC or 50 anti-Factor Xa IU/kg body weight SC 2 hrs before surgery and then once daily until the patients has been mobilized.
1556	Tioconazole 1% Cream	D01AC07000 G1001XX	A	Skin fungal infections resistant to antifungal drugs such as miconazole and clotrimazole	Gently massage into the affected and surrounding area 1-2 times daily
1557	Tioconazole 100 mg Vaginal Tablet	G01AF08000 S1001XX	A	Vulvovaginal candidiasis	Adult & Child > 12yr: Insert nightly on retiring for 3-6 or 14 days
1558	Tioconazole 6.5% Vaginal Ointment	G01AF08000 G5001XX	A	Vulvaginal candidiasis	Apply 4.6 g intravaginally prior to bedtime as a single dose therapy, therapy may extend to 7 days
1559	Tiotropium 2.5mcg/puff solution for inhalation	R03BB04320 A3001XX	A/KK	Maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD) in which the diagnosis of COPD is confirmed by spirometry.	5 mcg (2 puff) once daily, at the same time of the day
1560	Tiotropium Bromide 18 mcg Inhalation Capsules	R03BB04320 C9901XX	A/KK	Long term maintenance treatment of bronchospasm and dypsnoea associated with COPD. Tiotropium has usually been added to standard therapy (e.g. inhaled steroids, theophylline, albuterol rescue)	Contents of one capsule is inhaled once daily with the Handihaler inhalation device at the same time of the day.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1561	Tirofiban HCl 0.25 mg/ml Injection	B01AC17110 P9901XX	A*	Unstable angina or non-ST segment elevation myocardial infarction with the following: elevated cardiac markers, refractory chest pain, ST-segment changes and thrombolysis in myocardial infarction (TIMI) risk score 4	By IV infusion, 0.4 mcg/kg/min for 30 minutes, then 0.1 mcg/kg/min for at least 48 hours, maximum 108 hours
1562	Tocilizumab 20 mg/ml Injection	L04AC07000 P3001XX	A*	Indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients: i) with inadequate respond or intolerance to conventional disease- modifying antirheumatic drugs (DMARDS) ii) who has failed antitumour necrosis factors (antiTNFs) iii) where TNF is contraindicated (patients with history of pulmonary tuberculosis [PTB]) It also can be used as monotherapy or with combination with methotrexate (MTX) and/ or other DMARDS.	Recommended dose for rheumatoid arthritis of tocilizumab for adult patients is 8mg/kg given once every 4 weeks as a single-drip IV infusion over 1 hour. It should be diluted to 100 ml by a healthcare professional with sterile 0.9% w/v sodium chloride solution over 1 hour. For patients whose body weight is more than 100kg, doses exceeding 800mg per infusion are not recommended
1563	Tolterodine Tartrate ER 4 mg Capsule	G04BD07123 C2002XX	A*	Treatment of overactive bladder with symptoms of urinary, frequency or urge incontinence	4 mg once daily. May decrease to 2 mg once daily depending on response and tolerability
1564	Topiramate 100 mg Tablet	N03AX11000 T1003XX	A*	Add-on therapy for intractable partial epilepsy	ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1565	Topiramate 15 mg Capsule Sprinkle	N03AX11000 C1001XX	A*	Add-on therapy for intractable partial epilepsy	ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
1566	Topiramate 25 mg Capsule Sprinkle	N03AX11000 C1002XX	A*	Add-on therapy for intractable partial epilepsy	ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
1567	Topiramate 25 mg Tablet	N03AX11000 T1001XX	A*	Add-on therapy for intractable partial epilepsy	ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1568	Topiramate 50 mg Tablet	N03AX11000 T1002XX	A*	Add-on therapy for intractable partial epilepsy	ADULT: Initially 25-50mg nightly for 1 week. Subsequently at wkly or bi-wkly intervals, increase dose by 25-50 to 100mg/day in 2 divided doses. CHILD aged 2 and above: Approx 5-9 mg/kg/day in 2 divided doses. Titrate at 25mg (or less, based on a range of 1-3mg/kg/day) nightly for the 1st week. Subsequently at 1 or 2 wkly intervals, with increments of 1-3 mg/kg/day in 2 divided dose.
1569	Trace Elements and Electrolytes (Adult) Solution	B05XA30905 P3001XX	A*	Only to be used to cover daily loss of electrolyte and trace elements for patient on parenteral nutrition	10 ml added to 500-1000 ml solution, given by IV infusion
1570	Trace Elements and Electrolytes (Paediatric) Solution	B05XA30905 P3002XX	A*	Only to be used to cover daily loss of electrolyte and trace elements for patient on parenteral nutrition	According to the needs of the patient. INFANT and CHILD weighing 15 kg or less: Basal requirements of the included trace elements are covered by 1 ml/kg/day to a maximum dose of 15 ml. CHILD weighing 15 kg or more, a daily dose of 15 ml, should meet basic trace element requirements. However, for patients weighing more than 40 kg the adult preparation trace element should be used
1571	Tramadol HCl 100 mg Suppository	N02AX02110 S2001XX	A	Post-operative pain, chronic cancer pain, analgesia/pain relief for patients with impaired renal function	100mg rectally up to qds
1572	Tramadol HCl 100 mg/ml Drops	N02AX02110 D5001XX	A	Post-operative pain, chronic cancer pain, analgesia/pain relief for patients with impaired renal function.	50 - 100 mg every 4 hours. Max : 400 mg daily. Not recommended in children
1573	Tramadol HCl 50 mg Capsule	N02AX02110 C1001XX	A/KK	Moderate to severe acute or chronic pain (eg. Post-operative pain, chronic cancer pain and analgesia/pain relief for patients with impaired renal function)	ADULT: 50mg initially, can take another 50mg after 30 - 60 min if pain not relieved. Max 400 mg daily. CHILD: 1mg/kg/dose repeated every 6 hours (Max:

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					2mg/kg/dose and 100mg/dose)
1574	Tramadol HCl 50 mg/ml Injection	N02AX02110 P3001XX	A	Moderate to severe acute or chronic pain (eg. Post-operative pain, chronic cancer pain and analgesia/pain relief for patients with impaired renal function)	ADULT: IV/IM/SC 50 - 100mg. (IV inj over 2-3 min or IV infusion). Initially 100 mg then 50 - 100 mg every 4 - 6 hours. . Max: 400 mg daily. CHILD (1 year and above): 1 - 2mg/kg/dose
1575	Tranexamic Acid 100 mg/ml Injection	B02AA02000 P3001XX	B	Haemorrhage associated with excessive fibrinolysis	ADULT: Slow IV 0.5-1 g (10 - 15 mg/kg) 3 times daily. Continuous infusion at a rate of 25 - 50 mg/kg daily. CHILD: slow IV 10 mg/kg/day 2-3 times daily
1576	Tranexamic Acid 250 mg Capsule	B02AA02000 C1001XX	B	Haemorrhage associated with excessive fibrinolysis	ADULT: 1-1.5 g (15-25 mg/kg) 2-4 times daily. CHILD: 25 mg/kg/day 2-3 times daily. Menorrhagia (initiated when menstruation has started), 1 g 3 times daily for up to 4 days; maximum 4 g daily
1577	Trastuzumab 440 mg Injection	L01XC03000P 4001XX	A*	Used only in adjuvant setting for patients with HER2 over-expressed breast cancer, that is HER2 3+ by immunohistochemistry and over-expressed by FISH (Fluorescence in situ hybridization) and high risk group	Initial loading dose is 4 mg/kg administered as a 90 minutes IV infusion. Subsequent doses is 2 mg/kg administered as 30 minutes IV infusion weekly for 51 weeks
1578	Travoprost 0.004% & Timolol 0.5% Eye Drops	S01ED51990 D2003XX	A*	To decrease intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to other topical anti glaucomas	1 drop in the affected eye(s) once daily
1579	Tretinoin 0.01% Gel	D10AD01000 G3001XX	A/KK	Acne vulgaris, recalcitrant cases of acne (comedonal type)	Apply thinly to the affected area once daily or twice daily. Avoid exposure to sunlight. Duration of treatment: 8-12 weeks is required before any noticeable response

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1580	Tretinoin 0.05% Cream	D10AD01000 G1001XX	A/KK	Acne vulgaris and recalcitrant cases of acne (comedonal type)	Apply thinly to the affected area once daily or twice daily. Avoid exposure to sunlight. Duration of treatment: 8 - 12 weeks is required before any noticeable response
1581	Tretinoin 0.1% Cream	D10AD01000 G1002XX	A	Acne vulgaris and recalcitrant cases of acne (comedonal type)	Apply thinly to the affected area once daily or twice daily. Avoid exposure to sunlight. Duration of treatment: 8 - 12 weeks is required before any noticeable response
1582	Triamcinolone Acetonide 0.1% Oral Paste	A01AC01351 G3101XX	B	Oral and perioral lesions	Apply a thin layer to affected area 2-4 times daily
1583	Triamcinolone Acetonide 10 mg/ml Injection	H02AB08351 P3001XX	A	Inflammation of joints, bursae and tendon sheaths	Smaller joints: 2.5 - 5 mg and larger joints: 5 - 15 mg. Treatment should be limited to 1 mg/injection site to prevent cutaneous atrophy
1584	Triamcinolone Acetonide 40 mg/ml Injection	H02AB08351 P3002XX	A/KK	Allergies, dermatoses, rheumatoid arthritis and inflammatory opthalmic diseases	40-80 mg deep into the gluteal muscle
1585	Trifluoperazine HCl 5 mg Tablet	N05AB06110 T1001XX	B	Psychotic disorder	ADULT: Initially 5 mg twice daily, increase by 5 mg after 1 week, then at 3-day intervals. Maximum 40 mg/day. CHILD up to 12 years: Initially up to 5 mg daily in divided doses adjusted to response, age and body weight
1586	Trimetazidine 20 mg Tablet	C01EB15110 T1001XX	B	Prophylactic treatment of episodes of angina pectoris	20 mg 3 times daily
1587	Trimetazidine 35 mg MR Tablet	C01EB15110 T5001XX	B	Prophylactic treatment of episodes of angina pectoris	35 mg twice daily in the morning and evening with meals
1588	Trimethoprim 100 mg Tablet	J01EA01000T 1001XX	B	Treatment of urinary tract infections due to susceptible pathogens	ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute infection: 200 mg twice daily. CHILD: 6-8 mg/kg/day in 2 divided doses. 6 - 12 years: 100 mg twice daily; 6 months - 5 years: 50 mg

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					twice daily. 6 weeks - 5 months: 25mg twice daily
1589	Trimethoprim 300 mg Tablet	J01EA01000T1002XX	B	Treatment of urinary tract infections due to susceptible pathogens	ADULT: 200 mg daily in 1 or 2 divided doses or 300 mg daily as a single dose. Acute infection: 200 mg twice daily. CHILD: 6 - 12 years: 100 mg twice daily; 6 months - 5 years: 50 mg twice daily. 6 weeks - 5 months: 25mg twice daily
1590	Trioxsalen 5 mg Tablet	D05BA01000T1001XX	A	Vitiligo	5 - 10 mg daily, 2 - 4 hours before exposure to sunlight. To increase pigmentation: 10 mg daily, 2 hours prior to UV irradiation
1591	Triprolidine HCl 1.25 mg and Pseudoephedrine HCl 30 mg per 5 ml Syrup	R01BA52110L9001XX	B	Decongestion of the upper respiratory tract in common cold, hay fever, allergic and vasomotor rhinitis and sinusitis. Doses to be taken twice daily or three times daily	ADULT and CHILD more than 12 year : 10 ml. CHILD 6 - 12 years : 5 ml, 2 - 5 years : 2.5 ml
1592	Triprolidine HCl 2.5 mg and Pseudoephedrine HCl 60 mg Tablet	R01BA52988T1002XX	B	Decongestion of the upper respiratory tract in common cold, hay fever, allergic and vasomotor rhinitis and aerotitis	ADULT 2.5 mg every 4 - 6 hours; maximum dose 10 mg/day. CHILD 6 - 12 years : 1.25 mg every 4 - 6 hours; maximum dose 5 mg/day, 2 - 4 years : 0.625 mg every 4 - 6 hours; maximum dose 2.5 mg/day, 4 - 6 years : 0.938 mg every 4 - 6 hours; maximum dose 3.744 mg/day
1593	Triptorelin 3.75 mg Injection	L02AE04000P2001XX	A	i) Treatment of confirmed central precocious puberty (preterm sexual development) in girls under 9 years, boys under 10 years of age ii) Genital and extragenital endometriosis (stage I to stage IV). Treatment should not be administered for more than 6 months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.	1 intramuscular injection every 4 weeks. The treatment must be started in the first 5 days of the menstrual cycle. The duration of treatment depends on the initial severity of the endometriosis and the changes observed in the clinical features. In principle, the treatment should be administered for at least 4 months and for at most 6

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					months. It is not recommended to start a second treatment course with triptorelin or another GnRH analogue.
1594	Tropicamide 1% Eye Drops	S01FA06000 D2002XX	A/KK	Topical use to produce cycloplegic refraction for diagnostic purposes	1 - 2 drops several times a day
1595	Trospium Chloride 20mg coated tablet	G04BD09100 C1001XX	A*	Symptomatic treatment for urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (eg. Idiopathic or neurologic detrusor overactivity) Place in therapy: As first line treatment for overactive bladder in patients with Parkinsonism, Alzheimer?s or other cognitive disease	1 tablet twice daily. Tablet should be swallowed whole with a glass of water before meals on empty stomach. Severe renal impairment (CrCl between 10 & 30 mL/min/1.73 m2): 1 tab daily or every 2nd day
1596	Tuberculine PPD Injection	V04CF01000 P3001XX	B	For routine Mantoux (tuberculin sensitivity) test	10 units is injected intradermally
1597	Typhoid Vaccine Capsule	J07AP01000C 1001XX	B	Active immunization against typhoid fever in adult and child 6 years of age or older	ADULT and CHILD 6 years of age or older, 1 capsule on days 1, 3 and 5
1598	Typhoid Vaccine Injection (20 doses)	J07AP02000P 3001XX	B	Active immunization against typhoid fever in adult and child more than 2 years	0.5 ml single IM injection into the deltoid or vastus lateralis, may reimmunize with 0.5 ml IM every 3 years if needed.
1599	Ulipristal Acetate 30mg Tablet	G03AD02122 T1001XX	A	Emergency contraception within 4-5 days of unprotected sexual intercourse for sexual assault victim.	Dosage is one tablet to be taken orally as soon as possible, but no later than 120 hours (5 days) after unprotected sexual intercourse or contraceptive failure.
1600	Urofollitropin (FSH) 150 IU Injection	G03GA04000 P3002XX	A*	Stimulation of follicular growth in infertile women	To be individualized. 75 IU-150 IU daily and maybe increased or decreased by up to 75 IU/day at 7 or 14 day intervals if necessary
1601	Urofollitropin (FSH) 75 IU Injection	G03GA04000 P3001XX	A*	Stimulation of follicular growth in infertile women	To be individualized. 75 IU-150 IU daily and maybe increased or decreased by up to 75 IU/day at 7 or 14 day intervals if necessary

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1602	Urokinase 6000 IU Injection	B01AD04000 P4001XX	A	Treatment of thromboembolic disease such as mycocardial infarction, peripheral artery occlusion, pulmonary embolism, retinal artery thrombosis and other ophthalmologic use	ADULT: Acute pulmonary embolism: IV loading dose 4400 iu/kg over 10 mins, maintenance 4400 iu/kg/hour for 12 hours. Peripheral vascular occlusion: infuse 2500 iu/ml into clot at a rate of 4000 iu/min for 2 hours. This may be repeated up to 4 times. Hyphaema: 5000 IU in 2 ml saline solution is injected and withdrawn repeatedly over the iris. If residual clot remains, leave 0.3ml in the anterior chambers for 24-48 hours to facilitate futher dissolution
1603	Ursodeoxycholic Acid 250 mg Capsule	A05AA02000 C1001XX	A	Cholestatic liver diseases (eg. primary biliary cirrhosis, primary cholangitis etc)	10-15 mg/kg daily in 2 to 4 divided doses usually for 3 months to 2 years. If there is no decrease in stone size after 18 months, further treatment seems not to be useful
1604	Ustekinumab 90 mg/ml Injection	L04AC05000 P3002XX	A*	Treatment of moderate to severe plaque psoriasis in adults who failed to, or who have contraindication to, or are intolerant to conventional systemic therapies including ciclosporin, methotrexate and photochemotherapy (PUVA).	Body weight less than 100kg: Initial dose of 45 mg SC, followed by 45 mg 4 weeks later, then every 12 weeks thereafter. Body weight more than 100 kg: initial dose 90 mg SC, followed by 90 mg 4 weeks later, & then every 12 weeks thereafter.
1605	Valganciclovir 450 mg Tablet	J05AB14110T 1001XX	A*	For the prevention of cytomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplant from a CMV-positive donor	For adult patients who have received other than kidney transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 100 days post-transplantation. For adult patients who have received a kidney transplant, the recommended dose is 900 mg (two 450 mg tablets)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					once a day starting within 10 days of transplantation until 200 days post-transplantation.
1606	Valproic Acid and Sodium Valproate (ER) 500mg Tablet	N03AG01520 T5001XX	B	i) In the treatment of generalized or partial epilepsy, particularly with the following patterns of seizures:absence, myoclonic, tonic-clonic, atonic-mixed as well as, for partial epilepsy:simple or complex seizures, secondary generalized seizures, specific syndrome (West, Lennox-Gastatut). ii) Treatment and prevention of mania associated with bipolar disorders.	i) Adults: Dosage should start at 500mg daily increasing by 200mg at three-day intervals until control is achieved. This is generally within the dosage range 1000mg to 2000mg per day. Children: >20KG: 500mg/day (irrespective of weight) with spaced increases until control is achieved. ii) Initial dose of 1000mg/day, to be increase rapidly as possible to achieve lowest therapeutic dose, which produce desired clinical effects. Recommend initial dose is 1000mg & 2000mg daily. Max dose 3000mg daily.
1607	Valsartan 160 mg and Hydrochlorothiazide 12.5 mg Tablet	C09DA03935 T1005XX	A/KK	Treatment of essential hypertension	1 tablet once daily
1608	Valsartan 160 mg Tablet	C09CA03000 T1002XX	A/KK	Patients who cannot tolerate ACE inhibitors because of cough, in i) Hypertension ii) Heart failure iii) Post myocardial infarction	i) 80 or 160 mg once daily. May be increased to 320 mg once daily. ii) 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily. Max: 320 mg in divided doses. iii) 20 mg twice daily. Uptitration to max of 160 mg twice daily.
1609	Valsartan 80 mg and Hydrochlorothiazide 12.5 mg Tablet	C09DA03935 T1001XX	A/KK	Hypertension in patients who cannot tolerate ACE inhibitors because of cough	1 tablet once daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1610	Valsartan 80 mg Tablet	C09CA03000 T1001XX	A/KK	Patients who cannot tolerate ACE inhibitors because of cough, in i) Hypertension ii) Heart failure iii) Post myocardial infarction	i) 80 or 160 mg once daily. May be increased to 320 mg once daily. ii) 40 mg twice daily. Uptitration to 80 mg and 160mg twice daily. Max: 320 mg in divided doses. iii) 20 mg twice daily increased over several weeks to 160mg twice daily if tolerated.
1611	Vancomycin HCl 500 mg Injection	J01XA01110P 4001XX	A*	Only for the treatment of MRSA and CAPD peritonitis	Slow IV infusion, ADULT: 500 mg over at least 60 minutes every 6 hours or 1 g over at least 100 minutes every 12 hours. NEONATE up to 1 week, 15 mg/kg initially, then 10 mg/kg every 12 hours. INFANT 1 - 4 weeks, 15 mg/kg initially then 10 mg/kg every 8 hours. CHILD over 1 month, 10 mg/kg every 6 hours
1612	Varenicline Tartrate 0.5 mg and 1 mg Tablet	N07BA03123 T1001XX	A/KK	Smoking cessation treatment	0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks
1613	Varenicline Tartrate 1 mg Tablet	N07BA03123 T1002XX	A/KK	Smoking cessation treatment	0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks
1614	Varicella Virus Vaccine Live Attenuated Injection	J07BK01000P 4001XX	A*	i) Health staff working with children, pregnant women, transplant, cancer and immunocompromised patients who are at high risk of contacting varicella and transmitting it to at risk patients ii) Transplant patients or candidates who are: a) Immunocompetent and not receiving immunosuppressant drugs, do not have graft versus host disease 2 years or more after transplant b) Susceptible to Varicella-Zoster virus at least 3 weeks before grafting iii) Children: a) with impaired humoral immunity	ADULT and CHILD 13 years or more: 2 doses of 0.5 ml SC injection separated by 4 - 8 weeks apart. CHILD 12 months - 12 years: 0.5ml SC as a single dose

No.	Generic Name	MDC	Category	Indication(s)	Dosage
				b) HIV-infected children more than 12 months of age, in CDC class N1 (asymptomatic) or A1 (mildly symptomatic) with age specific CD4 more than 25% c) with conditions that require systemic steroid therapy less than 2 mg/kg body weight or a total of 20 mg/day of prednisolone or its equivalent. [Those receiving high doses of systemic steroids at 2 mg/kg body weight or more of prednisolone for more than 2 weeks may be vaccinated after steroid therapy has been discontinued for at least three months] iv) Acute lymphoblastic leukemia (ALL) patients with negative history of varicella who:- a) are 12 months to 17 years of age b) have leukemia in remission for at least 12 months c) have a peripheral blood lymphocyte count 700 cells/ mm3 or more. [If platelet count of greater 100,000/mm3 within 24 hours of vaccination are not being submitted to radiotherapy. Chemotherapy should be withheld for seven days before and after immunisation] v) Susceptible subjects in clinical trials who will be submitted for chemotherapy vi) Children and susceptible patients on chronic dialysis	
1615	Vasopressin 20 units/ml Injection	H01BA01000 P3001XX	A	i) Pituitary diabetes insipidus ii) Oesophageal variceal bleeding	i) 5 - 20 units SC or IM every 4 hours ii) 20 units in 100 - 200 ml 5% dextrose saline over 15 minutes as infusion which may be repeated after at intervals of 1 - 2 hours. Maximum: 4 doses

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1616	Vecuronium Bromide 10 mg/10 ml Injection	M03AC03320 P3001XX	A*	As an adjunct in anaesthesia to produce skeletal muscle relaxation	ADULT & NEONATES > 5 MONTHS Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg, adjust according to response. Alternatively, as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg. NEONATE and INFANT up to 4 months: Initially 10 - 20 mcg/kg, then incremental dose to achieve response
1617	Vecuronium Bromide 4 mg/ml Injection	M03AC03320 P3002XX	A*	As an adjunct in anaesthesia to produce skeletal muscle relaxation	ADULT & NEONATES > 5 MONTHS Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg, adjust according to response. Alternatively, as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg. NEONATE and INFANT up to 4 months: Initially 10 - 20 mcg/kg, then incremental dose to achieve response.
1618	Venlafaxine HCl 150 mg Extended Release Capsule	N06AX16110 C2002XX	A*	i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorder	i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1619	Venlafaxine HCl 75 mg Extended Release Capsule	N06AX16110 C2001XX	A*	i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorder	i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended
1620	Verapamil HCl 2.5 mg/ml Injection	C08DA01110 P3001XX	A/KK	Supraventricular tachycardia	Initially 5-10mg given by slow IV over at least 2 minutes. The dose can be repeated 10mg 30 minutes after the first dose if the initial response is not adequate.
1621	Verapamil HCl 40 mg Tablet	C08DA01110 T1001XX	B	i) Supraventricular tachyarrhythmias (SVT) prophylaxis ii) angina	ADULT: 40 - 80 mg 3-4 times daily. In oral long term therapy, max: 480 mg daily
1622	Vildagliptin 50 mg and Metformin HCl 1000 mg Tablet	A10BD08926 T1002XX	A*	Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.	50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride.
1623	Vildagliptin 50 mg and Metformin HCl 500 mg Tablet	A10BD08926 T1003XX	A*	Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.	50/500mg or 50/850mg or 50/1000mg twice daily. Maximum daily dose is 100mg vildagliptin and 2000mg metformin.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1624	Vildagliptin 50 mg and Metformin HCl 850 mg Tablet	A10BD08926 T1001XX	A*	Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.	50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride.
1625	Vildagliptin 50 mg Tablet	A10BH02000 T1001XX	A*	i) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of metformin monotherapy and high risk of hypoglycaemia. ii) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of sulphonylurea and intolerant/contraindicated for metformin therapy. iii) As third line therapy in type 2 diabetes patients inadequately controlled with dual OAD combination therapy with sulphonylurea and metformin iv) As a monotherapy in type 2 diabetes mellitus patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. v)An adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus: As a dual therapy in combination with insulin in patients with insufficient glycaemic control. Insulin dose and regimen should be optimized before addition of vildagliptin.	ADULT over 18 years: 50mg bd when combine with metformin, 50 mg od when combine with sulphonylurea

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1626	Vinblastine Sulphate 10 mg Injection	L01CA01183 P3002XX	A	Hodgkin's disease, choriocarcinoma resistant to other chemotherapeutic agents, non-small cell lung cancer, Langerhans cell histiocytosis	Adult: Initially, 3.7 mg/m2, increase dose weekly based on WBC counts in increments of about 1.8 mg/m2 until leukocyte count decreases to about 3000/mm3, or maximum weekly dose of 18.5 mg/m2 reached. Usual dose: 5.5-7.4 mg/m2 per week. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3. Child: Initial 2.5 mg/m2 of BSA, increased dose at weekly intervals in increments of about 1.25 mg/m2 until leukocyte count decreases to about 3000/ mm3, or maximum weekly dose of 12.5 mg/m2 reached. Do not increase dose once leukocyte count reaches approximately 3000 cells/mm3, instead, a dose of 1 increment smaller to be admin at wkly intervals for maintenance. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3.
1627	Vincristine Sulphate 1 mg Injection	L01CA02183 P3001XX	A	i) Solid tumours ii) Gestational trophoblastic disease iii) Non-Hodgkin's lymphoma iv) Multiple myeloma v) Acute lymphoblastic leukemia	i) ADULT: 1.4 mg/m2 weekly (maximum 2 mg weekly) ii) Refer to protocol iii) 1.4 mg/m2 weekly (maximum 2 mg weekly) iv) 0.4 mg/m2 IV continuous infusion on days 1 - 4 v) Refer to protocol. CHILD: 1 mg/m2 to 2 mg/m2 weekly according to protocol (0.05 mg/kg for infants less than 10kg)

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1628	Vinorelbine 10 mg Injection	L01CA04000 P4001XX	A*	i) First line treatment in non-small cell lung cancer in combination with cisplatin/ifosfomide ii) Metastatic breast cancer	i) Single agent: Adult 30mg/m2 IV administered over 6-10 minutes once weekly Combination with cisplatin : 30mg/m2 IV administered over 6-10mintes once weekly combination with cisplatin IV on days and 29 and then every 6 weeks or Vinolrebine administered at a dose of 25mg/m2 IV weekly in combination with cisplatin given every 4 weeks at a dose of 100mg/m2 ii) 25 - 30 mg/m2 diluted in saline solution, infused over 6 - 10 minutes, administered weekly or vinolrebine maybe given as an 8mg/m2 IV BOLUS followed by 8mg/m2 as a 96-hour intravenous infusion
1629	Vinorelbine 50 mg Injection	L01CA04000 P4002XX	A*	i) First line treatment in non-small cell lung cancer in combination with cisplatin/ifosfomide ii) Metastatic breast cancer	i) Single agent: Adult 30mg/m2 IV administered over 6-10 minutes once weekly Combination with cisplatin : 30mg/m2 IV administered over 6-10mintes once weekly combination with cisplatin IV on days and 29 and then every 6 weeks or Vinolrebine administered at a dose of 25mg/m2 IV weekly in combination with cisplatin given every 4 weeks at a dose of 100mg/m2 ii) 25 - 30 mg/m2 diluted in saline solution, infused over 6 - 10 minutes, administered weekly or vinolrebine maybe given as an 8mg/m2 IV BOLUS followed by 8mg/m2 as a 96-hour intravenous infusion.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1630	Vitamin A & D (Cod Liver Oil)	A11CB00901 L5001XX	C	Prevention of ricketts	Not more than 10 ml daily, allowance being made for Vitamin D obtained from other sources
1631	Vitamin A & D Concentrate 25,000 units/0.6ml Liquid	A11CB00901 L5002XX	B	Prevention of ricketts	0.06 - 0.6ml (2,500-25,000 IU of Vitamin A and 250-2,500 IU of D) daily, allowance being made for A and D obtained from other sources
1632	Vitamin A 50,000 IU Capsule	A11CA01000 C1001XX	C	Children with measles malnutrition and serious infections. Category C can use this drug for Orang Asli and in Sabah	i) 0-5 months, 50,000 IU ii) 6-11 months, 100,000 IU iii) 1-5 years, 200,000 IU. Frequency twice daily
1633	Vitamin B Complex 10 ml Injection	A11EX00901 P3001XX	B	Prophylaxis and treatment of vitamin B deficiency	1-2 ml daily by IM
1634	Vitamin B Complex Tablet	A11EA00901 T1001XX	C+	Prophylaxis and treatment of vitamin B deficiency	1-2 tablets daily
1635	Vitamin B1, B6, B12 Injection	A11DB00901 P3001XX	B	For deficiency or raised requirement of Vitamin B1, B6, B12	Mild cases: 1 ampoule given by IM 2-3 times weekly. Severe cases: 1 ampoule daily
1636	Vitamin B1, B6, B12 Tablet	A11DB00901 T1001XX	B	For deficiency or raised requirement of Vitamin B1, B6, B12	1 - 3 tablets 3 times daily swallowed unchewed.
1637	Vitamin C 10% Eye Drops	S01XA15000 D2001XX	B	For all types of severe chemical corneal burns especially acid and alkali burns	1 to 4 times daily depending on severity of case
1638	Vitamin E, B12, B6, Nicotinamide Tablet	A11E000901 T1001XX	A	To improve appetite and growth. Neurasthenia, nausea and vomiting in pregnancy, radiation sickness and neuritis due to isoniazid therapy and alcoholism	1 - 2 tablet daily
1639	Vitamin K1 1 mg/ml Injection	B02BA01000 P3001XX	C+	Vitamin K deficiency in neonates	Prophylaxis of vitamin K deficiency bleeding in neonates Child: Neonate: 0.5-1 mg, given as a single dose via IM inj. Alternatively, 2 mg may be given orally, followed by a 2nd dose of 2 mg after 4-7 days. Intravenous Vitamin K deficiency bleeding in neonates Child: Infant: 1 mg by IV/IM/SC inj, further doses may be given if

No.	Generic Name	MDC	Category	Indication(s)	Dosage
					necessary
1640	Vitamin K1 10 mg/ml Injection	B02BA01000 P3002XX	B	Haemorrhage associated with hypoprothrombinaemia caused by overdose of anticoagulants	0.5 - 20 mg by very slow IV at a rate not exceeding 1 mg per minute
1641	Vitamin K1 Mixed Micelle 2 mg/0.2 ml Injection	B02BA01000 P3004XX	B	Prevention of bleeding in neonates	Healthy neonate 2 mg orally at birth or soon after followed by 2 mg at 4 - 7 days. Exclusively breastfed baby, in addition, 2 mg orally at monthly intervals until end of breastfeeding period. Neonate at special risk, 1 mg IM/IV at birth or soon after if oral route is not suitable. Treatment: 1 mg IV initially. Further doses depend on clinical picture and coagulation status
1642	Voriconazole 200 mg Injection	J02AC03000P 3001XX	A*	i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, serious fungal infections caused by Scedosporium species and Fusarium species ii)Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients	Adult and Children 12 years and greater: Loading dose: 6 mg/kg 12 hourly for first 24 hours. Maintenance: i) 4 mg/kg 12 hourly ii) 3 mg/kg 12 hourly. Dose may be increased to 4 mg/kg 12 hourly if response is inadequate. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 7mg/kg 12hourly
1643	Voriconazole 200 mg Tablet	J02AC03000T 1002XX	A*	i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients	Adult and Children 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly. Children aged 2years to <12years with normal hepatic and renal function: No loading dose needed; 200mg 12hourly

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1644	Voriconazole 50 mg Tablet	J02AC03000T1001XX	A*	i) Treatment of immunocompromised patients with progressive, possibly life-threatening infections such as invasive aspergillosis, fluconazole-resistant serious invasive candidiasis, candidiasis of the oesophagus, serious fungal infections caused by Scedosporium species and Fusarium species ii) Prevention of breakthrough fungal infections in febrile high-risk neutropenic patients	ADULT and CHILDREN 12 years and greater and over 40 kg: Loading dose: 400 mg 12 hourly for first 24 hours. Maintenance: 200 - 300 mg 12 hourly. Less than 40 kg: Loading dose: 200 mg 12 hourly for first 24 hours. Maintenance: 100 - 150 mg 12 hourly
1645	Warfarin Sodium 1 mg Tablet	B01AA03520T1001XX	B	Treatment and prophylaxis of thromboembolic disorders	Initially 10 mg daily for 2 days. Maintenance dose, 3-9 mg daily according to the INR (taken at the same time each day)
1646	Warfarin Sodium 2 mg Tablet	B01AA03520T1002XX	B	Treatment and prophylaxis of thromboembolic disorders	Initially 10 mg daily for 2 days. Maintenance dose, 3-9 mg daily according to the INR (taken at the same time each day)
1647	Warfarin Sodium 3 mg Tablet	B01AA03520T1003XX	B	Treatment and prophylaxis of thromboembolic disorders	Initially 10 mg daily for 2 days. Maintenance dose, 3-10 mg daily according to the INR (taken at the same time each day)
1648	Warfarin Sodium 5 mg Tablet	B01AA03520T1004XX	B	Treatment and prophylaxis of thromboembolic disorders	Initially 10 mg daily for 2 days. Maintenance dose, 3-10 mg daily according to the INR (taken at the same time each day)
1649	Water for Injection	V07AB00000P3001XX	C+	As a diluent and vehicle for the administration of medications	According to the needs of the patient
1650	White Petroleum Anhydrous Liquid Landin, Mineral Oil Eye Ointment	S01XA20900G5101XX	A	Keeping the eye lubricated and comfortable during the night	Apply a small amount into the eye

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1651	Zidovudine 1% Injection	J05AF01000P3001XX	A	To reduce the rate of maternal-foetal transmission of HIV in: i) HIV-positive pregnant women over 14 weeks of gestation ii) Their newborn infants	i) Prophylaxis of maternal-foetal HIV transmission during labour and delivery Adult: Loading dose: 2 mg/kg, followed by continuous infusion of 1 mg/kg/hr until umbilical cord is clamped. If caesarean section is planned, start the IV infusion 4 hr before the operation. Renal and Hepatic impairment: Dose reduction may be needed. HIV infection (to be discuss: not in indication) Adult: 1-2 mg/kg every 4 hr, given as 2-4 mg/ml infusion over 1 hr. Child: As continuous infusion: 20 mg/m2/hr. Alternatively, as intermittent infusion: 120 mg/m2 every 6 hr. Renal impairment: Haemodialysis or peritoneal dialysis: 1 mg/kg every 6-8 hr. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 1.5 mg/kg every 6 hr. Start treatment within 12 hr after birth and continue for 1st 6 wk of life. Dose to be given via IV infusion over 30 minutes. Renal impairment: Dose adjustment may be needed.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1652	Zidovudine 10 mg/ml Syrup	J05AF01000L 9001XX	A*	i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts less than 500 cu. mm. ii) Neonatal prophylaxis	i) HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. Renal and Hepatic impairment: Dose reduction may be needed. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for 1st 6 wk of life, starting within 12 hr after birth. Renal and hepatic impairment: Dose adjustment may be needed.
1653	Zidovudine 100 mg Capsule	J05AF01000C 1001XX	A/KK	i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts less than 500 cu. mm ii) Neonatal prophylaxis	i) HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. Renal and Hepatic impairment: Dose reduction may be needed. ii) Prophylaxis of HIV infection in neonates Child: Neonates: 2 mg/kg every 6 hr for 1st 6 wk of life, starting within 12 hr after birth. Renal and hepatic impairment: Dose adjustment may be needed.
1654	Zidovudine 300 mg & Lamivudine 150 mg Tablet	J05AR01964T 1001XX	A/KK	HIV infection in combination with at least one other antiretroviral drug	ADULT and CHILD over 12 years: 1 tablet twice daily

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1655	Zidovudine 300 mg Tablet	J05AF01000T 1001XX	A*	i) Management of patients with asymptomatic and symptomatic (early or advanced) HIV infections with CD4 cell counts < 500 cu. mm ii) HIV positive pregnant mothers	HIV infection Adult: 600 mg daily in divided doses, in combination with other antiretroviral agents. Child: 6 wk - 12 yr: 160 mg/m2 every 8 hr. Max: 200 mg every 8 hr. May be used in combination with other anti-retrovirals. ii)Prophylaxis of maternal-foetal HIV transmission Adult: 100 mg 5 times daily or 200 mg tid or 300 mg bid. Start treatment after 14th wk of gestation until the start of labour. Haemodialysis or peritoneal dialysis (CrCl <10 ml/min: 100 mg every 6-8 hr.
1656	Zinc Oxide Cream	D02AB00000 G1001XX	C+	Skin protective in various skin conditions such as nappy rash, eczema and problem skin	Apply 3 times daily or as required
1657	Zinc Oxide Ointment	D02AB00240 G5001XX	C	Skin protective in various skin conditions such as nappy rash and eczema	Apply 3 times daily or as required
1658	zinc oxide, benzyl benzoate and balsam peru suppository	C05AX04931 S1001XX	C	For relief of pruritus, burning and soreness in patients with haemorrhoids and perianal conditions	Insert 1 suppository night and morning after bowel movements; does not use for longer than 7 days OR please refer to the product insert.
1659	Ziprasidone 20 mg/ml Injection	N05AE04110 P3001XX	A*	Acute agitation in schizophrenia	ADULT: Initially 10 mg (every 2 hour) or 20 mg (every 4 hour). Maximum: 40 mg/day. IM administration more than 3 days has not been studied
1660	Zoledronic Acid 4 mg Injection	M05BA08000 P3001XX	A*	i) Treatment of hypercalcaemia of malignancy ii) Prevention of skeletal related events in patients with multiple myeloma involving multiple bone lesions	4 mg reconstituted and should be given as a 15 minutes IV infusion every 3-4 weeks

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1661	Zolpidem Tartrate 10 mg Tablet	N05CF02123 T1001XX	A	For treatment of insomnia	10-mg tablet daily. Stilnox should always be taken just before going to bed. In elderly patients or patients with hepatic insufficiency: Dosage should be halved ie, 5 mg. Dosage must never exceed 10 mg/day.
1662	Zonisamide 100mg tablet	N03AX15000 T1001XX	A*	As adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Restrictions: As adjunctive therapy in the treatment of partial seizures in adults with epilepsy when 1st line and 2nd line therapy failed.	For adults, usually 100 to 200mg of zonisomide is to be administered orally 1 to 3 times a day initially. The dose is gradually increased at every one to two weeks up to 200-400mg daily, in 1 to 3 divided doses. The maximum daily dose should not exceed 600mg per day.
1663	Zuclopenthixol 20 mg/ml Drops	N05AF05000 D5001XX	A*	Only for psychoses with insight or compliance	Acute Schizophrenia and Other Acute Psychoses; Severe Acute States of Agitation; Mania: Oral treatment: Usually 10-50 mg/day. In moderate to severe cases initially 20 mg/day increased, if necessary, by 10-20 mg/day every 2-3 days to ≥75 mg daily.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1664	Zuclopenthixol Acetate 100 mg/2 ml Injection	N05AF05122 P3002XX	A*	Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugs	Clopixol-Acuphase: Clopixol-Acuphase is administered by IM injection. The dosage range should normally be 50-150 mg (1-3 mL) IM repeated if necessary, preferably with a time interval of 2-3 days. In a few patients, an additional injection may be needed 24-48 hrs following the 1st injection. In the maintenance therapy, treatment should be continued with oral Clopixol or Clopixol Depot IM after the following guidelines: Change to Oral Clopixol: 2-3 days after the last injection of Clopixol-Acuphase, a patient who has been treated with 100 mg Clopixol-Acuphase, oral treatment should be started at a dosage of about 40 mg daily, possibly in divided dosages. If necessary, the dose can be further increased by 10-20 mg every 2-3 days up to 75 mg or more.

No.	Generic Name	MDC	Category	Indication(s)	Dosage
1665	Zuclopenthixol Acetate 50 mg/ml Injection	N05AF05122 P3001XX	A*	Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugs	Clopixol-Acuphase: Clopixol-Acuphase is administered by IM injection. The dosage range should normally be 50-150 mg (1-3 mL) IM repeated if necessary, preferably with a time interval of 2-3 days. In a few patients, an additional injection may be needed 24-48 hrs following the 1st injection. In the maintenance therapy, treatment should be continued with oral Clopixol or Clopixol Depot IM after the following guidelines: Change to Oral Clopixol: 2-3 days after the last injection of Clopixol-Acuphase, a patient who has been treated with 100 mg Clopixol-Acuphase, oral treatment should be started at a dosage of about 40 mg daily, possibly in divided dosages. If necessary, the dose can be further increased by 10-20 mg every 2-3 days up to 75 mg or more.
1666	Zuclopenthixol Decanoate 200 mg/ml Injection	N05AF05135 P2001XX	A*	Only for treatment of agitated and violent patients suffering from schizophrenia who are not responding to the available standard drugs	By deep IM injection test dose 100 mg followed after 7 - 28 days by 100 - 200 mg or more followed by 200 - 400 mg at intervals of 2 - 4 weeks adjusted according to response. Maximum 600 mg weekly. Child not recommended